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Ovine herpesvirus 2 (OvHV-2) is a gammaherpesvirus of domestic sheep and causes the 
lymphoproliferative disease malignant catarrhal fever (MCF) in susceptible ruminants, 
including cattle. Sheep are latently infected but do not develop disease. MCF is characterised 
by proliferation of non-antigen specific cytotoxic large granular lymphocytes which leads to 
necrosis of infiltrated tissues and death. The molecular basis underlying MCF pathogenesis is 
poorly understood and it is unknown what controls the differences in the clinical outcome of 
infection between sheep and cattle, two closely related species.  
microRNAs (miRNAs) are short noncoding RNAs that post-transcriptionally regulate gene 
expression through targeting of mRNA. A number of herpesviruses have been shown to 
encode miRNAs that are capable of regulating of both viral and cellular gene expression which 
can often have an effect on the pathogenesis of the virus. Following RNA seq analysis of an 
OvHV-2-infected bovine T-cell line (BJ1035) forty-five miRNAs were predicted to be 
encoded. Eight miRNAs were previously validated by northern blotting, and a further twenty-
seven were confirmed using two PCR methods described in this project. 
It was hypothesised that these virus-encoded miRNAs may differentially target cellular genes 
in sheep and MCF-susceptible species. Previous work using the technique CLASH 
(Crosslinking Ligation and Sequencing of Hybrids) identified Delta-like 1 (DLL1), a ligand 
for Notch signalling, as a potential target of ovhv2-miR-17-2. Initially, differential targeting 
of DLL1 between sheep and cattle was hypothesised due to differences in the sequence and 
number of binding sites for ovhv2-miR-17-2. The sheep DLL1 mRNA was shown to be 
targeted however, due to incorrect annotation of the sheep genome, targeting of DLL1 is likely 
in both sheep and cattle. One OvHV-2-encoded miRNA, ovhv2-miR-73-1, has partial 
homology to a mammalian miRNA, miR-216a. Based on this homology it was predicted that 
ovhv2-miR-73-1 may target Phosphatase and Tensin Homolog (PTEN) and Y Box Binding 
Protein 1 (YB-1), as they are known targets of miR-216a. A GFP-reporter system was used to 
demonstrate that despite having similar seed sequences, ovhv2-miR-73-1 does not target 
PTEN or YB-1. Bioinformatic prediction was used to identify MHC class II genes as potential 
targets of OvHV-2-encoded miRNAs. Two miRNAs, ovhv2-miR-17-25 and ovhv2-miR-17-9 
were shown to target sheep MHC class II genes (DRA and DQB respectively) using a luciferase 
reporter system. These miRNAs were not predicted to target the equivalent genes in cattle 
indicating that these genes may be differentially regulated between sheep and cattle. 
It was also shown that two OvHV-2-encoded miRNAs, ovhv2-miR-17-10 and ovhv2-miR-61-
1, target the viral protein Ov2. Ov2 is predicted to contain a basic leucine zipper (bZIP) domain 
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and is therefore likely to be a transcription factor. Other closely related gammaherpesviruses 
encode proteins that contain bZIP domains and these play major roles in the reactivation of 
the virus from latency. Immunofluorescence and confocal microscopy was performed to 
confirm the nuclear localisation of Ov2. RT-qPCRs were performed to investigate whether 
Ov2 could regulate the expression of any cellular genes. Of the two genes investigated, one of 
these, Jagged (JAG1), was downregulated in the presence of an Ov2-EGFPN1 construct 
compared to a control plasmid. JAG1 is another ligand for Notch signalling indicating that the 
virus may manipulate Notch signalling using multiple methods. Immunoprecipitation and 
mass spectrometry analysis of an Ov2HA-pcDNA3.1+ construct was performed and a number 





Malignant catarrhal fever (MCF) is a fatal disease of cattle, bison and deer caused by infection 
with the virus Ovine herpesvirus 2 (OvHV-2). Sheep are infected from a very young age and 
carry the infection for life without any signs of disease. This virus can spread to other sheep 
and also to cattle, bison and deer; if these “foreign” hosts catch the virus they develop MCF. 
This disease is economically important not only in the UK but also in Sub-Saharan Africa and 
other areas of the developing world where it places a major burden on food production. OvHV-
2 infects and persists in particular types of cells in the immune system. In sheep, these cells 
continue to function normally however in cattle these same immune cells change and as a 
result are able to attack and kill other cells in the body resulting in disease and ultimately death. 
Given that sheep and cattle are very closely related species in terms of their genetics, one of 
the major questions in OvHV-2 biology is why sheep survive and cattle die. Herpesviruses are 
wide-spread throughout nature and usually only infect one species and have co-existed and 
evolved with that species for millions of years.  
Messenger RNA (mRNA) carries the message or “blueprint” of the DNA to be able to make 
the protein. Previous work in the group has predicted that a number of molecules, termed 
microRNAs (miRNAs), would be produced by the virus. miRNAs work by affecting how 
much of a particular protein is produced in a cell by binding to the mRNA or blueprint for a 
particular protein and stopping its production. The hypothesis is that the OvHV-2 miRNAs 
have evolved to work in sheep immune cells, allowing the virus to persist, and that these 
miRNAs encoded by OvHV-2 may not do the same thing in a “foreign” host such as cattle.  
The first aim of this project was to validate the predicted virus miRNAs and it was found that 
OvHV-2 produces at least thirty-five miRNAs. The next objectives were to find out what some 
of the targets of these miRNAs are in sheep and cattle. Computer prediction programmes were 
used to predict targets in sheep and cattle and experiments to confirm these interactions were 
performed. Two targets were confirmed in sheep and cattle and both of these play a role in the 
immune response to infection. One of these is potentially targeted differently between sheep 
and cattle indicating that this may influence the outcome of disease in the closely related 
species. Another confirmed target was a virus protein that is thought to be important in 
interacting with the host, although its exact function is unknown. Experiments are being 
continued by others in the group to find out the function of this virus protein and how it relates 
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Herpesviruses are large, double stranded (ds) DNA viruses that are widely distributed in 
nature. Most animal species are thought to be infected with at least one herpesvirus (Pellet & 
Roizman, 2007). Over two hundred herpesviruses have been isolated so far, and it is likely 
that many more exist but have not yet been discovered due to lack of research in a number of 
animal species (Wibbelt et al., 2007). Herpesviruses are thought to have co-evolved closely 
with their hosts for millions of years. This is supported by evidence that shows sequence 
divergence but conserved function of open reading frame (ORF) homologues between 
different herpesviruses (Fossum et al., 2009). 
Herpesviruses can cause a broad range of clinical outcomes from an asymptomatic infection 
through to death. Fatal conditions caused by herpesvirus infection such as encephalitis and 
tumour formation are usually associated with immunocompromised hosts or infection in a 
non-natural host.  
The Herpesviridae family share a number of biological properties. First, herpesviruses encode 
a large number of enzymes involved in DNA synthesis, nucleic acid metabolism and protein 
processing. Second, herpesvirus genome replication and capsid assembly occurs in the 
nucleus. Third, herpesviruses are capable of maintaining a lifelong infection (latent infection) 
in their natural host. During latency, the virus genome is present within the cell as an episome 
and a small subset of viral genes are expressed. Latent virus is able to reactivate following a 
stress event where full gene expression and production of infectious virions occur (Pellet & 
Roizman, 2007).  
1.1.1 Herpesvirus Structure 
The structure of herpesviruses is well conserved. A typical herpesvirus virion is shown in 
Figure 1.1. The core of the particle contains the linear ds genome of the virus tightly packed 
within an icosahedral capsid of T = 16 symmetry. The approximate size of the capsid is 
between 100 and 110 nm in diameter. The capsid is surrounded by the tegument; a loosely 
organised protein structure. It is thought that proteins in the tegument play important roles in 
initiating infection, regulation of virus gene expression and virus assembly (Penkert & Kalejta, 
2011; Yu et al., 2011). A lipid envelope derived from the infected cell surrounds the tegument. 
Embedded within the envelope are a number of viral glycoproteins which play a role in virus 
entry (discussed further in section 1.3.1). The size of the virion including tegument and 
envelop can range from 120 nm to 300 nm due to variation in the thickness of the tegument 
(Pellet & Roizman, 2007). 




Figure 1.1 A typical herpesvirus virion 
A: An electron micrograph of herpes simplex virus 1 (taken from 
http://web.stanford.edu/group/virus/herpes/2000/herpes2000.html).  
B: A diagrammatical representation showing the major structural features envelope, 
capsid, tegument and glycoproteins (adapted from 
http://viralzone.expasy.org/all_by_protein/987.html)  
Envelope Tegument Capsid Glycoproteins 
A 
B 
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1.1.2 Herpesvirus Genomes 
The genomes of herpesviruses range in length from approximately 120 to 245 kilobase pairs 
(kbp) and encode at least 70 ORFs (McGeoch et al., 2006). The upper limit of number of ORFs 
encoded by herpesviruses is not defined. Human cytomegalovirus is estimated to encode 
between 164 and 252 ORFs although recent evidence has shown that there may be as many as 
751 ORFs translated (Davison et al., 2003; Murphy et al., 2003; Stern-Ginossar et al., 2012). 
A minimum of 43 ORFs are thought to be conserved across the herpesvirus family; these core 
genes code for proteins involved in DNA replication as well as for capsid and tegument 
proteins (McGeoch & Davison, 1999). The remaining ORFs may be conserved within 
herpesvirus subfamilies (alpha, beta and gamma) or may be unique to the herpesvirus itself. 
In addition many herpesviruses have one or more non-coding regions of the genome which do 
not contain any ORFs but may code for non-coding RNAs (Chandriani et al., 2010; Hart et 
al., 2007). Several herpesviruses have been shown to code for microRNAs (miRNAs), and 
this will be discussed further in section 1.7 (Kincaid & Sullivan, 2012). 
The unique sequence of herpesvirus DNA is often flanked by inverted or terminal repeat 
(reiterated) sequences. The copy number of these terminal repeat sequences can affect the 
length of the genome of any given herpesvirus. This explains why herpesvirus genome length 
is often written as an approximation rather than an exact value. Herpesviruses can be 
categorised into six groups A – F depending on the presence, location and number of the repeat 
sequences (Roizmann et al., 1992). Figure 1.2 shows a diagrammatic representation of the six 
groups based on their repeat sequence architecture. Group A viruses have a large region from 
one terminus of the genome directly repeated at the other terminus. These regions are 
designated the left terminal repeat (LTR) and right terminal repeat (RTR). In group B viruses, 
a variable number of directly repeated sequences are present at both ends of the genome. Group 
C viruses also contain a variable number of directly repeated sequences at both ends of the 
genome however these are often fewer in number compared to group B viruses. Group C 
viruses also contain unrelated, directly repeated sequences greater than 100 base pairs (bp) 
that subdivide the genome. In group D viruses, the unique sequence is divided into unique 
long (UL) and unique short (US) regions. The US region is separated from the UL region by an 
inverted repeat of the sequence at the other terminus of the US region. Similarly the genomes 
of group E viruses are divided into UL and US regions. Both the UL and US  regions are flanked 
by their own inverted repeat sequence (designated RL or RS). The genomes of group F viruses 
have not been found to contain any repeat sequences (Roizmann et al., 1992).  




Figure 1.2 Schematic diagram of the sequence arrangement of the 6 classes 
of viral genomes in the Herpesviridae family. 
Genomes are represented by lines and repeat sequences by rectangles. Relative 
orientations of repeat sequences are indicated by arrows. The genomes of group A viruses 
(e.g. channel catfish herpesvirus) contain a large sequence from one terminus directly 
repeated at the other terminus. Group B viruses (e.g. Saimiriine herpesvirus 2) have 
genomes which contain a variable number of directly repeated sequences at both termini. 
The genomes of group C viruses (e.g. Epstein-Barr virus) contain both terminal repeats 
and other unrelated repeat sequences that subdivide the genome. The unique regions of the 
genomes of group D viruses (e.g. varicella-zoster virus) are divided into two segments 
separated by an inverted repeat of the terminal region from the short (Us) region. The 
unique regions of the genomes of group E viruses (e.g. herpes simplex virus and human 
cytomegalovirus) are similarly divided with inverted repeats flanking both the long (UL) 
and Us regions. No repeat regions have been described in the genomes of group F viruses 
(e.g. tupaia herpesvirus). Adapted from Roizmann et al., 1992. 
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1.2 Herpesvirus Classification 
The Herpesviridae family is divided into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae. Classification of herpesviruses into the three 
subfamilies used to be based on biological characteristics such as host range and cell type in 
which a latent infection was established. Classification of herpesviruses is now based on DNA 
and protein sequence homology and similarities in genome arrangement (Roizmann et al., 
1992). This has resulted in the re-classification of Marek’s disease virus (MDV) as an 
alphaherpesvirus rather than a gammaherpesvirus.  
1.2.1 Alphaherpesviruses 
The Alphaherpesvirinae subfamily is divided into 4 genera: Simplexvirus, Varicellovirus, 
Mardivirus and Iltovirus. The Simplexvirus genus includes herpes simplex virus 1 (HSV-1) 
and herpes simplex virus 2 (HSV-2). The Varicellovirus genus include varicella-zoster virus 
(VZV). The Mardivirus genus includes MDV and the Iltovirus genus includes infectious 
laryngotracheitis virus (ILTV). Alphaherpesviruses can productively infect a broad range of 
cell types however latency is primarily established in neuronal cells.  
HSV-1 (human herpesvirus 1, HHV-1) and HSV-2 (human herpesvirus 2, HHV-2) were the 
first of the human herpesviruses discovered, and as the naming of the viruses suggests are 
closely related. HSV-1 and HSV-2 are widespread and are associated with oral and genital 
infections respectively. Outcomes of HSV infection can range from mild cutaneous lesions to 
encephalitis which can often be fatal. Primary HSV infection is usually asymptomatic and 
latency is established in the sensory ganglia innervating the site of infection. Reactivation of 
HSV-1 from latency is associated with disease; symptoms (typically cold sores) include small, 
grouped vesicles or blisters on epithelial surfaces. These then pustulate, ulcerate and later form 
a crust. Other conditions associated with HSV-1 infection include eczema, conjunctivitis 
leading to vision loss, erythema multiforme and fatal encephalitis. Transmission of HSV-2 
from mother to foetus during pregnancy occurs rarely but can also cause encephalitis (Whitley 
& Roizman, 2001). 
VZV (human herpesvirus 3, HHV-3) is the aetiological agent of chicken pox (also known as 
varicella), characterised by widespread skin lesions. VZV, like HSV-1 and HSV-2 is also 
widespread throughout the population. It is highly transmissible with primary infection 
occurring during childhood via skin to skin contact and inhalation of infected droplets. Primary 
infection with VZV can also be associated with a severe pneumonia, minor abnormalities in 
liver function, encephalitis and cerebellar ataxia (Moffat et al., 2007). VZV establishes latency 
in sensory ganglia, and, in contrast to HSV infections, reactivation usually occurs only once 
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unless an individual is immunocompromised (Kennedy et al., 1998). Reactivation of VZV 
results in herpes zoster or shingles, characterised by a painful, unilateral vesicular rash 
restricted to a single dermatome. Post-herpetic neuralgia can occur after resolution of the 
herpes zoster rash. 
MDV (gallid herpesvirus 2, GaHV-2) is the causative agent of Marek’s disease in chickens 
and is associated with T cell lymphoma. Due to the oncogenic potential of MDV it was 
originally classified as a gammaherpesvirus but was reclassified as an alphaherpesvirus based 
on its sequence homology and gene organisation (Buckmaster et al., 1988). MDV primary 
infection occurs in B lymphocytes and macrophages in the lungs following inhalation of virus 
particles in contaminated dust. Latency is established in T cells (mainly CD4+), some of which 
will then undergo transformation resulting in lymphoma. This is different from other 
alphaherpesviruses described which only enter latency in neuronal cells (Couteaudier & 
Denesvre, 2014). Vaccines for MDV exist which exhibit a strong ability to control the disease 
however they do not protect against MDV infection (Haq et al., 2013). 
1.2.2 Betaherpesviruses 
The Betaheresvirinae subfamily is divided into 4 genera: Cytomegalovirus (including human 
cytomegalovirus, HCMV), Muromegalovirus (including murine cytomegalovirus, MCMV), 
Roseolovirus (including human herpesvirus 6, HHV-6 and human herpesvirus 7, HHV-7) and 
Proboscivirus (including elephant endotheliotropic herpesvirus). Betaherpesviruses typically 
have a narrower host range than that of alphaherpesviruses and have a long replication cycle. 
Productive infection of betaherpesviruses occurs in a wide range of cell types within the host 
however latency of HCMV is thought to establish in CD34+ cells and cells of the myeloid 
lineage (Hanley & Bollard, 2014) 
HCMV (human herpesvirus 5, HHV-5) is a leading cause of congenital infections worldwide. 
Congenital HCMV infection is associated with hearing loss, mental retardation and seizures 
in neonates (Pass et al., 2006).  It is also of major concern in immunocompromised individuals, 
such as transplant patients and human immunodeficiency virus (HIV) infected individuals 
where HCMV-associated pneumonia can be potentially fatal (Gandhi et al., 2003). Primary 
HCMV infection (in an immunocompetent host) is usually asymptomatic although it can result 
in an infectious mononucleosis (IM, similar to that caused by Epstein-Barr virus, EBV). 
Latency establishment and maintenance is poorly understood in HCMV. Reactivation of the 
virus can occur in response to immunosuppression or stress however the mechanism has not 
yet been elucidated (Crough & Khanna, 2009).  




The Gammaherpesvirinae subfamily was traditionally divided into 2 genera: 
Lymphocryptovirus (including EBV) and Rhadinovirus (including Kaposi’s sarcoma-
associated herpesvirus, KSHV, and murine gammaherpesvirus 68, MHV-68). The 
Herpesviridae Study Group of the International Committee on Taxonomy of Viruses has 
increased the number of genera from two to four to include Macavirus (including viruses 
associated with malignant catarrhal fever, MCF, see section 1.4 for details) and Percavirus 
(including equine herpesvirus 2) (Davison et al., 2009; McGeoch et al., 2006). 
Gammaherpesviruses are typically thought to have a narrow host range, however this can 
sometimes extend across the order or family to which the natural host belongs. Unlike 
alphaherpesviruses and betaherpesviruses, lytic replication of gammaherpesviruses occurs in 
a small subset of cells. In addition, gammaherpesviruses establish and maintain latency in 
lymphocytes, usually either B lymphocytes or T lymphocytes. Gammaherpesviruses also tend 
to encode unique genes not conserved across the Herpesviridae family. These are usually 
located towards the termini of the genome, can be homologues of cellular genes and often play 
roles in viral pathogenesis.  
EBV (human herpesvirus 4, HHV-4) is the best studied gammaherpesvirus. EBV is highly 
prevalent and is thought to infect over 90% of the human population worldwide. Transmission 
of EBV is thought to be by the oral route, however infection can also occur through blood 
transfusion and organ donation. Primary infection usually occurs in childhood and is 
asymptomatic, however if primary infection does not occur until adolescence IM can develop 
(Chen, 2011). Symptoms of IM include fever, pharyngitis, lymphadenopathy, malaise and 
fatigue (Rea et al., 2001). Latency is established in B lymphocytes and is associated with a 
number of malignancies including Burkitt’s lymphoma, Hodgkin’s lymphoma, 
nasopharyngeal carcinoma (NPC), primary effusion lymphoma and post-transplant 
lymphoproliferative disease (Ambinder & Cesarman, 2007). Although EBV-associated 
malignancies are associated with the immunocompromised, immunocompetent individuals 
may develop EBV-associated cancers due to the genetic background of the host or 
environmental factors. Latency of EBV will be discussed further in section 1.3.3. 
KSHV (human herpesvirus 8, HHV-8) is the most recently discovered human herpesvirus. 
Like EBV, KSHV is associated with a number of malignancies including Kaposi’s sarcoma 
(KS), multicentric Castleman’s disease and primary effusion lymphoma. KSHV is endemic in 
sub-Saharan Africa and regions surrounding the Mediterranean. KS was historically seen in 
elderly Mediterranean men and presents with a small number of cutaneous lesions on the lower 
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legs (classic KS). A rise in the incidence of KS occurred in the 1980s as a result of the 
HIV/AIDS (acquired immunodeficiency syndrome) epidemic. Furthermore, KS is the most 
common cancer diagnosed in AIDS patients in sub-Saharan Africa (Mesri et al., 2010). AIDS-
associated KS is a much more aggressive cancer than classic KS; lesions are widespread and 
often form on the lining of internal organs. Primary infection most likely occurs at an early 
age from contact via saliva and latency is established and maintained primarily in peripheral 
B lymphocytes (Blackbourn et al., 2000; Martro et al., 2004). Latency of KSHV will be 
discussed further in section 1.3.3.  
MHV-68 (murid herpesvirus 4, MHV-4) is a member of the Rhadinovirus genus and is a useful 
model for the study of gammaherpesvirus infection in vivo (Simas & Efstathiou, 1998; Sunil-
Chandra et al., 1992). As MHV-68 was originally isolated from the bank vole (Cletrinomys 
glarioulus) in Slovakia, the in vivo model of MHV-68 does not represent a natural infection 
(Blaskovic et al., 1980). Transmission of MHV-68 occurs through the intranasal route and 
lytic infection takes place in the alveolar epithelial cells in the lung. Following this, virus 
dissemination occurs and latent infection of B lymphocytes takes place. Splenomegaly is a 
hallmark of latent infection as infected B lymphocytes reside in the spleen (Nash et al., 2001). 
The splenomegaly resolves over the course of a few weeks and long term latent infection is 
maintained. Although the spleen is the major reservoir for latent MHV-68, the virus can be 
found latently infecting other tissues including the lung (Flaño et al., 2003).  
Saimiriine herpesvirus 2, (herpesvirus saimiri, HVS) is the prototypic Rhadinovirus. The 
natural host of HVS is the squirrel monkey (Saimiri sciureus). They become infected early in 
life through contact with saliva of other infected squirrel monkeys. HVS does not cause 
apparent disease in its natural host but is capable of causing lymphomas, particularly induction 
of T cell lymphoma, in other monkey species following experimental infection (Fickenscher 
& Fleckenstein, 2001). The immortalisation of human T lymphocytes in cell culture has been 
made possible because certain strains of HVS (e.g. C488) have the ability to transform human 
T lymphocytes without the need for re-stimulation by an antigen or mitogen (Fleckenstein & 
Ensser, 2001).  
Viruses in the genus Macavirus include ovine herpesvirus 2 (OvHV-2) and alcelaphine 
herpesvirus-1 (AlHV-1) and have been shown to cause MCF in susceptible species (Russell et 
al., 2009). These viruses will be discussed further in section 1.5. 
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1.3 Herpesvirus Lifecycle 
Herpesviruses have two distinct stages in their host: the lytic stage and the latent stage. The 
lytic stage involves expression of the majority of virus-encoded ORFs followed by production 
and subsequent release of infectious virus particles. This is in contrast to the latent stage where 
gene expression is highly restricted and the viral genome persists in the infected cell as an 
episome. No infectious virus is produced during latency. It could be said that a third stage of 
the herpesvirus lifecycle exists which is reactivation from latency. Latent virus is able to 
reactivate following a number of stimuli such as immunosuppression or cellular stress. Full 
viral replication resumes and infectious virus is produced and released.  
1.3.1 Attachment and Entry 
The first stage in the herpesvirus lifecycle is attachment and entry. Attachment and entry (or 
fusion) are two different processes in herpesviruses often utilising different viral proteins and 
host receptors. Given that herpesviruses undergo lytic replication and establish and maintain 
latency in different cell types it is not surprising that the mechanism of attachment and entry 
is very complicated for herpesviruses. They code for a number of different glycoproteins that 
act as mediators of attachment and entry and can also utilise a number of different cellular 
receptors. Endocytosis or cell fusion are the most common methods of herpesvirus entry into 
a host cell (Shukla & Spear, 2001).  
In EBV eight glycoproteins have been identified that play a role in virus entry of either B 
lymphocytes or epithelial cells (Hutt-Fletcher, 2007). Attachment of EBV in B lymphocytes 
involves the interaction of the EBV envelope protein gp350/220 and the cellular complement 
receptor type 2 (CR2) (Fingeroth et al., 1984). Fusion of EBV with a B cell is mediated by 
endocytosis and requires the viral proteins gHgL, gB and gp42. gHgL and gB are conserved 
across herpesviruses and make up the core fusion machinery. gp42 is only conserved across 
the genus Lymphocryptovirus and together with gHgL acts as the trigger for fusion in B cells 
(Hutt-Fletcher, 2007; Rivailler et al., 2002). In epithelial cells it is not known whether CR2 is 
expressed in vivo however there is low level expression of CR2 in some cultured cells. In the 
absence of CR2, gHgL can act as a ligand for attachment to an unknown cellular receptor 
(Molesworth et al., 2000). Another candidate for attachment of EBV is the virus membrane 
protein BMRF2 which has been shown to interact with a number of integrins (Tugizov et al., 
2003; Xiao et al., 2007). Fusion of EBV with epithelial cells does not appear to require 
endocytosis (Miller & Hutt-Fletcher, 1992). In contrast to fusion with B cells, gp42 is 
dispensable and its presence is in fact inhibitory (Wang et al., 1998). gB is required for fusion 
with epithelial cells in higher amounts than for B cell penetration suggesting that gB is not 
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required for endocytosis but plays a large role in fusion (Neuhierl et al., 2002). It also possible 
that gp350/220 can impede attachment and entry of EBV with epithelial cells; antibodies to 
gp350/220 which are capable of blocking B cell attachment enhance epithelial cell infection 
(Turk et al., 2006). 
KSHV encodes a number of viral glycoproteins, some of which are conserved across 
herpesviruses (gB, gH, gL, gM and gN) and some of which are unique (ORF4, gpK8.1A, 
gpK8.1B, K1, K14 and K15). The attachment of KSHV is mediated through interactions with 
the widely expressed cell surface proteoglycan heparan sulfate (HS). Several KSHV-encoded 
glycoproteins are known to interact with HS including gB, gpK8.1A and gH (Birkmann et al., 
2001; Hahn et al., 2009; Wang et al., 2003). As in EBV, integrins have also been implicated 
as entry receptors for KSHV, at least in adherent cells in vitro (Akula et al., 2002). It is unlikely 
that the interaction of KSHV with integrins is sufficient to trigger fusion and that a more 
complex interplay of virus-host interactions is required (Veettil et al., 2008). One of the 
cellular receptors identified for cellular fusion is the cystine transporter xCT. As xCT has not 
been detected in B cells it is most likely that this interaction plays a role in KSHV entry of 
cells supporting lytic infection such as endothelial cells (Kaleeba & Berger, 2006). Dendritic 
cell specific intracellular adhesion molecule-3 (ICAM-3) grabbing non-integrin (DC-SIGN) is 
a C-type lectin usually expressed on dendritic cells (DCs) but can also be expressed on 
macrophages and B lymphocytes. DC-SIGN has been shown to be a mediator of endocytosis 
for KSHV on DCs, macrophages and B lymphocytes (Rappocciolo et al., 2008). A third entry 
receptor, ephrin receptor A2 (EphA2), has been identified for KSHV. gHgL binds to EphA2 
and triggers EphA2 phosphorylation and endocytosis and therefore internalisation of the virus 
in epithelial and endothelial cells in vitro (Hahn et al., 2012).  
1.3.2 Lytic Replication 
Herpesvirus gene expression occurs in a highly regulated temporal cascade. In HSV-1 
infection, immediate early (IE) genes (also known as alpha or α genes) are most highly 
expressed 3 to 4 hrs post infection. IE gene expression is followed by early (E) gene expression 
(also known as beta or β genes), which are most highly expressed 5 to 7 hrs post infection. 
Lastly, late (L) genes (also known as gamma or γ genes) are most highly expressed around 12 
hrs post infection (Honess & Roizman, 1974). 
In EBV two transactivator proteins control the lytic replication programme; BZLF1 (also 
known as Zta) and BRLF1 (also known as replication and transcription activator, RTA). 
BZLF1 and BRLF1 have non-redundant roles and co-operation of these two transactivators is 
required for virus production (Feederle et al., 2000). The homologues of BZLF1 and BRLF1 
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in KSHV are K8 (K-bZIP) and ORF50 respectively. Expression of ORF50 alone, but not K8 
alone, is sufficient to trigger lytic replication and is therefore the major transactivator in KSHV 
(Wang et al., 2004b). The role of K8 is less well defined than that of ORF50 but is thought to 
co-regulate the function and modulate the transcriptional activity of ORF50 (Izumiya et al., 
2003). Another IE gene expressed is the mRNA transport and accumulation protein (Mta). In 
EBV this is also designated BMLF1 and ORF57 in KSHV. The role of ORF57 in KSHV 
infection is well studied. It is essential for virus production and plays role in accumulation, 
stabilisation and export of viral mRNAs (Boyne et al., 2010). BMLF1 is thought to play a 
similar role in EBV infection as ORF57 does in KSHV infection (Semmes et al., 1998). 
The products of the IE genes initiate transcription of the E genes. E genes are primarily 
involved in DNA replication. These include the DNA polymerase (EBV BALF-5, KSHV 
ORF9), single stranded DNA binding protein (EBV BALF-2, KSHV ORF6) and viral primase 
(EBV BSLF1, KSHV ORF56). Other E gene products are involved in processes such as 
nucleotide metabolism. These include thymidine kinase (EBV BXLF1, KSHV ORF21) and 
ribonucleotide reductase (EBV BORF2 and BORF1 KSHV ORF61 and ORF60) (Jenner et al., 
2001). Herpesvirus DNA replication is dependent upon sites that function as lytic origins of 
replication (oriLyt). The EBV genome has one oriLyt whereas the KSHV genome has two 
(AuCoin et al., 2002; Hammerschmidt & Sugden, 1988). It is proposed that herpesvirus DNA 
replication initiates through a theta mechanism in a bidirectional manner from the origin(s) of 
replication. The predominant mode of herpesvirus DNA replication is rolling circle 
replication; the switch between theta replication and rolling circle replication is undefined. 
Rolling circle replication results in the productions of long head-to-tail concatemers of viral 
DNA (Boehmer & Nimonkar, 2003).  
Finally, late genes are transcribed which code for the proteins necessary for assembly and 
egress of the virus. A complex of proteins are required for the assembly of the virus capsid. In 
EBV these proteins are BcLF1, BORF1, BDLF1, BFRF3, BdRF1 and BVRF2. BdRF1 acts as 
a scaffold for the other proteins (except for BVRF2) for a procapsid structure to form (Henson 
et al., 2009).  Concatemers of DNA are cleaved and packaged into the newly formed capsids. 
This process is tightly coupled; cleavage occurs once one virus genome has filled one capsid 
(Boehmer & Lehman, 1997). The function of BVRF2 is to cleave the BdRF1 scaffold once 
the viral DNA has been packaged to form a mature capsid structure (Henson et al., 2009). 
Following packaging of viral DNA into capsids, nuclear egress occurs. The first step in this 
process is envelopment of the capsid in the inner nuclear membrane through budding into the 
perinuclear space (Johnson & Baines, 2011). Fusion with the outer nuclear membrane results 
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in de-envelopment of the capsid. At this point the tegument surrounds the capsid and a second 
envelope is acquired by budding through the trans-Golgi network. This results in 
transportation of virus particles to the plasma membrane for release by exocytosis 
(Mettenleiter, 2002).  
1.3.3 Latency 
During latency the viral genome circularises and is present as episomes within infected cells. 
No replication of the viral genome occurs and gene expression is highly restricted. The level 
of gene expression varies between herpesviruses. In this section, HSV-1 latency, as well as 
EBV and KSHV latency, will also be discussed. 
Gene expression during HSV-1 latency is restricted to the latency associated transcripts 
(LATs) (Rock et al., 1987; Stevens et al., 1987; Wagner & Bloom, 1997). The LAT region 
lies antisense to ICP0, a major transactivator of HSV-1 gene expression (Kent et al., 2003). 
As such, the LATs are thought to repress ICP0 function and regulate latency/reactivation 
(Jones, 2013). No protein is thought to be produced by the LATs and instead a number of small 
non-coding RNAs are produced. Eight miRNAs have been identified that map to, or near to, 
the LATs (Umbach et al., 2009). It has been shown that miRNA-H2 encoded by HSV-1 
specifically targets ICP0 expression promoting latency and increasing neurovirulence (Jiang 
et al., 2015; Pan et al., 2014). The function of herpesvirus-encoded miRNAs is discussed 
further in section 1.7. The LATs have anti-apoptotic effects and immune evasion properties. 
Viruses with deletions in the LATs have been shown to increase the rate of apoptosis in 
infected cells in vivo (Perng et al., 2000). There is also evidence that LAT-deletion viruses 
show greater lytic gene expression implying that LATs down-regulate virus gene expression 
contributing to neurovirulence and survival (Garber et al., 1997). This function also 
contributes to the immune evasion properties of LATs. Activation of the immune system could 
lead to a decrease in the number of latently infected cells (Chen et al., 2000). 
The latent state of KSHV is thought to be critical in the formation of tumours. During KSHV 
latency, at least six proteins are known to be expressed. These are the latency associated 
nuclear antigen (LANA, ORF73), v-cyclin (ORF72), v-FLIP (K13, ORF71) and the Kaposin 
transcripts A, B and C (K12) (Ganem, 2006). LANA is considered to play a major factor in 
the maintenance of latency. One of the main functions of LANA is to bind to the terminal 
repeat region of the viral genome and associate with nucleosomal proteins in order to tether 
the viral genome to the host genome thus maintaining viral episomes in daughter cells during 
cell division (Uppal et al., 2014). LANA is, however, a multifunctional protein capable of the 
perturbation of many cellular pathways contributing to oncogenesis. Functions include 
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inhibiting the activity of tumour suppressors such as p53 and retinoblastoma (Rb) and 
promoting cell cycle progression (Wen & Damania, 2010). Two of the proteins listed above, 
v-cyclin and v-FLIP are homologues of cellular genes. v-cyclin is a homologue of cyclin D, a 
regulator of cell cycle progression. v-cyclin binds to, and activates, cyclin-dependent kinase 
6, promoting cells to enter the S-phase of the cell cycle (Ganem, 2006). v-FLIP is a FLICE 
(FADD [Fas-associated death domain protein]-like interleukin-1 beta-converting enzyme) 
inhibitory protein. v-FLIP has anti-apoptostic functions, and is capable of blocking Fas-
mediated apoptosis through abrogation of the interaction between FADD and caspase 8 
(CASP8) (Wen & Damania, 2010). Kaposin A is encoded by ORF K12 and Kaposin B and C 
are expressed through differential initiation of translation; the start sites of translation of 
Kaposin B and C are upstream of Kaposin A (Ganem, 2006). Kaposin A has been shown to 
have oncogenic potential through interaction with cytohesin-1 and subsequent activation of 
the ERK (extracellular signal-regulated kinases) MAPK (mitogen activated protein kinase) 
signalling pathway (Kliche et al., 2001). Kaposin B is known to activate the MAPK kinase 2 
(MK2), which is usually a target of p38 phosphorylation. This results in the blocking of 
cytokine mRNA decay and enhancement of release of proinflammatory cytokines 
(McCormick & Ganem, 2006). A number of KSHV-encoded miRNAs are expressed during 
latency (Ramalingam et al., 2012). 
Like KSHV, latency in EBV is associated with tumorigenesis. There are three different 
programmes of latency in EBV infection, termed latency I, II and III which are defined by the 
viral transcripts present in the infected cell (Rowe et al., 1992). The different states of latency 
are also associated with different populations of B cells and different cancers. Latency I is 
associated with memory B lymphocytes and Burkitt’s lymphoma. Latency II is associated with 
induction of B lymphocyte differentiation and Hodgkin’s lymphoma and NPC. Latency III is 
associated with activation of naïve B lymphocytes and post-transplantation 
lymphoproliferative diseases (Kang & Kieff, 2015; Odumade et al., 2011). Two classes of 
protein – EBV nuclear antigen (EBNA) and latent membrane protein (LMP) are expressed 
along with EBV-encoded small RNAs (EBERs) and BART RNAs in latency. EBNA-1, LMP-
2A/B, EBER1/2 RNA and BART RNA are detected in latency I. In latency II, the genes 
expressed include those in latency I and LMP-1. In latency III most of the latent genes are 
expressed; those expressed in latency I and II and five more EBNA proteins: EBNA-leader 
protein (EBNA-LP), EBNA-2, EBNA-3A, EBNA-EB and EBNA-3C (Kang & Kieff, 2015). 
As EBNA-1 is the homologue of LANA its functions will not be discussed further. The other 
EBNA proteins play roles in B lymphocyte transformation (EBNA-2, EBNA-3A and EBNA-
3B) and perturbation of Notch signalling (Notch signalling is discussed further in section 4.3.1 
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and chapter 6), and have been shown to interact with p53 and Rb (EBNA-LP) and induce the 
expression of cellular CD40 (EBNA-3B) (Young & Murray, 2003). LMP-1 is often described 
as an oncogene in the literature and contributes to oncogenesis as a constitutively active CD40-
like receptor inducing the expression of NF-ĸB (Pratt et al., 2012). LMP-2A is thought to play 
a role in the maintenance of latency. It is thought that activation of the B cell receptor (BCR) 
is thought to disrupt latency; LMP-2A is capable of inhibiting BCR signalling and therefore 
preventing exit from latency (Masucci, 2004). LMP-2B, an amino-terminally truncated 
version of LMP-2A, has been shown to modulate LMP-2A activity through binding to and 
preventing phosphorylation of LMP-2A (Rovedo & Longnecker, 2007). The EBERs are 
proposed to play significant roles in EBV pathogenesis. They promote resistance to apoptosis 
by inhibiting protein kinase R (PKR) activation. EBER2 induces interleukin 6 (IL-6) 
expression contributing to B cell transformation (Iwakiri & Takada, 2010). It is now known 
that the BART RNAs produce a number of miRNAs (Pfeffer et al., 2004). 
1.3.4 Reactivation 
Reactivation from latency is a highly controlled process. The mechanisms of reactivation for 
many herpesviruses have been elucidated however only some of the triggers have been 
identified. The outcome of reactivation is specific to different herpesviruses. Reactivation of 
alphaherpesviruses usually results in clinical symptoms such as cold sores and herpes zoster 
for HSV-1 and VZV respectively (Grinde, 2013). The reactivation of CMV is often controlled 
by the immune system in immunocompetent individuals however in the immunocompromised 
serious disease is often the outcome (Sinclair & Sissons, 2006). For the cancer-causing 
gammaherpesviruses EBV and KSHV, oncogenesis is usually associated with latency, 
however recent reports demonstrate an important role for subsets of infected cells undergoing 
lytic replication in the development of tumours (Cai et al., 2010; Murata & Tsurumi, 2014).  
Reactivation of KSHV from latency requires expression of the major transactivator ORF50. 
The triggers for reactivation are largely unknown however it has been shown that hypoxia may 
trigger the expression of ORF50. A number of chemical agents are also capable of reactivating 
the virus in vitro including sodium butyrate (NaB) and the protein kinase c inhibitor TPA 
(tetradecanoylphorbol acetate) (Cai et al., 2010). Chromatin remodelling and epigenetic 
control of the KSHV genome have been shown to be critical in both the maintenance of and 
reactivation from latency. During latency, the KSHV genome undergoes chromatinisation and 
subsequent epigenetic modification to control gene expression (Lieberman, 2013). Tail 
modifications of histones play roles in regulation of chromatin structure and chromatin 
condensation, important factors in the regulation of transcription. The action of histone 
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acetyltransferases (HATs) leads to the loosening of chromatin increasing transcriptional 
availability; histone deacteylases (HDACs) have the opposite effect of tightening the 
chromatin structure leading to transcriptional inactivity (Niedermeier et al., 2006). 
Furthermore, HDAC inhibitors have been shown to be able to reactivate KSHV from latency 
through remodelling of the promoter region of ORF50, which has been shown to be highly 
responsive to HDAC inhibitors (Lu et al., 2003). DNA methylation (CpG dinucleotide 
methylation) is a method of epigenetic control of latency and reactivation. The ORF50 
promoter has been shown to be heavily methylated during latency and demethylation of this 
region would be required for transcription of ORF50 and therefore subsequent reactivation 
(Chen et al., 2001). Chromatin remodelling and epigenetic modification is not the whole story 
in KSHV reactivation; LANA, the major protein involved in the promotion of latency is also 
capable of repressing lytic gene expression (Lu et al., 2006). It has been shown that 
inactivation of LANA through phosphorylation by cellular kinases Pim-1 and Pim-3 
contributes to virus reactivation in vitro (Cheng et al., 2009).  
The triggers for reactivation of EBV also remain largely unknown, although it has been 
hypothesised that hypoxia can also lead to reactivation of EBV (Jiang et al., 2006). 
Reactivation of EBV in vitro has been performed using a number of chemicals including NaB 
and TPA. Transforming growth factor beta (TGF-β) has also been shown to trigger EBV 
reactivation (Fahmi et al., 2000). In contrast to KSHV reactivation where ORF50 is the major 
gene involved in reactivation, the EBV homologue BRLF1 is not thought to be important for 
EBV reactivation. Instead, BZLF1 is the major reactivation protein in EBV (Murata, 2014). 
Ectopic BZLF1 expression is sufficient to trigger EBV reactivation and subsequent lytic gene 
expression through binding of the oriLyt and acting as an adapter protein to recruit the viral 
replication machinery (Murata & Tsurumi, 2014; Schepers et al., 1996). A cellular 
transcription factor, zinc finger E-box-binding homeobox 1 (ZEB1), can bind to the proximal 
promoter of BZLF1 and repress the transcription of BZLF1. A 2 base pair mutation in the 
silencer element of the promoter region was sufficient to reactivate EBV resulting in 
production of IE, E and L genes in vitro, indicating that ZEB1 plays a critical role in regulating 
the latent-lytic switch of EBV (Yu et al., 2007). Activation of the cellular pathways 
Sma/mothers against decapentaplegic homologue (SMAD) and MAPK have been shown to 
be essential for EBV reactivation (Fahmi et al., 2000; Liang et al., 2002a). Both pathways are 
induced by expression of TGF-β possibly explaining why TGF-β is a trigger for EBV 
reactivation. Furthermore, BZLF1 also induces the expression of TGF-β creating a positive 
feedback loop initiating reactivation (Murata & Tsurumi, 2014). As in KSHV reactivation, 
EBV latency maintenance and reactivation requires chromatin remodelling and epigenetic 
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modifications (Lieberman, 2013). It has been demonstrated that high levels of histone 
acetylation is correlated with reactivation of EBV and that epigenetic silencing of the EBV 
genome occurs during latency (Countryman et al., 2008; Ramasubramanyan et al., 2012).  
1.4 Malignant Catarrhal Fever 
MCF is a frequently fatal lymphoproliferative disease that affects cattle and other ungulate 
species including deer, bison and pigs (Russell et al., 2009). It is caused by viruses in the genus 
Macavirus, also known as the MCF virus (MCFV) group. Ten viruses have been identified so 
far that belong to the Macavirus genus (see Table 1.1 for a summary). Of these viruses, six 
(AlHV-1, AlHV-2, OvHV-2, CpHV-2, MCFV-WTD and Ibex-MCFV) have been associated 
with MCF in susceptible species. There have been no reported cases of MCF associated with 
the other four viruses, however it is possible that they are capable of causing disease in 
susceptible species (Li et al., 2014). AlHV-1 and OvHV-2 are the main causative agents of 
MCF and will be discussed further in section 1.5.  
1.4.1 Occurrence and Significance 
MCF has a long history in veterinary medicine, South African farmers and Maasai pastoralists 
referred to the disease as snotziekte (mucous sickness). The association of MCF with 
wildebeest was made in the early 1920s (Mettam, 1924) . The association of MCF with sheep 
was made around 1930 when a number of cattle were able to be infected experimentally by 
being kept in close contact with sheep (Mushi & Rurangirwa, 1981). Wildebeest-associated 
MCF (WA-MCF) is a major problem in Africa and in zoological collections where susceptible 
species are housed closely with wildebeest (Heuschele, 1988; Meteyer et al., 1989). Sheep-
associated MCF (SA-MCF) is a problem worldwide as well as in zoological collections. 
Susceptibility to MCF varies widely between different species, SA-MCF can be a significant 
problem in highly susceptible species such as Bali cattle, farmed deer, Père David’s deer and 
bison (Li et al., 2014; Russell et al., 2009). MCF has been documented in over thirty species 
including moose, reindeer, bongo (African forest antelope) and anoa (midget buffalo) (das 
Neves et al., 2013; Gasper et al., 2012; Li et al., 2011b; Vikoren et al., 2006). 
The economic impact of MCF is unknown as there is no enforced reporting system for the 
disease. MCF is generally a sporadic disease with isolated cases although severe outbreaks can 
occur. In North America, outbreaks of MCF have forced bison producers out of business, with 
one case reporting loss of over eight hundred bison and financial losses of $1 million (Li et 
al., 2006; O'Toole et al., 2002).  
  
Chapter 1  Introduction 
18 
 
Virus Natural Host Susceptible Hosts 
Alcelaphine herpesvirus 1 Wildebeest 
Cattle 
Deer 
Alcelaphine herpesvirus 2 
Hartebeest Barbary red deer 
Topi Bison 
Hippotragine herpesvirus 1  Roan antelope Not reported 
Oryx-MCFV  Oryx Not reported 






Caprine herpesvirus 2  Goat 
Sika deer 
White-tailed deer 
MCFV-white tailed deer  Goat 
White-tailed deer 
Red brocket deer 
Reindeer 




Muskox-MCFV Muskox Not reported 
Aoudad-MCFV  Aoudad Not reported 
  
Table 1.1 MCF viruses and their hosts 
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1.4.2 Clinical Forms of MCF 
There are five distinct clinical forms of MCF: head and eye, peracute, alimentary, neurological 
and cutaneous. The head and eye form is the most commonly reported form of MCF. The 
clinical course of infection varies depending on the susceptibility of the infected animal to 
MCF. In cattle, the incubation period is on average between two and ten weeks, however 
periods of up to nine months have been reported (O’Toole & Li, 2014). Typical signs of the 
head and eye form include pyrexia, depression, diarrhoea, ocular and nasal discharge and 
lesions of the buccal cavity and muzzle (Russell et al., 2009). The peracute form of MCF is 
the most severe with death occurring in 24 to 72 hrs; bison are particularly affected by this 
form (O’Toole & Li, 2014). Symptoms often include depression, dysentery and diarrhoea 
(Holliman et al., 2007). Symptoms of the alimentary form of MCF include ulceration in the 
gut and bloody, profuse diarrhoea (Brenner et al., 2002). The cutaneous form is a rare form of 
MCF that presents with lesions on the base of the horns, dewclaws and the interdigital space 
(David et al., 2005). Lethargy is often seen in the neurological form of MCF, as well as neck 
rigidity, incoordination and a stiff legged gait (Brenner et al., 2002). 
1.4.3 Pathology of MCF 
Upon post mortem examination, gross findings include petechial haemorrhages on the tongue, 
buccal mucosa, gastrointestinal and respiratory tracts and urinary bladder (Figure 1.3). Raised 
pale foci are often seen on the kidneys and there is general lymph node enlargement (Russell 
et al., 2009). Lymphoid accumulation is the main histological finding in a wide range of 
tissues. Lymphocytes and lymphoblasts are the main constituents of infiltration with fewer 
macrophages and monocytes present, however in severe lesions more macrophages than 
lymphocytes are present (Liggitt & DeMartini, 1980). Lymphoid accumulation in tissues is 
associated with degeneration and necrosis in many tissues, especially the epithelium. In 
general, virus particles are not found in lesions and it has been proposed that formation of 
lesions is due to lymphocyte dysregulation rather than direct antiviral responses, however one 
study has found evidence of OvHV-2 infected T lymphocytes in lesions (Li et al., 2014; Simon 














Figure 1.3 Clinical symptoms of MCF 
a: An infected cow with a severe head and eye form of MCF. Corneal opacity and nasal 
discharge can be seen (picture courtesy of Dr Bob Dalziel). b – e:  lesions on the reticulum, 
bladder, buccal papillae and kidney respectively. H indicates areas of haemorrhaging 
(image adapted from Russell et al. 2009). 
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1.5 Ovine Herpesvirus 2 and Alcelaphine Herpesvirus 1 
OvHV-2 and AlHV-1 are the major causative agents of MCF and will be discussed in further 
detail in the following sections. In the past, the question has been raised whether OvHV-2 and 
AlHV-1 are in fact the same virus. Development of advanced molecular tools has revealed 
differences not only at the genome level of these viruses but in their routes of transmission, 
shedding patterns and pathogenesis leading to the conclusion that OvHV-2 and AlHV-1 are 
distinct viruses. Unlike AlHV-1, OvHV-2 cannot be propagated in vitro and as such studies 
into OvHV-2 replication and pathogenesis have been highly limited. An experimental 
infection system of OvHV-2 has been developed using nasal secretions from naturally infected 
sheep which contain high levels of OvHV-2 (Taus et al., 2006). This model has been used to 
evaluate OvHV-2 infection in rabbits, bison and sheep (Cunha et al., 2012; Cunha et al., 2013; 
Li et al., 2008a; Reid et al., 1986).  
1.5.1 Genome structure 
The genomes of both OvHV-2 and AlHV-1 have been fully sequenced (Ensser et al., 1997; 
Hart et al., 2007). The unique regions of OvHV-2 and AlHV-1 are both approximately 130 
kbp in length. Sequence similarity between OvHV-2 and AlHV-1 ranges from 22% to 83% 
across the genome. OvHV-2 has 73 predicted ORFs, 62 of which have homology in other γ-
herpesviruses. A number of ORFs are unique to OvHV-2 and AlHV-1, which are summarised 
in Table 1.2. Three ORFs are unique to OvHV-2: Ov2.5 (interleukin-10 homologue), Ov3.5 
(unknown function) and Ov8.5 (unknown function). AlHV-1 encodes two unique ORFs A1 
and A4 (Hart et al., 2007). Another major difference between the OvHV-2 and AlHV-1 
genomes is that OvHV-2 codes for ORF49 whereas AlHV-1 does not. ORF49 has homologues 
in KSHV EBV, and MHV-68 and is thought to co-operate with ORF50 to induce lytic 
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OvHV-2 ORF AlHV-1 homologue Predicted Function 
n/a A1 Unknown function 
Ov2 A2 Transcription Factor 
Ov2.5 n/a IL-10 homologue 
Ov3 A3 
Homologous to proteins of the semaphorin 
family 
Ov3.5 n/a Unknown function 
n/a A4 Unknown function 
Ov4.5 A4.5 B cell lymphoma 2 (Bcl-2) homologue 
Ov5 A5 G protein-coupled receptor 
Ov6 A6 Transcriptional activator (putative) 
Ov7 A7 Glycoprotein 
Ov8 A8 Glycoprotein 
Ov8.5 n/a Unknown function 
Ov9 A9 Bcl-2 homologue 
Ov9.5 A9.5 Secreted glycoprotein 
Ov10 A10 Unknown 
  
Table 1.2 Unique ORFs shared by OvHV-2 and AlHV-1  
Figure 1.4 A comparison of gammaherpesvirus genomes 
Representative genetic maps for seven different gammaherpesviruses. For details of 
unique genes to alcelaphine herpesvirus 1 (AHV-1) and OvHV-2 see Table 1.2. (Adapted 
from http://microbewiki.kenyon.edu/images/d/df/Gammaherpesvirus_genomes.jpg.) 




Transmission of both OvHV-2 and AlHV-1 is thought to occur primarily through inhalation 
of virus particles, however contact with secretions containing virus particles and contaminated 
foodstuff and/or water are also possible routes of transmission (Li et al., 2014). Transmission 
of OvHV-2 from sheep to bison over a distance of 5.1 km has been reported in the literature, 
emphasising the need for separation of natural and susceptible hosts (Li et al., 2008b). It is 
unclear whether other factors, such as birds or insects, play a role in this long distance 
transmission. Both horizontal and vertical transmission have been reported in AlHV-1. 
Infected wildebeest calves shed virus through nasal secretions. Neutralising antibodies 
develop around 3 months of age resulting in a decrease in virus shedding. This leads to a 
seasonal pattern of WA-MCF that occurs during wildebeest calving (Mushi, 1981).  The 
pattern of infection of OvHV-2 differs from AlHV-1 in a number of ways. Firstly, vertical 
transmission of OvHV-2 is thought to be extremely rare or to not occur at all. Secondly, lambs 
are generally not infected with OvHV-2 until after two months of age (Li et al., 1998). OvHV-
2 can be detected in nasal secretions continuously, however the highest levels of OvHV-2 
DNA are found between the ages of six and nine months suggesting that this is the peak time 
of virus shedding (Li et al., 2001). Thirdly, SA-MCF occurs year-round although a moderate 
increase in SA-MCF does occur during lambing season. The increase in SA-MCF is not 
associated with lambing as new-born lambs are not infected with OvHV-2 and there does not 
appear to be a correlation between parturition and shedding of virus (Harris et al., 1978; 
Muller-Doblies et al., 2001). A short but intense pattern of shedding is observed for OvHV-2 
infected sheep most likely reflecting a single cycle of virus replication (Li et al., 2004). 
Transmission of AlHV-1 and OvHV-2 does not occur between susceptible species.    
1.5.3 OvHV-2 Replication 
There are three stages of OvHV-2 replication in sheep: entry, maintenance and exit (Figure 
1.4). Primary infection occurs in the lung, specifically alveolar epithelial cells (Taus et al., 
2010). ORF25, a late transcript encoding for the major capsid protein, can be detected as early 
as 1 day post infection (DPI) in lung tissue with the peak of virus DNA and transcripts 
occurring 7 DPI, and dropping by 9 DPI (Li et al., 2008a). It is thought that this initial 
replication of OvHV-2 in the lung is required for a switch in cell tropism enabling 
dissemination and latency; a mechanism similar to that seen in EBV where the ratio of 
glycoproteins associated with infection of epithelial cells and B cells is altered to allow for 
more efficient infection of B cells following the initial replication in epithelial cells (Borza & 
Hutt-Fletcher, 2002). Primary OvHV-2 infection in sheep stimulates a rapid and effective 
immune response which is thought to clear cells infected with lytic OvHV-2 promoting virus 
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dissemination in peripheral blood lymphocytes (O’Toole & Li, 2014). During virus 
dissemination, OvHV-2 DNA is detectable in a wide range of tissues, however ORF25 
transcripts are not detectable indicating that OvHV-2 is in a predominantly latent state (Li et 
al., 2008a). A study using a natural method of OvHV-2 infection of previously uninfected 
sheep revealed that the primary cells infected during latency are CD2+ lymphocytes. During 
earlier stages of infection these cells were also CD4+ positive, most likely reflecting a T helper 
cell population. At later stages of infection, there was a shift towards a CD8+ positive 
phenotype probably representing a cytotoxic T cell population. OvHV-2 DNA was also 
detected sporadically in monocytes and other immune cells including B cells and γδ T cells 
(Meier-Trummer et al., 2010). The trigger for reactivation of latent OvHV-2 is unknown. In 
sheep actively shedding OvHV-2, ORF25 transcripts can be detected in epithelial cells found 
in nasal secretions and in turbinate tissues (Cunha et al., 2008; Taus et al., 2010). The unique 
shedding pattern of OvHV-2 described in section 1.5.2 is in line with another switch in cell 
tropism which does not allow for reinfection of turbinate epithelial cells. 
As there is no transmission between susceptible species there are only two stages of OvHV-2 
replication: entry and maintenance (Figure 1.4). Initial infection and replication of OvHV-2 in 
susceptible species also occurs in the lung. In contrast to infection in sheep, the immune 
response observed is much smaller with only a subtle increase in immune response transcripts 
observed in experimentally infected bison compared to sheep (Cunha et al., 2012). Virus 
dissemination occurs following initial replication, however this is associated with a lytic gene 
expression pattern with detection of ORF25 and ORF50 transcripts in the majority of tissues 
in experimentally infected rabbits (Cunha et al., 2013). This has been observed by others who 
have detected ORF43 and ORF63 (both code for structural proteins) in epithelial cells and M 
cells of the appendix of experimentally infected rabbits (Meier-Trummer et al., 2009b). The 
lytic pattern of gene expression in susceptible species indicates a role for virus replication in 
the development of disease.   




Figure 1.5 OvHV-2 Lifecycles in Sheep and Bison 
A cartoon representation of the lifecycle of OvHV-2 in the natural host sheep and 
susceptible species bison. Three stages (entry, maintenance and exit) exist in sheep 
however only two of these (entry and maintenance) are seen in susceptible species. Entry 
in both species is fairly similar however there are large differences in the immune response 
observed between sheep and bison. Maintenance occurs in the same tissues in both natural 
and susceptible species however MCF lesions only develop in susceptible species. There 
is no lytic replication of OvHV-2 observed during maintenance in sheep. Reactivation and 
subsequent shedding of the virus occurs in sheep. This is not seen in susceptible species 
which are dead end hosts. Details of the lifecycle of OvHV-2 are found in section 1.5.3. 
(Republished with permission from Li et al. 2014)  
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1.5.4 Proposed Model of Pathogenesis 
The pathology of MCF has been well documented, however what contributes to the 
development of lesions is not fully understood. Many studies have demonstrated that CD8+ T 
cells are the predominant cell type associated with lesions leading to the hypothesis that these 
are the primary cells responsible for the pathology observed in MCF (Dewals & 
Vanderplasschen, 2011; Ellis et al., 1992; Nakajima et al., 1992; Simon et al., 2003). Lesions 
from bison experimentally-infected with OvHV-2 were found to contain CD8+, perforin+ γδ T 
cells (cytotoxic cells of the innate immune system), regulatory CD4+, perforin- αβ T cells and 
B cells indicating that pathogenesis of MCF is linked to dysregulation of the immune system 
(Nelson et al., 2010). OvHV-2 infected cells have a large granular lymphocyte (LGL) 
phenotype and exhibit non MHC-restricted killing activity and vary in their expression of CD2, 
CD4 and CD8 (Schock et al., 1998; Swa et al., 2001). LGL cell lines derived from MCF-
affected animals, including the cell line BJ1035, were found to be CD2+, CD3+ and CD6+ 
(general T cell markers) with a proportion of cells positive for the scavenger receptor 
workshop cluster 1 (WC1). They were CD4-, CD8- and were negative for γδ T cell, B cell and 
natural killer cell markers (Dr Inga Dry, personal communication). BJ1035 cells are thought 
to constitutively express tumour necrosis factor α (TNFα), interferon γ (IFNγ), IL-10 and IL-
4 however no expression of IL-1β or IL-2 has been detected consistent with the hypothesis 
that OvHV-2 infected cells have an unregulated cytotoxic cell phenotype (Schock et al., 1998; 
Swa et al., 2001).  
IL-2 is known as a major T cell growth factor and it is required for the in vitro growth of T 
cell lines, including the BJ1035 cell line mentioned previously (Kundig et al., 1993). However, 
some studies have challenged this view as mice lacking IL-2 or receptor genes are not 
immunocompromised and instead develop an autoimmune disease (Almeida et al., 2002; 
Kramer et al., 1995). A number of hypotheses for this contradiction have been postulated; the 
major two of which are the role of IL-2 in promotion of activation-induced cell death (AICD) 
and the requirement of IL-2 for the establishment of stable and sizeable populations of 
regulatory T cells (Almeida et al., 2002; Lenardo, 1991). Although IL-2 is able to promote 
AICD in vitro it has been shown that this may not be the major mechanism in vivo and that the 
major role of IL-2 in vivo is to promote thymic development and peripheral expansion of 
regulatory T cells (Nelson, 2004). The clinical signs observed in MCF are consistent with the 
phenotype of IL-2 deficient mice described. Significantly lower levels of IL-2 have been 
detected in tissues of SA-MCF affected animals compared to their healthy counterparts (Cunha 
et al., 2012; Cunha et al., 2013; Meier-Trummer et al., 2009a). In cattle experimentally 
infected with OvHV-2, IL-2 transcript was far less abundant than in healthy animals and it was 
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hypothesised that down-regulation of IL-2 transcription may lead to an IL-2 deficiency and 
may be an important factor in pathogenesis of MCF (Meier-Trummer et al., 2009a). 
Although many studies have investigated the populations of immune cells associated with 
lesions, little research has been done into the role the virus plays in MCF pathogenesis. One 
study has demonstrated the presence of OvHV-2 infected CD8+ lymphocytes in lesions from 
SA-MCF affected cattle and bison (Simon et al., 2003). ORF25 protein has been found in 
fibroblasts in vascular lesions from bison with SA-MCF (Nelson et al., 2013). Moreover, the 
severity of MCF lesions positively correlates with ORF25 expression levels in tissues of SA-
MCF affected bison and rabbits (Cunha et al., 2012; Cunha et al., 2013). It is therefore likely 
that the virus has a direct role in pathogenesis, as well as indirect dysregulation of the immune 
system leading to the development of lesions. It is important to note that there have been 
reports of subclinical infection in the absence of clinical disease in both cattle and bison 
(O'Toole et al., 2002; Powers et al., 2005). This complicates matters even further, as there may 
be other extraneous factors involved in the pathogenesis of MCF including genetic 
susceptibility (Traul et al., 2007). Experimentally, it has been shown that different titres of 
OvHV-2 inoculum can result in different outcomes of infection, from a negative result through 
subclinical infection and development of MCF (Li et al., 2014) 
A number of differences in pathogenesis have been observed between OvHV-2 and AlHV-1. 
In SA-MCF affected animals, proliferation of CD8+ T cells, CD4+ T cells and B cells in 
peripheral blood has been observed whereas in WA-MCF affected animals, proliferation of 
only CD8+ T cells in peripheral blood has been observed (Dewals et al., 2008; Li et al., 2011a). 
The development of MCF in AlHV-1 infected animals is predominantly associated with latent 
infection. In rabbits experimentally infected with AlHV-1, ORF73 was readily detected in 
infected tissue (Dewals et al., 2008). Furthermore, a role for ORF73 in the pathogenesis of 
MCF has been described. A mutated AlHV-1 lacking ORF73 was produced which did not 
impair initial virus replication but abrogated pathogenesis and development of MCF in 
experimentally-infected calves (Palmeira et al., 2013). This latency-associated pathogenesis 
of WA-MCF is in contrast to SA-MCF in which tissues from experimentally-infected rabbits 
contained the lytic transcripts ORF25 and ORF50 (Li et al., 2011a). However, conflicting data 
from euthanised cattle infected with OvHV-2, suggested a latent profile of infection as only 
ORF73 could be detected in affected tissues (Meier-Trummer et al., 2009a). The differences 
observed between these two studies could be due to differences in disease stage, the sensitivity 
of the detection methods used or individual susceptibility and further research into this is 
clearly warranted. 




miRNAs are short (~22 nt) non-coding RNAs that regulate gene expression at the post 
transcriptional level (Bartel, 2004). The first miRNA was discovered simultaneously by two 
groups researching the development of Caenorhabditis elegans (C. elegans). It was shown 
that the lin-4 gene did not code for protein but produced a small RNA that was antisense to 
the 3’ UTR of the lin-14 gene resulting in repression of this gene (Lee et al., 1993; Wightman 
et al., 1993). However the field of miRNA research did not really begin until a second miRNA, 
let-7, was discovered, also in C. elegans in 2000 (Reinhart et al., 2000). The discovery of these 
two small RNAs led to the naming of miRNAs and research began to investigate whether other 
species had miRNAs and what roles they played in biology (Lee & Ambros, 2001). To date 
there are 35828 mature miRNAs in 223 species within the miRNA database miRbase 
(http://www.mirbase.org/). These species include algae, protozoa, arthropods, nematodes, 
mammals, plants and viruses (Bartel, 2004; Grundhoff & Sullivan, 2011; Lee et al., 2004b). 
miRNAs have been shown to function in nearly every biological process ranging from 
development, cell fate determination, cell proliferation and death to the immune response and 
disease development (Bhatt et al., 2011; Dong et al., 2013; Stark et al., 2003). In fact, over 
60% of the human protein-coding genes have been shown to contain at least one conserved 
miRNA binding site (Ha & Kim, 2014). 
1.6.1 miRNA biogenesis 
The biogenesis and processing of miRNAs is a complex multi-step process (Figure 1.5). The 
majority of miRNA genes are transcribed by RNA polymerase II (pol II), although some are 
transcribed by RNA polymerase III (Lee et al., 2002; Monteys et al., 2010). These primary 
transcripts are typically over 1 kb in length, have a 5’ cap and 3’ polyadenylation and are 
termed primary miRNAs (pri-miRNAs) (Cai et al., 2004; Ha & Kim, 2014). The majority of 
pri-miRNAs are located in intergenic regions of the genome or in an antisense direction to 
annotated genes, however some are located in introns and exons (Ha & Kim, 2014; Kim, 2005; 
Lee et al., 2004a). pri-miRNAs are capable of generating a single miRNA (monocistronic) or 
a  number of miRNAs (polycistronic transcript); these can be under a single promoter or 
multiple promoters for each individual miRNA (Cai et al., 2004; Lee et al., 2002; Song & 
Wang, 2008). Structurally, pri-miRNAs include an imperfect dsRNA stem loop flanked by 
single stranded RNA. One arm of the stem loop structure contains the mature miRNA 
sequence (Zeng & Cullen, 2005).  
Processing of pri-miRNAs occurs through interactions with the microprocessor complex. The 
microprocessor complex consists of the RNase III enzyme Drosha and its cofactor protein 
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microprocessor complex subunit DGCR8 (encoded by DiGeorge syndrome critical region 
gene 8) (Beezhold et al., 2010; Davis-Dusenbery & Hata, 2010; Landthaler et al., 2004). 
DGCR8 interacts with the stem loop structure of the pri-miRNA and recruits Drosha, which 
results in the cleavage of the pri-miRNA at the stem loop structure liberating a 60 – 100 
nucleotide (nt) dsRNA loop structure termed a precursor-miRNA (pre-miRNA). Important 
structural features of pre-miRNAs include a 5’ phosphate and a 2 nt overhang at the 3’ end 
(Kim et al., 2009; Zeng & Cullen, 2005; Zeng et al., 2005). The 3’ overhang feature is 
recognised by the Exportin/Ran complex (consisting of Exportin 5 and Ran-GTP co-factor) 
facilitating export of the pre-miRNA from the nucleus into the cytoplasm (Bohnsack et al., 
2004).  
Hydrolysis of Ran-GTP to Ran-GDP releases the pre-miRNA from the export complex (Wang 
et al., 2011). The pre-miRNA then interacts with the RNA induced silencing complex (RISC) 
loading complex (RLC). The RLC is comprised of the RNase III enzyme Dicer and its 
cofactors TAR RNA‑binding protein (TRBP), protein activator of PKR (PACT) and the 
argonaute-2 (Ago-2) protein (Gregory et al., 2005; Haase et al., 2005; Lee et al., 2006; 
MacRae et al., 2008). Although not absolutely necessary for pre-miRNA processing, TRBP 
and PACT play roles in stabilisation of Dicer, Ago-2 recruitment and formation of the RLC 
(Chendrimada et al., 2005; Kok et al., 2007; Lee et al., 2006).  The pre-miRNA is recognised 
by the piwi-argonaute-zwille (PAZ) and RNase IIIa and RNase IIIb domains of Dicer. 
Cleavage of the pre-miRNA stem loop structure is carried out by Dicer resulting in an 
approximately 22 nt dsRNA duplex with a 5’ phosphate and a 3’ hydroxyl group with 2 nt 
overhangs at the 3’ ends (Lingel et al., 2003; MacRae et al., 2007; Yan et al., 2003; Zhang et 
al., 2004).  
The effector complex RISC is generated through interaction of the miRNA duplex with an 
Ago protein (Gregory et al., 2005; Hutvágner & Zamore, 2002; Mourelatos et al., 2002). The 
Ago proteins are the key effector molecules of the RISC and contain PAZ, middle (MID) and 
P-element-induced whimpy testes (PIWI) domains (Maniataki et al., 2005). The PAZ domain 
recognises the 2 nt overhang at the 3’ ends and the MID domain acts to anchor the 5’ ends of 
the miRNA duplex (Jinek & Doudna, 2009; Lingel et al., 2004; Ma et al., 2004). The PIWI 
domain has a similar structure to RNase H and is thought to play a role in the cleavage of the 
target mRNA (Kim et al., 2009; Ma et al., 2005; Parker et al., 2005). There are four Ago 
proteins in mammals (Ago-1 to -4) however only Ago-2 has been found to have an 
enzymatically active PIWI domain capable of cleaving target mRNAs with perfect 
complementarity to the mature miRNA (Liu et al., 2004; Meister et al., 2004). 
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Upon loading of the miRNA duplex into the RISC, the duplex is unwound by helicases. Only 
one strand remains in the RISC and becomes the mature miRNA or guide strand. The other 
strand (or passenger strand) is released from the RISC and is either degraded or incorporated 
into other RISCs where it can act as another mature miRNA (Ghildiyal et al., 2010; Hutvágner 
& Zamore, 2002; Kim et al., 2009; Okamura et al., 2008). The thermodynamic stability of the 
strands of the duplex dictate which strand is selected as the guide strand. The strand with less 
stable base pairing at the 5’ end becomes the mature miRNA (Khvorova et al., 2003). If both 
strands are capable of acting as mature miRNAs then 5p or 3p is added to the name of the 
miRNA to denote from which strand of the duplex the miRNA originated (Griffiths-Jones et 
al., 2006).  
  





Figure 1.6 miRNA biogenesis pathway 
See section 1.6.1 for details of the miRNA biogenesis pathway. Adapted from Winter et 
al., 2009. 
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1.6.2 Target Recognition of miRNAs 
miRNA-mediated gene regulation occurs through binding of the miRNA to a target mRNA in 
a sequence specific manner. The level of complementarity between the miRNA and target 
mRNA can vary and this dictates the outcome of miRNA binding. For example, miRNAs 
encoded by plants often show perfect or near perfect complementarity to their target mRNAs 
resulting in translational repression through degradation of the target mRNA (Brodersen et al., 
2008). In animals (and viruses), it is thought that a six to eight nt sequence (termed the seed 
sequence) located at the 5’ end of the miRNA (usually nucleotides 2-8) is most important in 
target mRNA recognition (Gottwein & Cullen, 2007). Binding of the miRNA to a target 
mRNA through the seed sequence is known as canonical binding and it is this seed sequence 
which is most conserved across different species (Lewis et al., 2005; Lim et al., 2005). 
Although the majority of target recognition by miRNAs involves binding at the 5’ end, non-
canonical interactions can occur. Examples of this include bulges in the seed sequence, binding 
of only the 3’ end or centre of the miRNA and mismatched nucleotides (Helwak et al., 2013; 
Lee et al., 2009; Shin et al., 2010). Helwak et al. used a technique called Cross-linking 
Ligation and Sequencing of Hybrids (CLASH) to elucidate targets of human miRNAs and 
discovered that in fact 60% of the interactions between miRNAs and mRNAs were non-
canonical. Furthermore, 18% of interactions involved only base pairing at the 3’ end with no 
5’ base pairing involved (Helwak et al., 2013). Mismatched nucleotide base pairing, usually 
G:U pairing (instead of the canonical G:C pairing), can occur in the seed sequence of miRNAs 
and result in functional activity, however, it is thought that this does affect the level of target 
repression (Brennecke et al., 2005; Didiano & Hobert, 2006; Doench & Sharp, 2004). It was 
originally thought that the action of miRNAs was through binding to the 3’UTR of a target 
mRNA however other groups have since shown that binding in the 5’UTR and coding region 
is possible (Grey et al., 2010; Lee et al., 2009; Lytle et al., 2007; Riaz et al., 2014).  
1.6.3 Modes of Action of miRNAs 
The major two modes of action of miRNAs are translational repression and degradation of 
target mRNAs. miRNA-mediated translational repression can occur at the translation initiation 
or post-initiation stages (Chekulaeva & Filipowicz, 2009; Filipowicz et al., 2008; Huntzinger 
& Izaurralde, 2011; Hussain, 2012). It has been demonstrated that mRNAs that do not have a 
5’ cap show some resistance to miRNA-mediated translational repression indicating that 
silencing interferes with the cap recognition process or binding of the eukaryotic translation 
initiation factor 4E (eIF4E) to the cap (Humphreys et al., 2005; Mathonnet et al., 2007; Meijer 
et al., 2013; Pillai et al., 2005; Wakiyama et al., 2007). Furthermore, it has been postulated 
that Ago-2 interacts with the 5’ cap of the target mRNA preventing the binding of eIF4E and 
Chapter 1  Introduction 
33 
 
thus initiation of translation (Mathonnet et al., 2007). Many studies have demonstrated the 
presence of repressed mRNAs associated with actively translating polysomes or in polysomal 
fractions suggesting that repression of translation can occur post-initiation, either by 
degradation of the nascent polypeptide chain or by initiating premature ribosome drop off from 
the target mRNA (Maroney et al., 2006; Nottrott et al., 2006; Olsen & Ambros, 1999; Petersen 
et al., 2006).  
Translational repression can be associated with destabilisation and subsequent degradation of 
the target mRNA. This process usually requires deadenylation and/or 5’ decapping (Behm-
Ansmant et al., 2006; Eulalio et al., 2009; Humphreys et al., 2005). Degradation of the target 
mRNA is thought to occur in P-bodies (Eulalio et al., 2007; Liu et al., 2005; Parker & Sheth, 
2007). Proteins involved in the deadenylation and degradation process have been well 
characterised, however the exact mechanism of recruitment of these proteins to the RISC has 
not been elucidated (Braun et al., 2011; Fabian et al., 2011; Fabian et al., 2009; Hussain, 2012; 
Yamashita et al., 2005; Zekri et al., 2009). Decapping of target mRNAs occurs through the 
canonical mechanism by recruitment of the decapping complex and subsequent exonuclease 
activity to degrade the mRNA (Cougot et al., 2004; Rehwinkel et al., 2005). miRNA-mediated 
translational activation can be achieved in two ways; direct activation of the target mRNA by 
the miRNA or through abrogation of a repressive miRNA leading to relief of repression (Lin 
et al., 2011; Vasudevan, 2012; Vasudevan et al., 2007). 
1.6.4 Approaches for miRNA target identification 
Since their discovery, a major area of research has been target identification and the functional 
analysis of miRNAs. Elucidation of targets of miRNAs and understanding their role in biology 
has proved to be challenging. Several approaches to identify targets of miRNAs have been 
applied including both bioinformatic and experimental approaches however a combination of 
these appears to be the most successful. 
A number of computer programmes have been developed to aid miRNA target identification 
(Peterson et al., 2014). These programmes include miRanda, (John et al., 2004) PicTar (Lall 
et al., 2006), TargetScan (Ruby et al., 2007), PITA (Kertesz et al., 2007), DIANA-microT 
(Kiriakidou et al., 2004), rna22 (Miranda et al., 2006) and RNAHybrid (Rehmsmeier et al., 
2004). All of these algorithms use slightly different parameters to identify targets of miRNAs 
including the sequence complementarity of the seed sequence of the miRNA and target 
mRNA, thermodynamic stability and conservation of the target site between orthologous 
genes. As such, it is often difficult to identify the same target of a certain miRNA in different 
programmes. Also, some programmes are only capable of predicting targets of miRNAs in the 
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3’UTRs of mRNAs. Another limitation of using a bioinformatic approach is that a significant 
number of false positives are generated and so experimental validation of targets is required. 
There are three main experimental approaches to miRNA target identification: transcriptome 
analysis, biochemical approaches and proteomic analysis. Transcriptome analysis allows for 
the measurement of gene expression in the presence or absence of a specific miRNA. The most 
common form of transcriptome analysis is a microarray, however RNA-seq can also be used 
(Donohoe et al., 2015; Jia et al., 2015; Kanda et al., 2015; Ma et al., 2015; Ramalingam et al., 
2015; Xing et al., 2015). The limitations of using a microarray or RNA-seq include not being 
able to directly identify the target mRNA(s) of the miRNA(s) of interest as only overall 
changes in gene expression are determined. 
Using a biochemical approach can attempt to overcome the limitation of transcriptome 
analysis as these methods use the principle of purifying miRNAs bound to their target mRNAs 
through immunoprecipitation (IP) of an Ago protein in the RISC (RISC-IP) (Beitzinger et al., 
2007; Grey et al., 2010). The immunoprecipitated mRNAs can then be identified by 
microarray or RNA-seq approaches. Limitations of this method include indirect mRNA targets 
of miRNAs pulled down due to the low stringency of the IP method and specific interacting 
sites of miRNAs are not identified. 
The RISC-IP method has been improved upon with the development of the high throughput 
sequencing of RNAs isolated by UV crosslinking and immunoprecipitation (HITS-CLIP) 
method (Chi et al., 2009; Moore et al., 2014). By crosslinking the miRNA-mRNA complex to 
Ago-2 a higher stringency can be used in this technique to increase confidence in the mRNA 
targets identified. A number of targets of KSHV-encoded and EBV-encoded miRNAs have 
been identified using this method (Haecker et al., 2012; Haecker & Renne, 2014; Riley et al., 
2012). HITS-CLIP has been improved through the development of the photoactivable-
ribonucleoside-enhanced-CLIP (PAR-CLIP) method. The PAR-CLIP method has an 
improved efficiency of crosslinking increasing the amount of mRNA pulled down compared 
to HITS-CLIP (Hafner et al., 2010). A number of groups have used PAR-CLIP to identify 
targets of KSHV-encoded and EBV-encoded miRNAs (Gottwein et al., 2011; Skalsky et al., 
2012). However, neither HITS-CLIP nor PAR-CLIP are capable of definitively identifying 
targets of miRNAs.  
Most recently, CLASH has been developed as a method of miRNA target identification that 
overcomes the limitations of previous CLIP methods. An intramolecular ligation step is 
included in the CLASH protocol to ligate miRNAs to their target mRNAs resulting in miRNA-
mRNA hybrids that can be identified by subsequent sequencing (Helwak et al., 2013). CLASH 
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has mainly been used to map the human miRNA interactome however CLASH has been used 
to identify targets of OvHV-2-encoded miRNAs by the Dalziel lab (see section 4.1) 
(Friedländer et al., 2014; Helwak et al., 2013; Helwak & Tollervey, 2014; Liu et al., 2014; 
Riaz, 2014).  
Proteomic approaches to miRNA target identification include measuring the levels of newly 
synthesised proteins using (pSILAC) (Ebner & Selbach, 2011; Kaller et al., 2014). This 
method is of particular use when the decrease in protein from miRNA-mediated repression is 
modest and would not be detected by other proteomic or transcriptomic approaches.  
1.7 Virus-encoded miRNAs 
It is well known that viruses modulate a number of host pathways to create a cellular 
environment that favours the virus for facilitation of replication and evasion of the immune 
response. It is therefore not surprising that it was hypothesised that viruses might encode 
miRNAs to help mediate these subversive processes (Sullivan, 2008; Tuddenham & Pfeffer, 
2006). Moreover, miRNAs are an ideal mechanism for viruses to modulate the host as they 
are non-immunogenic and occupy little genome space (Sarnow et al., 2006).  
The first virus-encoded miRNAs were identified in EBV and it was shown that the encoded 
miRNAs were differentially expressed depending on the life cycle stage of the virus (Pfeffer 
et al., 2004). The current release of miRbase lists 498 mature miRNAs from 27 different 
viruses (Table 1.3). The majority of viruses that encode miRNAs are DNA viruses. Most DNA 
viruses replicate in the nucleus and so have access to the necessary machinery for correct 
miRNA processing; DNA viruses that replicate in the cytoplasm such as poxviruses might not 
have evolved to code for miRNAs due to their inability to access the processing enzyme 
Drosha (Cullen, 2010; Kincaid & Sullivan, 2012; Tuddenham & Pfeffer, 2006). DNA viruses 
also often have larger genomes than RNA viruses and so have the coding capacity for 
miRNAs. There is very little evidence that RNA viruses encode miRNAs, although it has been 
shown that Dengue virus and West Nile virus encode miRNA-like molecules (Hussain & 
Asgari, 2014; Hussain et al., 2012; Ospina-Bedoya et al., 2014). There is also controversial 
evidence that HIV-1 encodes a number of miRNAs (Bennasser et al., 2004; Omoto et al., 
2004) however some studies have contradicted these findings (Lin & Cullen, 2007; Pfeffer et 
al., 2005). However another retrovirus, bovine leukaemia virus (BLV), clearly encodes a 
number of miRNAs (Rosewick et al., 2013). These miRNAs are clustered in the BLV genome 
and are transcribed by RNA polymerase III. (Kincaid et al., 2012).   
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The majority of virus-encoded miRNAs (over 90%) discovered so far are encoded by 
herpesviruses (Grundhoff & Sullivan, 2011). The functional targets of a large percentage of 
herpesvirus-encoded miRNAs remain unknown, however targets that have been elucidated 
include both virus and cellular mRNAs and play roles in latency, immune evasion and 
pathogenesis. Tables 1.4 and 1.5 show selected known cellular targets and viral targets of 
herpesvirus-encoded miRNAs respectively. It is out with the scope of this thesis to discuss all 
the known targets and so a select number will be discussed in the following sections.  
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Family Subfamily Virus No. mature miRNAs 
Herpesvirus 
α-herpesvirus 
bovine herpesvirus 1 12 
bovine herpesvirus 5 5 
fuck enteritis virus 33 
herpes B virus 15 
















rhesus lymphocryptovirus 68 
rhesus monkey rhadinovirus  11 
Papillomavirus 
  
BPCV1  1 
BPCV2 1 
Polyomavirus 
BK polyomavirus 2 
JC polyomavirus 2 
Merkel cell polyomavirus 2 
simian virus 40 2 
Retrovirus 
BLV 10 
bovine foamy virus 4 
  
Table 1.3 Virus-encoded miRNAs 
Adapted from miRbase (v21 June 2014) (http://www.mirbase.org/) 
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1.7.1 Cellular targets of Herpesvirus-encoded miRNAs 
Many of the known cellular targets of herpesvirus-encoded miRNAs are involved in the 
maintenance of latency through a number of pathways such as prevention of apoptosis and 
immune evasion (Table 1.4). Regulation of the cell cycle can also be important, not only for 
maintenance of latency but also for pathogenesis and oncogenesis in herpesviruses such as 
KSHV.  
A number of herpesviruses encode one or more miRNAs known to target the apoptosis 
pathway. The EBV-encoded miRNA miR-BART5 has been shown to target p53-up-regulated 
modulator of apoptosis (PUMA), the protein product of which belongs to the B cell lymphoma 
2 (Bcl-2) family of proteins (Choy et al., 2008). HCMV and KSHV encode miRNAs (HCMV-
miR-UL112-1 and KSHV-miR-K5, -miR-K9 and -miR-K10a/b) that target the Bcl-2 
associated transcription factor 1 (BCLAF1), the protein of which is another promotor of 
apoptosis (Sarras et al., 2010; Ziegelbauer et al., 2009). KSHV also targets the apoptosis 
pathway through targeting of a number of other proteins. KSHV-miR-K12-1, miR-K12-4-3p 
and miR-K12-3 have all been shown to target caspase 3 (CASP3), the protein product of which 
is involved in the activation of the cascade of caspases that trigger apoptosis (Suffert et al., 
2011). KSHV-miR-K12-1 has also been shown to target MAF (V-Maf Avian 
Musculoaponeurotic Fibrosarcoma Oncogene Homolog), which codes for a transcription 
factor which has several roles including increasing the susceptibility of T cells to apoptosis. 
KSHV-miR-K12-6-5p and miR-K12-11 (a miR-155 orthologue, see section 4.1 for further 
details) have also been shown to target MAF (Hansen et al., 2010). It has been demonstrated 
that KSHV-miR-K12-10a can down-regulate tumour necrosis factor receptor superfamily 
member 12A (tweak-receptor or TWEAKR), which codes for a receptor for the cytokine 
tumour necrosis factor ligand superfamily member 12 (TNFSF12). TNFSF12 has some 
overlapping features with the TNF signalling pathway and, as the name suggests, induces weak 
apoptosis in certain cell types (Abend et al., 2010). SMAD5, the protein product of which is a 
component of the TGFβ signalling pathway has shown to be a target of KSHV-miR-K12-11 
(Liu et al., 2012). TGFβ is a potent inhibitor of cell proliferation as well as a regulator of many 
other cell processes such as differentiation and apoptosis. Another SMAD gene, SMAD2, has 
been shown to be targeted by an MDV-encoded miRNA MDV-miR-3; down-regulation of 
SMAD2 has been reported to suppress cisplatin-induced apoptosis (Xu et al., 2011). 
Immune evasion is thought to be critical for maintenance of latency and so it is not surprising 
that a number of herpesviruses encode multiple miRNAs that suppress or subvert the immune 
system. HCMV, EBV and KSHV all encode miRNAs (HCMV-miR-UL112-1, KSHV-miR-
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K-12-7 and EBV-miR-BART2-5p) that target MHC Class I Polypeptide-Related Sequence B 
(MICB) (Nachmani et al., 2009; Stern-Ginossar et al., 2012). MICB is a ligand for the 
activating natural killer (NK) cell receptor natural-killer group 2, member D (NKG2D). Down-
regulation of MICB leads to an inhibition of NK cells and thus reduced recognition and killing 
of virus infected cells. HCMV also codes for miR-UL148D, which targets RANTES (regulated 
on activation, normal T cell expressed and secreted), which codes for a chemokine which acts 
as a chemoattractant for blood monocytes, memory T helper cells and eosinophils (Kim et al., 
2012). It is a known major suppressor of HIV replication (Coffey et al., 1997). Another 
chemokine gene, chemokine (C-X-C motif) ligand 11 (CXCL11), is targeted by EBV-miR-
BHRF1-3 (Xia 2008). Gene expression of CXCL11 is potently induced by IFNγ and as such 
is thought to have antiviral effects (Murayama et al., 2012). KSHV-miR-K-12-9 targets IRAK1 
(interleukin-1 receptor-associated kinase 1) and MYD88 (Myeloid differentiation primary 
response gene 88). The protein products of both of these genes are involved in the IL-1 and 
Toll-like Receptor signalling pathways. IRAK1 associates with Myd88 and downstream 
signalling leads to NF-ĸB activation and the transcription of type I IFNs thus playing a critical 
role in the initiation of the innate immune response (Abend et al., 2012).  
Other notable targets of herpesvirus-encoded miRNAs include those that target cell cycle 
genes. CCNE2 (cyclin E2), which codes for a protein that plays a role in the G1/S phase 
transition is targeted by HCMV-miR-US25-1 (Grey et al., 2010). KSHV encodes two 
miRNAs, miR-K12-1 and miR-K12-4-5p, which target P21 (codes for a regulator of G1 
progression) and RBL2 (Retinoblastoma-Like 2, the protein product of which is a regulator of 
entry into cell division) respectively (Gottwein & Cullen, 2010; Lu et al., 2010a). Four KSHV-
encoded miRNAs, miR-K12-1, miR-K3-3p, miR-K6-3p and miR-K11 target thrombospondin 
1 (THBS1) (Lu et al., 2010a; Samols et al., 2007). THBS1 is an adhesive glycoprotein that 
mediates cell-cell and cell-matric interactions and has been shown to play roles in angiogenesis 
and tumourigenesis.  
  





Target Virus miRNA 
miRNA 
Target Virus miRNA 
BACH1 KSHV miR-K12-11 MyD88 KSHV miR-K12-9 
BCLAF1 KSHV miR-K5 NFIB KSHV miR-K12-3 
    miR-K9   KSHV miR-K12-7 
    miR-K10a/b   KSHV miR-K12-11 
  HCMV miR-UL112-1 p21 KSHV miR-K12-1 
CASP3 KSHV miR-K12-1 PU.1 MDV1 miR-M4 
  KSHV miR-K12-4-3p PUMA EBV miR-BART5 
  KSHV miR-K12-3 RANTES HCMV miR-UL148D 
CCNE2 HCMV miR-US25-1 Rbl2 KSHV miR-K12-4-5p 
CXCL-11 EBV mir-BHRF1-3 SMAD2 MDV1 miR-M3 
GPM6B MDV1 miR-M4 SMAD5 KSHV miR-K12-11 
IRAK1 KSHV miR-K12-9 THBS1 KSHV miR-K12-1 
MAF KSHV miR-K12-1     miR-K3-3p 
    miR-K12-6-5p     miR-K6-3p 
    miR-K12-11     miR-K11 
MAP3K2 EBV miR-BART-18-5p TWEAKR KSHV miR-K12-10a 
MICB HCMV miR-UL112-1    
  KSHV miR-K12-7    
  EBV miR-BART2-5p    
Table 1.4 Cellular targets of herpesvirus-encoded miRNAs 
Targets in red are genes associated with apoptosis. Targets in purple are associated with 
the cell cycle. Targtes in blue are associated with the immune system. Targets in black 
include genes involved in other signalling pathways and tumourigenesis. Adapted from 
Grey 2015 and Grundhoff et al., 2011. 
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1.7.2 Viral targets of Herpesvirus-encoded miRNAs 
As well as regulating a number of cellular genes, herpesviruses have been shown to regulate 
their own gene expression through miRNAs (Table 1.5). Many herpesviruses encode miRNAs 
that target IE genes. As the majority of herpesvirus-encoded miRNAs are thought to be 
expressed during latency it is thought that this targeting is a mechanism of maintenance of 
latency however down-regulation of IE genes could also be a mechanism of promoting or 
establishing latency. The major transactivators of KSHV (RTA), EBV (BZLF1 and BRLF1), 
HCMV (IE72/IE1) and MDV-1 (ICP4) are targeted by KSHV-miR-K12-9* and miR-K12-7-
5p, EBV-miR-BART20-5p, HCMV-miR-UL112-1 and MDV-miR-M7-5p respectively 
(Bellare & Ganem, 2009; Grey et al., 2007; Jung et al., 2014; Lei et al., 2010; Lu et al., 2010a; 
Murphy et al., 2008; Strassheim et al., 2012). The DNA polymerase of EBV, BALF5, is also 
targeted by an EBV-encoded miRNA, miR-BART2 (Barth et al., 2008). ICP27, the MDV-1 
homologue of ORF57 is also targeted by MDV-miR-M7-5p (Strassheim et al., 2012). MDV-
miR-M4 targets UL28 and UL32, involved in cleavage and packaging of viral DNA 
(Muylkens et al., 2010). EBV encodes miRNAs that target genes involved in latency; LMP1 
is a target of EBV-miR-BART1-5p, miR-BART16 and miR-BART17-5p. The expression of 
LMP1 is thought to be under tight regulation because it has been shown that overexpression 
of LMP1 can lead to growth inhibition and apoptosis which would obviously not be favourable 
for EBV (Lo et al., 2007). LMP2A, another latency associated protein, is targeted by EBV-
miR-BART22. LMP2A is a strongly immunogenic antigen, and that down-regulation of 
LMP2A by miR-BART22 may lead to the escape of EBV from the immune system and may 
facilitate NPC progression (Lung et al., 2009). 
Taken together it appears that herpesvirus-encoded miRNAs play critical role in regulation of 
both cellular and viral gene expression to module a number of pathways facilitating 
pathogenesis of these viruses.  
  




Virus miRNA Target Gene Function 
EBV miR-BART22 LMP-2a Latency 
EBV miR-BART1-5p LMP1 Latency 
  miR-BART16     
  miR-BART17-5p     
EBV miR-BART2 BALF5 DNA polymerase 
EBV miR-BART-20-5p BZLF1 Virus Transactivator 
EBV miR-BART-20-5p BRLF1 Virus Transactivator 
KSHV miR-K12-9* RTA Virus Transactivator 
  miR-K12-7-5p     
HCMV miR-UL112-1 IE72 Major IE gene 
MDV-1 miR-M4 UL28 Cleavage/Packaging of Viral DNA 
    UL32 Cleavage/Packaging of Viral DNA 
MDV-1 miR-M7-5p ICP4 Virus Transactivator 
    ICP27 IE gene (ORF57 homologue) 
Table 1.5 Viral targets of herpesvirus-encoded miRNAs 
Chapter 1  Introduction 
43 
 
1.7.3 OvHV-2-encoded miRNAs 
As other herpesviruses encode miRNAs it was hypothesised that OvHV-2 encoded miRNAs. 
High throughput sequencing and bioinformatics analysis of the BJ1035 cell line was 
performed and from this forty-five miRNAs were predicted (described in further detail in 
section 3.1, see Figure 3.4 for their location in the OvHV-2 genome) (Levy, 2011). The eight 
predicted miRNAs with the highest number of reads from the RNA-seq were validated by 
northern blotting (Levy et al., 2012).  
Bioinformatic analysis was used to predict targets within the 5’ and 3’UTRs of OvHV-2 ORFs 
and luciferase assays confirmed the targeting of ORF73 and ORF50 by ovhv2-miR-17-1 and 
ovhv2-miR-17-10 (Riaz et al., 2014). The targeting of ORF50 is in line with current evidence 
discussed in section 1.7.2 that virus-encoded miRNAs target IE genes as a mechanism of 
latency maintenance.  
Dr Riaz also performed CLASH in the BJ1035 cell line and in sheep embryo fibroblast cells 
transduced with a lentivirus containing ovhv2-miR-17-1, miR-17-2 and miR-17-3. Luciferase 
assays confirmed that U2 (a component of the spliceosome) was a target of ovhv2-miR-17-28. 
DLL1 was also confirmed as a target of ovhv2-miR-17-2 by luciferase assay (see section 4.3 
and sections therein for further details) (Riaz, 2014).  
1.8 Aims 
The identification of OvHV-2-encoded miRNAs is an important step forwards in the 
understanding of OvHV-2 biology. Validation and target identification of these miRNAs is 
required to elucidate their roles in virus biology, especially in order to determine whether they 
play a role in the different outcomes observed between sheep and susceptible species.  
The major aims of this thesis were to: 
 Validate the remaining thirty-seven predicted miRNAs to confirm whether or not they 
are expressed by OvHV-2. 
 Elucidate the targets of OvHV-2-encoded miRNAs in sheep and cattle by a number of 
methods including further validation of the CLASH data performed by Dr Riaz (in 
particular targeting of DLL1). Bioinformatic analysis will also be used to predict 
mRNAs that may be differentially targeted in sheep and cattle. 
 Identification and functional characterisation of other viral targets of OvHV-2-
encoded miRNAs by bioinformatic analysis.
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2.1 Tissue Culture 
2.1.1 Growth of stable adherent cell lines 
HEK-293T (Human embryonic kidney) cells, SEF (sheep embryonic fibroblasts, a gift from 
Dr Gerry McLaughlin, Roslin Institute) cells, MDBK (Madin-Darby bovine kidney) cells and 
L929 (mouse aneuploidy fibrosarcoma) cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM, Sigma-Aldrich, Gillingham, UK) supplemented with 10% foetal bovine 
serum (FBS, Life Technologies, Paisley, UK) and 1% penicillin-streptomycin-glutamine 
(Invitrogen). L929 cells transfected with cosmid vectors expressing the ovine major 
histocompatibility complex (MHC) class II genes DRA and DRB (hereafter referred to as 
LT8.1 cells, Professor John Hopkins, Roslin Institute) were grown in the same conditions as 
all other cells. Cells were grown in either 75 cm2 or 175 cm2 tissue culture flasks 
(ThermoScientific, Loughborough, UK) in a 37°C, 5% CO2 incubator. 
 
Confluent cell monolayers were removed from the surface of the flask using Trypsin-EDTA 
(Ethylenediaminetetraacetic acid, Sigma-Aldrich). The media was poured off and replaced 
with an equivalent amount of phosphate buffered saline (PBS) to wash the cells. This was 
removed and a sufficient volume (enough to cover the cell monolayer) of trypsin-EDTA was 
added and incubated at 37°C, 5% CO2 until all cells had detached, with the exception of HEK-
293T cells which were incubated at room temperature for 1 min. Cells were resuspended in 10 
ml of complete DMEM. New tissue culture flasks were seeded at appropriate densities in either 
15 ml (75 cm2) or 25 ml (175 cm2) of DMEM.  
2.1.2 Growth of established cell lines in suspension 
BJ1035 cells (a gift from Dr G Russell, Moredun Research Institute) were grown in 25 cm2 
tissue culture flasks in suspension, maintained in Iscove’s Modified Dulbecco’s Medium (Life 
Technologies) supplemented with 10% FBS, 1% penicillin-streptomycin, Interleukin-2 (350 
IU/ml) (Novartis Pharmaceuticals UK, Camberley, UK) and 0.12% -mercaptoethanol 
(Sigma-Aldrich) and incubated at 37°C, 5% CO2. Growth media was replaced every 2-3 days 
and once enough large clumps of cells were seen to cover the bottom of the flask the cells were 
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2.1.3 Establishment of IL-2 dependent cells 
Bovine lymphoblasts were generated by Dr Suzanne Esper from isolated peripheral blood 
mononuclear cells from the buffy coat of bovine blood and subsequent stimulation with 
concanavalin A at a concentration of 2.5 μg/ml (Bujdoso et al., 1990). Cells were grown in 25 
cm2 tissue culture flasks and maintained in Roswell Park Memorial Institute (RPMI, 
Invitrogen) medium supplemented with 10% FBS, 1% penicillin-streptomycin, 0.1% -
mercaptoethanol and 100 U/ml IL-2. Growth media was replaced every 2-3 days. Cells were 
grown in a 37°C incubator with 5% CO2. 
2.1.4 Preparation of cells for long term storage 
Cells were resuspended to 5 x 106 cells/ml and pelleted at 500 x g for 5 mins. The supernatant 
was removed and cells were resuspended in 1 ml of freezing medium (90% FBS, 10% [v/v] 
dimethyl sulphoxide) and transferred to a cryovial. Samples were wrapped in cotton wool, 
placed in a Styrofoam box and stored at -80ᵒC overnight. Samples were put in liquid nitrogen 
the following day for long term storage. 
2.1.5 Growth of cell lines from frozen stock 
Vials of cells were removed from liquid nitrogen and placed in a 37ᵒC water bath to thaw 
quickly. The cells were either added to a 25 cm2 tissue culture flask (suspension cell lines) or 
a 75 cm2 flask (adherent cell lines) and an appropriate volume of pre-warmed growth medium 
was added. Cells were incubated at 37°C, 5% CO2 overnight and medium changed the 
following day.  
2.1.6 Reverse transfection of cell lines by Lipofectamine 2000 
HEK-293T cells were grown in 75 cm2 flasks until they were 90% confluent. Cells were 
trypsinised as described in section 2.1.1, counted and resuspended in antibiotic-free DMEM 
supplemented with 10% FBS at 6 x 105 cells/ml. 300 ng of plasmid DNA and 100 nM miRNA 
mimic (Qiagen, Manchester, UK) were mixed with Opti-MEM (Life Technologies) to a total 
volume of 25 μl. 1 μl of Lipofectamine 2000 (Life Technologies) and 24 μl of Opti-MEM were 
mixed and incubated at room temperature for 5 mins. The Lipofectamine 2000-Opti-MEM 
mixture was added to the DNA-miRNA mimic mixture and complexes were allowed to form 
by incubating at room temperature for 15 mins. 100 μl of HEK-293T cells at 6 x 105 cells/ml 
were added to the complexes and the total 150 μl volume was transferred to one well of a 96 
well plate. Cells were incubated for 48 hrs at 37°C with 5% CO2 before harvesting. 
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2.1.7 Transfection of cell lines by Lipofectamine 2000 
HEK-293T cells were seeded at 7.5 x 105 cells per well of a 6 well plate in DMEM 
supplemented with 10% FBS the day before transfection. Before seeding the cells the wells 
were treated with poly-L-lysine (Sigma). 400 μl of poly-L-lysine was added to each well and 
incubated for 5 mins at room temperature. The poly-L-lysine was aspirated from the wells and 
the wells allowed to air-dry before seeding cells. 2.5 μg of plasmid DNA was complexed with 
10 μl of Lipofectamine 2000 in Opti-MEM to a total volume of 300 μl as described in section 
2.1.6. Growth media was removed from the cell monolayers and replaced with 700 μl of 
DMEM supplemented with 10% FBS. The total 300 μl of Lipofectamine 2000-DNA mixture 
was added to the cells and incubated for 48 hrs at 37°C with 5% CO2 before harvesting. 
 
The day before transfection 2 x 105 HEK-293T cells were seeded in one well of a 12 well plate 
in DMEM supplemented with 10% FBS. 100 ng of plasmid DNA and 100 nM miRNA mimic 
were complexed with 5 μl of Lipofectamine 2000 in Opti-MEM to a total volume of 100 μl as 
described in section 2.1.6. The total 100 μl of Lipofectamine 2000-DNA-miRNA mimic 
complexes were added to the cells and incubated for 48 hrs at 37°C with 5% CO2 before 
harvesting. 
 
For transfections in 96 well plates, HEK-293T cells were seeded the day before at 3 x 104 cells 
per well in DMEM supplemented with 10% FBS. 10 ng of plasmid DNA and 100 nM miRNA 
mimic were complexed with 0.5 μl of Lipofectamine 2000 in Opti-MEM to a total volume of 
10 μl as described in section 2.1.6. The total 10 μl Lipofectamine 2000-DNA-miRNA mimic 
complexes were added to the cells and incubated for 48 hrs at 37°C with 5% CO2 before 
harvesting. 
2.1.8 Transfection onto coverslips 
The wells of a 24 well plate were treated with 200 μl poly-L-lysine as described above. One 
coverslip (12 mm in diameter, Scientific Laboratory Supplies, Coatbridge, UK) was placed 
into one well of a 24 well plate. Coverslips were sterilised in 1 ml Ethanol. This was removed 
and coverslips were allowed to air-dry. HEK-293T cells were seeded at 1.5 x 105 cells per well 
in DMEM supplemented with 10% FBS the day before transfection. 500 ng of plasmid DNA 
was complexed with 1 μl of Lipofectamine 2000 in Opti-MEM to a total volume of 50 μl as 
described in section 2.1.6. The total 50 μl of Lipofectamine 2000-DNA mixture was added to 
the cells and incubated for 48 hrs at 37°C with 5% CO2 before harvesting. 
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2.1.9 Transfection of cell lines by nucleofection 
MDBK cells were grown in 75 cm2 flasks until they were 90% confluent. Cells were 
trypsinised as described in section 2.1.1, counted and resuspended in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin-glutamine at 1 x 106 cells per sample. Cells 
were spun at 500 x g for 5 mins at room temperature. The supernatant was completely removed 
from the pellet and cells were resuspended in 100 μl of room temperature Nucleofector® 
Solution (part of the Cell Line Nucleofector® kit R, Lonza, Slough, UK) per sample. 100 μl 
cell suspension was combined with 2 μg of plasmid DNA and transferred into the supplied 
cuvettes, and the cap placed on the cuvette. The cuvette was placed into the Nucleofector II 
(Lonza), programme X-001 was selected and the programme was applied. The cuvette was 
removed from the holder and incubated for 10 mins at room temperature. Following 
incubation, 500 μl of DMEM supplemented with 10% FBS and penicillin-streptomycin-
glutamine was added and samples were immediately transferred to prepared 6 well plates using 
the supplied pipettes. 6 well plates were prepared by adding 1 ml of DMEM supplemented 
with 10% FBS and penicillin-streptomycin-glutamine and incubating at 37°C with 5% CO2. 
Cells were incubated for 48 hrs at 37°C with 5% CO2 before harvesting.  
 
Table 2.1 Summary of Transfection Protocols 
 
















6 7.5 x 105 10 2.5 n/a 
12 2 x 105 5 0.1 100 
24 1.5 x 105 1 0.5 n/a 
96 3 x 104 0.5 0.001 100 
Reverse HEK-293T 96 6 x 104 1 0.3 100 
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2.2 PCR methods 
 
2.2.1 DNA Isolation 
Total DNA was isolated from a maximum of 5 x 106 cells per sample using the DNeasy Blood 
and Tissue Kit (Qiagen) according to the manufacturer’s protocol. DNA concentration was 
determined using a NanoDrop ND-100 Spectrophotometer (Thermo Scientific) and stored at 
-20ᵒC. 
2.2.2 RNA Isolation  
Total RNA was isolated from a maximum of 1 x 107 cells per sample using the RNeasy Mini 
Kit (Qiagen) according to the manufacturer’s protocol. RNA concentration was determined 
using a NanoDrop ND-100 Spectrophotometer and stored at -80ᵒC. 
2.2.3 Reverse Transcription of RNA 
Before reverse transcription (RT), DNase treatment of RNA was performed using the TURBO 
DNA-free™ Kit (Life Technologies). 1 μg of RNA was treated in a 50 μl reaction volume 
according to the manufacturer’s protocol. 10 μl of DNase-treated RNA was incubated with 1 
μl of either random heaxamer primers or oligo(dT) primers (both Promega, Southampton, UK) 
at 70ᵒC for 5 mins before placing on ice. 30 U Avian Myeloblastosis Virus Reverse 
Transcriptase (Promega), 2.5 μl 10 mM dNTPs (Bioline, London, UK) and 5 μl supplied buffer 
were added to the DNase-treated RNA and primer mix to a total volume of 25 μl and incubated 
at either 37ᵒC (random hexamer primers) or 42ᵒC (oligo(dT)) primers for 1 hr. cDNA 
concentration was determined using a NanoDrop ND-100 Spectrophotometer and stored at -
20ᵒC. 
2.2.4 Reverse Transcription of small RNAs  
Reverse transcription was performed using the miScript II RT Kit (Qiagen). 200 ng of RNA 
was used in a total reaction volume of 10 μl with the miScript HiSpec Buffer (supplied with 
miScript II RT Kit) according to the manufacturer’s protocol.  
 
miRNA-specific hairpin-loop reverse transcription primers were designed as described in 
(Varkonyi-Gasic & Hellens, 2011) and were supplied by Eurofins Genomics (Ebersberg, 
Germany). A reverse transcription reaction containing 25 μl 200 μM stock of reverse 
transcription (RT) primer, and 10 x RT Omniscript buffer (Qiagen) to a total volume of 100 
μl was used to anneal the RT primer. Conditions for annealing were as follows: 95ᵒC 30 for 
mins, 72ᵒC for 2 mins, 37ᵒC for 2 mins and 25ᵒC for 2 mins. RT primer concentration after 
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annealing was 50 μM and working concentration was 5 μM. A list of RT primers can be found 
in Appendix 2.  
 
RT reactions contained 200 ng RNA in a total reaction volume of 15 μl with 10 x RT 
Omniscript buffer, 1.5 pmols RT primer, 0.15 μl 10 mM dNTPs ,0.19 μl RNaisin (Promega) 
and 1 μl Multiscribe Reverse Transcriptase (Life Technologies). Reverse transcription cycling 
conditions were as follows: 16ᵒC 30 mins, 42ᵒC 30 mins, 85ᵒC 5 mins. cDNA was stored at -
20ᵒC. 
2.2.5 Polymerase Chain Reaction 
All Polymerase chain reactions (PCR) (and subsequent PCRs herein with the exception of 
sections 2.2.6 and 2.2.10) were carried out in a Veriti 96-well thermal cycler (Life 
Technologies). primer3 (http://primer3.ut.ee/) was used for primer design. A total reaction 
volume of 20 μl contained 1 - 2 μl cDNA template, 8 pmols forward and reverse primers, 1 u 
HotStarTaq DNA Polymerase (Qiagen), 0.4 μl dNTPS (10 mM) and 2 μl 10 x PCR Buffer 
(supplied with HotStarTaq DNA Polymerase). Cycling conditions were as follows: 95ᵒC for 5 
mins, 35 cycles of 95ᵒC for 30 sec, 55-60ᵒC (depending on Tm of primers) for 1 min, 72ᵒC for 
1 min followed by a final 72ᵒC for 7 mins. 
2.2.6 PCR of cDNA made using the Qiagen miScript Reverse Transcription Kit 
PCR was performed using the miScript SYBR Green PCR Kit (Qiagen). A 20 μl total reaction 
volume in 0.1 ml thin-walled PCR tubes (Qiagen) was set up containing 500 ng cDNA, 10 
pmols specific forward primer (Life Technologies), 10 pmols universal reverse primer  and 10 
μl 2 x SYBR green (both supplied in miScript SYBR Green PCR Kit). PCR cycling conditions 
were as recommended by the manufacturer’s protocol, with the exception of the annealing 
temperature which changed in accordance with the Tm of the forward primer. PCR was carried 
out in either a Rotor-Gene Q or Rotor-Gene RG-3000 (both Qiagen). A list of lists forward 
primer sequences and annealing temperatures can be found in Appendix 2.  
2.2.7 PCR of miRNA-specific cDNA 
PCR carried out using miRNA-specific cDNA was performed using the PCR protocol in 
section 2.2.5 with the forward and reverse primer concentration increased to 12 pmol. Cycling 
conditions were as follows: 95ᵒC for 5 mins, 40 cycles of 95ᵒC for 30 sec, 60ᵒC for 30 sec and 
72ᵒC for 1 min, followed by 72ᵒC for 7 mins. A list of forward primers and the universal 
reverse primer can be found in Appendix 2.  
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2.2.8 Site-directed Mutagenesis PCR 
Site-directed mutagenesis PCR was carried out using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies, Manchester, UK). Mutagenesis primers were 
designed using the QuikChange Primer Design Program (www.agilent.com/genomics/qcpd) 
and are listed in Appendix 2. Reactions, cycling parameters and Dpn I restriction enzyme 
digestion were carried out according to the manufacturer’s protocol. 
2.2.9 Rapid Amplification of cDNA ends PCR 
Rapid Amplification of cDNA ends (RACE)-ready sheep mesenteric lymph node PCR product 
was a kind gift from Louise Nicol. RACE PCR was performed using the GeneRacer Kit (Life 
Technologies). Gene-specific primers were designed according to the manufacturer’s protocol 
and are listed in Appendix 2. PCR reactions were set up using PlatinumTaq (Life 
Technologies) according to the manufacturer’s protocol except for 50 mM MgSO4 which was 
replaced with 50 mM MgCl2. Cycling parameters were performed according to the 
manufacturer’s protocol. 
2.2.10 Quantitative PCR 
Quantitative PCR (RT-qPCR) was carried out in either a Rotor-Gene Q or Rotor-Gene RG-
3000. SensiFAST SYBR Hi-ROX Kit (Bioline) was used for amplification. 20 μl total reaction 
volumes were set up according to the manufacturer’s protocol using 500 ng cDNA. primer3 
(http://primer3.ut.ee/) was used for primer design of amplicons no more than 200 bp in length 
(see Appendix 2 for a list of primers). 3-step cycling parameters were performed according to 
the manufacturer’s protocol. Samples for RT-qPCRs described in section 5.4.2 were set up 
with the aid of the CAS-1200 Liquid Handling System (Qiagen). 
2.2.11 Agarose Gel Electrophoresis 
DNA was analysed by electrophoresis in 0.8 – 3% agarose gels containing 1x SYBR® Safe 
DNA Gel Stain (Life Technologies) in Tris-acetate buffer (TAE) buffer. Samples up to 15 μl 
were mixed with 5 x loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol, 0.1 M 
EDTA, 30% glycerol in H2O). Electrophoresis was carried out in tanks containing TAE buffer 
at 80-90 V for 50 ml gels and 80 – 100 V for 100 ml gels. Estimation of DNA size was 
performed by comparison to 1 kb, 100 bp or 50 bp GeneRuler DNA Ladders (Thermo 
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2.3 Cloning Methods 
 
2.3.1 Purification of PCR products 
PCR products were purified using the Illustra GFX PCR DNA and Gel Band Purification Kit 
(GE Healthcare, Amersham, UK) according to the manufacturer’s protocol.  
2.3.2 Annealing of Oligonucleotides for Cloning 
Oligonucleotides up to 100 bases in length were synthesised along with their reverse 
complement counterpart by either Invitrogen or Sigma (see Appendix 2 for a list of 
oligonucleotides). Oligonucleotides were resuspended to 100 μM. 1 μl of each pair of 
oligonucleotides was mixed with 5 μl of 10 x Buffer 2 (supplied with New England Biolabs 
[NEB] Restriction Endonucleases) to a total volume of 50 μl. The sample was heated at 95ᵒC 
for 5 minutes in a heat block which was then turned off and allowed to cool to room 
temperature. Annealed oligonucleotides were then treated with T4 Polynucleotide Kinase 
(NEB, Hitchin, UK). 6 μl T4 DNA Ligase buffer (NEB) and 4 μl T4 Polynucleotide Kinase 
were added to 50 μl of annealed oligonucleotides and incubated at 37ᵒC for 30 mins. Ligations 
with annealed oligonucleotides could then be performed into vectors cut with appropriate 
restriction endonucleases. Oligonucleotides longer than 100 bases in length were synthesised 
as dsDNA by Integrated DNA Technologies (Leuven, Belgium) and required digestion with 
appropriate restriction endonucleases before ligation.  
2.3.4 DNA Ligation 
When PCR products only required sequencing the TOPO® TA Cloning® Kit (Life 
Technologies) was used for ligation. 4 μl PCR purified product was added to 1 μl Salt solution 
and 1 μl TOPO 2.1 vector and left for 15 mins at room temperature.  
 
For cloning DNA digested with appropriate restriction endonucleases into expression vectors 
(see appendix 1 for vector maps) the LigaFast™ Rapid DNA Ligation System (Promega) was 
used. A ratio of 1:3 of vector to insert DNA was used for cloning with 3 u of T4 DNA Ligase 
(supplied in the LigaFast™ kit) in a final total of 10 μl. Ligations were incubated for 15 mins 
at room temperature before transformation.   
2.3.5 Transformation of One-Shot Chemically Competent Cells 
5 μl ligated PCR product was added to 25 μl TOP10 chemically competent cells (Life 
Technologies) and left on ice for 30 mins. Samples were heat shocked at 42ᵒC for exactly 45 
sec and placed back on ice for 2 mins. 250 μl SOC medium (Life Technologies) was added 
and cells placed in a shaking incubator at 200 rpm for 1 hr at 37ᵒC. The cells were spread on 
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Luria-Bertani (LB) plates supplemented with appropriate antibiotic (100 μg/ml ampicillin or 
50 μg/ml kanamycin) and incubated at 37ᵒC overnight. 
2.3.6 Transformation of XL-10 Gold Ultracompetent Cells 
2 μl of β-Mercaptoethanol was added to 45 μl XL-10 Gold Ultracompetent cells (supplied with 
QuikChange Lightning Site-Directed Mutagenesis Kit) and incubated on ice for 10 mins with 
occasional swirling. 2 μl of ligated product was added to the cells and incubated for 30 mins 
on ice. Cells were then heatshocked at 42ᵒC for exactly 30 sec and placed back on ice for 2 
mins. 400 μl SOC medium was added and cells placed in a shaking incubator at 200 rpm for 
1 hr at 37ᵒC. The cells were spread on Luria-Bertani (LB)/Agar plates supplemented with 
appropriate antibiotic (100 μg/ml ampicillin or 50 μg/ml kanamycin) and incubated at 37ᵒC 
overnight. 
2.3.7 Preparation of Bacterial stocks for long term storage 
A single bacterial colony was picked from LB/Agar plates and used to inoculate 4 ml of LB 
medium supplemented with the appropriate antibiotic (100 μg/ml ampicillin or 50 μg/ml 
kanamycin). Cultures were shaken overnight at 200 rpm in a shaker at 37ᵒC. 500 μl of culture 
was added to 500 μl of sterile 80% glycerol in H20 and mixed thoroughly by inversion. 
Samples were stored at -80ᵒC. 
2.3.8 Plasmid DNA Isolation from Bacteria (Small Scale) 
A single bacterial colony was isolated from LB/Agar plates and used to inoculate 4 ml of LB 
medium supplemented with the appropriate antibiotic (100 μg/ml ampicillin or 50 μg/ml 
kanamycin). Cultures were shaken overnight at 200 rpm in a shaker at 37ᵒC. Plasmids were 
isolated using the QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s 
protocol and resuspended in milli-Q H2O (Millipore, Watford, UK). The concentration of 
purified plasmids was determined using a NanoDrop as in section 2.2.1. Plasmids were stored 
at -20ᵒC. 
2.3.9 Plasmid DNA Isolation from Bacteria (Large Scale) 
100 ml of LB medium supplemented with the appropriate antibiotic (100 μg/ml ampicillin or 
50 μg/ml kanamycin) was inoculated with 100 μl of culture set up as in section 2.3.8. Cultures 
were shaken overnight at 200 rpm in a shaker at 37ᵒC. Plasmids were isolated using the Qiagen 
Plasmid Midi Kit (Qiagen) according to the manufacturer’s protocol and resuspended in milli-
Q H2O. The concentration of purified plasmids was determined using a NanoDrop as in section 
2.2.1. Plasmids were stored at -20ᵒC. 
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2.3.10 Restriction Digest of DNA 
DNA was digested with restriction endonucleases (EcoRI, XhoI, NotI, KpnI, BamHI and 
HindIII, NEB) according to manufacturer’s instructions using the supplied buffers. Restriction 
digests were incubated at 37ᵒC for 1 hr in a total volume of 25 μl. When performing restriction 
digests for cloning purposes, 2 μg of vector DNA was incubated with 2 U of the appropriate 
restriction endonucleases in a total volume of 50 μl at 37ᵒC for 1 hr. Digested samples were 
analysed on a 0.8% agarose gel. Bands were excised from the gel with a clean sharp scalpel 
blade and DNA purified as described in section 2.3.1. The concentration of vector DNA was 
determined before treating the cut vector with FastAP Thermosensitive Alkaline Phosphatase 
(Thermo Scientific) according to the manufacturer’s protocol. 
2.3.11 Sequencing of Plasmid DNA 
Plasmid DNA was sent for sequencing at GATC biotech (London, UK) according to their 
instructions.  
2.3.12 Sequence Analysis 
DNA Sequences were analysed using NCBI nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast) and Ensembl BLAT 
(http://www.ensembl.org/Multi/Tools/Blast). NEBcutter (http://tools.neb.com/NEBcutter2/) 

















Chapter 2  Materials and Methods 
55 
 
2.4 Western Blotting  
 
2.4.1 Protein Sample Preparation 
Laemmli sample buffer (Bio-Rad, Hemel Hempstead, UK) was prepared by adding 50 μl of 
β-Mercaptoethanol to 950 μl Laemmli sample buffer. The supernatant of transfected cell 
monolayers was removed and a minimum of 200 μl of prepared Laemmli sample buffer was 
added to each well of a 12 well dish. Samples were mixed thoroughly with a pipette to ensure 
proper lysis before being transferred to a 1.5 ml microcentrifuge tube. Samples were boiled 
for 5 minutes at 95ᵒC before loading onto an SDS-PAGE gel.  
2.4.2 SDS-polyacrylamide gel electrophoresis 
4-20% Mini-PROTEAN® TGX™ Gels (Bio-Rad) were used for SDS-PAGE. 1x 
Tris/Glycine/SDS running buffer was prepared by mixing 10x Tris/Glycine/SDS (Bio-Rad) 
with H2O. Samples were loaded into wells and run at 120 V for 1 – 1.5 hrs or until the blue 
dye front had reached the bottom of the gel. The Odyssey® Protein Molecular Weight Marker 
(LI-COR) was used to determine approximate protein size.  
2.4.3 Transfer of Protein to Nitrocellulose Membranes 
Transfer buffer was prepared with 20% v/v methanol in 1x Novex® Tris-Glycine Transfer 
Buffer (Life Technologies) to 1x in H2O. Nitrocellulose membrane and filter paper 
(Nitrocellulose/Filter Paper Sandwich, 0.45 µm pore size, 8.5 cm x 13.5 cm, Life 
Technologies) were cut to size and soaked in transfer buffer before assembly of transfer 
cassette. A sponge pad was laid on the black side of the cassette followed by 1 piece of filter 
paper, protein gel, nitrocellulose membrane, 1 piece of filter paper and a sponge pad. The 
cassette was closed and inserted into the transfer unit. Transfer was run at 100 V for 1 hr. 4% 
w/v Amersham ECL Prime Blocking Reagent (GE Healthcare Sciences) in PBS-T (PBS with 
0.1% v/v Tween 20 [Sigma-Aldrich]) was used and the nitrocellulose membrane was 
incubated with rocking at room temperature for 1 hr, followed by 3 x 5 min washes in PBS-T. 
2.4.4 Immunological Staining of Protein Blots 
Membranes were incubated with primary antibodies (Table 2.2). All antibodies were used at 
the dilution suggested by the manufacturer in PBS-T. A rabbit Anti-Ov2 Antibody was 
synthesised using EKK and RRS peptides by Dundee Cell Products (Dundee, UK) and was 
used at a dilution of 1:1000 in PBS-T. Primary antibody incubations were carried out with 
rocking at 4ᵒC overnight. Three x 5 min washes in PBS-T were performed before incubation 
with secondary antibodies (LI-COR Biotechnology, Cambridge, UK, Table 2.2). Secondary 
antibodies were diluted 1:10000 in PBS-T and membranes were incubated with rocking at 
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room temperature for 45 mins before a further three x 5 min washes in PBS-T. Membranes 
were visualised on the Odyssey CLx (LI-COR Biotechnology). 
2.4.5 Quantitative Analysis of Protein Blots 
Analysis of protein blots was performed using Image Studio Lite version 3.1 (LI-COR 
Biotechnology). Protein levels were quantified by determining the signal of each band and 
normalising the protein band of interest to a housekeeping gene. 
 
Table 2.2. Antibodies and their appropriate dilutions   
 




Primary Antibodies Dilution Use Manufacturer 
Rabbit anti-Ov2 1:1000 WB/IF Dundee Cell Products 
Mouse anti-Actin 1:1000 WB Abcam (Cambridge, UK) 
Rat anti-MHC class II (SW73.2) 1:1000 FC Kind gift from Professor John 
Hopkins (Hopkins et al., 
1986) 
Rat IgG 1:500 FC Kind gift from Professor John 
Hopkins 
Rat anti-HA 1:1000 IF Roche (Burgess Hill, UK) 
Secondary Antibodies Dilution  Use Manufacturer 
IRDye 680RD Donkey Anti-Mouse IgG 1:10000 WB LI-COR 
IRDye 800CW Donkey Anti-Rabbit 1:10000 WB LI-COR 
Anti-Rat IgG Alexa Fluor 488 1:1000 FC Cell Signalling Technology 
(Leiden, Netherlands) 
Anti-Rat  IgG Alexa Fluor 555 1:1000 IF Cell Signalling Technology 
Anti-Rabbit IgG Alexa Fluor 488 1:1000 IF Cell Signalling Technology 





2.5.1 Cell Lysate Preparation 
The supernatant of transfected cell monolayers was removed and 500 μl ice cold PBS added 
to each well. The PBS was removed and 400 μl of ice cold lysis buffer (25 mM Tris HCl pH 
7.4, 1 mM EDTA, 150 mM NaCl, 1% NP-40, 5% glycerol) supplemented with 1 mM 
phenylmethanesulfonylfluoride (PMSF) and 1:100 protease inhibitor cocktail (both Active 
Motif, La Hulpe, Belgium) was added. Cells were incubated on ice for 15 mins. Samples were 
mixed thoroughly with a pipette to ensure proper lysis before being transferred to a 1.5 ml 
microcentrifuge tube. Samples were spun at 15000 x g for 15 mins. The supernatant was 
transferred to a clean microcentrifuge tube and lysates were stored at -80 ᵒC if they were not 
used immediately.  
2.5.2 Immunoprecipitation 
Immunoprecipitation (IP) was performed using Pierce Anti-HA Magnetic beads (Thermo 
Scientific). A magnetic stand was used to separate the beads. 25 μl of bead slurry was used per 
sample. Beads were washed twice in Tris-buffered saline with Tween (TBS-T, 0.05% Tween, 
Thermo Scientific) before adding the cell lysate. Samples were incubated for 30 mins at room 
temperature with rotation. The beads were separated and the unbound sample removed and 
stored at -20 ᵒC. The beads were thoroughly suspended in 300 μl of TBS-T, magnetically 
separated and the supernatant removed three times before a final wash in 300 μl of ultrapure 
water. For samples to be eluted from the beads to confirm that the immunoprecipitation was 
successful, the beads were magnetically separated, the supernatant was removed and 100 μl of 
laemmli sample buffer was added. Samples were stored at -20 ᵒC until further use. 
Confirmation of the presence of the protein of interest was confirmed by western blotting as 
described in sections 2.4.2 to 2.4.5. For samples subsequently analysed by mass spectrometry, 
the beads were magnetically separated, the supernatant was removed and the beads stored at -
20 ᵒC until further use. These were processed by the Proteomics and Metabolomics Facility at 
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2.5.3 Mass Spectrometry  
Liquid chromatography tandem mass spectrometry (LC-MS/MS) and data analysis were 
carried out by the Proteomics and Metabolomics Facility at the Roslin Institute. LC-MS/MS 
was performed by coupling a RSLCnano LC system (Thermo Scientific) to a micrOTOF-II 
mass spectrometer (Bruker, Germany). Spectra were deconvoluted and the peak lists exported 
as Mascot Generic Files (MGF) and searched using Mascot 2.4 server (Matrix Science, 
London, UK) against the Uniprot Human sequence database appended with the Ov2 sequence 
(entry Q2VSN7). The search was performed using the following parameters: MS 
tolerance = ±25 ppm, MS/MS tolerance = ±0.1 Da and peptide charge 2+ and 3+. False 
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2.6 Flow Cytometry 
 
2.6.1 Staining of Cells 
Cells were trypsinised as described in 2.1.1. Cells were pelleted at 500 x g for 5 mins, counted 
and resuspended at 2 x 107 cells/ml in PBS with 0.5% w/v bovine serum albumin (BSA, 
Thermo Scientific), 2% v/v FBS and 2 nM EDTA (Thermo Scientific). 1 x 106 cells were 
added to each well in a 96 well plate. An equal volume of primary antibody (Table 2.2) was 
added and incubated at 4ᵒC for 30 mins. Rat IgG was used as an isotype control. Cells were 
spun at 500 x g for 5 mins and washed in PBS/BSA/FBS/EDTA solution 3 times. Cells were 
resuspended in 100 μl of secondary antibody (Table 2.2) at 4ᵒC for 30 mins in the dark. Cells 
were washed in PBS/BSA/FBS/EDTA solution 3 times and transferred to FACS tubes (BD 
Biosciences, Oxford, UK) in a total volume of 400 μl PBS/BSA/FBS/EDTA solution. 
2.6.2 Harvesting of Cells Transfected with GFP Constructs 
Growth Medium was removed from the cells and 50 μl Tryspin-EDTA added to each well. 50 
μl growth medium was added and cells were resuspended and transferred to a 96-well u bottom 
plate. Cells were pelleted at 500 x g for 5 mins. Cells were washed in PBS with 1% w/v BSA 
and pelleted at 500 x g for 5 mins before being resuspended in 200 μl PBS with 1% w/v BSA. 
Cells were stored at 4ᵒC until used.  
2.6.3 Flow Cytometry using FACSCalibur 
A FACSCalibur (BD Biosciences) was used to analyse cells stained as described in section 
2.6.1. Forward scatter (cell size) and side scatter (cell granularity) were used to gate live cells. 
10,000 live cells were counted and FL1 fluorescence was used to measure MHC class II 
positive cells.  
2.6.4 Flow Cytometry using Fortessa High Throughput Sampler 
An LSRFortessa High Throughput Sampler (BD Biosciences) was used to analyse 96 well 
plates with cells transfected with GFP constructs. Forward scatter (cell size) and side scatter 
(cell granularity) were used to gate live cells. The 530/30 (FL1) filter was used to detect and 
count 7500 GFP-positive cells. Cell doublets were removed from data analysis using forward 
scatter area over height. 
2.6.5 Flow Cytometry Analysis 
Flow Cytometry data was analysed using version 10.0.6 of FlowJo.  Median Fluorescence 
Intensity (MFI) was used as a measure of knockdown of genes of interest by miRNAs. 
Statistical analysis was performed on the MFI values as described in section 2.6.3. 





2.7.1 Fixing and Immunostaining of Cells 
The supernatant of transfected cell monolayers on coverslips was removed and 1 ml of PBS 
added to each well. The PBS was removed and 1 ml of Acetone/Methanol (1:1 v/v) was added. 
Coverslips were incubated on ice for 10 mins. This was removed and the coverslips were 
washed in PBS three times. Coverslips were incubated for 10 mins at room temperature in 10 
mM Ammonium Chloride and the subsequently washed in PBS three times. Coverslips were 
blocked for 30 mins in 3% v/v Normal Goat Serum (NGS, Cell Signalling Technology)/PBS 
at room temperature. Primary antibodies (Table 2.2) were diluted in 3% NGS/PBS and 
coverslips were incubated in the primary antibody for 1 hr at room temperature. Three washes 
in PBS were performed before adding the secondary antibodies (Table 2.2, also diluted in 3% 
NGS/PBS). Coverslips were incubated for 45 mins at room temperature in the dark. Three 
washes in PBS were performed before staining with 4',6-diamidino-2-phenylindole (DAPI, 
Cell Signalling Technology), diluted 1:1000 in 3% NGS/PBS. Coverslips were incubated with 
DAPI for 5 mins at room temperature in the dark before three washes in PBS and one wash in 
distilled water were performed. Coverslips were mounted onto superfrost slides (Thermo 
Scientific) with ProLong Gold antifade (Invitrogen) and cured overnight at room temperature 
in the dark. Coverslips were sealed onto the slide the following day with clear nail varnish and 
were stored at 4ᵒC until imaged. 
2.7.2 Confocal Microscopy 
Slides were imaged on a Zeiss LSM 710 confocal microscope at the Roslin Institute Bio-
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2.8 Other Methods 
 
2.8.1 Luciferase Assays 
Luciferase assays were carried out using the Dual Luciferase Reporter Assay System 
(Promega). Cells were transfected as in section 2.1.6. Passive lysis of cells in 96 well plates 
was carried out according to the manufacturer’s protocol except that the cells were not washed 
in PBS before addition of passive lysis buffer and cells were incubated with rocking for 30 
mins. Luciferase Assay Reagent II (LAR II) and Stop & Glo Reagent were prepared according 
to the manufacturer’s protocol but was used at a dilution of 1:10. 50 μl of both LAR II and 
Stop & Glo Reagent were used per reaction instead of the suggested 100 μl. 10 μl of cell lysate 
was transferred to a 96 well white plate (Sigma-Aldrich) and luciferase assay activity was read 
using the GlowMax Multi Detection System (Promega).  
2.8.2 Statistical Analysis 
Statistical analysis was performed using Minitab 17 software. Graphs were made using the 
Graphpad Prism 6 software. All error bars on graphs represent standard error of the mean 
unless otherwise stated. Following advice from Dr. Helen Brown, senior statistician at the 
Roslin Institute differences between scrambled siRNA and miRNA mimics were analysed 
using a general linear model followed by a post-hoc Tukey’s analysis. P values represent 
results from the post-hoc test. This method of analysis was used for all luciferase assays, GFP 
flow cytometry assays and Western Blotting performed in subsequent sections. RT-qPCRs 
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Commonly Used Solutions 
 
PBS 
50 x TAE buffer 
LB medium 
LB/Agar 
All solutions provided by the Central Services Unit at the Roslin Institute. 
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To investigate whether OvHV-2 encoded miRNAs, massively parallel sequencing of small 
RNAs from the OvHV-2 immortalised bovine LGL cell line BJ1035 was performed previously 
by Dr Levy. Reads were mapped to the virus genome and grouped together based on their 
genomic position (Levy et al., 2012). Groups were subjected to secondary structure analysis 
to confirm whether they represented putative miRNAs. Criteria used for this analysis included 
a stem loop of 60 – 110 nucleotides recognised by the enzyme Drosha; 3’ overhangs in the 
miRNA/miRNA* duplex due to cleavage by Drosha and another miRNA processing enzyme 
Dicer; and ≤ 16 base pairs within the miRNA/miRNA* duplex required for stability. Forty-
five groups were found to fit these criteria, forty-two on the minus-strand and three on the 
plus-strand of the virus genome. The eight groups with the highest number of reads from the 
small RNA sequencing data were validated by Dr Levy by northern hybridisation and were 
named ovhv2-miR-1 to -8. 
As the remaining thirty-seven miRNAs were only predictions, confirmation that these are 
miRNAs encoded by OvHV-2 was necessary. A PCR strategy for validation of the remaining 
candidate miRNAs was adopted for a number of reasons. Firstly, PCR is a more amenable 
method for a larger number of samples than northern hybridisation. Secondly, PCR also allows 
for possible quantification of miRNA transcripts unlike northern hybridisation which is a non-
quantitative method. A quantitative system could be particularly useful in an animal model of 
MCF and provide insight into what roles virus-encoded miRNAs play during infection. 
Finally, the number of reads from the small RNA sequencing data ranged from 1 to 46048 (see 
Table 3.1) and consequently a more sensitive approach such as PCR was needed.  
The following sections describe two PCR methods used to validate the expression of OvHV-
2-encoded miRNAs.  
3.2 Aims 
The aim of this part of the project was to validate the expression of the remaining predicted 
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3.3 RT-PCR using the miScript Kit 
RNA was extracted from BJ1035 cells and reverse transcription performed as in sections 2.2.2 
and 2.2.4. Previous work had used the Theileria parva-immortalised bovine T-cell line 
495TPM as a negative control however this was not available for use when the PCR validation 
work was carried out. Instead, bovine lymphoblasts generated as in section 2.1.3 were used as 
the negative control cell line throughout the validation of OvHV2-encoded miRNAs by PCR 
methods. miRNA-specific forward primers were designed using the first ~16 nucleotides of 
the predicted miRNA sequence so that resulting products could be cloned and sequenced. 
PCRs were performed in triplicate using the miScript SYBR Green PCR Kit as described in 
section 2.2.6 and analysed by gel electrophoresis. Due to the polyadenylation step and use of 
an oligo-dT primer with a 3’ universal tag during reverse transcription genomic DNA is not 
detected during the PCR and so minus reverse transcription (minus RT) controls were not 
necessary. 
Resulting products are shown in Figure 3.2 for thirty-three out of thirty-seven groups analysed. 
No amplification by RT-PCR was observed for two groups (1 and 3p) and so were not analysed 
by agarose gel electrophoresis.  
Group 217 (renamed ovhv2-miR-73-1) displays 5’ homology to the mammalian miRNA miR-
216a (Figure 3.1) and was not analysed by this first PCR method. Group 67 is the only miRNA 
confirmed by sequencing for which a gel image is absent. According to the Qiagen miScript 
PCR System Handbook the expected PCR product size of mature miRNAs should be 85-87 
bp. The majority of groups (with the exception of groups 46, 95, 163, 64p and 96p) displayed 
a product of between 50 and 100 bp which fits with the expected product size. Group 46 had 
a product size of approximately 125 bp and group 96p had a product size of approximately 
150 bp. Product was only observed in BJ1035 samples for group 46. This larger product size 
could represent a pre-miRNA form however this is unlikely due to the priming of the cDNA 
during the PCR. Upon cloning and subsequent restriction digest a band of the correct size was 
observed. It is possible that a product of the correct size was generated but not discerned by 
agarose gel electrophoresis and as this product is smaller it would be more efficiently cloned. 
The product observed for group 96p could represent off-target priming of cellular cDNA as a 
band of the same size is also observed in the bovine lymphoblast samples. A second band of 
approximately 100 bp and 125 bp was observed for groups 181 and 182 respectively. The 
larger size product could again represent off-target amplification as the band can be seen in 
both BJ1035 and bovine lymphoblast samples. 
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Any sample that showed a band regardless of size was cloned and sent for sequencing. As no 
distinct band could be discerned for groups 95, 163 and 64p they were not sequenced. Twenty- 
two out of thirty-two groups sequenced were confirmed to be miRNAs using this method. 
When the remaining nine groups (3, 13, 45, 53, 60, 128, 181, 182, 96p) were sequenced the 
resulting sequence contained either the primer sequence followed by a few nucleotides that 
did not match the predicted miRNA sequence or the primer sequence followed by a number 
of nucleotides that aligned to a bovine mRNA sequence. This most likely represents off-target 
effects of the primers which could not be improved due to the constriction of primer design. 
These latter results were similar to the sequences obtained when any bovine lymphoblast 
samples were sequenced and as such could not be confirmed by this method. 
                                                
              A        GGC     ACUGUG 
miR-216a              5' UAAUCUC    GCU         A                  A    3' 
ovhv2-miR-73-1  5' UAAUCUC    GCU         A                  A     3' 
                                                       U        CCA     UUGUAA     U 
Figure 3.1. Comparison of the sequences of ovhv2-miR-73-1 and 
miR-216a  
Seed sequences are shown in red.  




3 BJ 3 Bov 6 BJ 6 Bov 13 BJ 13 Bov 
34 BJ 34 Bov 37 Bov 37 BJ 
38 BJ 38 Bov 39 BJ 39 Bov 40 BJ 40 Bov 
41 BJ 41 Bov 42 BJ 42 Bov 43 BJ 43 Bov 


























36 BJ 36 Bov 
49 BJ 49 Bov 50 BJ 50 Bov 51 BJ 51 Bov 




















60 BJ 60 Bov 58 BJ 58 Bov 62 BJ 62 Bov 
63 BJ 63 Bov 83 BJ 83 Bov 95 BJ 95 Bov 
















181 BJ 181 Bov 






Figure 3.2. Analysis of OvHV-2-encoded miRNA expression using the miScript 
Kits 
RT-PCRs for candidate miRNAs were analysed by agarose gel electrophoresis. Numbers 
represent groups, BJ = BJ1035 samples and Bov = uninfected bovine lymphoblast samples. 
Each assay was carried out in triplicate. Any group with a product observed was cloned and 
subsequently sequenced.  
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3.4 Specific cDNA method 
To confirm whether or not the remaining fifteen candidates were real miRNAs or not a second 
PCR approach was used. This method was adapted from (Varkonyi-Gasic et al., 2007) but did 
not include a SYBR Green assay and was carried out as described in sections 2.2.4 and 2.2.7. 
The stem-loop RT primer covers the last six nucleotides of the miRNA and the forward primer 
covers the full length of the miRNA excluding the last six nucleotides. Therefore sequencing 
of the resulting product would be meaningless as any sequence would contain only the primer 
sequences. For this reason a product observed by agarose gel electrophoresis in the BJ1035 
sample but not bovine lymphoblast sample was taken as a positive result. Five out of fifteen 
putative miRNAs were confirmed by this method (Figure 3.3 A). Minus RT controls for 
BJ1035 samples positive for the miRNA of interest were performed to ensure amplification 










lymphoblasts  BJ1035 M M         -RT 
A B 
Figure 3.3. Analysis of OvHV-2-encoded miRNA expression using miRNA 
specific RT-PCR.  
A) Expression of five predicted OvHV-2-encoded miRNAs in BJ1035 cells but not 
uninfected bovine lymphoblasts was confirmed by miRNA specific RT-PCR. Each assay 
was carried out in triplicate. M : 50bp and 100bp markers. B) miRNA specific RT-PCR 
was carried out along with a no RT (-RT) control.   
BJ1035 




A total of twenty-seven miRNAs were confirmed by either PCR method bringing the total 
number of confirmed miRNAs to thirty-five. Table 3.1 lists the miRNAs confirmed with their 
consensus sequence, 5’ and 3’ co-ordinates in the OvHV-2 genome (accession 
no. AY839756.1) and validation method. All the miRNAs validated are on the minus strand 
i.e. they are transcribed in the same orientation, right to left. Figure 3.4 shows the OvHV-2 
genome with relative locations of confirmed miRNAs. By convention, virus-encoded miRNAs 
are named in relation to the nearest ORF transcribed in the same direction as the miRNA. 
Confirmed miRNAs have been named according to this nomenclature, including those 
confirmed by Dr Levy, previously designated ovhv2-miR-1 to 8. Two miRNAs are encoded 
at the left hand end of the genome between the terminal repeat region and 3’ end of ORF Ov2 
and are named ovhv2-miR-Ov2-1 and -2. Like AlHV-1 and equine herpesvirus 2 (EHV-2), 
OvHV-2 also contains two large regions of the genome where no ORFs are predicted (Hart et 
al., 2007). The majority of the miRNAs (thirty out of thirty-five) are located in two clusters in 
the larger of these two regions. Twenty seven miRNAs are located at the left hand of this 
region in a cluster spanning 4377 bp and a smaller cluster containing three miRNAs are located 
at the right hand of this region spanning 320 bp. These miRNAs have been named ovhv2-miR-
17-1 to -30. One miRNA is encoded in a non-coding region towards the right end of the 
genome and is designated ovhv2-miR-73-1. Finally, two miRNAs are encoded within ORFs 
24 and 61 and are consequently named ovhv2-miR-24-1 and ovhv2-miR-61-1 respectively. 
This work was published in 2014 and the paper can be found in Appendix 11 (Nightingale et 
al., 2014). 
The number of miRNAs expressed by individual herpesviruses ranges from at least three to 
fifty (Kincaid & Sullivan, 2012) and OvHV-2 encodes at least thirty-five miRNAs. An 
algorithm used by (Walz et al., 2010) predicted sixty-one hairpin sites in the OvHV-2 genome 
that might encode miRNAs. Of these, 32 have been confirmed to be expressed. Three of the 
miRNAs (ovhv2-miR-24-1, -61-1 and -73-1) confirmed by the PCR methods used here were 
not predicted by Walz et al.. CLASH was performed by a previous PhD student and will be 
described in further detail in section 4.1 (Riaz, 2014). Although the main aim of this method 
is to elucidate targets of miRNAs the data can also be used as a validation of the first RNA 
sequencing assay performed by Dr Levy. Thirty-three of the thirty-five miRNAs confirmed by 
either PCR or northern hybridisation were found in the CLASH data. ovhv2-miR-24-1 and -
61-1 were the two miRNAs not detected in the CLASH protocol; these miRNAs were also the 
only two miRNAs confirmed by PCR that only had one read in the small RNA sequencing 
data. None of the miRNAs, not confirmed by PCR but predicted by Dr Levy, were detected in 
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the CLASH protocol providing further support that the miRNAs confirmed by PCR are 
expressed by the virus.  
The lack of a tissue culture system for OvHV-2 means that investigating miRNAs in the 
context of infection is challenging, unless performed in the rabbit model of MCF which is out 
with the scope of this project. The small RNA sequencing originally performed by Dr Levy is 
a snapshot of what is happening at that precise moment in the cell; expression of virus-encoded 
miRNAs is often highly context dependent (Forte & Luftig, 2011) and the miRNAs not 
detected by PCR may be subject to tight regulation of their expression. The BJ1035 cells do 
not represent a natural infection of OvHV-2 as the virus does not appear to be truly latent but 
also does not go through a full replication cycle resulting in the production of virus. It is 
therefore entirely possible that the ten miRNAs not found are only expressed in the context of 
a natural infection and would therefore not be detected by any of the methods used in BJ1035 
cells.  
One of the reasons PCR was chosen over northern hybridisation for validating the remaining 
candidate miRNAs was the potential for quantification, however this was not performed. As 
the only available material to work with within the scope of the project was the BJ1035 cells 
it was deemed that quantification would not necessarily add any insight into virus biology. 
miRNA* candidates were also not investigated however there is potential to use the PCR 
methods described to carry out validation of these in the future if it becomes of interest. 
Mapping the transcripts and promoter region of the large cluster of OvHV-2-encoded miRNAs 
by northern hybridisation was unsuccessfully attempted by Dr Riaz. Mapping of promoter 
regions for other OvHV-2-encoded miRNAs was not attempted as it was out with the scope 
of this project and characterisation of the targets of OvHV-2-encoded miRNAs was deemed 
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5’nt 3’nt Sequence 
Validation 
Method 
Ov2-2 miR-1 10588 √ 927 906 AAGGCUUGAUAAGUAGCACUGA Levy et al. 
Ov2-1   253 √ 1182 1161 AUGCUUGUUUAGGCCCCAUGAA Sequencing 
17-30  434 √ 27722 27702 UUUGGGUGUCUCCUGUCAUCU Sequencing 
17-29 miR-2
 
 39169 √ 27903 27881 AUCUUGGACGCAUCUGUCAGUAG Levy et al. 
17-28   6200 √ 28066 28045 UCUAGGUUGCAUUUUGCUGUAG Sequencing 
17-27 
 6015 √ 28209 28188 CCCACAUUUAAGGUGCUCGUGU Sequencing 
17-26 
 322 √ 28381 28361 AUAUUCGUUUAGACGCAAGUA Sequencing 
17-25 
 4717 √ 28515 28495 CAAUGCUGCUUUGGUGCCUCA Sequencing 
17-24 
 1014 √ 28683 28661 GGGUUCCUCGAGUGGAUAUUGUU Sequencing 
17-23 
 21686 √ 28781 28761 AUACACACUGAAAGAGCUAGA Sequencing 
17-22 
 740 √ 28888 28866 AUAAGGCCAACACUAGGUGCUGU Sequencing 
17-21 
 31227 √ 29052 29028 AAGCACCUUGGGUGAUGUCUCUGUU Sequencing 
17-20 miR-3
 
 14694 √ 29248 29226 UCUGUAUCAUAGGGGUUGUGUUG Levy et al. 
17-19 
 6487 √ 29345 29323 AAGCAUAGCUGGGAGUGUCUAGA Specific cDNA 
17-18 
 9219 √ 29455 29434 UAGUAGUCCGUUAACGCAAAGU Sequencing 
17-17 miR-4
 
 17508 √ 29637 29616 AAGGAUCCUUAAGUGACGAACG Levy et al. 
17-16 
 8095 √ 29745 29725 UAAACUGGUGGUAGGCGGUCU Sequencing 
17-15 
 2967 √ 29945 29923 UAGCAGUUAUGCAGGUAUCUGGU Sequencing 
17-14 
 3794 √ 30091 30067 UGGCAUUUCCAGGAGCCUGUUGUUC Sequencing 
17-13 
 24497 √ 30338 30316 UUGGGUCCAACAUGAGACGCGGU Sequencing 
17-12 
 14966 √ 30510 30489 UAUGUCAGAAGUGAAGCUGAGA Specific cDNA 




 1357 √ 30632 30611 UGGUUUGCAUCUGCACCCAGUU Sequencing 
17-10 miR-5 11187 √ 30818 30796 UGAAGUUACAGCUGCACCUGGAU Levy et al. 
17-9 
 5457 √ 30980 30956 UAGAGUUACUAAGGAUUCCCUGGUA Sequencing 
17-8 
 942 √ 31085 31066 AAUCGCCGGUGGCCUUCUAG Sequencing 
17-7 
 351 √ 31359 31340 UAUAGACGGGUAUGCUGCCG  Specific cDNA 
17-6 miR-6 10378 √ 31462 31440 UAUUUUUAGCGGAGACCUCUAGG Levy et al. 
17-5 
 1535 √ 31603 31582 CCUUUUUGGUGAGUUGCCCUGU Sequencing 
17-4 
 517 √ 32075 32054 GAUUUGAUAAAGCCUGCCUGCG Sequencing 
17-3 miR-7 16574 √ 36313 36289 GAAGGCGCAUCAUAGACACCACUUC Levy et al. 
17-2 
 7834 √ 36462 36441 ACCCCGGGGGUAUGUGCAGGAC Sequencing 
17-1 miR-8 46048 √ 36575 36554 UGGCUCAGCGUGACUGCUCUUC Levy et al. 
24-1 
 1 x 48585 48560 GAGCAGUACUACACAGCAGACAACAU Sequencing 
61-1 
 1 x 96435 96411 UUGGGGACGUGCUGGCUGACGACGU Specific cDNA 
73-1 
 6064 x 117122 117100 UAAUCUCUGCUCCAAUUGUAAAU Specific cDNA 
The 35 validated miRNAs are listed. Previous name: designation in Levy et al. 2012. Abundance (RNA-seq): Total number of sequence 
tags representing the miRNA in the RNA-seq data. Walz et al.: miRNAs predicted by Walz et al. √ = yes; X= no. 5’nt/3’nt: the first and 
last nucleotides of the mature miRNA on the OvHV-2 genome (AY839756). Sequence: sequence of the mature miRNA. Validation method: 
Levy et al.: validated previously; Sequencing: validated using RT-PCR and subsequent sequencing; Specific cDNA: validated using the 
specific cDNA method.  
 





  Figure 3.4. Location of miRNAs in the OvHV-2 genome. 
A) The relative positions of the predicted miRNAs in the OvHV-2 genome are shown. Numbering is from Hart 
et al. The genome is represented by a thin line and ORFs are indicated by blue boxes. Boxes above the line 
represent ORFs transcribed left to right; those below the line represent ORFs which are transcribed right to left. 
Only those ORFs adjacent to predicted miRNAs are named. Arrows indicate the position of the predicted 
miRNAs; arrows above the line represent miRNAs transcribed left to right, those below the line represent 
miRNAs which are transcribed right to left. Dark blue vertical arrows indicate validated miRNAs, Red arrows 
indicate non-validated miRNAs named according to their groups (see Figure 3.2). Those OvHV-2 ORFs closest 
to validated miRNAs and after which those miRNAs are named are shown in dark blue. B) The locations of 
ovhv2-miR-17-1 to -30 are shown in more detail. Numbers in brackets are the previous names of miRNAs 
validated by C. Levy. 
















4.3 Validation of DLL1 as a target of OvHV-2-encoded miRNAs 
4.4: Investigating targets of ovhv2-miR-73-1 based on its         
homology to miR-216a 








Identification of cellular targets of OvHV-2 miRNAs is necessary in order to support the 
hypothesis that virus-encoded miRNAs may play a role in the differences observed in 
pathogenesis of MCF and to begin to explain the difference between the outcome of OvHV-2 
infection in sheep and cattle. The effect of virus-encoded miRNAs on pathogenesis is well 
documented in a number of herpesviruses including MDV, KSHV and EBV. MDV encodes a 
miR-155 homologue, mdv1-miR-M4, shown to be critical in the development of lymphomas. 
Upon deletion of this miRNA the ability of the virus to induce lymphomas was abolished 
(Zhao et al., 2011), however this has not been confirmed in very virulent strains of MDV (Yu 
et al., 2014). KSHV also encodes a miR-155 homologue which may also contribute to the 
induction of B cell tumours (Gottwein et al., 2007; Skalsky et al., 2007). Although EBV does 
not encode a miR-155 homologue it has been shown to induce cellular miR-155 expression 
(Linnstaedt et al., 2010) allowing for B cell immortalisation. It has also been shown that EBV-
encoded miRNAs play a role in cellular transformation; recombinant EBV that lacks the 
BHRF1 cluster of miRNAs displays reduced transforming capability (Feederle et al., 2011). 
The development of MCF in susceptible species is poorly understood and it is possible that 
OvHV-2-encoded miRNAs play a role. It is likely that OvHV-2 co-evolved with sheep, its 
natural host, and therefore it is likely that virus-encoded miRNAs also evolved to target sheep 
genes. When OvHV-2 infects a susceptible host virus-encoded miRNAs may not target the 
same pathways as in sheep or may target entirely different pathways which may contribute to 
MCF pathogenesis. It is not only important to elucidate targets of OvHV-2-encoded miRNAs, 
but also determine whether there is differential targeting of sheep and cattle transcripts, and 
whether this could explain any differences observed in the pathogenesis of the virus between 
the two closely related species. 
Previous work looking a target identification used a biochemical technique called CLASH 
(described in section 1.6.4). SEFs were transduced with a lentivirus containing ovhv2-miR-
17-1, -2 and -3 and CLASH was performed (Riaz, 2014). Delta-like 1 (DLL1), a ligand for 
Notch receptor signalling, was the only gene to be identified in all 3 biological replicates and 
as a differentially enriched gene this was taken forward for validation.  
Another method for target identification is to determine whether any OvHV-2-encoded 
miRNAs share homology to any cellular miRNAs; and it was shown (Levy, 2011) that ovhv2-
miR-73-1 is homologous to miR-216a (Figure 3.1). miR-216a has been shown to target 
phosphatase and tensin homologue (PTEN), a negative regulator of Akt signalling, and Y box 
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binding protein 1 (YB-1), a DNA binding protein (Kato et al., 2009; Kato et al., 2010). Both 
PTEN and YB-1 were chosen for validation as targets of ovhv2-miR-73-1.  
A final method for target identification is to use bioinformatics. For the purposes of this thesis, 
RNAHybrid was chosen as the preferred prediction programme. Based on the fact that many 
viruses interact with the MHC class II pathway as a mechanism of immune evasion it was 
hypothesised that MHC class II genes could be a target of OvHV-2-encoded miRNAs (Zuo & 
Rowe, 2012a). 
4.2 Aims 
The aim of this part of the project was to identify cellular targets of OvHV-2-encoded miRNAs 
using a combination of biochemical and bioinformatic prediction methods. Differences in 
targeting between sheep and cattle were also investigated to determine whether miRNAs play 
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4.3 Validation of DLL1 as a target of OvHV-2-encoded miRNAs 
 
4.3.1 DLL1 introduction 
DLL1 is one of the ligands for the Notch receptor and binding of DLL1 to Notch causes 
activation of the Notch signalling pathway. DLL1 is a membrane-bound ligand and as such 
activation of Notch signalling is cell-cell mediated. Notch was originally identified as a 
pleiotropic regulator of cell fate, in almost every cell type, and as a major determinant in 
lymphocyte differentiation (Andersson et al., 2011; Guruharsha et al., 2012). Since the initial 
discovery of Notch, subsequent research has expanded our understanding of the roles of Notch 
further into control of cell lineages in the innate immune system, as well as regulation of T 
cell function and differentiation. Inactivation of Notch signalling leads to a block early in T 
cell development (Radtke et al., 2013). It was observed in vitro that DLL1 could completely 
block B cell differentiation while promoting emergence of cells with a T cell/natural killer cell 
precursor phenotype (Jaleco et al., 2001). As OvHV-2 infects T cells, the ability of the virus 
to modulate T cell function is likely to be key to a successful latent infection. It has been shown 
that EBV infects any B cell and drives it into a memory B cell phenotype enabling a circulating 
population of infected cells to persist (Thorley-Lawson, 1998). OvHV-2 may also need to alter 
the phenotype of infected T cells to allow for persistence. It therefore makes sense that Notch 
signalling may be altered and down-regulation of DLL1 leading to lower levels of Notch 
signalling could be favourable for maintenance of latency of OvHV-2 in sheep. If the targeting 
of DLL1 in sheep can be confirmed and there is differential targeting of DLL1 in cattle (i.e. no 
or little targeting of DLL1) this could be a contributing factor promoting latency in sheep in 
contrast to the progression of infected cattle cells into large granular lymphocytes 
characteristic of MCF. 
Canonical Notch signalling begins with binding of one of five ligands belonging to either the 
Jagged family (Jagged 1 and Jagged 2) or Delta-like family (DLL1, DLL3 and DLL4) to the 
Notch receptor. This triggers two proteolytic cleavage events which release the Notch 
intracellular domain (NICD) from the membrane. NICD then translocates to the nucleus where 
it binds the J kappa-recombination signal binding protein (RBPJ) family of transcription 
factors inducing expression of downstream genes (Radtke et al., 2013). Published Notch target 
genes include transcription factors belonging to the hairy/enhance of split family (these genes 
play a key role in development and cell fate decision), the transcription factor GATA3 which 
is a master regulator of T cell development and Th1/Th2 lineage commitment, and interleukin 
2 receptor, alpha chain (IL2RA or CD25) (Borggrefe & Oswald, 2009).  
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Interaction with RBPJ by both EBV and KSHV is well-documented. It has been shown that 
EBNA2, the major initiator of transcription of genes involved in type III latency, and NICD 
have partially interchangeable functions in regards to B cell target gene expression (Rowe et 
al., 2014; Zimber-Strobl & Strobl, 2001). In KSHV, ORF50, the major reactivation protein of 
the virus, interacts with RBPJ (Liang et al., 2002b). It is interesting that KSHV uses 
constitutive activation of Notch signalling as a strategy for reactivation from latency whereas 
EBV uses the Notch pathway to enter latency. If OvHV-2 modulates Notch signalling it is not 
clear which aspect of virus biology it would influence.  
Although no virus-encoded miRNAs have been shown to target DLL1 or the Notch signalling 
pathway, the cellular miRNA miR-1 has been shown to negatively regulate DLL1 protein 
levels in mouse embryonic stem cells (Wang et al., 2010). 
DLL1 was identified as a target of ovhv2-miR-17-2 in CLASH performed by Dr Riaz (Riaz, 
2014). The role DLL1 and Notch signalling may play in MCF pathogenesis, and the fact that 
DLL1 formed the most hybrids in all three CLASH tests made it a prime candidate for further 
investigation. Initial validation of DLL1 as a target of ovhv2-miR-17-2 and luciferase assays 
showed an approximately 60% down-regulation of relative luciferase levels with ovhv2-miR-
17-2 compared to a scrambled siRNA with a luciferase construct containing two DLL1 target 
sites (Riaz, 2014). Due to time constraints, mutagenesis of the target sites was not performed. 
Analysis of other DLL1 target sites revealed by CLASH, and examination of the cattle DLL1 
sequences for target sites was also not performed.  
4.3.2 RNAHybrid analysis of DLL1 mRNA sequences 
RNAHybrid was used to investigate the predicted sheep DLL1 mRNA sequence (accession 
number XM_004011569.1) and the cattle DLL1 transcript variant 1 mRNA sequence 
(XM_002690401.2) for targets of ovhv2-miR-17-2. Analyses can be seen in Figure 4.1. 
Targets identified by RNAHybrid had perfect complementarity between nucleotides 2 and 8 
of the miRNA and no G:U base pairing in that region.  
Analysis of the sheep DLL1 mRNA sequence revealed three potential binding sites of ovhv2-
miR-17-2, located in the coding region. The site starting at position 2642 (site 1) was the 
primary target site identified in CLASH and was used in the initial luciferase assays (Riaz 
2014). The other two sites revealed by RNAHybrid were also found as hybrids in the CLASH 
data. One of these, starting at position 2591 (site 3) is in close proximity to site 1. The other 
site, starting at position 1241, was not included in the validation work described in subsequent 
sections. A fourth target site, not shown by RNAHybrid in this analysis was also identified in 
CLASH; nucleotides 2644-2650 are the nucleotides bound by the seed site of ovhv2-miR-17-
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2 (site 2). This site overlaps site 1 which is why it was not identified by RNAHybrid and was 
therefore also included in the initial luciferase assay.   
Analysis of the cattle DLL1 coding region only gave rise to one predicted binding site for 
ovhv2-miR-17-2, the position of which was homologous to site 3 in the sheep DLL1 sequence. 
Sites 1 and 2 were not present in the cattle DLL1 mRNA sequence. Analysis of the cattle DLL1 
mRNA sequence also identified two ovhv2-miR-17-2 binding sites in the 5’UTR region 
(RNAHybrid analysis not shown).  
It should be noted that the sequence of sheep DLL1 in Ensembl (ENSOART00000005568) 
differs to the sequence used here for RNAHybrid analysis and that NCBI now has an updated 
sequence for DLL1 (XM_012183355.1). The differences observed between sequences will be 
discussed further in section 4.3.4. 
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TARGET : Sheep_DLL1 
length: 3021 
MIRNA  : ovhv2-miR-17-2 
length: 22 
 
mfe: -39.9 kcal/mol 
p-value: undefined 
 
position  1241 
target 5' U      C  A          A 3' 
           UCCUGC CG GCUCCCGGGG     
           AGGACG GU UGGGGGCCCC     
miRNA  3' C      U  A          A 5' 
 
TARGET : Sheep_DLL1 
length: 3021 
MIRNA  : ovhv2-miR-17-2 
length: 22 
 
mfe: -32.9 kcal/mol 
p-value: undefined 
 
position  2591 (site 3) 
target 5'  A       GA    G       C 3' 
            CCUGUGC  GUGU CCCGGGG     
            GGACGUG  UAUG GGGCCCC     
miRNA  3' CA             G       A 5' 
 
TARGET : Sheep_DLL1 
length: 3021 
MIRNA  : ovhv2-miR-17-2 
length: 22 
 
mfe: -30.6 kcal/mol 
p-value: undefined 
 
position  2642 (site 1) 
target 5' U   CGGGGAGG    CCCG  A       G 3' 
           UCC        GCGC    AC CCCGGGG     
           AGG        CGUG    UG GGGCCCC     
miRNA  3' C   A           UA    G       A 5' 
 
TARGET : Cattle_DLL1 
length: 5060 
MIRNA  : ovhv2-miR-17-2 
length: 22 
 
mfe: -34.8 kcal/mol 
p-value: undefined 
 
position  2381 
target 5'  A     GUGA    G       C 3' 
            CCUGU    GUGC CCCGGGG     
            GGACG    UAUG GGGCCCC     
miRNA  3' CA     UG      G       A 5' 
 
Figure 4.1 RNA Hybrid analyses of Sheep and Cattle DLL1 mRNA sequences for 
target sites of ovhv2-miR-17-2 
Mfe = minimum free energy. Constraints on RNAHybrid analysis included perfect 
complementarity between nucleotides 2 and 8 with no G:U pairing. Positions refer to 
nucleotide start sites in accession numbers referenced in section 4.3.2. Targets shown are 
located in the coding region. 
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4.3.3 Validation of DLL1 as a target of ovhv2-miR-17-2 by luciferase assay and 
mutagenesis of target sites 
Due to the changes in annotation of the DLL1 mRNA sequence since the initial luciferase 
assays (Riaz 2014), and the fact that site 3 was in close proximity to sites 1 and 2, new 
luciferase constructs were made to include site 3. Oligonucleotides containing nucleotides 
2580-2682 were cloned into psiCHECK-2. Three mutated oligonucleotides were designed; 
one with site 1 mutated into a BamHI restriction enzyme site, one with site 3 mutated into a 
BamH1 restriction enzyme site and one with both site 1 and site 3 mutated into BamHI and 
EcoRV restriction enzyme sites respectively. Restriction enzyme sites were chosen to 
substitute seed sequence sites as they ablated ovhv2-miR-17-2 binding and served as a 
diagnostic tool for cloning. Site 2 was not mutated independently as mutation of this site would 
disrupt the 3’ of ovhv2-miR-17-2 binding to site 1. 
Luciferase assays were carried out as described in section 2.8.1. psiCHECK-2 expresses both 
Renilla luciferase and firefly luciferase. The multiple cloning site is located in the 3’UTR of 
Renilla luciferase and firefly luciferase acts an internal control. Renilla luciferase expression 
is normalised to firefly luciferase expression so that any changes in Renilla luciferase 
expression are due to co-transfection of miRNA mimics. Figure 4.2 shows the combined 
results of two independent luciferase assays with n = 12. No significant knockdown was 
observed when an ovhv2-miR-17-2 mimic was co-transfected with psiCHECK-2 compared to 
a scrambled siRNA control. When the same mimic was co-transfected into cells with a 
psiCHECK-2 construct containing the DLL1 sequence described above a 35% reduction in 
relative luciferase expression was observed compared to a scrambled siRNA control (p ≤ 
0.0001). When an ovhv2-miR-17-2 mimic was co-transfected with psiCHECK-2 constructs 
containing site 1 mutated or site 3 mutated DLL1 constructs approximately 30% (p ≤  0.01) 
and 25% (p ≤ 0.0001) reductions in relative luciferase expression was observed compared to 
a scrambled siRNA control. When an ovhv2-miR-17-2 mimic was co-transfected with a 
psiCHECK-2 construct containing both site 1 and site 3 mutations in the DLL1 sequence 
relative luciferase levels were restored with no significant difference observed between 
scrambled siRNA and ovhv2-miR17-2.  
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*** *****
Figure 4.2 Relative luciferase expression levels of DLL1-psiCHECK-2 and 
mutant DLL1-psiCHECK-2 constructs with ovhv2-miR-17-2 compared to a 
scrambled siRNA 
293T cells were co-transfected with a psiCHECK-2 construct containing a 100 bp region 
of DLL1 containing the predicted miRNA sites; or with the first site mutated, the third site 
mutated or both the first and third site mutated and an ovhv2-miR-17-2 mimic or a 
scrambled siRNA control. After 48 hrs, Renilla luciferase levels were measured, 
normalised to firefly luciferase levels and expression in control and test miRNA compared.  
** = p < 0.01, *** = p <0.0001 
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4.3.4 Analysis of genome sequences of sheep DLL1 
Comparison of the sheep DLL1 mRNA sequence in NCBI (XM_004011569.1) and Ensembl 
(ENSOART00000005568) revealed striking differences in the coding region of DLL1, which 
is summarised in Figure 4.3 (Appendix 3 for alignments). At the genomic level, the sequences 
in NCBI and Ensembl are identical. The NCBI DLL1 mRNA sequence is 3021 bp long 
whereas the Ensembl DLL1 mRNA sequence is only 1845 bp long. The main difference 
between these two sequences is that the 5’ end of the NCBI sequence is not present in the 
Ensembl sequence, which does not start with an ATG codon. This implies that the start site of 
the coding region of DLL1 may be incorrectly annotated in Ensembl. The other main region 
of variation between the two sequences is located towards the 3’ of the sequence, where three 
of the predicted ovhv2-miR-17-2 binding sites are located. In Ensembl, the distance of site 3 
from site 1 is approximately 200 bp more than in NCBI. Site 3 is located in a different exon to 
sites 1 and 2; the intron in between is largely unannotated hence the precise intron/exon 
boundary cannot be fully mapped.  
4.3.5 Amplification of the DLL1 region containing ovhv2-miR-17-2 target sites 
In order to determine whether NCBI or Ensembl had the correct sequence in regards to the 
location of ovhv2-miR-17-2 target sites, primers were designed to amplify the region spanning 
the three sites (Appendix 2 for sequences), from nucleotides 2416 to 2745 of the NCBI sheep 
DLL1 sequence (Figure 4.3 “c”). PCR was performed on cDNA made from sheep mesenteric 
lymph node RNA (a kind gift from Louise Nicol). Sequencing of the PCR product revealed 
that the only ovhv2-miR-17-2 binding site present was site 3, and that the sequence obtained 
was highly similar to the bovine DLL1 sequence. To elucidate the intron/exon boundary site 
that was mapped differently in NCBI and Ensembl versions of DLL1, the same primers were 
used to amplify the region from SEF genomic DNA. The PCR product from the genomic DNA 
was identical in size and sequence to that obtained from cDNA showing that there is no intron 
in this region. 
  





NCBI Sheep Sequence: 1 2 3 
Ensembl Sheep Sequence: 
1 1845 
1 2 3 
1 2169 
NCBI Cattle Sequence: 
3 
 SEF gDNA SheepMes LN cDNA  Sheep Mes LN RACE cDNA 
1 3021 
Obtained Sequence: 
to poly A tail 
2400 1500 
3 a b c d 
e 
Figure 4.3 Schematic of aligned DLL1 sequences  
Black horizontal bars represent coding sequence, with numbers representing nucleotide number. Black vertical bars represent target binding sites for ovhv2-
miR-17-2. White boxes represent obtained sequence of DLL1 from SEF gDNA. The light grey box represents sequence obtained from 3’ RACE PCR 
performed with mesenteric lymph node cDNA. The dark grey box represents sequence obtained from mesenteric lymph node cDNA. The diagonal striped 
dark grey and white box represents a region where both SEF gDNA and mesenteric lymph node cDNA have been used to obtain sequence. Small letters a 
to e represent the order in which sequencing was performed. 
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4.3.6 Validation of confirmed DLL1 sequence as a target of ovhv2-miR-17-2 by 
luciferase assay 
Primers tagged with appropriate restriction enzymes (forward primer with XhoI and reverse 
primer with NotI, Appendix 2) were used to amplify nucleotides 2416-2745 and were 
subsequently cloned into psiCHECK-2. Luciferase assays were carried out as described in 
section 2.8.1 with n = 12 for each plasmid. A statistically significant (p = 0.001) reduction of 
25% of relative luciferase expression levels was observed when ovhv2-miR-17-2 was co-
transfected with the psiCHECK-2 plasmid containing DLL1 sequence compared to the 
scrambled siRNA (Figure 4.4). No significant knockdown was observed when an ovhv2-miR-
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Figure 4.4 Relative luciferase expression levels of obtainedDLL1-
psiCHECK-2 with ovhv2-miR-17-2 compared to a scramble siRNA 
293T cells were co-transfected with a psiCHECK-2 construct containing a 330 bp region 
of DLL1 (diagonal striped dark grey and white box in Figureure 4.3), and an ovhv2-miR-
17-2 mimic or a scrambled siRNA control. After 48 hrs, Renilla luciferase levels were 
measured, normalised to firefly luciferase levels and expression in control and test 
miRNA compared.  
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4.3.7 Amplification of DLL1 and RACE PCR 
Two regions of the DLL1 gene were chosen for amplification in order to develop an RT-qPCR 
assay (Figure 4.3 “a” and “b”).  Primers were designed to amplify a 150 bp region (nucleotides 
1970 to 2119, Figure 4.3 “a”). PCR was performed on SEF gDNA and subsequent sequencing 
revealed a 130 bp insert in the middle of the sequence of the PCR product which partially 
aligned to the genomic sequence of DLL1 (Appendix 3). Region “b” was designed to amplify 
a 218 bp region from nucleotide 1538-1756. PCR was performed on SEF gDNA and the 
sequence obtained matched the NCBI sheep DLL1 sequence. Due to difficulty in finding a 
sheep cell line that expressed DLL1 and the inconsistencies in the reported sequences of DLL1 
the RT-qPCR was not developed any further. 
To determine whether the ovhv2-miR-17-2 binding sites 1 and 2 were present in the cDNA of 
DLL1, 5’ and 3’ RACE PCR were performed. Primers were designed using the sequences 
obtained from the hybrids in CLASH (Appendix 2 for primers). RACE PCR was performed 
on cDNA made from sheep mesenteric lymph node. The PCR product was analysed by agarose 
gel electrophoresis and one band was extracted and purified from the 3’ RACE sample. The 
remaining 3’ RACE PCR product and 5’ RACE PCR product were purified and cloned into 
pCR2.1-TOPO. A number of colonies were picked and a restriction digest performed. Four 5’ 
RACE colonies were sent for sequencing, however none contained the primer sequence or 
mapped to DLL1, and this was not investigated further. Of the seven colonies sent for 
sequencing from the 3’ RACE PCR purified product, one was 99% identical to goat 
(XM_005685019.1) and 97 % identical to cattle (XM_002690401.2) DLL1 (Appendix 3). The 
seven colonies from the 3’ RACE extracted band also all mapped to goat and cattle DLL1 with 
partial alignment to the sheep genome (Appendix 3).  
The sequence obtained from 3’ RACE did not contain ovhv2-miR-binding site 1 or site 2, and 
did not overlap with the sequencing obtained in section 4.3.5. Primers were designed to 
amplify the region between these two sites (Figure 4.3 “e”, Appendix 2 for primer sequence). 
PCR was performed on sheep mesenteric lymph node cDNA and the sequence obtained again 
aligned to the cattle DLL1 sequence. A combined sequence was made from the sequence 
obtained in section 4.3.5, the 3’ RACE sequencing and the sequence joining those two regions 
(Appendix 3). This sequence had no significant similarity to the sheep DLL1 cDNA sequence 
in NCBI but did partially map to chromosome 8 in the sheep genome assembly OARv3.1, in 
the region where DLL1 is predicted (Appendix 3). Importantly, the ovhv2-miR-17-2 binding 
sites 1 and 2 were not present in this sequence, and as such this work was not continued. 
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4.4 Investigating targets of ovhv2-miR-73-1 based on its homology to miR-216a 
 
4.4.1 PTEN Introduction 
PTEN is a well-known tumour suppressor (Song et al., 2012). Its primary role is to 
dephosphorylate phosphatidylinositol 3,4,5-trisphosphate (PIP3), preventing accumulation of 
PIP3 in the cell allowing Akt (v-Akt murine thymoma viral oncogene homolog 1) activation 
and downstream signalling (Maehama & Dixon, 1998; Stambolic et al., 1998). PIP3 is 
generated by the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to PIP3 by 
phosphatidylinositol-3-kinase (PI3K) which occurs when the cell receives growth stimulation 
signals (Salmena et al., 2008). Akt is recruited to the site of PIP3 by direct interaction with its 
pleckstrin homology domain; the action of two kinases subsequently activate Akt. Akt can be 
considered a hub protein as it is able to interact with a large number of proteins in the cell. The 
outcomes of these interactions can be loosely classed into a few major pathways; survival, 
proliferation and cell growth (Vivanco & Sawyers, 2002). Akt also plays a role in metabolism, 
angiogenesis and glucose uptake, which are of high significance in enabling tumorigenesis 
(Manning & Cantley, 2007). Figure 4.5 summarises some of the downstream targets of Akt 
signalling and the pathways that are affected.  
Given that an OvHV-2 infected cell needs to be able to avoid apoptosis, induce cell growth, 
and increase glucose uptake and metabolism to cope with virus replication; and that 
uncontrolled proliferation is one of the hallmarks of MCF pathogenesis it was hypothesised 
that targeting of the Akt pathway by OvHV-2 would be consistent with the observed biology. 
The suppression of apoptosis is of particular importance for herpesviruses which need to 
maintain a latent state. In EBV, LMP1 can activate PI3K, stimulating Akt activation, which 
significantly contributes to B cell transformation (Chen, 2012). It has been shown that Akt 
signalling may also be required for reactivation of EBV from latency (Iwakiri & Takada, 
2004). EBV also encodes a miRNA, miR-BART7-3p that specifically targets PTEN and has 
been shown to promote epithelial-mesenchymal transition and metastasis of NPC cells (Cai et 
al., 2014). Cellular miRNAs have also been shown to directly target PTEN including miR-21, 
miR-32 and miR-144, as well as miR-216a (Kato et al., 2009; Meng et al., 2007; Poliseno et 
al., 2010; Wu et al., 2013; Zhang et al., 2013). As ovhv2-miR-73-1 shares homology with 
miR-216a it was hypothesised that it might also target PTEN.  
 




























Figure 4.5 Schematic of Akt substrates and involved pathways 
Phosphorylation of Akt leads to activation (arrows) or inhibition (blocking arrows) of twelve substrates shown here. The different 
background colours of the genes represent the different pathways they are involved in (see key for details). Connecting dark blue 
and dark green lines represent that the genes are involved in either metabolism or proliferation respectively.  
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4.4.2 YB-1 Introduction 
YB-1 is a member of the cold-shock domain containing family Y-box transcription factors, 
first identified as a protein able to bind to the Y-box sequence present in MHC class II 
promoters (Mihailovich et al., 2015). YB-1 can bind both DNA and RNA and is a major 
component of messenger ribonucleoprotein complexes (mRNPs). It plays a role in a large 
range of DNA- and mRNA-dependent processes including transcription, pre-mRNA splicing, 
translation and stabilisation of mRNA transcripts (Eliseeva et al., 2015). YB-1 binds  in 
proximity to the 5’ cap structure of mRNAs and is thought to be able to compete with the 
translation initiation factors eIF4E and eIF4G for binding, allowing translational repression of  
target transcripts (Evdokimova et al., 2006a). Phosphorylation of YB-1 can release transcripts 
returning them to the translational pool. TSC22 Domain Family, Member 1 (TSC22D1) 
mRNA is known to be repressed by YB-1. TSC22D1 can interact with an E-box regulator 
transcription factor E3 (TFE3) and in turn increase collagen type I α-2 expression (Kato et al., 
2010). Down-regulation of YB-1 by an OvHV-2-encoded miRNA to release TSC22D1 
transcripts could explain why sclerosis is often seen in MCF.  
Research into the role YB-1 plays during virus infection has largely focused on the interaction 
of the human polyoma JC virus (JCV) large T antigen with YB-1 and the effect this has on the 
modulation of transcription of JCV-encoded genes (Safak et al., 1999). There is also evidence 
that HIV and adenoviruses also interact with YB-1 and it has been shown that the latent 
membrane protein LMP2A of EBV may down-regulate YB-1 expression in gastric carcinomas 
(Eliseeva et al., 2015; Zhang et al., 2014). 
Investigating the relationship YB-1 has with miRNAs reveals a 2-way interaction; cellular 
miRNAs can target and down-regulate YB-1 expression, and conversely due to the RNA 
binding capabilities of YB-1, it has the potential to silence miRNA expression (Blenkiron et 
al., 2013). Cellular miRNAs known to target YB-1 include miR-216a and miR-137 (Kato et 
al., 2010; Zhu et al., 2013). 
There is some crosstalk between the functions of PTEN and YB-1. YB-1 is a direct target of 
Akt phosphorylation which has been shown to weaken the ability of YB-1 to bind the 5’ of 
capped mRNAs (Evdokimova et al., 2006b). This phosphorylation has no effect on the RNA-
binding ability of YB-1 and is thought to be a specific mechanism of Akt to increase cellular 
translation (Evdokimova et al., 2006a).  
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4.4.3 RNAHybrid analysis of PTEN and YB-1 
Figures 4.6 and 4.7 show the predicted binding of ovhv2-miR-73-1 and miR-216a to PTEN 
and YB-1 in sheep (XM_004020012.2 and NM_001093786.1) and cattle (XM_613125.6 and 
NM_174815.2). All predicted targets are located in the 3’UTR of either PTEN or YB-1. 
Analysis of the cattle PTEN sequence reveals one target site for both ovhv2-miR-73-1 and 
miR-216a; this is the site that had been previously validated for miR-216a (Kato et al., 2009). 
The miR-216a binding site has perfect complementarity and no G:U pairing between 
nucleotides 2 and 8 whereas only nucleotides 2 to 7 in the ovhv2-miR-73-1 binding site share 
the same qualities. This difference in binding most likely explains the increase in the minimum 
free energy (mfe) observed for ovhv2-miR-73-1 (-13.3 kcal/mol versus -17.3 kcal/mol for 
miR-216a). The binding of the 3’end of ovhv2-miR-73-1 is also different to that of miR-216a, 
but this is expected, due to the differences in miRNA sequence between the two miRNAs. In 
sheep there are two binding sites for both ovhv2-miR-73-1 and miR-216a although only the 
site starting at position 1098 for miR-216a has been previously validated (Kato et al., 2009). 
This site displays exactly the same binding qualities for both ovhv2-miR-73-1 and miR-216a 
as it does in cattle. The other site in sheep, starting at position 5815 for miR-216a, is of interest 
as it appears that ovhv2-miR-73-1 binds more strongly (-17.1 kcal/mol versus -14.1 kcal/mol 
for miR-216a).  
Analysis of the cattle YB-1 sequence showed one binding site for both ovhv2-miR-73-1 and 
miR-216a which is the site that had been previously validated (Kato et al., 2010). Again, the 
miR-216a binding site has perfect complementarity and no G:U pairing between nucleotides 
2 and 8 whereas for ovhv2-miR-73-1 there was only perfect complementarity and no G:U 
pairing between nucleotides 2 and 7. A lower mfe for ovhv2-miR-73-1 is observed (-16.3 
kcal/mol versus -21.3 kcal/mol for miR-216a). The predicted targeting of ovhv2-miR-73-1 and 
miR-216a in sheep YB-1 is identical to that described for cattle YB-1. 





miRNA : ovhv2-miR-73-1 
length: 23 
 
mfe: -13.3 kcal/mol 
p-value: 1.000000e+00 
 
position  1094 
target 5'   C    CA    AAUUUCAAUUU      C 3' 
             UGCA   GGA           GAGAUU     
             AUGU   CCU           CUCUAA     




miRNA : miR-216a 
length: 21 
 
mfe: -17.3 kcal/mol 
p-value: 1.000000e+00 
 
position  1096 
target 5' G     GAAAUU   AU        C 3' 
           CACAG      UCA  UUGAGAUU     
           GUGUC      GGU  GACUCUAA     




miRNA : ovhv2-miR-73-1 
length: 23 
 
mfe: -17.1 kcal/mol 
p-value: 1.000000e+00 
 
position  5814 
target 5'  G     UG    UUCUCAUCU  UCUUAAAAUGGUU       U 3' 
            UUACA  UGGA         GU             AGAGAUU     
            AAUGU  ACCU         CG             UCUCUAA     





miRNA : ovhv2-miR-73-1 
length: 23 
 
mfe: -13.3 kcal/mol 
p-value: 1.000000e+00 
 
position  1096 
target 5'   C    CA    AAUUUCAAUUU      C 3' 
             UGCA   GGA           GAGAUU     
             AUGU   CCU           CUCUAA     













miRNA : miR-216a 
length: 21 
 
mfe: -17.3 kcal/mol 
p-value: 1.000000e+00 
 
position  1098 
target 5' G     GAAAUU   AU        C 3' 
           CACAG      UCA  UUGAGAUU     
           GUGUC      GGU  GACUCUAA     





miRNA : miR-216a 
length: 21 
 
mfe: -14.1 kcal/mol 
p-value: 1.000000e+00 
 
position  5815 
target 5' U    U  GGAUUCUCAUC    CUUAAAAU    A      U 3' 
           UACA GU           UGUU        GGUU GAGAUU     
           GUGU CA           ACGG        UCGA CUCUAA     
miRNA  3'                                           U 5' 
 
Figure 4.6 RNA Hybrid analyses of Sheep and Cattle PTEN mRNA sequences 
for target sites of ovhv2-miR-73-1 and miR-216a. 
Mfe = minimum free energy. Constraints on RNAHybrid analysis included perfect 
complementarity between nucleotides 2 and 8 with no G:U pairing. Positions refer to 
nucleotide start sites in accession numbers referenced in section 4.4.3. Targets shown are 
located in the 3’UTR.  





miRNA : ovhv2-miR-73-1 
length: 23 
 
mfe: -16.3 kcal/mol 
p-value: 1.000000e+00 
 
position  292 
target 5'    C   UC   UCA   U      U 3' 
              AUA  UGG   AGU GAGAUU     
              UGU  ACC   UCG CUCUAA     




miRNA : miR-216a 
length: 21 
 
mfe: -21.3 kcal/mol 
p-value: 1.000000e+00 
 
position  291 
target 5' U    UCUG   A          U 3' 
           CAUA    GUC AGUUGAGAUU     
           GUGU    CGG UCGACUCUAA     
miRNA  3'      CAA               U 5' 
 
Figure 4.7 RNA Hybrid analyses of Cattle YB-1 mRNA sequences for target sites 
of ovhv2-miR-73-1 and miR-216a. 
Mfe = minimum free energy. Constraints on RNAHybrid analysis included perfect 
complementarity between nucleotides 2 and 8 with no G:U pairing. Positions refer to 
nucleotide start sites in accession numbers referenced in section 4.4.3. Targets shown are 
located in the 3’UTR.  
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4.4.4 Validation of PTEN and YB-1 as targets of ovhv2-miR-73-1 by luciferase 
assay 
A 100 bp sequence surrounding the target site (starting position 1096 for miR-216a in the 
cattle PTEN sequence) was cloned into psiCHECK-2 and luciferase assays were performed 
according to section 2.8.1 with n = 12. Figure 4.8 shows the relative luciferase expression 
levels for PTEN-psiCHECK-2 and YB-1-psiCHECK-2 with miR-216a and ovhv2-miR-73-1. 
A miR-216a mimic did not show any statistically significant difference when co-transfected 
with psiCHECK-2 compared to a scrambled siRNA. When a miR-216a mimic was co-
transfected with a PTEN-psiCHECK-2 construct a statistically significant reduction (p ≤ 
0.0001) of 35% was observed compared to a scrambled siRNA. When an ovhv2-miR-73-1 
mimic was co-transfected with the control psiCHECK-2 plasmid, a statistically significant 
increase in relative luciferase expression levels was observed. A statistically significant 
increase (p ≤ 0.01) was also observed when an ovhv2-miR-73-1 mimic was co-transfected 
with a PTEN-psiCHECK-2 construct compared with a scrambled siRNA.  
A 100 bp sequence surrounding the target site for ovhv2-miR-73-1 and miR-216a in YB-1 was 
cloned into psiCHECK-2 and luciferase assays were performed according to section 2.8.1 with 
n = 12. As the 3’UTR of YB-1 is only approximately 400 bp this was also cloned into 
psiCHECK-2 to determine whether the context of the target site is important in the luciferase 
reporter system (Appendix 2 for primer sequences). When a miR-216a mimic was co-
transfected with either of the YB-1-psiCHECK-2 constructs a statistically significant 
reduction (p ≤ 0.0001 for both constructs) of approximately 32-35% was observed compared 
to a scrambled siRNA. When an ovhv2-miR-73-1 mimic was co-transfected with the control 
psiCHECK-2 plasmid, a statistically significant increase (p ≤ 00001) in relative luciferase 
expression levels was observed. A statistically significant increase (p ≤ 0.0001) was also 
observed when an ovhv2-miR-73-1 mimic was co-transfected with a psiCHECK-2 construct 
containing the 3’UTR of YB-1 compared with a scrambled siRNA. An increase in relative 
luciferase levels was observed when ovhv2-miR-73-1 was co-transfected with a psiCHECK-
2 plasmid containing the 100 bp sequence of YB-1 however this was not statistically 
significant. Due to the ovhv2-miR-73-1 mimic having a significant effect on psiCHECK-2 
normalised luciferase expression it cannot be confirmed whether ovhv2-miR-73-1 targets 
PTEN and/or YB-1 and a different validation method was required. 
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Figure 4.8 Relative luciferase expression levels of PTEN-psiCHECK-2 and 
YB-1-psiCHECK-2 with miR-216a and ovhv2-miR-73-1 compared to a 
scrambled siRNA 
293T cells were co-transfected with a psiCHECK-2 construct containing a 100 bp region 
of PTEN (A), a 100 bp region of YB-1 or the 3’ UTR of YB-1 (B), and an ovhv2-miR-
73-1 mimic, a miR-216a mimic or a scrambled siRNA control. After 48 hrs, Renilla 
luciferase levels were measured, normalised to firefly luciferase levels and expression in 
control and test miRNAs compared. ** = p < 0.01, *** = p < 0.0001 
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4.4.5 Validation of PTEN and YB-1 as targets of ovhv2-miR-73-1 by flow 
cytometry 
The same 100 bp sequences of PTEN and YB-1 that were used in the luciferase assays 
described in section 4.4.4 were also cloned into the 3’UTR of GFP in the GFP-expressing 
vector pEGFPC1. Transfections and flow cytometry were carried out as described in sections 
2.1.7, 2.6.2 and 2.6.4 with n = 12 for each condition. Between replicates and conditions the 
percentage of GFP positive cells remained consistent (on average 31.5%, standard deviation 
4.84) indicating the transfection efficiency was not altered when the EGFPC1 constructs were 
co-transfected with different mimics. GFP positive cells were counted and the median 
fluorescent intensity (MFI) for each replicate was determined and used as an indicator of GFP 
expression levels (Figure 4.9). When either a miR-216a mimic or an ovhv2-miR-73-1 mimic 
was co-transfected with EGFPC1 there was no statistically significant difference in MFI 
compared to a scrambled control. A statistically significant, reduction of approximately 15% 
for both YB-1-EGFPC1 (p ≤ 0.005) and PTEN-EGFPC1 (p ≤ 0.001) was observed when a 
miR-216a mimic was co-transfected with either plasmid compared to the scrambled siRNA 
control. When an ovhv2-miR-73-1 mimic was co-transfected with YB-1-EGFPC1 no 
statistically significant difference was observed. When an ovhv2-miR-73-1 mimic was co-
transfected with PTEN-EGFPC1 a statistically significant increase (p ≤ 0.05) in the relative 
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Figure 4.9 Relative median fluorescent intensity (MFI) of PTEN-EGFPC1 and 
YB-1-EGFPC1 with miR-216a and ovhv2-miR-73-1 compared to a scramble 
siRNA  
293T cells were co-transfected with an EGFPC1 construct containing a 100 bp region of 
PTEN or a 100 bp region of YB-1 in the 3’UTR of EGFP, and an ovhv2-miR-73-1 mimic, 
a miR-216a mimic or a scramble siRNA control. After 48 hrs, MFI of EGFP was 
determined by flow cytometry and control and test miRNAs compared. * = p < 0.05, ** = 
p < 0.001. 
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4.5 Validation of MHC class II as a target of OvHV-2-encoded miRNAs 
 
4.5.1 MHC class II 
The MHC is a major component of the immune system involved in antigen presentation. MHC 
class II molecules are expressed on professional antigen processing cells (APCs) and 
exogenous antigens. Proteins captured from outside the cell from e.g. bacteria or viruses are 
endocytosed and processed into peptides before presentation on the surface of APCs to 
antigen-specific CD4+ T lymphocytes (see Figure 4.10 for a simplified view of the presentation 
pathway). This stimulates their activation and differentiation into T helper subsets and 
subsequent interaction with B cells for production of antibodies against the antigen (Roche & 
Furuta, 2015). MHC class I molecules are expressed on all nucleated cells and present 
endogenous antigens on their surface. Presentation of antigens on MHC class I leads to 
activation of CD8+ cytotoxic T lymphocytes usually associated with killing of infected cells 
(Hewitt, 2003).  
As viruses are intracellular pathogens they are usually associated with presentation on MHC 
class I molecules. Herpesviruses utilise endosomal compartments for viral assembly and viral 
proteins are often extensively targeted to endosomes, some of these proteins will be degraded 
into peptides in the endosome. Therefore, herpesviruses such as EBV and KSHV that infect B 
cells will have viral antigens efficiently loaded and presented on MHC class II molecules 
(Hegde et al., 2003). It has also been shown that CD4+ T lymphocytes can have direct antiviral 
roles, usually through the production of antiviral cytokines (Hegde et al., 2003; Zuo & Rowe, 
2012b). It is therefore not surprising that herpesviruses modulate the MHC class II presentation 
pathway at a number of stages (Zuo & Rowe, 2012b) (Figure 4.10). The EBV-encoded protein 
BZLF1 and the KSHV-encoded protein viral interferon regulatory factor-3 (vIRF-3) both 
inhibit the transcription of class II MHC transactivator (CIITA), subsequently inhibiting the 
transcription of MHC class II molecules (Li et al., 2009; Schmidt et al., 2011). The KSHV-
encoded protein ShutOff and Exonuclease protein (SOX) can degrade cellular mRNAs and as 
such is capable of degrading CIITA mRNA and MHC class II molecule mRNAs (Glaunsinger 
& Ganem, 2004). BZLF1 can also interfere with the normal transport and loading of peptides 
to MHC class II molecules through manipulation of CD74 (Zuo et al., 2011). Finally, the EBV 
glycoprotein gp42 can abolish the interaction of the T cell receptor with MHC class II 
molecules thus abrogating peptide presentation to CD4+ T cells (Ressing et al., 2003).  
BJ1035 cells are MHC class II positive (Dr Inga Dry, personal communication). Although T 
cells are not professional APCs and would not usually express MHC class II, a number of 
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immune regulators such as IFNγ can stimulate MHC class II expression. Activated human T 
cells have also been shown to express MHC class II molecules on their surface (Holling et al., 
2004). More relevantly, many sheep and cattle T cells express MHC class II on their surface 
(Dutia et al., 1993). In line with this, there have been some reports of a reduction in the surface 
expression of MHC class I and class II molecules in cells supporting EBV lytic infection 
(Keating et al., 2002). The bovine DRB3 gene is the most widely expressed gene from the 
DRB locus, and polymorphisms associated with this gene (found in exon 2) have been 
associated with resistance to MCF in American bison (Das et al., 2012; Traul et al., 2007). As 
in cattle, OvHV-2-infected cells develop into LGLs that have an MHC-unrestricted phenotype, 
MHC class II genes are an interesting target for OvHV-2-encoded miRNAs and due to the 
complex nature of MHC class II, there is potential for differential regulation of MHC class II 
genes between sheep and cattle. 
Computational analysis of a large number of immune genes looking for miRNA targets 
suggested that there are no human miRNAs predicted to target the 3’UTR of MHC class II 
genes, however miR-145 and miR-198 specifically target the 3’UTR of CIITA (Tomasi et al., 
2010). However it was also suggested by Tomasi et al. that MICB is not targeted by any human 
miRNAs. The CMV-encoded miRNA hcmv-miR-UL112 has been shown to target the 3’UTR 
of MICB leading to down-regulation of expression (Stern-Ginossar et al., 2007). Furthermore, 
a KSHV-encoded miRNA, miR-K12-7, and an EBV-encoded miRNA, miR-BART2-5p have 
also been shown to target MICB (Nachmani et al., 2009). This indicates that although there 
are no predicted human miRNAs targeting MHC class II, viruses may have the ability to target 
these genes, specifically for pro-viral reasons such as immune evasion. 
While investigating potential targets of ovhv2-miR-73-1, BLASTN was used as a preliminary 
screen to investigate possible targets of this miRNA in sheep and cattle. BLASTN was used 
instead of RNAHybrid as a method of target identification as it is not feasible to use 
RNAHybrid to screen whole genomes. A large number of hits returned were in sheep MHC 
class II genes, with no cattle MHC class II hits (data not shown; updates to the sheep and cattle 
genome in NCBI now show different results than previously seen). This difference led to the 
hypothesis that MHC class II may be a target of OvHV-2-encoded miRNAs and that there may 
also be differential regulation of MHC class II genes between sheep and cattle. Down-
regulation of MHC class II in sheep but not in cattle may be an important immune evasion 
mechanism allowing long term persistence that occurs in sheep but not in cattle.  
  




Figure 4.10 MHC class II presentation pathway and it’s inhibition by EBV and 
KSHV 
Class II MHC transactivator (CIITA) protein is made and binds to the promoter region of 
MHC class II genes allowing their expression. Correct folding of MHC class II proteins 
occurs in the endoplasmic reticulum (ER) where CD74 (also known as invariant chain) 
binds to prevent loading of peptides in the ER. The invariant chain facilitates transport of 
MHC class II proteins through the trans golgi network which fuses with late endosomes. 
The invariant chain is broken down by proteases and is finally removed and allows binding 
of peptides. Exogenous proteins can be endocytosed and degraded into peptides in 
endosomes and as such can be loaded onto MHC class II molecules. This pathway can be 
inhibited at a number of stages by EBV and/or KSHV, as indicated by red stop signs 
numbered 1 through 4. 1: EBV BZLF1 and KSHV vIRF3 inhibit the CIITA promoter. 2: 
KSHV SOX can degrade the mRNA of CIITA and MHC class II molecules. 3: EBV 
BZLF1 modulates CD74 interfering with transport of MHC class II molecules. 4: EBV 
gp42 interferes with the binding of MHC class II molecules and the T cell receptor. 
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4.5.2 RNA Hybrid analysis of sheep MHC class II DQA and DRA genes 
Following the preliminary BLASTN screen with ovhv2-miR-73-1, RNAHybrid was used to 
predict target sites of ovhv2-encoded miRNAs in sheep MHC class II genes. Initially ovine 
DQA and DRA genes (M93430.1, M93433.1, M93431.1 and M73983.1) were investigated for 
potential target sites. DQB and DRB were not examined using RNAHybrid at this time. OvHV-
2-encoded miRNAs were chosen for analysis if they had three or more predicted target sites 
in more than one gene with minimum free energies below -15 kcal/mol. Table 4.1 A lists the 
ovhv2-miRNAs and corresponding RNAHybrid score for each gene analysed. Full details of 
the RNAHybrid analysis is in Appendix 4. ovhv2-miR-17-28 has predicted binding sites in 
DQA1, DQA2.1 and DQA2.2. ovhv2-miR-17-17 has two predicted binding sites in DQA1 and 
one in DRA. ovhv2-miR-17-6 has one predicted binding site in DQA2.2 and two in DRA and 
ovhv2-miR-17-2 has predicted binding sites in DQA1, DQA2.1 and DQA2.2. There were no 
predicted target sites of ovhv2-miR-73-1 in this analysis.  
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Table 4.1 Summary of RNAHybrid scores for ovhv2-encoded miRNAs against 
sheep and cattle MHC class II genes 
 
A: RNAHybrid scores for the four ovhv2-encoded miRNAs used in the flow    
cytometry assays 
Gene (Ovine) miRNA  RNAHybrid Score (kcal/mol) 
DQA1 ovhv2-miR-17-28 -22.6 
  ovhv2-miR-17-17 -22.7 
  ovhv2-miR-17-17 -19.8 
  ovhv2-miR-17-2 -24.7 
DQA2.1 ovhv2-miR-17-28 -21.4 
  ovhv2-miR-17-2 -28.1 
DQA2.2 ovhv2-miR-17-28 -24.5 
  ovhv2-miR-17-6 -23.6 
  ovhv2-miR-17-2 -28.1 
DRA ovhv2-miR-17-17 -19.4 
  ovhv2-miR-17-6 -23.3 
  ovhv2-miR-17-6 -19.5 
 
B: RNAHybrid scores for the ovhv2-encoded miRNAs used in the luciferase assays. 










Gene miRNA targets RNA Hybrid Score (kcal/mol) 
Ovine DQA ovhv2-miR-17-21 -24 
  ovhv2-miR-17-14 -20.3 
Bovine DQA ovhv2-miR-17-30 -18.9 
Ovine DQB ovhv2-miR-17-20 -19.8 
  ovhv2-miR-17-9 -25.6 
Ovine DRA ovhv2-miR-17-25 -19.5 
  ovhv2-miR-17-17 -19.4 
  ovhv2-miR-24-1 -27.6 
Bovine DRA ovhv2-miR-17-17 -19.4 
  ovhv2-miR-24-1 -20.9 
Bovine DRB ovhv2-miR-17-9 -21.8 
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4.5.3 Flow cytometry analysis of a sheep cell line constitutively expressing MHC 
class II transfected with OvHV-2-encoded miRNAs  
LT8.1 cells constitutively expressing  ovine DRA and DRB MHC class II genes (see section 
2.1.1 for details on how these cells were made) were kind gifts from Professor John Hopkins 
and Dr Keith Ballingall (Ballingall et al., 1995). LT8.1 cells were stained with an antibody 
against sheep MHC class II (SW73.2), sheep IgG as an isotype control, or the secondary 
antibody only, as described in section 2.6.1 to check for MHC class II expression (Hopkins et 
al., 1986). L929 cells, the cell line from which LT8.1 cells were made, was used as a negative 
control for all experiments described. Although the LT8.1 cells tested were positive (samples 
ranged from around 55% to over 90% positive depending on aliquot and passage number of 
cells), a fairly high percentage of positive cells was observed in cells stained with the 
secondary antibody alone (approximately 25%). To reduce non-specific activity of the 
secondary it was adsorbed against the LT8.1 cells. The secondary antibody was incubated with 
a 75 cm2 flask of LT8.1 cells overnight. The next day the cells were spun at 16000 x g for 30 
minutes. The supernatant containing unbound antibody was removed and stored at -80ºC. This 
significantly reduced the percentage of MHC class II positive cells observed in cells stained 
with the secondary antibody alone to levels of unstained cells. L929 cells were negative for 
MHC class II expression as expected.  
After optimisation of the staining protocol LT8.1 and L929 cells were transfected with a range 
of concentrations of ovhv2-miR-73-1 or a scrambled siRNA control and monitored at 24 and 
48 hrs to examine cell viability (results summarised in Table 4.2). Unexpectedly high levels 
of cell death were observed for both the scrambled siRNA and ovhv2-miR-73-1. At 48 hrs 
post transfection all of or the majority of LT8.1 cells transfected with either the scrambled 
siRNA or an ovhv2-miR-73-1 mimic at all of the concentrations tested were dead. At 24 hrs 
post transfection of LT8.1 cells the only concentration of scrambled siRNA or ovhv2-miR-73-
1 that did not result in cell death was 50 nM and so these were the conditions used for flow 
cytometry. 
LT8.1 cells were transfected in triplicate with 50 nM of ovhv2-miR--17-17, -17-6, and -73-1 
or a scrambled siRNA and flow cytometry was performed 24 hrs later according to section 
2.6.3 (Figure 4.11). The median fluorescent intensity (MFI) of MHC class II staining was 
measured and the biological replicates for each group averaged. The average MFI for each 
group was compared to the average MFI of the scrambled siRNA transfected cells (Figure 
4.12). There was no significant difference between any of the miRNA transfected cells and 
scrambled siRNA transfected cells. An incubation time of 48 hrs is preferable when looking 
Chapter 4  Identification and Validation of cellular targets of OvHV-2-encoded miRNAs 
105 
 
for knockdown of protein by miRNAs and so a more suitable method of validation was 
required. 
 




 24 hrs 
 untransfected mock 50 nM 100 nM 150 nM 200 nM 
LT8.1 scrambled    x x x 
LT8.1 miR-73-1  n/a  x x x 
L929 scrambled      x 
L929 miR-73-1  n/a  x x x 
 48 hrs 
 untransfected mock 50 nM 100 nM 150 nM 200 nM 
LT8.1 scrambled   x x x x 
LT8.1 miR-73-1  n/a x x x x 
L929 scrambled     x x 
L929 miR-73-1  n/a  x x x 
LT8.1 or L929 cells were transfected with a range of concentrations of either a scrambled 
siRNA or an ovhv2-miR-73-1 mimic. At 24 hours and 48 hours cell viability was 
determined by visualisation of cells on a light microscope. = healthy cells,  = cells 
look sick, some dead, but useable for flow cytometry and x = all or majority of cells dead 
and sample would not be useable for flow cytometry. 
 








LT8.1 Secondary Only 
5178 








Figure 4.11 Flow cytometry analysis of LT8.1 cells transfected with 4 ovhv2-
encoded miRNAs 
LT8.1 cells were transfected with ovhv2-miR-17-17, -17-6, or -73-1 mimics or a scramble 
siRNA. Unstained cells, cells only stained with the secondary antibody and cells stained 
with rat anti-sheep IgG (isotype control) are shown in the top row. The number below the 
name of each graph represents the number of cells used in the analysis. The number in the 
top right of each graph shows the percentage of MHC class II positive cells. One 
representative data set is shown for each miRNA-transfected sample.  
 




Figure 4.12 Relative MFI of MHC class II with ovhv2-encoded miRNAs or a 
scrambled siRNA 
LT8.1 cells were transfected with ovhv2-miR-17-17, 17-6, or 73-1 mimics or a scrambled 
siRNA in triplicate. The MFI for each sample was determined for each sample after 24 hrs 
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4.5.4 RNA Hybrid analysis of sheep and cattle MHC class II genes 
To further investigate MHC class II as a target of OvHV-2-encoded miRNAs RNAHybrid was 
used to analyse the 3’UTRs of both sheep and cattle MHC class II genes. Genes analysed were 
ovine DQA1 (M93430.1), DQB1 (L08792.1), DRA (M73983.1) and DRB1 (M73984.1) and 
bovine DQA1 (NM_001013601.3), DQB (NM_001034668.3), DRA (NM_001012677.1) and 
DRB3 (NM_001012680.2). More stringent conditions were applied to this RNAHybrid 
analysis than in section 4.5.2, in order to decrease the number of predicted miRNA binding 
sites and to increase the likelihood that predicted target sites would be actual sites of OvHV-
2-encoded miRNA binding. Requirements were: perfect complementarity between nucleotides 
2 and 8 and no G:U pairing in this region, and an RNAHybrid score of -15 kcal/mol or lower. 
Table 4.1 B shows a summary of predicted OvHV-2-encoded miRNA binding sites and 
corresponding RNAHybrid score. Full details of the RNAHybrid analysis can be seen in 
Appendix 4.  
There were no predicted OvHV-2-encoded binding sites for bovine DQB and ovine DRB1. 
Ovine DQB has 2 predicted binding sites, one each for ovhv2-miR-17-20 and ovhv2-miR-17-
9. Bovine DRB has one predicted binding site for ovhv2-miR-17-9. There are two predicted 
binding sites (one each for ovhv2-miR-17-21 and ovhv2-miR-17-14) in ovine DQA1 and only 
one predicted binding site (for ovhv2-miR-17-30) in bovine DQA1. The DRA gene is the only 
gene analysed in which there are binding sites for OvHV-2-encoded miRNAs in both sheep 
and cattle versions of the gene. ovhv2-miR-17-17 and ovhv2-miR-24-1 have one binding site 
each, in corresponding positions, in ovine DRA1 and bovine DRA1. Ovine DRA1 has an extra 
predicted binding site for ovhv2-miR-17-25. Overall these results indicate that there may be 
differential targeting of MHC class II genes between sheep and cattle warranting further 
investigation and validation.  
4.5.5 Validation of sheep and cattle MHC class II as targets of OvHV-2-encoded 
miRNAs by luciferase assay 
The 3’UTRs of ovine DQA, DQB and DRA and bovine DQA and DRA were cloned into 
psiCHECK-2 (see Appendix 2 for sequences) and luciferase assays were performed as 
described in section 2.8.1 with n =12 for each condition. The bovine DRB gene was not cloned 
and tested due to time constraints. For clarity, a summary table of results is shown in Table 
4.3. 
When an ovine DRA-psiCHECK-2 construct was co-transfected with ovhv2-miR-17-17 no 
statistical significance was observed compared to a scrambled siRNA control (Figure 4.13A). 
For ovhv2-miR-24-1 a statistically significant increase (p ≤ 0.01) in relative luciferase 
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expression was observed compared to a scrambled siRNA control. A statistically significant 
decrease (p ≤ 0.0001) of approximately 25% of relative luciferase expression levels was 
observed when ovhv2-miR-17-25 was co-transfected with the ovine DRA-psiCHECK-2 
construct compared to a scrambled siRNA control. When a bovine DRA-psiCHECK-2 
construct was co-transfected with either ovhv2-miR-17-17 or ovhv2-miR-24-1 an increase of 
approximately 25% was observed with ovhv2-miR-17-17 (p ≤ 0.05) whereas there was no 
difference in relative luciferase expression levels with ovhv2-miR-24-1 compared to a 
scrambled siRNA control. No statistically significant changes in relative luciferase levels were 
observed when ovhv2-miR-17-17, miR-24-1 or miR-17-25 were co-transfected with the 
psiCHECK-2 construct compared to a scrambled siRNA control.  
When an ovine DQB psi-CHECK-2 construct was co-transfected with either ovhv2-miR-17-
20 or miR-17-9, a decrease in relative luciferase levels (approximately 25%) was only 
observed for ovhv2-miR17-9 (p ≤ 0.01) compared to a scrambled siRNA (Figure 4.13 B). No 
significant difference was observed for ovhv2-miR-17-20 compared to a scrambled siRNA 
control. No significant difference was observed when either mimic was co-transfected with 
psiCHECK-2 compared to a scrambled siRNA.  
When ovhv2-miR-17-30, 17-21 and 17-14 were co-transfected with psiCHECK-2, significant 
decreases of 68% (p ≤ 0.0001), 55% (p ≤ 0.0001) and 37% (p ≤ 0.01) in relative luciferase 
levels were observed respectively compared to a scrambled siRNA (Figure4.13 C and D). 
Although a significant decrease (p ≤ 0.0001) in relative luciferase expression levels was 
observed when ovhv2-miR-17-30 was co-transfected with a bovine DQA-psiCHECK-2 
construct it cannot be confirmed whether this decrease is due to direct targeting of bovine DQA 
and further investigation would be needed. No significant difference was observed when 
ovhv2-miR-17-21 was co-transfected with an ovine DQA-psiCHECK-2 construct compared 
to a scrambled siRNA. A statistically significant decrease (p ≤ 0.05) in relative luciferase 
expression levels when ovhv2-miR-17-14 was co-transfected with and ovine DQA-
psiCHECK-2 construct was observed compared to a scrambled siRNA, however this decrease 
was smaller than that observed for psiCHECK-2 alone thus making it unlikely that ovhv2-
miR-17-14 targets ovine DQA.  
In summary, transfection with 2 OvHV-2-encoded miRNAs cause statistically significant 
decreases of approximately 25% in relative luciferase expression compared to a scrambled 
siRNA; ovhv2-miR-17-25 with ovine DRA-psiCHECK-2 and ovhv2-miR-17-9 with ovine 
DQB-psiCHECK-2. ovhv2-miR-17-30 may target bovine DQA however this could not be 
confirmed due to an observed decrease with this miRNA in the control plasmid. To confirm 
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these results a second method of validation would be required and due to time constraints this 
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Figure 4.13 Relative luciferase expression levels of MHC class II psiCHECK-
2 constructs with ovhv2-encoded miRNAs compared to a scrambled siRNA 
293T cells were co-transfected with psiCHECK-2 constructs containing the 3’UTRs of 
ovine DRA (A), DQB (B) and DQA (D) and bovine DRA (A) and DQA (C) and ovhv2-
encoded miRNAs with predicted targets in the region (Table 4.1). After 48 hrs, Renilla 
luciferase levels were measured, normalised to firefly luciferase levels and expression in 
control and test miRNAs compared. * = p < 0.05, ** = p < 0.01, *** = p < 0.0001 
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Plasmid Ovhv2-miRNA Effect 
Statistically 
significant? 
psiCHECK-2 ovhv2-miR-17-17 None No 
  ovhv2-miR-24-1 None No 
  ovhv2-miR-17-25 None No 
  ovhv2-miR-17-20 None No 
  ovhv2-miR-17-9 None No 
  ovhv2-miR-17-30 Down Yes 
  ovhv2-miR-17-21 Down Yes 
  ovhv2-miR-17-14 Down Yes 
Ovine DRA ovhv2-miR-17-17 Down No 
  ovhv2-miR-24-1 Up Yes 
  ovhv2-miR-17-25 Down Yes 
Bovine DRA ovhv2-miR-17-17 Up Yes 
  ovhv2-miR-24-1 Up No 
Ovine DQB ovhv2-miR-17-20 None No 
  ovhv2-miR-17-9 Down Yes 
Bovine DQA ovhv2-miR-17-30 Down Yes 
Ovine DQA ovhv2-miR-17-21 Down No 
  ovhv2-miR-17-14 Down Yes 




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
4.6.1 DLL1  
Validation of DLL1 as a target of ovhv2-miR-17-2 has been complicated by the incorrect 
annotation of the sheep genome assembly OARv3.1. Initial luciferase assays showed that 
ovhv2-miR-17-2 does target DLL1, with a reduction in relative luciferase expression of 
approximately 35%. Mutation of either site 1 or site 3 did not restore relative luciferase 
expression levels comparative to the scrambled siRNA however when both sites were mutated 
relative luciferase expression was restored. This implies that, in the luciferase reporter system, 
there is some redundancy of target sites and just one site is sufficient for reduction in relative 
luciferase expression. 
The major problem encountered in the validation of DLL1 was that the published sequence of 
sheep DLL1 in both NCBI and Ensembl was incorrect. PCR and sequencing of the region 
predicted to contain the three target sites revealed that sites 1 and 2 are not present in this 
region. The published sheep DLL1 mRNA sequence does not align to the cattle DLL1 mRNA 
sequence in this region however the sequence obtained by PCR performed in section 4.3.5 
aligned well to the cattle DLL1 mRNA sequence. Conservation of the sequence of DLL1 
between species is high (Appendix 3 for alignments) and so it was surprising that in sheep 
there was a high level of variation in the published sheep DLL1 sequence compared to the 
cattle sequence. Further PCRs including 5’ and 3’ RACE were performed in order to try and 
identify where in the sheep genome target sites 1 and 2 mapped; whether it was a different 
region of DLL1 or an entirely different gene not annotated in the sheep genome. Unfortunately 
5’ RACE did not yield any interesting results; none of the clones sequenced contained the 
primer sequence and were therefore excluded from further analysis. 3’ RACE was successful 
in that clones sequenced contained the primer sequence; the sequences obtained mapped to 
DLL1 sequences in closely related species such as goat and cattle; and the sequence obtained 
contained the complete 3’UTR. Frustratingly, target sites 1 and 2, which should have been 
adjacent to the primer sequence, were absent. As 3’ RACE amplifies from cDNA, and the 3 
target sites are predicted to be present in two consecutive exons, genomic DNA was sequenced 
to include the intron between the two exons. It could have been possible that the sequence 
identified in CLASH was an unusual transcript produced by alternative splicing, especially as 
the sequence of the intron was not defined. The results of this sequencing showed that this 
intron did not exist which, is again in line with the cattle DLL1 sequence. So although it was 
confirmed that ovhv2-miR-17-2 does target site 1, the identity of the gene remains unknown. 
Steps described above were taken to try and elucidate the identity of the target gene but this 
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was not successful. A BLASTN analysis of the hybrid sequence obtained from the CLASH 
study was performed against the sheep genome, the nucleotide collection database, the 
reference RNA database, the NCBI genomes databse and the expressed sequence tags 
database. The only match from these analyses was the sheep DLL1 sequence, which is clearly 
incorrect. The sequence did not correspond to any other annotated sheep gene. Further 
investigation into the location of site 1 was deemed to be too time consuming and more 
rewarding aspects of OvHV-2-encoded miRNA target identification were pursued.  
As target site 3 had definitely been confirmed to be present in the DLL1 sequence further 
luciferase assays carried out containing this sequence demonstrated a smaller, but still 
significant knockdown of approximately 25%. Mutagenesis of this site to confirm that site 3 
is the only target of ovhv2-miR-17-2 binding was not carried out due to time constraints. 
Analysis of differential targeting between sheep and cattle at this site was also not carried out 
due to time constraints, Comparison of the RNAHybrid scores for this site between the sheep 
and cattle DLL1 sequence indicate that targeting would be very similar. It is therefore unlikely 
that targeting of DLL1 plays a role in the different outcomes of virus infection between sheep 
and cattle.  
Further validation of DLL1 as a target of ovhv2-miR-17-2 by a different method was hindered 
by the lack of sheep and cattle cell lines that expressed DLL1. Although BJ1035 cells did 
express DLL1, the expression was below the level of accurate quantification, and as such was 
not an appropriate system to study DLL1 knockdown (data not shown); RT-qPCRs to examine 
knockdown of natively expressed DLL1 by ovhv2-miR-17-2 could therefore not be carried 
out.  
As DLL1 is a ligand and Notch signalling is cell-cell mediated it would be difficult to 
characterise the phenotypic changes seen in Notch signalling due to a down-regulation of 
DLL1. Additionally, there is no guarantee that an infected cell will come into contact with 
another infected cell thus altering the phenotype of infected cells. However, it is possible that 
the environment infected cells are in could alter the infected cell phenotype, for example 
through cytokine signalling. As mentioned in section 4.3.1, GATA3 expression can be induced 
by Notch, which can then induce the expression of IL-4 (Fang et al., 2007). IL-4 is a pleiotropic 
cytokine known to play a role in the promotion of the Th2 cell lineage (Seder et al., 1992). IL-
4 signals through signal transducer and activation of transcription 6 (STAT6). It has been 
shown that in B cells, STAT6 is capable of up-regulating MHC class II expression (Takeda et 
al., 1996). Therefore, it is possible that a reduction in activation of Notch signalling through 
reduced expression of DLL1 could result in lower IL-4 signalling and a reduction in expression 
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of MHC class II. This may contribute to the immune evasion which is likely required for 
successful latent infection of OvHV-2. Alternatively, in the context of MCF, a reduction in 
IL-4 signalling could have the effect of altering the balance of Th1/Th2 cells in the infected 
cell environment, with a potential polarisation towards Th1 cells. Polarisation towards Th1 
cells has the potential to result in inflammatory or autoimmune disease (Wurster et al., 2000). 
As MCF is a lymphoproliferative disease characterised by MHC-unrestricted cytotoxicity it 
could be somewhat described as an autoimmune disease and thus altered Notch signalling 
could be a contributing factor to the pathogenesis observed in affected animals. However, it is 
unlikely that this would be on the only factor, and a number of other modulations of the 
environment and the infected cell would be required to result in disease. 
Other OvHV-2-encoded miRNAs were predicted to target sheep and cattle DLL1 and as such 
differential targeting could still exist. However the sheep sequence of DLL1 is obviously 
incorrectly annotated and would most likely require further sequencing before confidence in 
RNAHybrid predictions could be gained.  Although an interesting target with high relevance 
for OvHV-2 infection and MCF pathogenesis it was decided to not continue the validation of 
DLL1 as a target of ovhv2-miR-17-2.   
4.6.2 PTEN and YB-1 
It was demonstrated that, despite having homology with mir-216a, ovhv2-miR-73-1 does not 
target PTEN and YB-1. As seen in Figure 3.1 the first 7 nucleotides of ovhv2-miR-73-1 are 
identical to miR-216a. The seed sequence of the miRNA has been thought to be most important 
in binding mRNA. Recent work has identified that perfect complementarity between the seed 
sequence of miRNA and target mRNA is not necessary for down-regulation of target mRNA 
(Helwak et al., 2013). Moreover, non-canonical binding may be much more widespread than 
first thought and this will be under represented by miRNA target prediction programmes that 
focus on perfect base pairing in the seed sequence (Helwak et al., 2013). In this case however 
it appears that canonical miRNA binding is the main determinant of PTEN and YB-1 
knockdown. The RNAHybrid predictions of ovhv2-miR-73-1 binding to PTEN and YB-1 
mRNA are of a lower mfe than miR-216a and do not have perfect complementarity between 
nucleotides 2 and 8. It is therefore likely that RNAHybrid is a good predictor of canonical 
miRNA binding. The other ovhv2-miR-73-1 and miR-216a binding site for PTEN in sheep 
discovered by RNAHybrid was not analysed due to time constraints. Limitations of 
RNAHybrid will be discussed in chapter 6.  
The major problem encountered in this section concerned the effect of ovhv2-miR-73-1 on the 
psiCHECK-2 vector. A significant increase in relative luciferase levels was consistently and 
Chapter 4  Identification and Validation of cellular targets of OvHV-2-encoded miRNAs 
116 
 
reproducibly observed when ovhv2-miR-73-1 was co-transfected with the empty psiCHECK-
2 vector compared to a scrambled siRNA control. RNAHybrid was performed on the 
psiCHECK-2 plasmid and no ovhv2-miR-73-1 binding sites were present in the coding region 
of either firefly luciferase or Renilla luciferase. This indicated that there was no off-target 
effects of ovhv2-miR-73-1 on the psiCHECK-2 plasmid. Attempts to eliminate this effect by 
changing parameters such as concentration of vector and mimic, incubation time, brands of 
mimics and cell type were unsuccessful. It was concluded that for this mimic luciferase assay 
was not an appropriate system for target validation and another system was required for 
validation. The kinds of off-target effects observed here have not been described in the 
literature. Furthermore, the effect of ovhv2-miR-73-1 in this assay may not be directly linked 
to a downregulation of luciferase and could be an un-identifiable artefact of the assay. More 
generally, few off-target effects have been described and are usually limited to the attempt to 
reduce off-target effects in the design of small interfering RNAs or short hairpin RNAs or in 
the use of miRNAs as therapeutics (Aleman et al., 2007; Jackson et al., 2006; Ji Diana Lee et 
al., 2015; Singh et al., 2011) 
A GFP reporter system was used as an alternative method for validation. When miR-216a was 
co-transfected with a GFP plasmid containing PTEN or YB-1 sequences the level of 
knockdown observed was smaller than in the luciferase reporter system but still statistically 
significant. The difference in knockdown observed is most likely due to variation of the 2 
different systems used. The problems observed with ovhv2-miR-73-1 in the luciferase reporter 
system were not seen in the GFP reporter system. It can therefore be concluded that, at least 
using a GFP reporter system, ovhv2-miR-73-1 does not target PTEN or YB-1. 
4.6.3 MHC class II 
Investigation into whether MHC class II is targeted by OvHV-2-encoded miRNAs is 
complicated by the fact that in sheep and cattle, MHC class II is a complex of four genes, 
DQA/B and DRA/B. Sheep DQA and DRA genes were analysed first as the LT8.1 cell line that 
constitutively expresses sheep MHC class II genes was readily available. No restrictions on 
binding dynamics were imposed in this initial RNAHybrid analysis, however to be taken 
forward for further analysis miRNAs had to target multiple genes. It should be noted that the 
initial interest in MHC class II arose from a BLASTN analysis of the seed sequence of ovhv2-
miR-73-1 against the sheep and cattle genome but that RNAHybrid did not predict any ovhv2-
miR-73-1 target sites in either sheep or cattle MHC class II genes.  
Transfection of LT8.1 and L929 cells was complicated by severe mimic toxicity, limiting both 
concentration of mimic and incubation period used when using flow cytometry as a method of 
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assessing knockdown of MHC class II by OvHV-2-encoded miRNAs. As this toxicity was 
observed with the scrambled siRNA as well as ovhv2-miR-73-1 it is likely that this is a cellular 
response to dsRNA transfection. L929 cells have been shown to be sensitive to TNFα 
(Humphreys & Wilson, 1999). TNFα can be induced by the dsRNA recognition molecule PKR 
(Takada et al., 2006; Yeung et al., 1996). It is possible that PKR can recognise the transfected 
mimics and induce a TNFα response leading to apoptosis. This mimic toxicity meant that a 
lower mimic concentration had to be used with a shorter incubation period. No difference in 
the MFI of MHC class II was observed in any of the OvHV-2-encoded miRNA mimic 
transfected cells compared to those transfected with a scrambled siRNA. As the transfection 
protocol had to be compromised to alleviate toxicity it could not be confirmed whether OvHV-
2-encoded miRNAs target MHC class II and another approach was required. 
The luciferase reporter system was implemented as a method of screening MHC class II genes 
for targets. As the luciferase reporter system included more MHC class II genes more stringent 
parameters were applied to this second RNAHybrid analysis than the first RNAHybrid 
analysis used for the flow cytometry analysis. This resulted in different OvHV-2-encoded 
miRNAs identified with potential binding sites in the MHC Class II genes analysed. Of the 
eight OvHV-2-encoded miRNAs chosen for analysis, three (ovhv2-miR-17-30, ovhv2-miR-
17-21 and ovhv2-miR-17-14) displayed a statistically significant down-regulation of relative 
luciferase expression levels in the psiCHECK-2 plasmid alone compared to the scrambled 
siRNA. When RNAHybrid was performed on ovhv2-miR-17-21 against the psiCHECK-2 
sequence no binding sites were predicted, even allowing for G:U pairing in the seed region. 
When RNAHybrid was performed on ovhv2-miR-17-30 and ovhv2-miR-17-14 a number of 
binding sites in the firefly luciferase and Renilla luciferase sequences were predicted when 
G:U pairing in the seed region was allowed (Appendix 5). ovh2-miR-17-30 has six predicted 
sites in the firefly luciferase sequence and five in the Renilla luciferase sequence. ovhv2-miR-
17-14 has two predicted targets sites in both the firefly luciferase and Renilla luciferase 
sequences. Predicted sites may not be functional target sites and so it could be possible that 
the predicted sites in Renilla luciferase are functional whereas those in firefly luciferase are 
not functional. If this is true, then down-regulation of relative luciferase levels observed when 
ovhv2-miR-17-30 and ovhv2-miR-17-14 are co-transfected with psiCHECK-2, is due to off 
target effects of these mimics.  
The other five OvHV-2-encoded miRNA mimics showed no significant difference in relative 
luciferase expression levels of the psiCHECK-2 plasmid alone compared to the scrambled 
siRNA. This allowed for the identification of two OvHV-2-encoded miRNAs, ovhv2-miR-17-
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25 and ovhv2-miR-17-9 that target sheep DRA and sheep DQB respectively. A third miRNA, 
ovhv2-miR-17-30 may target cattle DQA although, due to problems with the luciferase assay 
this could not be confirmed.  
The results presented here support the hypothesis that MHC class II may be down regulated 
in sheep as an immune evasion strategy and promoting and allowing the maintenance of 
latency. As outlined in section 4.5.1 many herpesviruses modulate the MHC class II signalling 
pathway as a mechanism of immune evasion, however these results are the first to demonstrate 
the potential for miRNA-mediated regulation of MHC class II. From these results, it appears 
that there may be differential targeting of MHC class II between sheep and cattle. It is therefore 
possible that MHC class II signalling is different between infected sheep and cattle leading to 
altered outcomes of latency establishment. However, it is unlikely to be just a single factor 
that results in the development of disease in one animal and not in another and more likely 
multiple factors acting on multiple different pathways. It is therefore unclear how targeting of 
MHC class II in cattle contributes to MCF pathogenesis, and any possible mechanism would 
be speculation, given the preliminary nature of this data. Further work, such as mutagenesis of 
the predicted target sites would be required to confirm the targeting, and use of another method 
of validation such as the GFP reporter system described for PTEN and YB-1 would be ideal.  
Other methods of validation and characterisation of these interactions could include 
development of a RT-qPCR and use of sheep and cattle lymphocytes to look at miRNA 
knockdown in a biologically relevant cell line. It would be important to test how knockdown 
of MHC class II genes at an RNA or protein level would affect surface expression levels of 
MHC class II over time. Time constraints on the project did not allow for full characterisation 
of miRNA knockdown and so any downstream experiments could not be followed up. Other 
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There are many documented examples of regulation of herpesvirus gene expression through 
expression of their own miRNAs (see section 1.7.2 for examples). These virus-encoded 
miRNAs often play roles in the maintenance of latency and pathogenesis of the virus. It has 
previously been shown by the Dalziel group that OvHV-2 encoded ORF50 and ORF73 are 
targets of ovhv2-miR-17-1 and 17-10 respectively (Riaz et al., 2014). ORF50 and ORF73 are 
two of the most well characterised genes in the gammaherpesvirus subfamily and the roles 
they play in virus biology are well defined. However, there are a number of genes unique to 
OvHV-2 and AlHV-1 (see section 1.5.1), the functions of which are less well characterised 
and it is therefore unknown what roles they play, if any, in pathogenesis. One of these proteins, 
Ov2, is predicted to contain a basic leucine zipper domain (bZIP domain). bZIP domains are 
bipartite; they have a basic domain that is capable of interacting with the DNA backbone and 
a leucine zipper motif (Vogt, 2001). The leucine zipper motif is characterised by heptad repeats 
of leucine residues that form an amphipathic helix (Landschulz et al., 1988). Upon 
dimerization with another protein containing a bZIP domain, a coiled coil conformation occurs 
with the leucine residues aligned along the contact surface (Rasmussen et al., 1991).  
Proteins with bZIP domains are often transcription factors. Activator protein 1 (AP-1) is a 
dimeric complex that contains members of the JUN, FOS, activating transcription factor (ATF) 
and musculoaponeurotic fibrosarcoma (MAF) protein families (Eferl & Wagner, 2003). 
Dimerization of bZIP proteins is required for functional activity; many of these proteins can 
form homodimers and/or heterodimers however some, like the FOS family, cannot form 
homodimers. The specificity of dimerization depends on the non-leucine residues of the zipper 
domain (Alber, 1992). Different combinations of homodimers and heterodimers can form AP-
1 and the combination of proteins in the dimer determines AP-1 function and which genes are 
regulated. The JUN family consists of c-JUN (originally named after the viral counterpart v-
Jun in avian sarcoma virus 17), JUNB and JUND (Lopez-Bergami et al., 2010; Maki et al., 
1987). The FOS family consists of c-FOS (originally named after the viral counterpart v-Fos 
in Finkel-Biskis-Jinkins osteosarcoma virus), FOSB, FOS-related antigen 1 (FRA1) and FRA2 
(Angel & Karin, 1991; Curran et al., 1982). c-FOS, FOSB and c-JUN all have potent 
transactivator domains; overexpression of these proteins leads to efficient transformation of 
cells in culture. Thus, they are defined as oncoproteins and therefore AP-1 can play an 
important role in tumorigenesis (Jochum et al., 2001). AP-1 is thought to regulate the 
expression of genes involved in all of the six “hallmarks of cancer” (sustaining proliferative 
signalling, evading growth suppressors, activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis and resisting cell death) (Eferl & Wagner, 
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2003; Hanahan & Weinberg, 2000; Lopez-Bergami et al., 2010; Shaulian & Karin, 2002). A 
c-JUN-FRA1 heterodimer leads to up-regulation of miR-21 expression, a key oncogene highly 
expressed in many cancers that is known to down-regulate tumour suppressors such as PTEN 
(Melnik, 2015). Conversely, AP-1 proteins that lack a potent transactivator domain can either 
have weak transforming potential (FRA1 and FRA2) or can have tumour suppressor effects 
(JUNB and JUND) (Bergers et al., 1995; Deng & Karin, 1993; Foletta et al., 1994; Pfarr et 
al., 1994). AP-1 can therefore have tumour promoting or tumour suppressing activity 
depending on the different combinations of proteins, however AP-1 activity is probably also 
influenced by type, stage and genetic background of the tumour (Eferl & Wagner, 2003). 
The potential for bZIP proteins to interact with a wide number of proteins that can influence 
gene expression on a large scale makes them an attractive choice for a herpesvirus that needs 
to manipulate the cellular environment with minimal coding capacity. Ov2 is therefore an 
interesting protein to study as it may have significant effects on the pathogenesis of OvHV-2 
and could also potentially interact with different cellular bZIP proteins between sheep and 
cattle. There is no published data available about the function of Ov2. One study on A2, the 
positional homologue of Ov2 in AlHV-1, has been published which shows A2 has an effect 
on the cellular transcriptome and cytotoxicity of LGLs in infected rabbits (Parameswaran et 
al., 2014).  In this study an A2 gene knockout AlHV-1 was produced and rabbits were infected 
with this virus, the wild-type, or a revertant A2 virus. All the infected rabbits succumbed to 
MCF, however the onset of MCF in rabbits infected with the A2 knockout virus was delayed 
compared to the wild-type or revertant viruses. This indicated that A2 is not a critical virulence 
factor for AlHV-1. Infected LGLs were obtained from infected rabbits and RNA-Seq was 
performed to identify differentially expressed genes. A2 was found to be involved in the 
transcriptional regulation of genes involved in immunological, cell cycle and apoptosis 
pathways. Partial inhibition of the cytotoxicity-associated pathways involving perforin and 
granzymes A and B (proteins found in cytotoxic granules) was observed in the A2 knockout 
virus compared to the controls indicating that A2 plays a role in enhancing the cytotoxicity in 
LGLs (Parameswaran et al., 2014). 
Positional homologues of herpesvirus-encoded genes can sometimes have shared or similar 
functions, especially in more conserved ORFs such as ORF73 in KSHV and MHV-68 and 
EBNA1 in EBV, which share functions. Positional homologues of Ov2 in other 
gammaherpesviruses include LMP-1 in EBV, K1 in KSHV, STP/Tip in HVS and M1 in MHV-
68 (Krug et al., 2013; Raab-Traub, 2012; Tsygankov, 2005; Wang et al., 2004a). LMP-1, K1 
and STP/Tip are all membrane proteins that play a role in virus-induced transformation of 
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cells. M1 is a secreted protein with superantigen-like activity that can lead to an increased 
establishment of latency in a particular subset of B cells (Krug et al., 2013). As none of these 
proteins contain a bZIP domain it is unlikely that there will be any shared functions between 
Ov2 and these other positional homologues. 
Other gammaherpesviruses encode bZIP proteins including EBV and KSHV, which encode 
BZLF1 and K8 respectively (described in more detail in section 1.3.2). MDV encodes the bZIP 
protein Meq, which is highly expressed in virus-induced lymphoblastoid tumours (Jones et al., 
1992). Meq resembles the FOS/JUN family of bZIP proteins and is capable of transforming 
chicken cells via the v-Jun transcriptional cascade (Levy et al., 2005). Meq is a target of the 
MDV-encoded miRNA miR-M4 and it has been shown that this miRNA is critical for the 
induction of lymphomas since either deletion of the miRNA or mutation of the seed region 
abolished the ability of MDV to induce lymphomas in vivo (Burnside et al., 2006; Zhao et al., 
2011).  
5.2 Aims 
The aims of this part of the project were to use bioinformatic analysis to investigate whether 
any OvHV-2-encoded miRNAs had potential binding sites in Ov2, and then to validate the 
predicted target sites using biochemical methods. Finally, as the function of Ov2 is currently 
unknown, perform functional analysis of Ov2 to determine subcellular localisation, identify 
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5.3 Validation of Ov2 as a target of OvHV-2-encoded miRNAs 
 
5.3.1 RNAHybrid analysis of Ov2 mRNA sequence 
RNAHybrid was used to investigate the Ov2 mRNA sequence (AY839756.1, reverse 
complement of nucleotides 1321 – 2480) for targets of OvHV-2-encoded miRNAs. Analyses 
of coding region targets can be seen in Fig. 5.1. A further four targets were identified in the 
3’UTR of Ov2 but were not taken forward for further validation (see Appendix 9). Targets 
identified by RNAHybrid had perfect complementarity between nucleotides 2 and 8 of the 
miRNA and no G:U base pairing in that region. Four OvHV-2-encoded miRNAs were shown 
to have targets in the coding region: ovhv2-miR-17-29, ovhv2-miR-17-10, ovhv2-miR-61-1 
and ovhv2-miR-73-1. 
5.3.2 Preliminary validation of Ov2 as a target of OvHV-2-encoded miRNAs by 
flow cytometry 
The coding region of Ov2 was cloned into pEGFPN1 (construct made by Dr Inga Dry). 
Transfections and flow cytometry were carried out as described in sections 2.1.7, 2.6.2 and 
2.6.4 with n = 3 for each condition. Between replicates and conditions the percentage of GFP 
positive cells remained consistent (on average 16.26%, standard deviation 2.71) indicating the 
transfection efficiency was not altered when the EGFPN1 constructs were co-transfected with 
different mimics. GFP positive cells were counted and the median fluorescent intensity (MFI) 
for each replicate was determined and used as an indicator of GFP expression levels (Fig. 5.2). 
Statistically significant reductions in the MFI were observed when ovhv2-miR-17-10 (p ≤ 
0.01), ovhv2-miR-61-1 (p ≤ 0.0001) and ovhv2-miR-73-1 (p ≤ 0.05) were co-transfected with 
an Ov2-EGFPN1 construct compared to the scrambled siRNA. A significant increase in the 
MFI was observed when ovhv2-miR-17-29 (p ≤ 0.05) was co-transfected with an Ov2-
EGFPN1 construct compared to the scrambled siRNA. When all four of the OvHV-2-encoded 
miRNAs predicted to target Ov2 were co-transfected with an Ov2-EGFPN1 construct the 
reduction in MFI observed compared to the scrambled siRNA was not significant. From this 
preliminary experiment, ovhv2-miR-17-10 and ovhv2-miR-61-1 were taken forward for 
further validation.  
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MIRNA  : ovhv2-miR-17-29 
length: 23 
 
mfe: -18.2 kcal/mol 
p-value: undefined 
 
position  46 
target 5'   C    AA   AAACAUA       A 3' 
             CUGA  AGA       UCCAAGA     
             GACU  UCU       AGGUUCU     
miRNA  3' GAU    G    ACGC          A 5' 
 
MIRNA  : ovhv2-miR-17-10 
length: 23 
 
mfe: -23.8 kcal/mol 
p-value: undefined 
 
position  104 
target 5'   G    A  ACAAAUAGAAG   AUCAC         A 3' 
             CAGG GC           AGC     GUAACUUCA     
             GUCC CG           UCG     CAUUGAAGU     
miRNA  3' UAG    A                A               5' 
 
MIRNA  : ovhv2-miR-61-1 
length: 25 
 
mfe: -30.7 kcal/mol 
p-value: undefined 
 
position  454 
target 5'      C    AA      UUAUG       C 3' 
                UCAG  CAGCAC     GUCCCCA     
                AGUC  GUCGUG     CAGGGGU     
miRNA  3' UGCAGC    G                   U 5' 
 
 
MIRNA  : ovhv2-miR-73-1 
length: 23 
 
mfe: -22.0 kcal/mol 
p-value: undefined 
 
position  304 
target 5'  C      GG    A UGAAAAGAAAAAAGA        G 3' 
            UUGCGG  GGAG U               AGAGAUUA     
            AAUGUU  CCUC G               UCUCUAAU     
miRNA  3' UA      AA                               5' 
 
 
Figure 5.1 RNAHybrid analysis of OvHV-2-encoded miRNAs against Ov2 
mfe = minimum free energy. Constraints on miRNA binding included perfect 
complementarity between nucleotides 2 and 8 and no G:U pairing within this region. 
Positions refer to nucleotide start sites in the Ov2 gene (AY839756.1, reverse complement of 
nucleotides 1321 – 2480). Targets shown are located in the coding region. 
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Figure 5.2 Relative MFI of OV2-EGFPN1 with OvHV-2-encoded miRNAs 
compared to a scrambled siRNA control 
293T cells were co-transfected with an Ov2-EGFPN1 construct and OvHV-2-encoded 
miRNAs predicted to target the coding region of Ov2 or a scrambled siRNA. The MFI for 
each sample was determined 48 hrs later by flow cytometry and test ovhv2-miRNAs were 
compared to a scrambled siRNA control. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.0001. 
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5.3.3 Validation of Ov2 as a target of ovhv2-miR-17-10 and ovhv2-miR-61-1 by 
flow cytometry 
Transfections and flow cytometry were carried out as described in sections 2.1.7, 2.6.2 and 
2.6.4 with n = 14 for each condition. Between replicates and conditions the percentage of GFP 
positive cells remained consistent (on average 31.5%, standard deviation 4.84) indicating the 
transfection efficiency was not altered when the EGFPN1 constructs were co-transfected with 
different mimics. GFP positive cells were counted and the MFI for each replicate was 
determined and used as an indicator of GFP expression levels (Fig. 5.3). Significant decreases 
(p ≤ 0.0001 for all) of 35%, 39% and 44% in the MFI were observed when ovhv2-miR-17-10, 
ovhv2-miR-61-1 or a combination of both ovhv2-miRs were cotransfected with an Ov2-
EGFPN1 construct respectively compared to a scrambled siRNA. No significant changes in 
the MFI were observed when ovhv2-miR-17-10 or a combination of both ovhv2-miRs were 
cotransfected with an EGFPN1 construct compared to a scramble siRNA. A significant 
decrease of 25% (p ≤ 0.01) in the MFI was observed when ovhv2-miR-61-1 was co-transfected 
with an EGFPN1 construct compared to the scrambled siRNA.  
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Figure 5.3 Relative MFI of EGFPN1 and Ov2-EGFPN1 with ovhv2-miR-17-10, 
ovhv2-miR-61-1 or a combination of both compared to a scrambled siRNA 
293T cells were co-transfected with either an EGFPN1 or an Ov2-EGFPN1 construct and 
ovhv2-miR-17-10, ovhv2-miR-61-1, a combination of both ovhv2-miRs or a scrambled 
siRNA. The MFI for each sample was determined 48 hrs later by flow cytometry and test 
ovhv2-miRNAs were compared to a scrambled siRNA control. ** = p ≤ 0.01, *** = p ≤ 
0.0001.  
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5.3.4 Validation of Ov2 as a target of ovhv2-miR-17-10 and ovhv2-miR-61-1 by 
western blotting 
The coding region of Ov2 was cloned into pcDNA3.1+ (construct made by Dr Inga Dry). 
Transfections of cells seeded in 12 well plates were carried out as described in section 2.1.7. 
Western Blotting was performed as described in section 2.4. Membranes were incubated with 
a rabbit anti-Ov2 and a mouse anti-actin primary antibodies before incubation with appropriate 
secondary antibodies. One representative western blot is shown in Fig. 5.4. A total of three 
independent western blots were performed with duplicates of each condition (Ov2-
pcDNA3.1+ co-transfected with one of scrambled siRNA, ovhv2-miR-17-10, ovhv2-miR-61-
1 or a combination of both) on each western blot (n = 6 total for each condition). For each 
sample, the levels of Ov2 were quantified and normalised to the level of actin. Test ovhv2-
miRNA samples were then compared to the scrambled siRNA (Fig. 5.6). When either ovhv2-
miR-17-10 or ovhv2-miR-61-1 were co-transfected with an Ov2-pcDNA3.1+ construct 
statistically significant reductions of approximately 40% (p ≤ 0.05 for both ovhv2-miRNAs) 
were observed compared to the scrambled siRNA. When both ovhv2-miRNAs were co-
transfected with an Ov2-pcDNA3.1+ construct a significant reduction (p ≤ 0.01) of 
approximately 60% was observed compared to the scrambled siRNA.  
5.3.5 Mutagenesis of the ovhv2-miR-17-10 and ovhv2-miR-61-1 Ov2 binding 
sites 
The binding sites of ovhv2-miR-17-10 and ovhv2-miR-61-1 (as shown in Fig 5.1) were 
mutated by site-directed mutagenesis (as described in section 2.2.8). The coding sequence of 
Ov2 was not altered. Western blotting was carried out with the same conditions as described 
in section 5.3.4. One representative western blot for each mutated Ov2-pcDNA3.1+ construct 
is shown in Fig. 5.5. A total of two independent western blots were performed with duplicates 
of each condition on each blot (n = 4 for each condition). For each sample, the levels of Ov2 
were quantified and normalised to the level of actin. Test ovhv2-miRNA samples were then 
compared to the scrambled siRNA (Fig. 5.6).  When ovhv2-miR-17-10, ovhv2-miR-61-1 or a 
combination of both ovhv2-miRNAs were co-transfected with an Ov2-pcDNA3.1+ construct 
with a mutated ovhv2-miR-17-10 binding site significant reductions of approximately 55%, 
60% and 70% respectively (p ≤ 0.01 for all conditions) were observed compared to the 
scrambled siRNA. When ovhv2-miR-17-10 was co-transfected with an Ov2-pcDNA3.1+ 
construct with a mutated ovhv2-miR-61-1 binding site a significant reduction (p ≤ 0.05) of 
approximately 40% was observed compared to the scrambled siRNA. When ovhv2-miR-61-1 
was co-transfected with an Ov2-pcDNA3.1+ construct with a mutated ovhv2-miR-61-1 
binding site no significant reduction was observed compared to the scrambled siRNA. When 
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a combination of both ovhv2-miRNAs were co-transfected with an Ov2-pcDNA3.1+ construct 
with a mutated ovhv2-miR-61-1 binding site a significant reduction (p ≤ 0.01) of 
approximately 50% was observed compared to the scrambled siRNA. These results, especially 
the continued inhibition observed in the Ov2 construct with a mutated ovhv2-miR-17-10 
binding site, will be discussed at the end of this chapter. 
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Figure 5.4 Western Blot of Ov2-pcDNA3.1+ with ovhv2-miR-17-10, ovhv2-
miR-61-1 or a combination of both compared to a scrambled siRNA 
293T cells were co-transfected with an Ov2-pcDNA3.1+ construct and ovhv2-miR-17-10, 
ovhv2-miR-61-1, a combination of both ovhv2-miRs or a scrambled siRNA. Cells were 
harvested 48 hrs post transfection and western blotting performed.  UT = untransfected 
control. One representative western blot is shown. 
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Figure 5.5 Western Blots of Ov2-pcDNA3.1+ with mutated ovhv2-miR-17-10 
or ovhv2-miR-61-1 binding sites with ovhv2-miR-17-10, ovhv2-miR-61-1 or a 
combination of both compared to a scrambled siRNA 
293T cells were co-transfected with either an Ov2-pcDNA3.1+ construct with a mutated 
ovhv2-miR-17-10 binding site (A) or an Ov2-pcDNA3.1+ construct with a mutated ovhv2-
miR-61-1 binding site (B) and ovhv2-miR-17-10, ovhv2-miR-61-1, a combination of both 
ovhv2-miRs or a scrambled siRNA. Cells were harvested 48 hrs post transfection and 
western blotting performed.  UT = untransfected control. One representative western blot 
is shown for each Ov2 construct. 
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Figure 5.6 Relative expression of Ov2-pcDNA3.1+ and mutated Ov2-
pcDNA3.1+ constructs with ovhv2-mIR-17-10, ovhv2-miR-61-1 or a 
combination of both compared to a scrambled siRNA  
Western blots were quantified using the LI-COR system. Expression of Ov2 was 
normalised to expression of actin for each sample. Test ovhv2-miRs were then compared 
to a scrambled siRNA. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.0001. 
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5.4 Functional Analysis of Ov2 
 
5.4.1 Determining the subcellular localisation of Ov2 
Coverslips were prepared and transfected with either an Ov2HA-pcDNA3.1+ construct or a 
pcDNA3.1+ construct as described in section 2.1.8. 24 hrs. Fixing and immunofluorescence 
was carried out 24 hrs post transfection as described in section 2.7.1. Coverslips were 
incubated with a rabbit anti-Ov2 primary antibody or a rat anti-HA primary antibody or both 
primary antibodies before incubation with appropriate secondary antibodies. The nucleus was 
stained for using DAPI in all coverslips. Confocal microscopy was performed as described in 
section 2.7.2. Representative images for each condition can be seen in Figure 5.7. Good co-
localisation of the anti-Ov2 and anti-HA antibody was observed (Fig 5.7. C) and Ov2 appears 
to have a nuclear localisation. To ensure the localisation observed was not due to 
overexpression and accumulation of Ov2 protein at 24 hrs further coverslips were prepared 
and transfected with either an Ov2HA-pcDNA3.1+ construct or a pcDNA3.1+ construct and 
stained for Ov2 with the anti-Ov2 antibody at 4 hrs, 8 hrs and 16 hrs post transfection. Figure 
5.8 shows representative images for each of these times points and even from the earliest time 
point of 4 hrs post transfection Ov2 is observed to be located in the nucleus.  
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Fig 5.7 Immunofluorescence of pcDNA3.1+ or Ov2HA-pcDNA3.1+ stained 
with either an anti-HA antibody, an anti-Ov2 antibody or a combination of 
both at 24 hrs post transfection 
293T cells were either transfected with a pcDNA3.1+ construct or an Ov2HA-pcDNA3.1+ 
construct. Fixing and immunostaining of cells was performed 24 hrs post transfection. 
Cells were either stained with a combination of an anti-Ov2 antibody and an anti-HA 
antibody (panels in A), an anti-Ov2 antibody (panels in B) or an anti-HA antibody (panels 
in C). DAPI staining was performed in all conditions to stain the nucleus. 
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Fig 5.8 Immunofluorescence of pcDNA3.1+ or Ov2HA-pcDNA3.1+ stained 
with an anti-Ov2 antibody at 4 hrs, 8 hrs and 16 hrs post transfection 
293T cells were either transfected with a pcDNA3.1+ construct or an Ov2HA-pcDNA3.1+ 
construct. Fixing and immunostaining of cells was performed 4 hrs, 8 hrs and 16 hrs post 
transfection. Cells were stained with an anti-Ov2 antibody (green) and DAPI (blue). 
Merged images are shown above. Split images can be found in Appendix 6. 
Chapter 5 Identification of the virus protein Ov2 as a target of OvHV-2-encoded miRNAs 
         
138 
 
5.4.2 Regulation of Jagged and Caspase 8 by Ov2 
In the study by Parameswaran et al. a number of genes were identified by RNA-Seq that were 
differentially regulated by an A2 deletant virus compared to wild type or a revertant virus. 
Two of these genes, JAG1 (Jagged) and CASP8, were investigated to see whether they were 
differentially regulated by Ov2. MDBK cells were nucleofected with either an Ov2-EGFPN1 
construct or an EGFPN1 construct as described in section 2.1.9. cDNA was made from RNA 
harvested 48 hrs post nucleofection as described in sections 2.2.2 and 2.2.3. RT-qPCR for four 
biological replicates (with two technical replicates per sample) were carried out as described 
in section 2.2.10 for JAG1 and CASP8 (Figure 5.9). Expression of both JAG1 and CASP8 were 
normalised to the expression of GAPDH for each sample and the ΔΔCt method of analysis 
was used to determine fold change for Ov2-EGFPN1 nucleofected cells compared to EGFPN1 
transfected cells (Livak & Schmittgen, 2001). No significant changes were observed in the 
relative expression levels of CASP8 when an Ov2-EGFPN1 construct was nucleofected 
compared to an EGFPN1 construct. A statistically significant reduction of approximately 25% 
(p ≤ 0.001) was observed in the relative expression levels of JAG1 when an Ov2-EGFPN1 
construct was nucleofected compared to an EGFPN1 construct.  
5.4.3 Ov2 immunoprecipitation and Mass Spectrometry analysis 
To determine potential interacting partners of Ov2, immunoprecipitation and subsequent mass 
spectrometry analysis was performed. 293T cells were either transfected with a pcDNA3.1+ 
construct or an Ov2HA-pcDNA3.1+ construct as described in section 2.1.7. Cell lysates were 
harvested 48 hrs post transfection as described in section 2.5.1. Immunoprecipitation using 
HA-tagged magnetic beads was carried out in duplicate as described in section 2.5.2. Western 
blotting was performed (as described in sections 2.4.2 to 2.4.4) on one set of samples to 
confirm the successful immunoprecipitation of Ov2 (Figure 5.10). Ov2 protein can be detected 
by the anti-Ov2 antibody in the Ov2HA-pcDNA3.1+ input and eluted samples but not in the 
pcDNA3.1+ input or eluted samples confirming that the immunoprecipitation was a success. 
The other set of samples immunoprecipitated at the same time were sent for mass spectrometry 
analysis as described in section 2.5.3. Analysis of the mass spectrometry data was performed 
using the following constraints: proteins must have a protein score of over forty and there must 
be more than one unique peptide matching the protein. The proteins unique to either 
pcDNA3.1+ or Ov2HA-pcDNA3.1+ are listed in Table 5.1A and 5.1B respectively. A large 
number of proteins were present in both pcDNA3.1+ and Ov2HA-pcDNA3.1+ samples; 
proteins that had a two-fold higher protein score in the Ov2HA-pcDNA3.1+ samples 
compared to the pcDNA3.1+ samples are listed in Table 5.2. For reference, the full list of 
proteins that met the constraints for both samples can be found in Appendix 7.  
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Figure 5.9 Relative expression of CASP8 and JAG1 in Ov2-EGFPN1 
transfected cells compared to EGFPN1 transfected cells 
MDBK cells were nucleofected with either an Ov2-EGFPN1 construct or an EGFPN1 
construct. cDNA was made from RNA harvested 48 hrs post nucleofection and RT-qPCR 
performed. The ΔΔCt method of analysis was used to determine fold change of Ov2-
EGFPN1 transfected cells compared to EGFPN1 transfected cells. The expression of 
CASP8 and JAG1 was normalised to the expression of GAPDH for each sample. Error bars 
represent upper and lower limits. 
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Figure 5.10 Western Blotting of pcDNA3.1+ and Ov2HA-pcDNA3.1+ 
immunoprecipitated samples 
293T cells were either transfected with a pcDNA3.1+ construct or an Ov2HA-pcDNA3.1+ 
construct. Cell lysates were harvested 48 hrs post transfection and immunoprecipitated 
using HA-tagged magnetic beads. Western blotting was performed to confirm the presence 
of Ov2 in the immunoprecipitated samples.  
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Table 5.1 Unique proteins identified by Mass Spectrometry in pcDNA3.1+ and Ov2HA-pcDNA3.1+ immunoprecipitated samples 














ID Gene Name 
Protein 
Score No. Unique Peptides 
Q5VTE0 Putative elongation factor 1-alpha-like 3 (EEF1A1P5)  180 5 
P58876 Histone H2B type 1-D (HIST1H2BD)  80 3 
H0YMV8 40S ribosomal protein S27 (RPS27L)  52 2 
K7EMH1 60S ribosomal protein L22 (Fragment) (RPL22)  46 2 
Protein 
ID Gene Name 
Protein 
Score No. Unique Peptides 
Q9NQ29 Putative RNA-binding protein Luc7-like 1 (LUC7L) 254 4 
P46776 60S ribosomal protein L27a (RPL27A)  199 5 
P42766 60S ribosomal protein L35 (RPL35)  199 2 
P08238 Heat shock protein HSP 90-beta (HSP90AB1)  142 4 
P07195 L-lactate dehydrogenase B chain (LDHB)  121 2 
H0Y5B4 60S ribosomal protein L36a (Fragment) (RPL36A)  115 2 
E9PI65 Heat shock cognate 71 kDa protein (Fragment) (HSPA8)  106 3 
F5H4F9 40S ribosomal protein S3a (RPS3A)  99 3 
J3KPD9 Nucleoside diphosphate kinase B (NME2)  74 2 
P50990 T-complex protein 1 subunit theta (CCT8)  62 2 
P62241 40S ribosomal protein S8 (RPS8)  60 2 
Q2VSN7 OvHV-2 Ov2 protein  55 2 
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Table 5.2: Proteins identified by Mass Spectrometry that have a Protein Score that is at least 2 Fold higher in Ov2HA-pcDNA3.1+ 

















Q06830 Peroxiredoxin-1 (PRDX1) 47 185 3.94 
P62854 40S ribosomal protein S26 (RPS26) 74 287 3.88 
P62937 Peptidyl-prolyl cis-trans isomerase A (PPIA) 52 181 3.48 
Q9Y383 Putative RNA-binding protein Luc7-like 2 (LUC7L2) 223 593 2.66 
P39019 40S ribosomal protein S19 (RPS19) 157 371 2.36 
P06733 Alpha-enolase (ENO1 ) 134 315 2.35 
P10809 60 kDa heat shock protein, mitochondrial (HSPD1) 139 316 2.27 
E9PR30 40S ribosomal protein S30 (FAU) 104 234 2.25 
P14618 Pyruvate kinase PKM (PKM) 93 206 2.22 
P62701 40S ribosomal protein S4, X isoform (RPS4X) 356 757 2.13 
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It was demonstrated that Ov2 is a target of ovhv2-miR-17-10 and ovhv2-miR-61-1. RNAHybrid was 
initially used to probe the Ov2 sequence for target sites of OvHV-2-encoded miRNAs. In total, eight 
sites were predicted (four in the coding region, see section 5.3.1 and four in the 3’ UTR, see Appendix 
9). As the coding region of Ov2 has already been cloned into a number of vectors (pcDNA3.1+, 
pcDNA3.1+ with an HA tag and pEGFPN1) only the coding region sites were investigated. It is worth 
noting that ovhv2-miR-17-13 had two predicted target sites in the 3’UTR that were in close proximity 
of each other. It is thought that when two binding sites for the same miRNA are present the magnitude 
of regulation is increased (Brennecke et al., 2005; Sætrom et al., 2007). If this work was to be continued 
it would therefore be of interest to investigate whether any of the predicted 3’UTR target sites are 
functional.  
It was traditionally thought that functional sites of miRNAs only existed in the 3’UTR however there 
is increasing evidence that miRNAs can bind to sites in the coding region with functional activity 
(Hausser et al., 2013). Moreover, it has been shown that small interfering RNAs that target the coding 
region can be effective at silencing (Saxena et al., 2003). In fact, there are a number of cases of targeting 
in the coding region by miRNAs in the literature, including a coding region target for the let-7 miRNA 
within Dicer, part of the miRNA biogenesis machinery (Elcheva et al., 2009; Forman et al., 2008; Liu 
et al., 2015a; Qin et al., 2010; Tay et al., 2008). However, it should be noted that it is thought that 
targeting in the coding region is often less effective in down-regulation of target transcript levels but 
can result in a similar efficiency of translational knockdown as targeting of the 3’UTR (Baek et al., 
2008; Fang & Rajewsky, 2011; Guo et al., 2010).  
A preliminary screen of the four predicted coding region target sites was carried out using an Ov2-
EGFPN1 construct. It had originally been planned to use a plate reader to measure the GFP signal as 
this would have been a very quick and simple method. However, the GFP signal was significantly 
reduced in the Ov2-EGFPN1 construct and the plate reader was no longer a useable method of 
quantifying GFP signal. Instead, flow cytometry was used to measure the intensity of the GFP signal 
and also had the added benefit of ensuring similar numbers of cells were transfected between samples. 
One miRNA, ovhv2-miR-17-29, appeared to increase the MFI of an Ov2-EGFPN1 compared to a 
scrambled siRNA control. There are a number of reports documented in which a miRNA appears to 
have a positive effect on a target transcript (Andersson Ørom et al., 2008; Ghosh et al., 2008; Lu et al., 
2010b; Ma et al., 2010; Vasudevan et al., 2007). For the purposes of this thesis, the effect of ovhv2-
miR-17-29 on Ov2 was not characterised any further. The other three miRNAs, ovhv2-miR-17-10, 
ovhv2-miR-61-1 and ovhv2-miR-73-1 all showed significant decreases in the MFI of an Ov2-EGFPN1 
construct compared to a scrambled siRNA control. The two that displayed the strongest effect on the 
MFI, ovhv2-miR-17-10 and ovhv2-miR-61-1 were taken forward for further validation.  
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The same method of validation was used as in the preliminary screen but this time the number of 
biological replicates was increased to 14 and appropriate controls were used. An empty vector control 
was included to check for off-target effects of ovhv2-miR-17-10 and ovhv2-miR-61-1. Similar levels 
of knockdown were observed for the miRNAs as in the preliminary screen however there was a 
statistically significant knockdown when ovhv2-miR-61-1 was co-transfected with pEGFPN1 
compared to a scrambled siRNA. The reduction observed was not as high as when ovhv2-miR-61-1 
was co-transfected with Ov2-EGFPN1 however another method of validation, not using EGFPN1 was 
required to confirm Ov2 as a target of ovhv2-miR-61-1. RNAHybrid analysis of ovhv2-miR-61-1 
against the pEGFPN1 vector revealed two potential target sites in the coding region of EGFP; both of 
which had perfect complementarity between nucleotides 1 and 7 and used G:U pairing in this region 
and so it is therefore possible that there are off-target effects of ovhv2-miR-61-1 on the vector which 
may potentially explain the knockdown observed in the pEGFPN1 control samples.  
As an antibody to Ov2 was available western blotting was performed on an untagged Ov2-pcDNA3.1+ 
construct co-transfected with a scrambled siRNA, ovhv2-miR-17-10, ovhv2-miR-61-1 or a 
combination of both ovhv2-miRNAs. The levels of knockdown of Ov2 were similar to that observed 
by flow cytometry indicating that ovhv2-miR-61-1 does target Ov2. To confirm that the sites predicted 
by RNAHybrid were the actual binding sites of ovhv2-miR-17-10 and ovhv2-miR-61-1 site directed 
mutagenesis was performed, whilst keeping the coding sequence the same. For ovhv2-miR-61-1, the 
complete binding site was mutated however for ovhv2-miR-17-10 only the seed sequence binding site 
was mutated due to the length of the predicted binding site. When ovhv2-miR-61-1 was co-transfected 
with the Ov2-pcDNA3.1+ construct with the relevant predicted binding site mutated no knockdown of 
Ov2 levels were observed. It is thus likely that the predicted target site for ovhv2-miR-61-1 is the actual 
binding site and results in functional knockdown of Ov2 protein levels. This mutation did not affect the 
knockdown of Ov2 by ovhv2-miR-17-10. The levels of knockdown of Ov2 when both ovhv2-miRNAs 
were co-transfected with an Ov2-pcDNA3.1+ construct were also not affected, indicating that there is 
no combinatorial effect of the two ovhv2-miRNAs.  
When ovhv2-miR-17-10 was co-transfected with the Ov2-pcDNA3.1+ construct with the relevant 
predicted binding site mutated knockdown of Ov2 was observed to similar levels as in the wild-type 
Ov2-pcDNA3.1+ construct. To disrupt ovhv2-miR-17-10 binding, three amino acids (an arginine, an 
asparagine and a phenylalanine) were mutated. There are only two codons available for asparagine 
(AAC and AAT) and phenylalanine (TTC and TTT) and as such mutation of these two amino acids 
results in changes in the base pairing of ovhv2-miR-17-10 with Ov2 from G:C to G:U. G:U pairing is 
allowed in seed sequences and can still result in functional knockdown of the target and as such this 
could explain why there was no restoration of Ov2 levels observed in the mutated construct. 
Furthermore, there are another two sites present in the Ov2 coding region that allow for G:U pairing 
with perfect complementarity between either nucleotides 1 and 7 or 2 and 8 (see Appendix 10 for 
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RNAHybrid analyses). Therefore from this analysis it cannot be confirmed whether the initial predicted 
ovhv2-miR-17-10 target site is the actual binding site and further investigation would be required, such 
as changing the protein sequence of Ov2 or using a different validation method. However, changing the 
coding sequence of Ov2 may have other unknown consequences on the activity of Ov2. Using a 
different approach such as the luciferase assays used for validation of DLL1 and MHC class II genes is 
beneficial as the sequence cloned into the vector can be mutated freely as the multiple cloning site is 
located in the 3’UTR of renilla (see appendix 1 for vector map of psiCHECK-2). However, there are 
limitations of the luciferase assay approach which are discussed in further details in chapter 6. 
The second part of this thesis chapter investigated the functional activity of Ov2 in a number of ways. 
Firstly, the subcellular localisation of Ov2 was determined and it was found to be localised in the 
nucleus. Importantly, there was a good correlation between the anti-HA antibody and anti-Ov2 antibody 
used, and an untagged Ov2 construct had the same subcellular localisation as the HA-tagged Ov2 
construct (see Appendix 6). The subcellular localisation of Ov2 observed is unlikely to be an artefact 
of overexpression of the construct as the same distribution of Ov2 was seen at 4 hrs, 8 hrs and 16 hrs 
post transfection. The nuclear localisation of Ov2 is not surprising as the sequence has two predicted 
nuclear localisation signal sequences, and as Ov2 is predicted to contain a bZIP domain it is likely to 
have a role in transcription.  
A second approach to investigating the function of Ov2 was based on the work published by 
Parameswaran et al. on the A2 protein of AlHV-1. A number of genes identified as either being up-
regulated or down-regulated during infection of rabbits with an A2 deletant virus compared to a wild-
type or revertant virus were selected for RT-qPCR analysis. Genes selected for analysis that were up-
regulated during infection with an A2 deletant virus included CASP8, DENN/MADD Domain 
Containing 2D (DENND2D, a guanine nucleotide exchange factor), Nuclear Factor Of Kappa Light 
Polypeptide Gene Enhancer In B-Cells 1 (NFKB1, a transcriptional regulator), Cyclin-Dependent 
Kinase 2 (CDK2, involved in cell cycle regulation) and IL-2. Genes selected for analysis that were 
down-regulated during infection with an A2 deletant virus included JAG1, PRF1 (perforin, a component 
of cytolytic granules), Nuclear Factor Of Activated T-Cells, Cytoplasmic, Calcineurin-Dependent 2 
(NFATC2, a transcription factor that plays a central role during activation of the immune response), 
GZMA (another component of cytolytic granules) and FOSB.  Due to limited availability of relevant  
cell lines not all of these genes were expressed in the MDBK cell line chosen; as expected the genes 
with expression restricted to lymphocytes such as PRF1, IL2, NFATC2 and GZMA were not expressed 
in MDBK cells. Furthermore, due to time restrictions, primer sets could not be optimised for NFKB1, 
CDK2 and DENND2D. Finally, although the primer set for FOSB was optimised, the expression levels 
in MDBK cells were low. Further optimisation was performed by altering the concentration of cDNA 
used in the reaction however this failed to improve the levels of FOSB observed in the RT-qPCR and 
as such the regulation of FOSB by Ov2 could not be investigated. In the study done by Parameswaran 
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et al. CASP8 was up-regulated two-fold in an A2 deletant virus compared to the wild-type or revertant 
viruses by RNA-Seq. However in an RT-qPCR performed in rabbit LGL cells no significant difference 
was observed (Parameswaran et al., 2014). In MDBK cells nucleofected with an Ov2-EGFPN1 
construct there was no difference in the expression of CASP8 compared to MDBK cells nucleofected 
with a pEGFPN1 construct. In the study by Parameswaran et al. JAG1 was down-regulated twenty-
seven-fold in an A2 deletant virus compared to the wild-type or revertant viruses by RNA-Seq. RT-
qPCR for JAG1 was not performed in the described study. In MDBK cells nucleofected with an Ov2-
EGFPN1 construct the expression of JAG1 was down-regulated 25% compared to MDBK cells 
nucleofected with an EGFPN1 construct. The Parameswaran et al. study implies that A2 would up-
regulate JAG1 expression however in the study performed as part of this thesis Ov2 down-regulates 
JAG1 expression. Obviously the two systems used are completely different in a number ways, including 
the species and type of cell lines used. The work done on A2 was in the context of the whole virus; as 
this method is not available for the study of OvHV-2 a different approach had to be taken. Work is 
ongoing to determine the effect of A2 on JAG1 using an A2-pEGFPN1 construct nucleofected into 
MDBK cells. This work, in combination with the work performed in section 4.3 showing that DLL1 is 
a target of OvHV-2-encoded miRNAs, is good evidence supporting the hypothesis that Notch signalling 
plays an important role during OvHV-2 biology. This will be discussed in further detail in chapter 6. 
Lastly, immunoprecipitation and LC MS/MS was performed to identify potential interacting partners 
of Ov2. A number of compromises were made in the proteomic study of Ov2, including the number of 
replicates, quantitative nature of the mass spectrometry and cell line in which the immunoprecipitation 
was performed. The immunoprecipitation of Ov2 was only performed once, and therefore would need 
to be repeated multiple times before any real conclusions could be drawn. There were a large number 
of proteins identified that were present in both samples. Although the protein score does approximately 
relate to the abundance of the protein other things such as number of peptides matching the protein are 
taken into consideration. In this analysis, there are a number of proteins that have a differential protein 
score of more than two-fold in the Ov2 sample compared to the control. This indicates that if this was 
to be repeated, a quantitative approach might be useful in determining whether the proteins that have a 
higher score in the Ov2 sample are potential interacting partners. There were also a large number of 
ribosomal proteins identified in both the Ov2 and control samples; this is most likely due to not using 
microcentrifuge tubes that have low protein-binding properties during the immunoprecipitation. Also 
worth noting was the fact that Ov2 had a low protein score itself of 54. When the Ov2 protein sequence 
was probed for trypsin cleavage sites (after arginine or lysine residues) only four peptides of an optimal 
length for LC MS/MS (approximately 1 kDa) were observed. Two of the four peptides were detected 
in this analysis, indicating that perhaps Ov2 is not an ideal candidate for LC MS/MS. Another potential 
issue with this analysis is that the immunoprecipitation was performed in 293T cells as they transfect 
easily. 293T cells are not a physiologically relevant cell line and perhaps a better choice would have 
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been a lymphocyte cell line, particularly sheep and/or cattle lymphocytes. However, lymphocytes are 
difficult to transfect and therefore it may be difficult to get enough protein sample to perform the 
immunoprecipitation. Moreover, performing the immunoprecipitation in sheep or cattle cell lines has 
the added complexity of having less well annotated genomes which may limit the results.  
Of the unique proteins identified in the Ov2HA-pcDNA3.1+ sample there are two proteins of particular 
interest; nucleoside diphosphate kinase B (NME2) and putative RNA-binding protein Luc7-like 1 
(LUC7L). NME2 belongs to a family of nucleoside diphosphate kinases which catalyse the transfer of 
γ-phosphates from nucleoside triphosphates to nucleoside diphosphates. NME genes are also involved 
in a number of cellular processes such as proliferation, differentiation, apoptosis and metastatic 
dissemination (Boissan et al., 2009; Liu et al., 2015b). A potential mechanism through which NME2 
suppresses metastatic activity is through interaction and sequestering of Integrin cytoplasmic domain-
associated protein 1 α, a negative regulator of cell adhesion (Fournier et al., 2002). NME2 is also 
capable of binding BCL2-Like 10 (BCL2L10), which can act as either a pro- or anti-apoptotic protein 
depending on the cellular context, thus providing a mechanism for NME2 to regulate apoptosis (Kang 
et al., 2007). Of particular interest to Ov2 biology is the observation that NME2 can act as a DNA-
binding factor and play a role in transcription (Postel, 2003). Furthermore, it was shown that NME2 can 
bind to a specific G-quadruplex motif located in the c-myc promoter and induce c-myc expression 
(Berberich & Postel, 1995; Postel, 2003; Yao et al., 2014). c-myc is a known oncogene that contributes 
to the development of many human cancers. It has been shown that deregulated Notch signalling 
pathways can induce c-myc expression in a T cell leukaemia mouse model (Sharma et al., 2006). Other 
viruses including EBV and human papillomavirus (HPV) can interact with another NME protein 
NME1. EBNA3C and EBNA1 of EBV can interact with and suppress the activity of NME1 promoting 
metastasis and the E7 protein of HPV can also bind NME1 and regulate tumour cell motility (Kaul et 
al., 2007; Mileo et al., 2006; Subramanian et al., 2001; Subramanian & Robertson, 2002). It could be 
possible that OvHV-2 uses Ov2 to regulate cell migration like EBV and HPV. Another possibility is 
that Ov2 could bind to NME2 and induce c-myc expression contributing to the lymphocyte proliferation 
observed in MCF. It is possible that this happens in cattle and not in sheep due to a dysregulation of 
OvHV-2-encoded miRNA expression, which leads to improper Ov2 expression in cattle. Obviously, to 
confirm interaction of Ov2 with NME2, further validation such as a co-immunoprecipitation or confocal 
microscopy to confirm co-localisation would be required. 
The other unique protein identified, LUC7L belongs to a family of Luc7 protein homologues. Luc7 is 
an essential subunit of the yeast U1 small nuclear ribonucleic protein (snRNP) that plays a role in 5’ 
splice site recognition. Luc7 mutants are unable to support any of the defined steps of splicing unless 
recombinant Luc7 protein is added (Fortes et al., 1999). It is worth noting that LUC7L2 was identified 
in both control and Ov2 immunoprecipitated samples however the protein score was 2.66 fold higher 
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in the Ov2 sample compared to the control sample. LUC7L3 was also identified in the Ov2 
immunoprecipitated sample however due to only have one unique peptide in the analysis it was 
excluded from the unique protein list. A list of proteins with only one unique sample in both the control 
and Ov2 samples can be found in Appendix 8. Moreover, LUC7L2 was identified as a differentially 
enriched gene in the CLASH work performed previously (Riaz, 2014). Differentially enriched genes 
are those that were precipitated more in one sample compared to the other; in this instance LUC7L2 
was enriched sixty-four fold in the control sample compared to the sample expressing OvHV-2-miR-
17-1, 17-2 and 17-3. If the OvHV2-miRNAs were targeting LUC7L2 then it should be differentially 
enriched in the test sample compared to the control, however if there was no regulation of LUC7L2 by 
the OvHV2-miRNAs similar levels of the transcript between the two samples should have been 
precipitated. This indicates that perhaps the OvHV-2-miRNAs are down-regulating an upstream 
regulator of LUC7L2 expression. Little work has been done on the function of LUC7L and LUC7L3 in 
humans however it has been shown that LUC7L3 interacts with the splicing factors SR-related protein 
of 53 kDa (SRrp53) and Serine/Arginine-Rich Splicing Factor 1 (SRSF1), and contains two zinc finger 
motifs (Cazalla et al., 2005). LUC7L2 has been shown to be a frequently mutated gene in some myeloid 
malignancies (Singh et al., 2013). It is thought to be involved in recognition of non-consensus splice 
sites and co-localises with the spliceosome marker U1-70K and is thus likely to associate with U1 
(Howell et al., 2007). However, in a number of studies that investigated the components of the 
spliceosome LUC7L2 was not present (Jurica & Moore, 2003). It is possible that LUC7L2 interacts 
with the spliceosome transiently and plays a potential auxiliary role in splicing through stabilisation of 
the spliceosome (Howell et al., 2007). LUC7L2 was identified as a potential interacting partner of the 
HIV encoded protein Tat by LC MS/MS however this interaction was not further validated (Gautier et 
al., 2009). The role that the potential interaction of Ov2 with the LUC7L proteins in OvHV-2 biology 
is unclear, as the majority of OvHV-2 ORFs are not spliced. Normally, splicing is required for efficient 
nuclear export through the recruitment of Aly, a protein that is associated with spliced mRNPs and 
recruits nuclear export factors (Zhou et al., 2000). It is known that other γ-herpesviruses such as KSHV, 
bypass splicing by recruitment of ORF57, which binds to the 5’ of viral mRNPs and directly recruits 
Aly facilitating nuclear export  (Boyne et al., 2008). Moreover, ICP27 of HSV-1 is known to inhibit 
cellular splicing through interactions with essential splicing factors named SR proteins; this interaction 
can affect the phosphorylation status of SR proteins and consequently impair the ability of these proteins 
to function in spliceosome assembly (Hardwicke & Sandri-Goldin, 1994; Hardy & Sandri-Goldin, 
1994; Sciabica et al., 2003). ICP27 can also interact with spliceosome associated protein 145 (SAP145), 
which can also lead to an inhibition of splicing, as a mutated ICP27 which does not inhibit splicing 
showed a reduced interaction with SAP145 (Bryant et al., 2001). Additionally, it has been shown that 
the HIV-encoded protein Vpr is also capable of inhibiting splicing through interaction with SAP145 
(Hashizume et al., 2007). It is possible that Ov2 functions to down-regulate splicing as a mechanism of 
host shut-off however as the study of OvHV-2 gene expression is limited by the lack of a propagation 
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system it could be difficult to demonstrate the function of an interaction between Ov2 and LUC7L 
proteins during infection.  
The lack of an obvious transcription factor in the Ov2 mass spectrometry samples could be interpreted 
as an indication that Ov2 does not play a role in the manipulation of cellular gene expression, however 
this cannot be ruled out by the preliminary analysis done in this thesis. It is possible that Ov2 is only 
capable of forming homodimers and as such this analysis would not indicate whether cellular gene 
expression was regulated. Alternatively, chromatin immunoprecipitation assays with sequencing could 
be used to determing DNA binding sites for Ov2 in order to study Ov2 control of gene expression. Due 
to time restrictions, confirmation that Ov2 interacts with itself was not able to be performed, but work 
is ongoing to investigate this. It is also possible that Ov2 may require other OvHV-2-encoded proteins 
in order to induce target gene expression; another viral protein Ov6 also contains a bZIP domain and so 
an interaction between Ov2 and Ov6 is possible. Alternative methods for identifying Ov2 binding 
partners could include yeast two-hybrid screens, or chemical cross-linking of proteins followed by mass 
spectrometry. Another potential hypothesis is that Ov2 only regulates virus gene expression; work is 
ongoing in the lab conducting promoter assays with Ov2 and a number of virus promoters. This 
preliminary analysis into the function of Ov2 has yielded some interesting results and further 
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This project had two major aims; firstly to validate the expression of previously predicted OvHV-2-
encoded miRNAs and secondly to identify and characterise cellular and viral targets of OvHV-2-
encoded miRNAs. The aims of this project were successful in that the expression of a total of 35 OvHV-
2-encoded miRNAs was demonstrated and that both cellular and virus targets of these virus-encoded 
miRNAs were identified and validated. 
The first aim of this project was described and discussed in Chapter 3. Any further characterisation of 
the validated OvHV-2-encoded miRNAs, such as how and when they are expressed during infection, 
was hindered by the lack of an appropriate model. Unlike, AlHV-1, OvHV-2 does not have a system 
for virus propagation in vitro. Moreover, there is a lack of a suitable model to study the natural infection 
of OvHV-2; a population of uninfected sheep can be raised in the correct conditions, however this is 
very expensive and would be out with the scope of this project (Meier-Trummer et al., 2010). The rabbit 
model of MCF could potentially be used to investigate the temporal expression of OvHV-2-encoded 
miRNAs however this was also out with the scope of this project. Based on the fact that miRNAs 
encoded by other gammeherpesviruses are expressed during latency, and that the majority of OvHV-2-
encoded miRNAs are clustered as in for example KSHV, it could be predicted that expression of OvHV-
2-encoded miRNAs would also be during latency. Therefore, it may be more biologically relevant to 
examine the temporal expression of OvHV-2-encoded miRNAs in sheep, which as mentioned above, 
is difficult. However, given the evidence presented in section 1.5.4 where subclinical infection of cattle 
can occur, it is also likely that there is latent infection of OvHV-2 in cattle and as such cattle could also 
be used to examine temporal expression of virus-encoded miRNAs during OvHV-2 infection.  
BJ1035 cells were the most readily available source of OvHV-2-infected material during this project 
and so were used to validate the expression of OvHV-2-encoded miRNAs. Additionally, as the initial 
RNA-seq experiment was performed in BJ1035s it was logical to perform the validation in the same 
cell type. However, it is possible that the OvHV-2 genome codes for a number of miRNAs not identified 
in the BJ1035 RNA-Seq experiment. Furthermore, as OvHV-2 will have co-evolved with sheep, there 
may be miRNAs that are only expressed in the natural host. Therefore, a criticism of this project could 
be that no sheep tissue was examined for the expression of OvHV-2-encoded miRNAs. Also, as BJ1305 
cells have been in culture for many years, it is likely that they do not represent OvHV-2 infection in 
cattle. Therefore, tissue from an OvHV-2-infected cow could also have been examined for the 
expression of OvHV-2-encoded miRNAs. 
The second aim of this project was split into two strands; identification and characterisation of cellular 
targets was described in Chapter 4 and the identification and characterisation of the OvHV-2-encoded 
protein Ov2 as a target of OvHV-2 encoded miRNAs was described in Chapter 5. The individual details 
of these results are discussed at the end of the relevant chapters. Studies on other herpesviruses have 
taken advantage of being able to manipulate the virus and construct viruses that lack one or more 
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miRNAs in order to identify potential targets. As this is not an option with OvHV-2-encoded miRNAs 
a different approach was taken. Dr Riaz performed CLASH (described in section 4.1) and had also 
performed a microarray to identify potential targets of ovhv2-miR-17-1, ovhv2-miR-17-2 and ovhv2-
miR-17-3 so these methods were not used in this thesis (Riaz, 2014). DLL1, a target of ovhv2-miR-17-
2 identified in the CLASH study performed by Dr Riaz, was confirmed by luciferase assay (see section 
4.3.6). Based on homology between the cellular miRNA miR-216a and ovhv2-miR-73-1 PTEN and YB-
1 were investigated as targets. Due to difficulties in the luciferase assay, which were described in section 
4.6.2, a GFP-reporter system was used to demonstrate that ovhv2-miR-73-1 does not target PTEN or 
YB-1 (section 4.4.5). Lastly, a bioinformatic approach using RNAHybrid was used to identify MHC 
class II genes and the OvHV-2-encoded protein Ov2 as potential targets of OvHV-2-encoded miRNAs. 
Two genes, (ovine DRA and ovine DQB) were confirmed as targets of ovhv2-miR-17-25 and ovhv2-
miR-17-9 respectively by luciferase assays. Further characterisation of these targets was not performed, 
due to difficulties in finding appropriate cell lines that could be used for study and also technical 
difficulties in the luciferase reporter system used for validation.   
There are a number of difficulties in working with a virus that infects sheep and cattle, which are not 
limited to, but include the lack of available reagents such as antibodies, physiologically-relevant cell 
lines and incomplete/inaccurate annotation of the sheep and cattle genome assemblies. Although the 
number of reagents available is increasing, there are still far fewer reagents available compared to the 
number of reagents available for work in human cells or mice. Attempts to use biologically relevant 
cell lines were made during this thesis; initially bovine turbinate cells were used instead of MDBK cells 
for the work described in section 5.4.2, however suitable levels of transfection efficiency could not be 
achieved, and optimisation of any nucleofection protocol was not viable in the time available. Although 
the MDBK cells do not transfect efficiently, there is an existing nucleofection protocol provided by 
Lonza (see section 2.1.9) to yield the highest nucleofection efficiency and minimal cell death. 
Furthermore work in lymphocytes, which are obviously of high biological relevance, is often difficult. 
Again there are problems in achieving high transfection efficiency, and it can be often difficult to grow 
these cells in culture in the amounts required for experimental work. Lastly, incorrect annotation of the 
sheep genome was a major problem encountered in the validation and characterisation of DLL1 as a 
target of ovhv2-mIR-17-2. Additionally, the immunoprecipitation and mass spectrometry analysis of 
Ov2 described in section 5.4.3 was performed in a human cell line to increase the chance of detecting 
proteins of interest due to the lack of a well annotated genomes for sheep and cattle. 
In addition to the technical problems and limitations described above, the methods of identification and 
validation of targets of OvHV-2-encoded miRNAs used in this thesis have their limitations. RNAHybrid 
was chosen as the primary bioinformatic programme used in OvHV-2-encoded miRNA target 
identification as it was deemed to be the only available option. Although it would have been 
advantageous in eliminating false-positives, the use of multiple prediction methods utilising different 
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strategies of prediction was not possible for the purposes of this thesis (Witkos et al., 2011). This was 
mainly because many other programmes can only predict targets of miRNAs within a single species 
(e.g. human miRNAs targeting human mRNAs). Depending on the programme used this can be 
extended to a few other species such as mouse and frog. As part of this project was identifying cellular 
targets of virus-encoded miRNAs many other prediction programmes (listed in section 1.6.4) were not 
suitable. Furthermore, many of these programmes base target prediction on evolutionary conservation 
of a target site, which again is not a suitable approach when investigating virus-encoded miRNAs that 
show little evolutionary conservation. There are currently two prediction programmes that are capable 
of predicting host targets of a virus-encoded miRNA. These are RepTar (Elefant et al., 2011) and vHOT 
DB (http://best.snu.ac.kr/vhot/). RepTar can only predict human targets of HCMV, KSHV and EBV 
encoded miRNAs and mouse targets of MCMV and MHV-68; it is therefore not suitable for the 
purposes of this thesis. vHOT DB can predict targets from any virus-encoded miRNA listed in miRbase 
in the following species: human, mouse, cow, rhesus monkey, rat and the viruses themselves. As the 
OvHV-2-encoded miRNAs are currently not listed in miRbase and prediction of targeting in sheep is 
not available using vHOT DB it is also not suitable for the purposes of this thesis.  
RNAHybrid predicts miRNA targets based on thermodynamic interactions. The limitation in using 
RNAHybrid is that genome wide analysis cannot be attempted as the potential target mRNA must be 
specified in the analysis. A number of potential targets may also be missed by the restrictions imposed 
on the search such as perfect complementarity in the seed sequence and whether or not G:U pairing is 
allowed in the seed sequence. If such restrictions are not imposed then the list of potential target sites 
is increased, which consequently decreases the chance of identifying a functional target site. 
Additionally, using only thermodynamic characteristics to predict target sites can lead to a high rate of 
false positives. However, for the purposes of this project RNAHybrid was the most suitable programme 
for target identification and did identify a number of targets that were successfully validated using a 
biochemical method. One of the methods used for validation of predicted targets in this project was the 
luciferase assay. This assay provides a direct link between the target site and the expression of the 
reporter gene used, in this case Renilla luciferase. However, off target effects of the OvHV-2-encoded 
miRNAs were found to be fairly common meaning that the luciferase assay was not a suitable approach 
to use in some instances. In the majority of cases in this project, to avoid losing the context of the target 
site, the entire 3’UTR of the gene of interest was cloned into the psiCHECK-2 vector. This was not 
always possible, for example in the case of PTEN the 3’UTR was too long. Additionally, the target site 
confirmed by luciferase assay in DLL1 was cloned into the 3’UTR of Renilla luciferase, however this 
target site is present in the coding region of DLL1. It could be possible to engineer the target site into 
the coding region of Renilla luciferase however this was not attempted in this project. 
Validation of Ov2 as a target of OvHV-2-encoded miRNAs was performed using a GFP reporter system 
and western blotting, with site-directed mutagenesis confirming the target site for ovhv2-miR-61-1. The 
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target site for ovhv2-miR-17-10 could not be confirmed using site-directed mutagenesis. 
Characterisation of the down-regulation of Ov2 at the transcript level could not be performed due to the 
fact that Ov2 mRNA was unable to be detected by PCR even when overexpressed. The levels of protein 
in similar overexpression experiments were confirmed by western blotting so the constructs used in this 
project were functional. A number of different primer sets were used and all were capable of amplifying 
Ov2 from genomic DNA possibly indicating that the Ov2 transcript has a very short half-life. In fact, 
many regulatory proteins including transcription factors often have a short half-life (Lamph et al., 1988; 
Rogers et al., 1986; Treier et al., 1994).  
The final part of this thesis involved the functional characterisation of Ov2 (section 5.4). 
Immunofluorescence confirmed the nuclear localisation of Ov2, RT-qPCR analysis of MDBK cells 
nucleofected with an Ov2-EGFPN1 construct demonstrated the down-regulation of expression of JAG1. 
Immunoprecipitation and subsequent mass spectrometry analysis revealed the potential interaction of 
Ov2 with NME2 and members of the LUC7L family of proteins. Validation of this work is obviously 
required to confirm any interaction. However this potential interaction, along with the identification of 
LUC7L2 as under-represented in SEFs transduced with a lentivirus containing ovhv2-miR-17-1, ovhv2-
miR-17-2 and ovhv2-miR-17-3 compared to SEFs transduced with the control lentivirus plasmid in the 
CLASH study performed by Dr Riaz are promising pieces of evidence towards the hypothesis that 
OvHV-2 disrupts cellular splicing that warrant further investigation. 
Notch signalling emerged as an area of potential regulation by OvHV-2 from the results of this thesis. 
Two ligands for Notch signalling, delta1 and jagged1 were identified to potentially be regulated by 
OvHV-2. It could be hypothesised that Notch signalling would be down-regulated in sheep in order to 
promote latency. As the virus will have co-evolved with sheep it is likely that cellular pathways in sheep 
are the “original” targets of OvHV-2-encoded proteins and miRNAs. Some of these pathways may be 
regulated in the same way in MCF-susceptible hosts however it is possible that due to slight differences 
in sequence between the sheep and cattle genome differential targeting occurs and, as a result of this 
dysregulation, MCF develops. It is also possible that there is a differential regulation of OvHV-2 gene 
expression, including expression of miRNAs, which lead to altered targeting of pathways and 
development of MCF. Due to the importance of Notch signalling during development in determination 
of cell fate (reviewed in Andersson et al. 2011) and the fact that constitutive activation of Notch in T 
cells causes acute lymphoblastoma, Notch signalling is under tight regulation (Schweisguth, 2004). 
OvHV-2-encoded miRNAs may contribute to this regulation during infection, as it is possible that 
Notch signalling is required at certain points during the lifecycle of OvHV-2. ovhv2-miR-17-2 appears 
to have a direct effect on the levels of DLL1 as confirmed by luciferase assay, whereas ovhv2-miR-17-
10 and ovhv2-miR-61-1 may be able to indirectly regulate the expression of Jagged through regulation 
of Ov2 expression. As it is not known when these miRNAs are expressed during infection, the context 
of regulation of Notch signalling is unclear. As there is no cell culture model of OvHV-2, and 
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investigating the role OvHV-2 plays in Notch signalling during infection of previously uninfected sheep 
would be difficult and very costly, any downstream effects OvHV-2-encoded miRNAs would have as 
a consequence of targeting Notch receptor ligands would be difficult to study. However, the rabbit 
model of MCF could be used as an alternative to look at the influence of OvHV-2 on Notch signalling 
in MCF-susceptible species.  
Results obtained from this thesis present novel mechanisms of potential regulation of cellular processes 
by OvHV-2-encoded miRNAs. These may contribute to the differential outcomes observed in OvHV-
2 infection in sheep and MCF-susceptible species. Although an incomplete story, mainly due to 
restrictions in both time and the availability of appropriate systems for the study of OvHV-2, this thesis 
paves the way for future investigations into the role of OvHV-2-encoded miRNAs in OvHV-2 biology.  
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miRNA RT-qPCR primers 
ovhv2-
miR 
Primer sequence RT-PCR Annealing temperature (°C) 
Ov2-1 ATGCTTGTTTAGGCCC 48 
17-30 TTTGGGTGTCTCCTG 46 
17-28 TCTAGGTTGCATTTTG 44 
17-27 CCCACATTTAAGGTG 44 
17-26 ATATTCGTTTAGACG 40 
17-25 CAATGCTGCTTTGGTG 48 
17-24 GGGTTCCTCGAGTGG 52 
17-23 ATACACACTGAAAGAGC 48 
17-22 ATAAGGCCAACACTAG 46 
17-21 AAGCACCTTGGGTGATGTC 58 
17-19 AAGCATAGCTGGGAGTG 52 
17-18 TAGTAGTCCGTTAACG 46 
17-16 TAAACTGGTGGTAGG 44 
17-15 TAGCAGTTATGCAGGTATC 54 
17-14 TGGCATTTCCAGGAGCCTG 60 
17-13 TTGGGTCCAACATGAGA 50 
17-12 TATGTCAGAAGTGAAGC 48 
17-11 TGGTTTGCATCTGCAC 52 
17-9 TAGAGTTACTAAGGATTC 48 
17-8 AATCGCCGGTGGCCTTC 56 
17-7 TATAGACGGGTATGC 44 
17-5 CCTTTTTGGTGAGTTGC 50 
17-4 GATTTGATAAAGCCTGC 48 
17-2 ACCCCGGGGGTATGTG 54 
24-1 GAGCAGTACTACACAGCAG 58 
61-1 TTGGGGACGTGCTGGCTG 60 
Group 1 TCCCGAGATGTCGGG 50 
Group 3 TTGCGGGGAAGGCCGC 56 
Group 13 GATGTAGGACAGGCCGC 56 
Group 34 TTTGGGTGTCTCCTG 46 
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Group 95 GCTGCGCTCGCTTGGG 56 
Group 128 ACGGGTGAGGTGGGGC 56 
Group 181 CATTGGGGAGGCCGG 52 
Group 182 AGTGGATGTAGTCCTGG 52 
Group 3p TCCCGAGATGTCGGG 50 
Group 64p GGGCGGCTTAGTAAC 48 
Group 96p TTGATAGCAGGATGTGC 50 
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miRNA specific cDNA primers 
 
ovhv2-miR PCR Forward Primer Sequence Reverse Transcription primer sequence 
17-19 GCGGCGAAGCATAGCTGGGAGTG    GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACTCTAGA 
17-12 GCGGCGTATGTCAGAAGTGAAG     GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACTCTCAG 
17-7 GCGGCGGTATAGACGGGTATG     GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCGGCAG 
61-1 GCGGCTTGGGGACGTGCTGGCTGA     GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACACGTCG 
73-1 GCGGCGTAATCTCTGCTCCAATT      GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACATTTAC 
Group 1 GCGGCGGTCCCGAGATGTCGG        GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCCAGTC 
Group 3 GCGGCGTTGCGGGGAAGGCCGC   GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACAAACAC 
Group 13 GCGGCGGATGTAGGACAGGCCG    GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCATCAG 
Group 34 GCGGCGTTTGGGTGTCTCCTG     GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACAGATGA 
Group 95 GCGGCGCTGCGCTCGCTTGGGGCC     GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACTTGAGG 
Group 128 GCGGCGGACGGGTGAGGTGGG        GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCCCTGC 
Group 181 GCGGCGCATTGGGGAGGCCGG        GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCTTCCC 
Group 182 GCGGCAGTGGATGTAGTCCTGGAAG    GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACTAAAGC 
Group 3p GCGGCGGTCCCGAGATGTCGG        GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCCAGTC 
Group 64p GCGGCGGGGCGGCTTAGTAA        GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCACATG 
Group 96p GCGGCGTTGATAGCAGGATGTG       GTCGTATCCAGTGCAGGGTCCCGAGGTATTCGCACTGGATACGACCAGGCA 
  PCR Universal Reverse Primer   
  GTGCAGGGTCCGAGGT   
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Target Gene Primers 
 
Gene Primer Sequence 
DLL1 1970-2119 "a" Forward ACTACTGCACGCACCACAAG 
DLL1 1970-2119 "a" Reverse GGTCCTGAGTGACGGAGAAG 
DLL1 1538-1756 "b" Forward CAGAAAGACTTATCAGCCGC 
DLL1 1538-1756 "b" Reverse TGCAGACTTTCTCCCCTCTC 
DLL1 2415-2475 Xho1 "c" Forward CTCGAGGACGACTGTGCCTCCTCC 
DLL1 2415-2475 Not1 "c" Reverse GCGGCCGCGTCTGCCTTCTTGTTGGTGT 
DLL1 RACE 5'  TAATTCTCGCGCCGGCCCCCGGGTGT 
DLL1 RACE 3' "d" TTCCAAGGGAGGGCGCCCCGACA 
DLL1 2711-2931"e" Forward CCACGCAGATCAAGAACACC 
DLL1 2711-2931 "e" Reverse CTGCTCCTCGGATATGACGT 
GAPDH Sheep/Cattle RT-qPCR Forward GGTGATGCTGGTGCTGAGTA 
GAPDH Sheep/Cattle RT-qPCR Reverse TCATAAGTCCCTCCACGATG 
Jagged Cattle/Sheep RT-qPCR Forward AAGTGCAAGAGTCAGTCGGG 
Jagged Cattle RT-qPCR Reverse AATGCACGCGTAGGAGTTCA 
Jagged Sheep RT-qPCR Reverse GATGCACGCGTAGGAGTTGA 
Caspase 8 sheep/cattle RT-qPCR Forward TCACAATCGCTTCCAGAGGA 
Caspase 8 sheep/cattle RT-qPCR Reverse TATCCCCGAGGTTTGCTTGT 
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Ovine MHC DRA Xho1 Forward AACTCGAGCACCTTTTCCGCAAGTTCCA 
Ovine MHC DRA Not1 Reverse AAGCGGCCGCAGACCCACTTGAAGTTTAC 
Ybx1 3'UTR Xho1 Forward AACTCGAGACCATCTCTACCATCATCCGG 
Ybx1 3'UTR Not1 Reverse AAGCGGCCGCACAGGTGCTTGCAGTTTGTT 
Ybx1 pEGFP-C1 Xho1 Forward AACTCGAGCTCAATACACCTTTA 
Ybx1 pEGFP-C1 Kpn1 Reverse AAGGTACCGCGGCCGCGTAAACT 
PTEN pEGFP-C1 Xho1 Forward AACTCGAGATATACAATATTTTG 
PTEN pEGFP-C1 Kpn1 Reverse AAGGTACCGCGGCCGCGGAATAA 
Ov2 ovhv2-miR-17-10 binding site mutagenesis 
Forward 
GCTCCTGTAACCTCTTCTTAAAATTGCGTGATGCCCTTCTATTTGTGCTCCTGC 
Ov2 ovhv2-miR-17-10 binding site mutagenesis 
Reverse 
GCAGGAGCACAAATAGAAGGGCATCACGCAATTTTAAGAAGAGGTTACAGGAGC 
Ov2 ovhv2-miR-61-1 binding site mutagenesis 
Forward 
CATCCACTCCCACCTACCTGAGGTGACCATAAATGTTGTTCGGAGTTGTAAAAATCATTTGT 
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Target Gene Oligonucleotides 
 
Gene  Oligonucleotide Sequence 
DLL1 Forward TCGAGGGCCTTCCGCTACCTGTGCGAGTGTGCCCGGGGCTACGGGGGACAGGCTGGGAAGGGG
GGCCTTCCCGGGGAGGGCGCCCCGACACCCGGGGGCCGGCGCGAGGC 
DLL1  Reverse Complement GGCCGCCTCGCGCCGGCCCCCGGGTGTCGGGGCGCCCTCCCCGGGAAGGCCCCCCTTCCCAGC
CTGTCCCCCGTAGCCCCGGGCACACTCGCACAGGTAGCGGAAGGCCC 
DLL1 1st site mutated Forward TCGAGGGCCTTCCGCTACCTGTGCGAGTGTGGGATCCCCTACGGGGGACAGGCTGGGAAGGGG
GGCCTTCCCGGGGAGGGCGCCCCGACACCCGGGGGCCGGCGCGAGGC 




DLL1 3rd site mutated Forward TCGAGGGCCTTCCGCTACCTGTGCGAGTGTGCCCGGGGCTACGGGGGACAGGCTGGGAAGGGG
GGCCTTCCCGGGGAGGGCGCCCCGACAGGATCCCGCCGGCGCGAGGC 












MHC class II  bovine DQA1 Forward TCGAGTTGCATACCATGGAATTGCTACGGTATTCCACCCAATTACCTAATCTCTAGC 
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PTEN Reverse Complement GGCCGCGAATAAGATCATAAATTTTTAAAGAAAAAAAAACCGCTTACTGTAGAATCTCAAATT
GAAATTTCCTGTGCAGCATTACAAAATATTGTATATC 
Ybx1 100bp Forward TCGAGCTCAATACACCTTTAAAGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAA
GAACCTCATTTTTAATTTGTAATAAAAGTTTACGC 
Ybx1 100bp Reverse Complement GGCCGCGTAAACTTTTATTACAAATTAAAAATGAGGTTCTTAAAAATCTCAACTTGACCAGATA
TGAAACAATTTAAAAACCTTTAAAGGTGTATTGAGC 
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Sheep DLL1 alignments 
 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          ATGGACCCACACTCCCAACCACTGCAGATCCTGCCGGCCCTGGGCTGGCCTGGGAAGCTG 60 
Sheep_NCBI_New      ------------------------------------------------------------ 0 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          TGCGTGTTTCTGATGCAGAAGACGGACTTCACAGAACCCCCTCAACCGCAGGCCAGGGTG 120 
Sheep_NCBI_New      ------------------------------------------------------------ 0 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GCGCCGGGGGGAGCAGGCAGGGCGCACAGCTGTGGGGTCGAGCGGTCAGGGAGACGCGGT 180 
Sheep_NCBI_New      ------------------------------------------------------------ 0 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          TCAGGGACCGCGACGGCGCCGAATCGCGAGTGCACCCTCAGCGCCGAGGCGACAGCCCCG 240 
Sheep_NCBI_New      ------------------------------------------------------------ 0 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CAGGCCCAGCCCTACCTAGAGACGCGCCAGGACACCGGAGACGCGCCCACGCCGCCCTCG 300 
Sheep_NCBI_New      ------------------------------------------------------------ 0 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GCCCTCAGCAGCTGTGCGCACTTCCGCTTCCCGTCGCGAGACCGCCCCGCCCGCGCGGGG 360 
Sheep_NCBI_New      --------------------ATGTGGCTCAGCAGCG-----------CGCCCCCGCCGGC 29 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GCGGGGCCTGCGCGGCCGGCCGGGAGGCGCCGGGAGCGCCACGCGCAGGCGCCTGAGAGC 420 
Sheep_NCBI_New      TCCCACCCCCCA----CCGCCACCCCCAGCCCAGACCGACATC--------------AGA 71 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GCGTGGCGGTGCCGGCTCCGGCTCTGCGCCCGTTGCCGCGGAAACCGCGCTGTGCTTCCG 480 
Sheep_NCBI_New      CGTTGCAGGAACCCACGCCC--AGTTCAGCAGGAAACAGGTGCCCACATCTGTTCCTGGG 129 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          AGGTCGGGGTCACGACTCGCTCGGCTTCCGCAGGCGTACCCGTTGGTGCTGTGGGCGGCG 540 
Sheep_NCBI_New      CGGGCAGATGCTCGCAGAAAGGAGGTGGGAGGCCGGGCAGGACGGCGCAGCCGCGCGGAG 189 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CAGCGGCGGTGGGGCCCCGCCTCGGTGCAGGTGACCGCGTGCGCCCTGTGCCGCGCGCCC 600 
Sheep_NCBI_New      CCGCTCGGGTGGGGCCCCGCCTCGGTGCAGGTGACCGCGTGCGCCCTGTGCCGCGCGCCC 249 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GGCGACCAGGGCTGGCCCGTCGACCTCGCCATCCCAGCCCGCGCGCATGTCCCTGCGACG 660 
Sheep_NCBI_New      GGCGACCAGGGCTGGCCCGTCGACCTCGCCATCCCAGCCCGCGCGCATGTCCCTGCGACG 309 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GGTGCCCGCCGCCGCCACCCACTCCAAGCCACCCTCTGGAGCGCCCACCGGCGCCGCACC 720 
Sheep_NCBI_New      GGTGCCCGCCGCCGCCACCCACTCCAAGCCACCCTCTGGAGCGCCCACCGGCGCCGCACC 369 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CCCTCCAGGCAGCCCTCCGGAGCGCCTGGCCCGGCGCGTTCAGTCGGGGGCCGCTCGGGC 780 
Sheep_NCBI_New      CCCTCCAGGCAGCCCTCCGGAGCGCCTGGCCCGGCGCGTTCAGTCGGGGGCCGCTCGGGC 429 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GGGAGCGCGGAGCAGCTGCGCGGTCATCTGATCCGGACAAAGGCGCCCGGAGCCGCGCCA 840 
Sheep_NCBI_New      GGGAGCGCGGAGCAGCTGCGCGGTCATCTGATCCGGACAAAGGCGCCCGGAGCCGCGCCA 489 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GTGAAAGTCACGTTTTGCCAGGACAGTGCAGTCCTGACAGAGAGGCCGGCTGCAGCACAC 900 
Sheep_NCBI_New      GTGAAAGTCACGTTTTGCCAGGACAGTGCAGTCCTGACAGAGAGGCCGGCTGCAGCACAC 549 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CTACAGCGAGGCCTCAGTGACCGGGCGCCCTGTGCGGTACTGCTCATCAACGTGACCTTT 960 
Sheep_NCBI_New      CTACAGCGAGGCCTCAGTGACCGGGCGCCCTGTGCGGTACTGCTCATCAACGTGACCTTT 609 
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Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          ACTCCACGCCCACACCTTTCACCCCGGATGACGGTGCCCCGGGTGTTGGGGGTGGGGGAG 1020 
Sheep_NCBI_New      ACTCCACGCCCACACCTTTCACCCCGGATGACGGTGCCCCGGGTGTTGGGGGTGGGGGAG 669 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          ATGGAAGGAGGAGCAGATAGGGGTGAGATAGAGACCTCAACCTATGCGGGCGGCCGGGAC 1080 
Sheep_NCBI_New      ATGGAAGGAGGAGCAGATAGGGGTGAGATAGAGACCTCAACCTATGCGGGCGGCCGGGAC 729 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CGCCGCCCCCGAGTGAGCCGGCCGGGCCGATCCTGCTCCACCGCCCCGGATTACCGCCTC 1140 
Sheep_NCBI_New      CGCCGCCCCCGAGTGAGCCGGCCGGGCCGATCCTGCTCCACCGCCCCGGATTACCGCCTC 789 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GCGCGCGGACCTAAGGAACCTGGGCCTCCGGAAGAGCCGGAGCCGGACCCTTCAGGAGAG 1200 
Sheep_NCBI_New      GCGCGCGGACCTAAGGAACCTGGGCCTCCGGAAGAGCCGGAGCCGGACCCTTCAGGAGAG 849 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          AAGTCCGCATTATCTCGGCCCGAGGCAGAGCGGCGGCGCTTTCCTGCCCGAGCTCCCGGG 1260 
Sheep_NCBI_New      AAGTCCGCATTATCTCGGCCCGAGGCAGAGCGGCGGCGCTTTCCTGCCCGAGCTCCCGGG 909 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          GACACCTTCCTCCTCCAGCGTCCCCTGACGACTTCGGAAGACAAGGCGGGGGGGCCCTCC 1320 
Sheep_NCBI_New      GACACCTTCCTCCTCCAGCGTCCCCTGACGACTTCGGAAGACAAGGCGGGGGGGCCCTCC 969 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          AAGCCCGGGTGGCTCACAGCCGGCGGCAGCGGCGAGGGGGTGTTGCGCGGGGTGACAGCC 1380 
Sheep_NCBI_New      AAGCCCGGGTGGCTCACAGCCGGCGGCAGCGGCGAGGGGGTGTTGCGCGGGGTGACAGCC 1029 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CCGGTTGAGAGCGGCGGAGAGGCCAAGCACCCGGGACGCTTCCGTGTCCGGTCTGCGCGC 1440 
Sheep_NCBI_New      CCGGTTGAGAGCGGCGGAGAGGCCAAGCACCCGGGACGCTTCCGTGTCCGGTCTGCGCGC 1089 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          CGAGCCGCGGAGCTGAAAGGACCCC----------------------------------- 1465 
Sheep_NCBI_New      CGAGCCGCGGAGCTGAAAGGACCCCTTCAAGTGGGAGAGTCCCAGTTCCGCAGCTCCTGG 1149 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          ------------------------------------------------------------ 1465 
Sheep_NCBI_New      ACCGGAAAGTGGAATCAGGCTCGCGAGGCTCACAGACCCTCCGCACGACACGCCGCGAGC 1209 
                                                                                 
 
Sheep_Ensembl       ------------------------------------------------------------ 0 
Sheep_NCBI          ------------------------------------------------------------ 1465 
Sheep_NCBI_New      AGACCTGCAGCCAGTGGGTTTCCCGGAACCCTTAGATTCTTCTGTAAACAGTTTTGCCTT 1269 
                                                                                 
 
Sheep_Ensembl       ---TTCTTCCTCCAGGGAACCTTCTCTCTGATCATTGAAGCGCTCCACACAGATTCTCCG 57 
Sheep_NCBI          ----------TTCAAGGAACCTTCTCTCTGATCATTGAAGCGCTCCACACAGATTCTCCG 1515 
Sheep_NCBI_New      CTGTTCTTCCTCCAGGGAACCTTCTCTCTGATCATTGAAGCGCTCCACACAGATTCTCCG 1329 
                              * ** ********************************************* 
 
Sheep_Ensembl       GATGACCTTGCAACAGAGAACCCAGAAAGACTTATCAGCCGCCTGGCCACACAGAGGCAC 117 
Sheep_NCBI          GATGACCTTGCAACAGAGAACCCAGAAAGACTTATCAGCCGCCTGGCCACACAGAGGCAC 1575 
Sheep_NCBI_New      GATGACCTTGCAACAGAGAACCCAGAAAGACTTATCAGCCGCCTGGCCACACAGAGGCAC 1389 
                    ************************************************************ 
 
Sheep_Ensembl       CTGGCCGTTGGGGAGGAGTGGTCCCAGGATCTGCACAGCAGCGGCCGCACGGACCTCAAG 177 
Sheep_NCBI          CTGGCCGTTGGGGAGGAGTGGTCCCAGGATCTGCACAGCAGCGGCCGCACGGACCTCAAG 1635 
Sheep_NCBI_New      CTGGCCGTTGGGGAGGAGTGGTCCCAGGATCTGCACAGCAGCGGCCGCACGGACCTCAAG 1449 
                    ************************************************************ 
 
Sheep_Ensembl       TACTCCTACCGCTTTGTGTGTGATGAGCACTACTTTGGCGAAGGCTGCTCCGTCTTCTGC 237 
Sheep_NCBI          TACTCCTACCGCTTTGTGTGTGATGAGCACTACTTTGGCGAAGGCTGCTCCGTCTTCTGC 1695 
Sheep_NCBI_New      TACTCCTACCGCTTTGTGTGTGATGAGCACTACTTTGGCGAAGGCTGCTCCGTCTTCTGC 1509 
                    ************************************************************ 
 
Sheep_Ensembl       CGCCCCCGAGATGACGCCTTTGGCCACTTCACCTGCGGGGAGAGAGGGGAGAAAGTCTGC 297 
Sheep_NCBI          CGCCCCCGAGATGACGCCTTTGGCCACTTCACCTGCGGGGAGAGAGGGGAGAAAGTCTGC 1755 
Sheep_NCBI_New      CGCCCCCGAGATGACGCCTTTGGCCACTTCACCTGCGGGGAGAGAGGGGAGAAAGTCTGC 1569 
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Sheep_Ensembl       AACCCTGGCTGGAAGGGCCAGTACTGCACAGAGCCCATCTGTTTGCCAGGGTGCGATGAG 357 
Sheep_NCBI          AACCCTGGCTGGAAGGGCCAGTACTGCACAGAGCCCATCTGTTTGCCAGGGTGCGATGAG 1815 
Sheep_NCBI_New      AACCCTGGCTGGAAGGGCCAGTACTGCACAGAGCCCATCTGTTTGCCAGGGTGCGATGAG 1629 
                    ************************************************************ 
 
Sheep_Ensembl       CAGCACGGATTTTGTGACAAGCCAGGGGAATGCAAAGTCAGACCCTCCTGGGGAGGAAGG 417 
Sheep_NCBI          CAGCACGGATTTTGTGACAAGCCAGGGGAATGCAAGG----------------------- 1852 
Sheep_NCBI_New      CAGCACGGATTTTGTGACAAGCCAGGGGAATGCAAGG----------------------- 1666 
                    *********************************** *                        
 
Sheep_Ensembl       AGCTGTCTGGCCCGTCTCGGCGCCCGGTCCCCCCGGTCCCCAGGCTGTCCCCGCGCCCCC 477 
Sheep_NCBI          ----------CCCGTCTCGGCGCCCGGTCCCCCCGGTCCCCAGGCTGTCCCCGCGCCCCC 1902 
Sheep_NCBI_New      ----------CCCGTCTCGGCGCCCGGTCCCCCCGGTCCCCAGGCTGTCCCCGCGCCCCC 1716 
                              ************************************************** 
 
Sheep_Ensembl       TGCCAGCAGCCCTGGCAATGCAACTGCCAGGAGGGCTGGGGGGGCCTCTTCTGCAACCAG 537 
Sheep_NCBI          TGCCAGCAGCCCTGGCAATGCAACTGCCAGGAGGGCTGGGGGGGCCTCTTCTGCAACCAG 1962 
Sheep_NCBI_New      TGCCAGCAGCCCTGGCAATGCAACTGCCAGGAGGGCTGGGGGGGCCTCTTCTGCAACCAG 1776 
                    ************************************************************ 
 
Sheep_Ensembl       GACCTCAACTACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCACCAACACG 597 
Sheep_NCBI          GACCTCAACTACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCACCAACACG 2022 
Sheep_NCBI_New      GACCTCAACTACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCACCAACACG 1836 
                    ************************************************************ 
 
Sheep_Ensembl       GGCCAAGGGAGCTACACGTGCTGGTCTGAGGCAGGACTGGGAGGGTTCTTGGGAGCGACT 657 
Sheep_NCBI          GGCCAAGGGAGCTACACGTGCTGGTCTGAGGCAGGACTGGGAGGGTTCTTGGGAGCGACT 2082 
Sheep_NCBI_New      GGCCAAGGGAGCTACACGTGCTGGTCTGAGGCAGGACTGGGAGGGTTCTTGGGAGCGACT 1896 
                    ************************************************************ 
 
Sheep_Ensembl       AGGAAAGCTTTCCTCGTCTTCTCCGTCACTCAGGACCTTGAGAACAGCTACTCCTGCACC 717 
Sheep_NCBI          AGGAAAGCTTTCCTCGTCTTCTCCGTCACTCAGGACCTTGAGAACAGCTACTCCTGCACC 2142 
Sheep_NCBI_New      AGGAAAGCTTTCCTCGTCTTCTCCGTCACTCAGGACCTTGAGAACAGCTACTCCTGCACC 1956 
                    ************************************************************ 
 
Sheep_Ensembl       TGCCCGCCTGGCTTCTACGGCAGGGTCTGCGAGCTGAGTGCCATGGTGTGTGCCGACGGC 777 
Sheep_NCBI          TGCCCGCCTGGCTTCTACGGCAGGGTCTGCGAGCTGAGTGCCATGGTGTGTGCCGACGGC 2202 
Sheep_NCBI_New      TGCCCGCCTGGCTTCTACGGCAGGGTCTGCGAGCTGAGTGCCATGGTGTGTGCCGACGGC 2016 
                    ************************************************************ 
 
Sheep_Ensembl       CCCTGCTTCAATGGGGGCCGGTGCTCCGACAACCCCGAGGGCGGGTACACCTGCCGCTGT 837 
Sheep_NCBI          CCCTGCTTCAATGGGGGCCGGTGCTCCGACAACCCCGAGGGCGGGTACACCTGCCGCTGT 2262 
Sheep_NCBI_New      CCCTGCTTCAATGGGGGCCGGTGCTCCGACAACCCCGAGGGCGGGTACACCTGCCGCTGT 2076 
                    ************************************************************ 
 
Sheep_Ensembl       CCTGGGGGCTTTTCTGGCTTTAACTGTGAGAAGAAGATGGATTCCTGCAGTTCCTCGCCT 897 
Sheep_NCBI          CCTGGGGGCTTTTCTGGCTTTAACTGTGAGAAGAAGATGGATTCCTGCAGTTCCTCGCCT 2322 
Sheep_NCBI_New      CCTGGGGGCTTTTCTGGCTTTAACTGTGAGAAGAAGATGGATTCCTGCAGTTCCTCGCCT 2136 
                    ************************************************************ 
 
Sheep_Ensembl       TGTTCCAATGGTGCGCAGTGCGTGGACCTCGGCGACGCTTACGTCTGCCGCTGCCAGGCT 957 
Sheep_NCBI          TGTTCCAATGGTGCGCAGTGCGTGGACCTCGGCGACGCTTACGTCTGCCGCTGCCAGGCT 2382 
Sheep_NCBI_New      TGTTCCAATGGTGCGCAGTGCGTGGACCTCGGCGACGCTTACGTCTGCCGCTGCCAGGCT 2196 
                    ************************************************************ 
 
Sheep_Ensembl       GGCTTCTCTGGGAGGCACTGTGACGACAACGTGGACGACTGTGCCTCCTCCCCGTGTGCC 1017 
Sheep_NCBI          GGCTTCTCTGGGAGGCACTGTGACGACAACGTGGACGACTGTGCCTCCTCCCCGTGTGCC 2442 
Sheep_NCBI_New      GGCTTCTCTGGGAGGCACTGTGACGACAACGTGGACGACTGTGCCTCCTCCCCGTGTGCC 2256 
                    ************************************************************ 
 
Sheep_Ensembl       CACGGGGGCACCTGCCGGGACGGCGTGAACGAGTACTCCTGCACCTGCCCCCCCGGGTAC 1077 
Sheep_NCBI          CACGGGGGCACCTGCCGGGACGGCGTGAACGAGTACTCCTGCACCTGCCCCCCCGGGTAC 2502 
Sheep_NCBI_New      CACGGGGGCACCTGCCGGGACGGCGTGAACGAGTACTCCTGCACCTGCCCCCCCGGGTAC 2316 
                    ************************************************************ 
 
Sheep_Ensembl       ACGGGCAGGAACTGCAGTGCCCCCATCAGCAGGTGCGAGCACGCGCCCTGCCACAACGGG 1137 
Sheep_NCBI          ACGGGCAGGAACTGCAGTGCCCCCATCAGCAGGTGCGAGCACGCGCCCTGCCACAACGGG 2562 
Sheep_NCBI_New      ACGGGCAGGAACTGCAGTGCCCCCATCAGCAGGTGCGAGCACGCGCCCTGCCACAACGGG 2376 
                    ************************************************************ 
 
Sheep_Ensembl       GCCACCTGCCACGAACGGGCCTTCCGCTACCTGTGCGAGTGTGCCCGGGGCTACGGGCCC 1197 
Sheep_NCBI          GCCACCTGCCACGAACGGGCCTTCCGCTACCTGTGCGAGTGTGCCCGGGGCTACGGGGGA 2622 
Sheep_NCBI_New      GCCACCTGCCACGAACGGGCCTTCCGCTACCTGTGCGAGTGTGCCCGGGGCTACGGGGGA 2436 
                    *********************************************************    
 
Sheep_Ensembl       ACACCGCCCGCCACAGGTCTCTGCGCGGGAGGAGACGGGCCCCCCGACACTCAGAGGGTG 1257 
Sheep_NCBI          CAGGCTGGGAAGGGGGGCCTTCCCGGGGAGGGCGCCCCGACACCCGGGG----------- 2671 
Sheep_NCBI_New      CAGGCTGGGAAGGGGGGCCTTCCCGGGGAGGGCGCCCCGACACCCGGGG----------- 2485 
                        *          ** **   ** **  ** * *  * * ****               
 
Sheep_Ensembl       AGTGCTTCGGCCTGGAGGGGGCACATGGGGAGGCCAGCTGGTCAGGGGGCCAGCTGGAGA 1317 
Sheep_NCBI          ------------------------------------------------------------ 2671 
Sheep_NCBI_New      ------------------------------------------------------------ 2485 
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Sheep_Ensembl       AGGTGCCCCGACACTCAAGGAATGGGCAGAACAAGCTGGGCAGGGGGGCCAGCTGGAGAG 1377 
Sheep_NCBI          ------------------------------------------------------------ 2671 
Sheep_NCBI_New      ------------------------------------------------------------ 2485 
                                                                                 
 
Sheep_Ensembl       GGCACCCCGACACCCGAGGGATGGGCAGGACAGGCTGGGAAGGGGGGCCTTCCCGGGGAG 1437 
Sheep_NCBI          ------------------------------------------------------------ 2671 
Sheep_NCBI_New      ------------------------------------------------------------ 2485 
                                                                                 
 
Sheep_Ensembl       GGCGCCCCGACACCCGGGGGCCGGCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCC 1497 
Sheep_NCBI          -------------------GCCGGCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCC 2712 
Sheep_NCBI_New      -------------------GCCGGCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCC 2526 
                                       ***************************************** 
 
Sheep_Ensembl       ACGCAGATCAAGAACACCAACAAGAAGGCAGACTTCCACGTGGAGCCCCGCGGGAGGAGA 1557 
Sheep_NCBI          ACGCAGATCAAGAACACCAACAAGAAGGCAGACTTCCACGTGGAGCCCCGCGGGAGGAGA 2772 
Sheep_NCBI_New      ACGCAGATCAAGAACACCAACAAGAAGGCAGACTTCCACGTGGAGCCCCGCGGGAGGAGA 2586 
                    ************************************************************ 
 
Sheep_Ensembl       CGGGCCCCCCGACACTCAGAGGGTGAGTGCTTCGGCCTGGAGGGGGCACATGGGGAGGCC 1617 
Sheep_NCBI          CGGGCCCCCCGACACTCAGAGGGTGAGTGCTTCGGCCTGGAGGGGGCACATGGGGAGGCC 2832 
Sheep_NCBI_New      CGGGCCCCCCGACACTCAGAGGAATTTT------------------------------CC 2616 
                    **********************     *                              ** 
 
Sheep_Ensembl       AGCTGGTCAGGGGGCCAGCTGGAGAAGGTGCCCCGACACTCAAGGAATGGGCAGAACAAG 1677 
Sheep_NCBI          AGCTGTGGAGAAGC---------------------------------------------- 2846 
Sheep_NCBI_New      TCTAGTGGAGAAGC---------------------------------------------- 2630 
                        *   **  *                                                
 
Sheep_Ensembl       CTGGGCAGGGGGGCCAGCTGGAGAGGGCACCCCGACACCCGAGGGATTGGAGAAGCGTCT 1737 
Sheep_NCBI          --------------------------------------------------------GTCT 2850 
Sheep_NCBI_New      --------------------------------------------------------GTCT 2634 
                                                                            **** 
 
Sheep_Ensembl       GAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACAAAGTACCAGTCGGTG 1797 
Sheep_NCBI          GAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACAAAGTACCAGTCGGTG 2910 
Sheep_NCBI_New      GAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACAAAGTACCAGTCGGTG 2694 
                    ************************************************************ 
 
Sheep_Ensembl       TACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGGTC------------ 1845 
Sheep_NCBI          TACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGGTCAGAGCGGGCTTG 2970 
Sheep_NCBI_New      TACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGGTGTGA--------- 2745 
                    ***********************************************              
 
Sheep_Ensembl       --------------------------------------------------- 1845 
Sheep_NCBI          CGGGGCCCGCCTGCAGCTGGGGAGCCAGAACTGGGCCTCCGGCCGCGCTAA 3021 
Sheep_NCBI_New      --------------------------------------------------- 2745 
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Sheep and Cattle DLL1 Sequence Alignment 
Sheep_NCBI      ATGGACCCACACTCCCAACCACTGCAGATCCTGCCGGCCCTGGGCTGGCCTGGGAAGCTG 60 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      TGCGTGTTTCTGATGCAGAAGACGGACTTCACAGAACCCCCTCAACCGCAGGCCAGGGTG 120 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GCGCCGGGGGGAGCAGGCAGGGCGCACAGCTGTGGGGTCGAGCGGTCAGGGAGACGCGGT 180 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      TCAGGGACCGCGACGGCGCCGAATCGCGAGTGCACCCTCAGCGCCGAGGCGACAGCCCCG 240 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                           
 
Sheep_NCBI      CAGGCCCAGCCCTACCTAGAGACGCGCCAGGACACCGGAGACGCGCCCACGCCGCCCTCG 300 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GCCCTCAGCAGCTGTGCGCACTTCCGCTTCCCGTCGCGAGACCGCCCCGCCCGCGCGGGG 360 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GCGGGGCCTGCGCGGCCGGCCGGGAGGCGCCGGGAGCGCCACGCGCAGGCGCCTGAGAGC 420 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GCGTGGCGGTGCCGGCTCCGGCTCTGCGCCCGTTGCCGCGGAAACCGCGCTGTGCTTCCG 480 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      AGGTCGGGGTCACGACTCGCTCGGCTTCCGCAGGCGTACCCGTTGGTGCTGTGGGCGGCG 540 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      CAGCGGCGGTGGGGCCCCGCCTCGGTGCAGGTGACCGCGTGCGCCCTGTGCCGCGCGCCC 600 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GGCGACCAGGGCTGGCCCGTCGACCTCGCCATCCCAGCCCGCGCGCATGTCCCTGCGACG 660 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GGTGCCCGCCGCCGCCACCCACTCCAAGCCACCCTCTGGAGCGCCCACCGGCGCCGCACC 720 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      CCCTCCAGGCAGCCCTCCGGAGCGCCTGGCCCGGCGCGTTCAGTCGGGGGCCGCTCGGGC 780 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GGGAGCGCGGAGCAGCTGCGCGGTCATCTGATCCGGACAAAGGCGCCCGGAGCCGCGCCA 840 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      GTGAAAGTCACGTTTTGCCAGGACAGTGCAGTCCTGACAGAGAGGCCGGCTGCAGCACAC 900 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      CTACAGCGAGGCCTCAGTGACCGGGCGCCCTGTGCGGTACTGCTCATCAACGTGACCTTT 960 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      ACTCCACGCCCACACCTTTCACCCCGGATGACGGTGCCCCGGGTGTTGGGGGTGGGGGAG 1020 
Cattle_NCBI     ------------------------------------------------------------ 0 
                                                                             
 
Sheep_NCBI      ATGGAAGGAGGAGCAGATAGGGGTGAGATAGAGACCTCAACCTATGCGGGCGGCCGGGAC 1080 
Cattle_NCBI     -----------------------------------------ATGGGCGGGC--------- 10 
                                                          *  ******          
 
Sheep_NCBI      CGCCGCCCCCGAGTGAGCCGGCCGGGCCGATCCTGCTCCACCGCCCCGGATTACCG---- 1136 
Cattle_NCBI     ------------------GGTGCGCCCTGACCCTCGCCGTACTCTCGGCCCTGCTGTGCC 52 
                                   *  **  * ** ***   *   * * * *   * * *     
 
 
Sheep_NCBI      ---CCTCGCGCGCGGACCTAAGGAACCTGGGCCTCCGGAAGAGCCGGAGCCGGACCCTTC 1193 
Cattle_NCBI     AGGTCTGGAGCTCCGGGGTGTTCGAGCTGAAGCTGCAGGAGTTCGTCAACAAGAAGGGGC 112 
                    ** * ** * *   *     * ***   ** * * **  *   * *  **     * 
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Sheep_NCBI      AGGAGAGAAGTCCGCATTATCTCGGCCCGAGGCAGAGCGGCGGCGCTTTCCTGCCCGAGC 1253 
Cattle_NCBI     TGCTGGGGAACC-GCA---ACTGCTGCCGCGGGGGCGCGGGGCCGCCGCCGTGC------ 162 
                 *  * * *  * ***    **    *** **  * **** * ***   * ***       
 
Sheep_NCBI      TCCCGGGGACACCTTCCTCCTCCAGCGTCCCCTGACGACTTCGGAAGACAAGGCGGGGGG 1313 
Cattle_NCBI     -GCCTGCAGGACCTTCTTCCGCGTGTG---CCTCA------AGCACTACCAGGCCAGCGT 212 
                  ** *    ****** *** *  * *   *** *       * *  ** ****  * *  
 
Sheep_NCBI      GCCCTCCAAGCCCGGGTGGCTCACAGCCGGCGGCAGCGGCGAGGGGGTGTTGCGCGGGGT 1373 
Cattle_NCBI     GTCCCCCGAGCCGCCCTGCACCTAC---GGCAGCGCCGTCACCCCGGTGCTGGGCACCGA 269 
                * ** ** ****    **   *      *** **  ** *     **** ** **   *  
 
Sheep_NCBI      GACAGCCCCGGTTGAGAGCGGCGGAGAGGCCAAGCACCCGGGACGCTTCCGTGTCCGGTC 1433 
Cattle_NCBI     CTCCTTCAGCCTCCCGGACGGCGCGGGCGCGGACC---------------CCGCCTTCAG 314 
                  *   *    *   *  *****  *  **  * *                 * *      
 
Sheep_NCBI      TGCGCGCCGAGCCGCGGAGCTGAAAGGACCCCTTCAAGGAACCTTCTCTCTGATCATTGA 1493 
Cattle_NCBI     CAACCCCATCCGCTTCCCCTTTGGCTTCACCTGGCCGGGAACCTTCTCTCTGATCATTGA 374 
                    * *     *       *        **   *  *********************** 
 
Sheep_NCBI      AGCGCTCCACACAGATTCTCCGGATGACCTTGCAACAGAGAACCCAGAAAGACTTATCAG 1553 
Cattle_NCBI     AGCTCTCCACACAGATTCTCCTGATGACCTTGCAACAGAGAACCCAGAAAGACTTATCAG 434 
                *** ***************** ************************************** 
 
Sheep_NCBI      CCGCCTGGCCACACAGAGGCACCTGGCCGTTGGGGAGGAGTGGTCCCAGGATCTGCACAG 1613 
Cattle_NCBI     CCGCCTGGCCACACAGAGGCACCTGGCGGTTGGGGAGGAGTGGTCCCAGGACCTGCACAG 494 
                *************************** *********************** ******** 
 
Sheep_NCBI      CAGCGGCCGCACGGACCTCAAGTACTCCTACCGCTTTGTGTGTGATGAGCACTACTTTGG 1673 
Cattle_NCBI     CAGCGGCCGCACAGACCTCAAGTACTCCTACCGCTTTGTGTGTGATGAGCACTACTTCGG 554 
                ************ ******************************************** ** 
 
Sheep_NCBI      CGAAGGCTGCTCCGTCTTCTGCCGCCCCCGAGATGACGCCTTTGGCCACTTCACCTGCGG 1733 
Cattle_NCBI     GGAAGGCTGCTCCGTCTTCTGCCGCCCCCGAGATGACGCCTTTGGACACTTCACCTGCGG 614 
                 ******************************************** ************** 
 
Sheep_NCBI      GGAGAGAGGGGAGAAAGTCTGCAACCCTGGCTGGAAGGGCCAGTACTGCACAGAGCCCAT 1793 
Cattle_NCBI     GGAGAGAGGGGAGAAAGTCTGCAACCCCGGCTGGAAGGGCCAGTACTGCACAGAACCCAT 674 
                *************************** ************************** ***** 
 
Sheep_NCBI      CTGTTTGCCAGGGTGCGATGAGCAGCACGGATTTTGTGACAAGCCAGGGGAATGCAAGGC 1853 
Cattle_NCBI     CTGTTTGCCAGGGTGCGATGAGCAGCACGGATTTTGTGACAAGCCAGGGGAATGCAAGTG 734 
                **********************************************************   
 
Sheep_NCBI      CCGTCTCGGCG------------------CCCGGTCCCCCCGGTCCCCAGGCTGTCCCCG 1895 
Cattle_NCBI     CAGAGTGGGCTGGCAGGGCCGGTACTGTGACCAGTGCATTCGGTACCCAGGCTGTCTCCA 794 
                * *  * ***                    ** ** *   **** *********** **  
 
Sheep_NCBI      CGCCCCCTGCCAGCAGCCCTGGCAATGCAACTGCCAGGAGGGCTGGGGGGGCCTCTTCTG 1955 
Cattle_NCBI     CGGCACCTGCCGGCAGCCCTGGCAATGCAACTGCCAGGAGGGCTGGGGGGGCCTTTTCTG 854 
                ** * ****** ****************************************** ***** 
 
Sheep_NCBI      CAACCAGGACCTCAACTACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCAC 2015 
Cattle_NCBI     CAACCAGGACCTCAACTACTGCACGCACCATAAGCCCTGCAGGAACGGGGCCACCTGCAC 914 
                ****************************** ***************** *********** 
 
Sheep_NCBI      CAACACGGGCCAAGGGAGCTACACGTGCTGGTCTGAGGCAGGACTGGGAGGGTTCTTGGG 2075 
Cattle_NCBI     CAACACGGGCCAAGGGAGCTACACATGCTCGTGCCGGCCTGGGTACACGGGGGCCAACTG 974 
                ************************ **** **    * * **       ***  *    * 
 
Sheep_NCBI      AGCGAC------------------TAGGAAAGCTTTCCTCGTCTTCTCCGTCACTCAGGA 2117 
Cattle_NCBI     TGAGACGGAGGTGGACGAGTGCAGCGCGGGGCCTTGCAGGAACGGAGGGAGCTGCACGGA 1034 
                 * ***                     *    *** *     *        *     *** 
 
Sheep_NCBI      CCTTGAGAACAGCTACTCCTGCACCTGCCCGCCTGGCTTCTACGGCAGGGTCTGCGAGCT 2177 
Cattle_NCBI     CCTTGAGAACAGCTACTCCTGCACCTGCCCACCCGGCTTCTACGGCAGGATCTGCGAGCT 1094 
                ****************************** ** *************** ********** 
 
Sheep_NCBI      GAGTGCCATGGTGTGTGCCGACGGCCCCTGCTTCAATGGGGGCCGGTGCTCCGACAACCC 2237 
Cattle_NCBI     GAGTGCCATGGTGTGTGCCGACGGTCCCTGCTTCAACGGGGGCCGGTGCTCCGACAACCC 1154 
                ************************ *********** *********************** 
 
Sheep_NCBI      CGAGGGCGGGTACACCTGCCGCTGTCCTGGGGGCTTTTCTGGCTTTAACTGTGAGAAGAA 2297 
Cattle_NCBI     CGAGGGCGGGTACACCTGCCGCTGCCCTGGGGGCTTCTCCGGCTTTAACTGTGAGAAGAA 1214 
                ************************ *********** ** ******************** 
 
Sheep_NCBI      GATGGATTCCTGCAGTTCCTCGCCTTGTTCCAATGGTGCGCAGTGCGTGGACCTCGGCGA 2357 
Cattle_NCBI     GACGGATTCCTGCAGCTCCTCGCCTTGTTCCAATGGTGCTCAATGCGTGGACCTCGGCGA 1274 
                ** ************ *********************** ** ***************** 
 
Sheep_NCBI      CGCTTACGTCTGCCGCTGCCAGGCTGGCTTCTCTGGGAGGCACTGTGACGACAACGTGGA 2417 
Cattle_NCBI     CGCTTACGCCTGCCGCTGCCAGGCCGGCTTCTCTGGGAGGCACTGTGACAACAACGTGGA 1334 
                ******** *************** ************************ ********** 
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Sheep_NCBI      CGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAACGAGTA 2477 
Cattle_NCBI     CGACTGTGCCTCCTCCCCATGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAACGAGTA 1394 
                ****************** ***************************************** 
 
Sheep_NCBI      CTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCCCCCATCAGCAGGTG 2537 
Cattle_NCBI     CTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCCCCCGTCAGCAGGTG 1454 
                ************************************************* ********** 
 
Sheep_NCBI      CGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTACCTGTG 2597 
Cattle_NCBI     CGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCATGAGCGGGCCTTCCGCTACCTGTG 1514 
                ************************************ ** ******************** 
 
Sheep_NCBI      CGAGTGTGCCCGGGGCTACGGGGGACAGGCTGGGAAGGGGGGCCTTCCCGGGGAGGGCGC 2657 
Cattle_NCBI     TGAGTGCGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAGCCGCCCCC 1574 
                 ***** ***************** *      *  **      ** **** *  *  * * 
 
Sheep_NCBI      CCCGACACCCGGGGG---CCGGCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCCAC 2714 
Cattle_NCBI     GGGCCCCGTGGTGGTGGACCTCACAGAGAAGTACGTGGAGGGCCAGGCCG------GCCC 1628 
                     *    * **    **     ****** ****    * *   * *        * * 
 
Sheep_NCBI      GCAGATCAAGAACACCAACAAGAAGGCAGACTTCCACGTGGAGC-CCCGCGGGAGGAGAC 2773 
Cattle_NCBI     GTTCCCCTGGGTGGCCGTCGGGGCGGGCGTGCTGCTGGTCCTCACGCTGCTGCTGGGCTG 1688 
                *     *  *    **  *  *  **  *   * *  **       * ** *  **     
 
Sheep_NCBI      GGGCCCCCCGACACTCAGAGGGTGAGTGCTTCG--GCCTGGAGGGGGCACATGGGGAGGC 2831 
Cattle_NCBI     CGCCGCCACGGTGGTCTGCGTGCGGCTGAGGCTGCAGAAGCGCCGGCCCCCTGCAGACCC 1748 
                 * * ** **    ** * * * *  **   *       *    ** * * **  **  * 
 
Sheep_NCBI      CAGCTGTGGA--------------------------GAAGCGTCTGAAAGAAAAAGGC-- 2863 
Cattle_NCBI     CTGCCGGGGAGAGACAGAGACCATGAACAACCTGGCCAACCGCCAGCGGGAGAAGGACAT 1808 
                * ** * ***                           ** ** * *   ** ** * *   
 
Sheep_NCBI      CGGACTCTGTGTACTCTGCTTCA--------AAAGACACAAAGTACCAGTCGGTG---TA 2912 
Cattle_NCBI     CTCTGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCAGACTTCCA 1868 
                *    ** * **  ** *   **        **  **** **  *  ** * *      * 
 
Sheep_NCBI      CGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGGTCAGAGCGGGCTTGCG 2972 
Cattle_NCBI     CGTGGAGCCCGGCGCGGAGAAAAACGGCCTCACGGCCCGAGA----------CTCTGCCG 1918 
                ***     ***  * * ** *  *  *  ***  **    **            **  ** 
 
Sheep_NCBI      GGGCCCGCCTGCAGCTGGGGAGCCAGAACTGGGCCTCCGGCCGCGCTAA----------- 3021 
Cattle_NCBI     TGGGCTGCAACCTGCTGCAGGGCCTTAAGGGCGCCGCAGCCACGGCGGGGCCCCACAGCG 1978 
                 ** * **   * ****  * ***  **  * *** * * *   **               
 
Sheep_NCBI      ------------------------------------------------------------ 3021 
Cattle_NCBI     TGCGCGATGCCAAGGGCCAGCCCCAAGGCTCTGCAGGGGAGGAGAAGGGCACCCCGACAC 2038 
                                                                             
 
Sheep_NCBI      ------------------------------------------------------------ 3021 
Cattle_NCBI     TCAGAGGTGGAGAAGCGTCTGAAAGAAAAAGGCCAGACTCTGTGTACTCTGCTTCAAAAG 2098 
                                                                             
 
Sheep_NCBI      ------------------------------------------------------------ 3021 
Cattle_NCBI     ACACAAAGTACCAGTCTGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCCA 2158 
                                                                             
 
Sheep_NCBI      ----------- 3021 
Cattle_NCBI     CTGAGGTGTGA 2169 
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DLL1 sequence “a” 
 
  1    ACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCACCAACACGGGCCAAGGGA  60 
 61    GCTACACGTGCTCCTGCCGGCCTGGGTACACGGGGGCCGGCTGCGAGACGGAGGTGGACG  120 
121    AGTGCCGCGGCGGGCCTTGCAGGAACGGCGGGAGCTGCACGGTGAGTCCAGCCGCCGCGG  180 
181    GCCGTCCCGTCGGCCGGGAGCCCTGGTCTGAGGCAGACTGGGAGGGTTCTTGGGAGCGAC  240 
241    TAGGAAAGCTTTCCTCGTCTTCTCCGTCACTCAGGACC     278 
 
DLL1 sequence “a” alignment against Sheep DLL1 (XM_004011569.1) 
 
Query  1     ACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCACCAACACGGGCCAAGGGA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1973  ACTGCACGCACCACAAGCCCTGCAGGAACGGCGCCACCTGCACCAACACGGGCCAAGGGA  2032 
 
Query  61    GCTACACGTGCT  72 
             |||||||||||| 
Sbjct  2033  GCTACACGTGCT  2044 
 
Query  203   CTGGTCTGAGGCA-GACTGGGAGGGTTCTTGGGAGCGACTAGGAAAGCTTTCCTCGTCTT  261 
             ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2043  CTGGTCTGAGGCAGGACTGGGAGGGTTCTTGGGAGCGACTAGGAAAGCTTTCCTCGTCTT  2102 
 
Query  262   CTCCGTCACTCAGGACC  278 
             ||||||||||||||||| 
Sbjct  2103  CTCCGTCACTCAGGACC  2119 
 
 
Query = sequence “a”. Subject = Sheep DLL1 sequence 
DLL1 sequence “b” 
 
  1     CAGAAAGACTTATCAGCCGCCTGGCCACACAGAGGCACCTGGCCGTTGGGGAGGAGTGGT  60 
 61     CCCAGGATCTGCACAGCAGCGGCCGCACGGACCTCAAGTACTCCTACCGCTTTGTGTGTG  120 
121     ATGAGCACTACTTTGGCGAAGGCTGCTCCGTCTTCTGCCGCCCCCGAGATGACGCCTTTG  180 
181     GCCACTTCACCTGCGGGGAGAGAGGGGAGAAAGTCTGCA                        219 
 
Sequence matches 100% to nucleotides 1538 – 1756 of XM_004011569.1 
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DLL1 sequence “c” 
 
  1     CGAGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  60 
 61     CGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAGCTGCAGTGCCCCCATCAG  120 
121     CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTA  180 
181     CCTGTGCGAGTGTGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAGAC  240 
241     CCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGCCAGCCGCCGGCGCGAGAAGGAC  300 
301     GTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGAGAC      356 
 
 
DLL1 sequence “c” alignment against Sheep DLL1 (XM_004011569.1) 
 
Query  1     CGAGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  60 
             || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2412  CGTGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  2471 
 
Query  61    CGAGTACTCCTGCACCTGcccccccGGGTACACGGGCAGGAGCTGCAGTGCCCCCATCAG  120 
             ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  2472  CGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCCCCCATCAG  2531 
 
Query  121   CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2532  CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTA  2591 
 
Query  181   CCTGTGCGAGTGTGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAGAC  240 
             ||||||||||||||||||||||||||||||     || | | |            | |   
Sbjct  2592  CCTGTGCGAGTGTGCCCGGGGCTACGGGGG-----ACAGGCTG-------GGAAGGGGGG  2639 
 
Query  241   CCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGCCAGCCGCCGGCGCGAGAAGGAC  300 
             || | |||||    || || | ||    ||| || ||      ||||||||||||||||| 
Sbjct  2640  CCTTCCCGGG----GAGGGCGCCC--CGACACCCGGG-----GGCCGGCGCGAGAAGGAC  2688 
 
Query  301   GTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGG-AGAC  356 
             |||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  2689  GTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCAGAC  2745 
 
Query = sequence “c”. Subject = Sheep DLL1 sequence 
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DLL1 sequence “c” alignment against Cattle DLL1 (XM_010808803.1) 
 
Query  1     CGAGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  60 
             || ||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  1848  CGTGGACGACTGTGCCTCCTCCCCATGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  1907 
 
Query  61    CGAGTACTCCTGCACCTGcccccccGGGTACACGGGCAGGAGCTGCAGTGCCCCCATCAG  120 
             ||||||||||||||||||||||||||||||||||||||||| ||||||||||||| |||| 
Sbjct  1908  CGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCCCCCGTCAG  1967 
 
Query  121   CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTA  180 
             |||||||||||||||||||||||||||||||||||||||||| || |||||||||||||| 
Sbjct  1968  CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCATGAGCGGGCCTTCCGCTA  2027 
 
Query  181   CCTGTGCGAGTGTGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAG  238 
             |||||| ||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2028  CCTGTGTGAGTGCGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAG  2085 
 
Query  237   AGACCCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGCCAGCCGCCGGCGCGAGAA  296 
             ||||||||||||||| ||||| |||||||||||||||||||||| ||||| ||| ||||| 
Sbjct  2262  AGACCCCTGCCGGGGAGAGACAGAGACCATGAACAACCTGGCCAACCGCCAGCGGGAGAA  2321 
 
Query  297   GGACGTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGG-AGA  355 
             |||| |||| |||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  2322  GGACATCTCTGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCAGA  2381 
 
Query  356   C  356 
             | 
Sbjct  2382  C  2382 
 
Query = sequence “c”. Subject = Cattle DLL1 sequence  
Appendix 3    DLL1 Alignments and Sequences 
         
181 
 
DLL1 sequence “d” (3’ RACE) 
 
  1    AGGGCGCCCCGACACTCAGAGGTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGT  60 
 61    ACTCTGCTTCAAAAGACACAAAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACG  120 
121    AGTGTGTCATCGCAACTGAGGTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAG  180 
181    AACAAGGAACTTCCGAGGTGTCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCC  240 
241    TGACTGCTGCTGGAAGCCAGGTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCG  300 
301    CTGCTCTGCCTCTAGGACGTTCCCATTGCACTATGGACGGTCGCTTTTAAAAAATATATA  360 
361    TTTAAATGAATGGACTTGATCACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCT  420 
421    GGATTCTTATGAGCCAGTCTTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCT  480 
481    TTTTGATACTAAAATGTGTTTTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGT  540 
541    AAAAATATTTTTCATGATATCTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAA  600 
601    TTTAAATTTTTGGTAAATATGTACAAAGGCACTTCGGGTCAATGTGACTATATTTTTTTG  660 
661    TATATAAATGTATTTATGGAATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTT  720 
721    AATGAAGAAATTCCTTTTTAAAATATTTTTCCAAAATAAATATTATGAACAACA        774 
 
 
DLL1 sequence “d” alignment against Goat DLL1 (XM_005685019.1) 
 
Query  21    GGTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACA  80 
             ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1345  GGTGGAGAAGCATCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACA  1404 
 
Query  81    AAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAG  140 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1405  AAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAG  1464 
 
Query  141   GTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGGTG  200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1465  GTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGGTG  1524 
 
Query  201   TCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCAG  260 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1525  TCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCAG  1584 
 
Query  261   GTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCTGCTCTGCCTCTAGGACGT  320 
             ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  1585  GTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCCGCTCTGCCTCTAGGACGT  1644 
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Query  321   TCCCATTGCACTATGGACGGTCGCTTTTAAAAAATATATATTTAAATGAATGGACTTGAT  380 
             ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  1645  TCCCATTGCACTATGGACGGTTGCTTTTAAAAAATATATATTTAAATGAATGGACTTGAT  1704 
 
Query  381   CACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCTGGATTCTTATGAGCCAGTCT  440 
             |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  1705  CACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTTTGGATTCTTATGAGCCAGTCT  1764 
 
Query  441   TCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTGTT  500 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1765  TCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTGTT  1824 
 
Query  501   TTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATAT  560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1825  TTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATAT  1884 
 
Query  561   CTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATAT  620 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1885  CTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATAT  1944 
 
Query  621   GTACAAAGGCACTTCGGGTCAATGTGACTATAtttttttGTATATAAATGTATTTATGGA  680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1945  GTACAAAGGCACTTCGGGTCAATGTGACTATATTTTTTTGTATATAAATGTATTTATGGA  2004 
 
Query  681   ATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTTAATGAAGAAATTCCTTTTTA  740 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2005  ATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTTAATGAAGAAATTCCTTTTTA  2064 
 
Query  741   AAATATTTTTCCAAAATAAATATTATGAACAACA  774 
             |||||||||||||||||||||||||||||||||| 
Sbjct  2065  AAATATTTTTCCAAAATAAATATTATGAACAACA  2098 
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DLL1 sequence “d” alignment against Cattle DLL1 (XM_010808803.1) 
 
Query  1     AGGGCGCCCCGACACTCAGAGGTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGT  60 
             ||||| ||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct  2543  AGGGCACCCCGACACTCAGAGGTGGAGAAGCGTCTGAAAGAAAAAGGCCAGACTCTGTGT  2602 
 
Query  61    ACTCTGCTTCAAAAGACACAAAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACG  120 
             ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
Sbjct  2603  ACTCTGCTTCAAAAGACACAAAGTACCAGTCTGTGTACGTCATATCCGAGGAGCAGGACG  2662 
 
Query  121   AGTGTGTCATCGCAACTGAGGTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAG  180 
             ||||||||||||| ||||||||||||| ||||||||||||||||||||||||| |||||| 
Sbjct  2663  AGTGTGTCATCGCCACTGAGGTGTGACATGGAGGTGACGGGGCAAGTTCCGTTTCTGCAG  2722 
 
Query  181   AACAAGGAACTTCCGAGGTGTCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCC  240 
             ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  2723  AACAAGGAACTTCCGAGGTGTCG-CCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCC  2781 
 
Query  241   TGACTGCTGCTGGAAGCCAGGTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCG  300 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  2782  TGACTGCTGCTGGAAGCCAGGTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCGGCCG  2841 
 
Query  301   CTGCTCTGCCTCTAGGACGTTCCCATTGCACTATGGACGGTCGCTTTTAAAAAATATATA  360 
             ||||||||||||||||||||| |||||||||||||||| || |||||||||||||||||| 
Sbjct  2842  CTGCTCTGCCTCTAGGACGTTTCCATTGCACTATGGACAGTTGCTTTTAAAAAATATATA  2901 
 
Query  361   TTTAAATGAATGGACTTGATCACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCT  420 
             |||||| ||||||||| |||||||| ||||||||||||| ||||||||||||| |||||| 
Sbjct  2902  TTTAAACGAATGGACTCGATCACTAGGTAAGAAGCACGCGCTGCCTGAAGTGTGTATTCT  2961 
 
Query  421   GGATTCTTATGAGCCAGTCTTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCT  480 
             ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  2962  GGATTCTTATGAGCCAGTCCTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCT  3021 
 
Query  481   TTTTGATACTAAAATGTGTTTTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGT  540 
             ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3022  TTTTGATACAAAAATGTGTTTTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGT  3081 
 
Query  541   AAAAATATTTTTCATGATATCTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3082  AAAAATATTTTTCATGATATCTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAA  3141 
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Query  601   TTTAAATTTTTGGTAAATATGTACAAAGGCACTTCGGGTCAATGTGACTATAtttttttG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3142  TTTAAATTTTTGGTAAATATGTACAAAGGCACTTCGGGTCAATGTGACTATATTTTTTTG  3201 
 
Query  661   TATATAAATGTATTTATGGAATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTT  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3202  TATATAAATGTATTTATGGAATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTT  3261 
 
Query  721   AATGAAGAAATTCCTTTTTAAAATATTTTTCCAAAATAAATATTATGAACAACA  774 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3262  AATGAAGAAATTCCTTTTTAAAATATTTTTCCAAAATAAATATTATGAACAACA  3315 
 
Query = sequence “c”. Subject = Cattle DLL1 sequence.  
 
DLL1 sequence “e”  
 
  1   CGCAGATCAAGAACACCAACAAGAAGGCAGACTTCCACGTGGAGCCCAGTGCGGAGAAAA  60 
 61   ATGGCCTCACAGCTCGAGACCCCGCCGTGGGCTACAACCTGCTGCAGGGCCTCAAGGGCA  120 
121   CCTCAGCCACTGCGGAGCCCCATGGCAAGCACGATGCCAAGTGCCAGCCCCAGGGCTCTG  180 
181   CGGGGGAGGAGAAGGGCGCCCCGACACTCAGAGGTGGAGAAGCGTCTGAAA           231 
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DLL1 combined sequence (sequences “c” through “e”) 
 
   1   CGAGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  60 
  61   CGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAGCTGCAGTGCCCCCATCAG  120 
 121   CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTA  180 
 181   CCTGTGCGAGTGTGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAGAC  240 
 241   CCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGCCAGCCGCCGGCGCGAGAAGGAC  300 
 301   GTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCAGACTTC  360 
 361   CACGTAGAGCCCAGTGCGGAGAAAAATGGCCTCACAGCTCGAGACCCCGCCGTGGGCTAC  420 
 421   AACCTGCTGCAGGGCCTCAAGGGCACCTCAGCCACTGCGGAGCCCCATGGCAAGCACGAT  480 
 481   GCCAAGTGCCAGCCCCAGGGCTCTGCGGGGGAGGAGAAGGGCGCCCCGACACTCAGAGGT  540 
 541   GGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACAAAG  600 
 601   TACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGGTG  660 
 661   TGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGGTGTCG  720 
 721   GCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCAGGTC  780 
 781   CTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCTGCTCTGCCTCTAGGACGTTCC  840 
 841   CATTGCACTATGGACGGTCGCTTTTAAAAAATATATATTTAAATGAATGGACTTGATCAC  900 
 901   TACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCTGGATTCTTATGAGCCAGTCTTCT  960 
 961   CTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTGTTTTT  1020 
1021   CTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATATCTG  1080 
1081   TAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATATGTA  1140 
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DLL1 combined sequence alignment against Cattle DLL1 (XM_010808803.1) 
 
Query  1    CGAGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  60 
            || ||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  198  CGTGGACGACTGTGCCTCCTCCCCATGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  257 
 
Query  61   CGAGTACTCCTGCACCTGcccccccGGGTACACGGGCAGGAGCTGCAGTGCCCCCATCAG  120 
            ||||||||||||||||||||||||||||||||||||||||| ||||||||||||| |||| 
Sbjct  258  CGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCCCCCGTCAG  317 
 
Query  121  CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTA  180 
            |||||||||||||||||||||||||||||||||||||||||| || |||||||||||||| 
Sbjct  318  CAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCATGAGCGGGCCTTCCGCTA  377 
 
Query  181  CCTGTGCGAGTGTGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAG  238 
            |||||| ||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  378  CCTGTGTGAGTGCGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTCCCCGAG  435 
 
 
Query  237   AGACCCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGCCAGCCGCCGGCGCGAGAA  296 
             ||||||||||||||| ||||| |||||||||||||||||||||| ||||| ||| ||||| 
Sbjct  612   AGACCCCTGCCGGGGAGAGACAGAGACCATGAACAACCTGGCCAACCGCCAGCGGGAGAA  671 
 
Query  297   GGACGTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCAGA  356 
             |||| |||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  672   GGACATCTCTGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCAGA  731 
 
Query  357   CTTCCACGTAGAGCCCAGTGCGGAGAAAAATGGCCTCACAGCTCGAGACCCCGCCGTGGG  416 
             ||||||||| |||||| | ||||||||||| |||||||| || |||||| | |||||||| 
Sbjct  732   CTTCCACGTGGAGCCCGGCGCGGAGAAAAACGGCCTCACGGCCCGAGACTCTGCCGTGGG  791 
 
Query  417   CTACAACCTGCTGCAGGGCCTCAAGGGCACCTCAGCCACTGCGGAGCCCCATGGCAAGCA  476 
             || |||||||||||||||||| |||||| || ||||||| |||| ||||||  ||  ||  
Sbjct  792   CTGCAACCTGCTGCAGGGCCTTAAGGGCGCCGCAGCCACGGCGGGGCCCCACAGCGTGCG  851 
 
Query  477   CGATGCCAAGTGCCAGCCCCAGGGCTCTGCGGGGGAGGAGAAGGGCGCCCCGACACTCAG  536 
             |||||||||| |||||||||| |||||||| ||||||||||||||| ||||||||||||| 
Sbjct  852   CGATGCCAAGGGCCAGCCCCAAGGCTCTGCAGGGGAGGAGAAGGGCACCCCGACACTCAG  911 
 
Query  537   AGGTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACAC  596 
             |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  912   AGGTGGAGAAGCGTCTGAAAGAAAAAGGCCAGACTCTGTGTACTCTGCTTCAAAAGACAC  971 
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Query  597   AAAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGA  656 
             |||||||||||| ||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  972   AAAGTACCAGTCTGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCCACTGA  1031 
 
Query  657   GGTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGGT  716 
             |||||||| ||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  1032  GGTGTGACATGGAGGTGACGGGGCAAGTTCCGTTTCTGCAGAACAAGGAACTTCCGAGGT  1091 
 
Query  717   GTCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCA  776 
             |||| | ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1092  GTCG-CTCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCA  1150 
 
Query  777   GGTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCTGCTCTGCCTCTAGGACG  836 
             |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  1151  GGTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCGGCCGCTGCTCTGCCTCTAGGACG  1210 
 
Query  837   TTCCCATTGCACTATGGACGGTCGCTTTTAAAAAATATATATTTAAATGAATGGACTTGA  896 
             || |||||||||||||||| || |||||||||||||||||||||||| ||||||||| || 
Sbjct  1211  TTTCCATTGCACTATGGACAGTTGCTTTTAAAAAATATATATTTAAACGAATGGACTCGA  1270 
 
Query  897   TCACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCTGGATTCTTATGAGCCAGTC  956 
             |||||| ||||||||||||| ||||||||||||| ||||||||||||||||||||||||| 
Sbjct  1271  TCACTAGGTAAGAAGCACGCGCTGCCTGAAGTGTGTATTCTGGATTCTTATGAGCCAGTC  1330 
 
Query  957   TTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTGT  1016 
              ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  1331  CTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACAAAAATGTGT  1390 
 
Query  1017  TTTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATA  1076 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1391  TTTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATA  1450 
 
Query  1077  TCTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATA  1136 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1451  TCTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATA  1510 
 
Query  1137  TGTACAAAGGCACTTCGGGTCAATGTGACTATAtttttttGTATATAAAT  1186 
             |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1511  TGTACAAAGGCACTTCGGGTCAATGTGACTATATTTTTTTGTATATAAAT  1560 
 
Query = DLL1 combined sequence. Subject = Cattle DLL1 
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DLL1 combined sequence alignment against Goat DLL1 (XM_005685019.1) 
 
Query  1     CGAGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAA  60 
             || |||||||||||||||||||||||||||||||||||||||| |||||| ||||||||| 
Sbjct  1098  CGTGGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCCGCCGGGGCGGCGTGAA  1157 
 
Query  61    CGAGTACTCCTGCACCTGcccccccGGGTACACGGGC  97 
             |||| ||||| ||||| |||||||| ||  |||| || 
Sbjct  1158  CGAGGACTCCCGCACCCGCCCCCCCCGGGCCACGCGC  1194 
 
 
Query  288   GCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAA  347 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1191  GCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAA  1250 
 
Query  348   GAAGGCAGACTTCCACGTAGAGCCCAGTGCGGAGAAAAATGGCCTCACAGCTCGAGACCC  407 
             ||||||||||||||| || ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1251  GAAGGCAGACTTCCATGTGGAGCCCAGTGCGGAGAAAAATGGCCTCACAGCTCGAGACCC  1310 
 
Query  408   CGCCGTGGGCTACAACCTGCTGCAGGG  434 
             ||||||||||||||||||||||||||| 
Sbjct  1311  CGCCGTGGGCTACAACCTGCTGCAGGG  1337 
 
 
Query  538   GGTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACA  597 
             ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1345  GGTGGAGAAGCATCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACA  1404 
 
Query  598   AAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAG  657 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1405  AAGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAG  1464 
 
Query  658   GTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGGTG  717 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1465  GTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGGTG  1524 
 
Query  718   TCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCAG  777 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1525  TCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCCAG  1584 
 
Query  778   GTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCTGCTCTGCCTCTAGGACGT  837 
             ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  1585  GTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCCGCTCTGCCTCTAGGACGT  1644 
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Query  838   TCCCATTGCACTATGGACGGTCGCTTTTAAAAAATATATATTTAAATGAATGGACTTGAT  897 
             ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  1645  TCCCATTGCACTATGGACGGTTGCTTTTAAAAAATATATATTTAAATGAATGGACTTGAT  1704 
 
Query  898   CACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCTGGATTCTTATGAGCCAGTCT  957 
             |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  1705  CACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTTTGGATTCTTATGAGCCAGTCT  1764 
 
Query  958   TCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTGTT  1017 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1765  TCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTGTT  1824 
 
Query  1018  TTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATAT  1077 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1825  TTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGATAT  1884 
 
Query  1078  CTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATAT  1137 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1885  CTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAATAT  1944 
 
Query  1138  GTACAAAGGCACTTCGGGTCAATGTGACTATAtttttttGTATATAAAT  1186 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1945  GTACAAAGGCACTTCGGGTCAATGTGACTATATTTTTTTGTATATAAAT  1993 
 
Query = DLL1 combined sequence. Subject = Goat DLL1 
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DLL1 combined sequence alignment against Sheep genome OAR v3.1 
 
Query  4         GGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAACGA  63 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90488244  GGACGACTGTGCCTCCTCCCCGTGTGCCCACGGGGGCACCTGCCGGGACGGCGTGAACGA  90488185 
 
Query  64        GTACTCCTGCACCTGcccccccGGGTACACGGGCAGGAGCTGCAGTGCCCCCATCAGCAG  123 
                 |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  90488184  GTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCCCCCATCAGCAG  90488125 
 
Query  124       GTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTACCT  183 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90488124  GTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCACGAACGGGCCTTCCGCTACCT  90488065 
 
Query  184       GTGCGAGTGTGCCCGGGGCTACGGGG  209 
                 |||||||||||||||||||||||||| 
Sbjct  90488064  GTGCGAGTGTGCCCGGGGCTACGGGG  90488039 
 
Query  284       GCCGGCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCA  343 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90487040  GCCGGCGCGAGAAGGACGTCTCCGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCA  90486981 
 
Query  344       ACAAGAAGGCAGACTTCCACGTAGAGCCC  372 
                 |||||||||||||||||||||| |||||| 
Sbjct  90486980  ACAAGAAGGCAGACTTCCACGTGGAGCCC  90486952 
 
Query  539       GTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACAA  598 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90486464  GTGGAGAAGCGTCTGAAAGAAAAAGGCCGGACTCTGTGTACTCTGCTTCAAAAGACACAA  90486405 
 
Query  599       AGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGG  658 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90486404  AGTACCAGTCGGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATCGCAACTGAGG  90486345 
 
Query  659       T  659 
                 | 
Sbjct  90486344  T  90486344 
 
Query  656       AGGTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGG  715 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90486255  AGGTGTGACGTGGAGGTGACGGGGCAAGTTCCGTTCCTGCAGAACAAGGAACTTCCGAGG  90486196 
 
Query  716       TGTCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCC  775 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90486195  TGTCGGCCCCGACGATGCTGCTGGGAGGAGCGGACGTGCTCCTGACTGCTGCTGGAAGCC  90486136 
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Query  776       AGGTCCTCTTCCTGCCGGGGGCGGCGGGCGCTCCCGCAGCCGCTGCTCTGCCTCTAGGAC  835 
                      | |  || || ||||| || |||||| |||||||||||||||||||||||||||| 
Sbjct  90486135  -----C-C--CCGGCGGGGGGGGGGGGGCGCCCCCGCAGCCGCTGCTCTGCCTCTAGGAC  90486084 
 
Query  836       GTTCCCATTGCACTATGGACGGtcgcttttaaaaaatatatatttaaatgaatggaCTTG  895 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90486083  GTTCCCATTGCACTATGGACGGTCGCTTTTAAAAAATATATATTTAAATGAATGGACTTG  90486024 
 
Query  896       ATCACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCTGGATTCTTATGAGCCAGT  955 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90486023  ATCACTACGTAAGAAGCACGCACTGCCTGAAGTGTATATTCTGGATTCTTATGAGCCAGT  90485964 
 
Query  956       CTTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGAtactaaaatgtg  1015 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90485963  CTTCTCTTGAATTAGAATCACAAACACTGCCTTTATTGTCCTTTTTGATACTAAAATGTG  90485904 
 
Query  1016      tttttctagGTGGAAAAAATGTGCGTTATTTTTTGgacttgtaaaaatatttttcatgat  1075 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90485903  TTTTTCTAGGTGGAAAAAATGTGCGTTATTTTTTGGACTTGTAAAAATATTTTTCATGAT  90485844 
 
Query  1076      atCTGTAAAGCTTGAGTATTTTGTGAtgttcattttttataatttaaatttttggtaAAT  1135 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90485843  ATCTGTAAAGCTTGAGTATTTTGTGATGTTCATTTTTTATAATTTAAATTTTTGGTAAAT  90485784 
 
Query  1136      ATGTACAAAGGCACTTCGGGtcaatgtgactatatttttttgtatataaatgtatttatg  1195 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90485783  ATGTACAAAGGCACTTCGGGTCAATGTGACTATATTTTTTTGTATATAAATGTATTTATG  90485724 
 
Query  1196      gaaTATTGTGCAAATGTTATTTGagttttttactgttttgttaatgaagaaattcctttt  1255 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  90485723  GAATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTGTTAATGAAGAAATTCCTTTT  90485664 
 
Query  1256      taaaatatttttccaaaataaatattatgaacaacA  1291 
                 |||||||||||||||||||||||||||||||||||| 
Sbjct  90485663  TAAAATATTTTTCCAAAATAAATATTATGAACAACA  90485628 
 
 
Query = DLL1 combined sequence. Subject = Sheep genome OAR v3.1 
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Cattle, Pig, Human and Mouse Alignment of DLL1 sequences 
 
Cattle_DLL1      ATGGGCGGGCGGTGCGCCCTGACCCTCGCCGTACTCTCGGCCCTGCTGTGCCAGGTCTGG 60 
Pig_DLL1         ATGGGCCGGCGGTGCGCCCTGGCCCTCGCCGTGCTTTCGGCCCTGCTGTGCCAGGTCTGG 60 
Human_DLL1       ATGGGCAGTCGGTGCGCGCTGGCCCTGGCGGTGCTCTCGGCCTTGCTGTGTCAGGTCTGG 60 
Mouse_DLL1       ATGGGCCGTCGGAGCGCGCTAGCCCTTGCCGTGGTCTCTGCCCTGCTGTGCCAGGTCTGG 60 
                 ****** * ***:**** **..**** ** **. * ** *** ******* ********* 
 
Cattle_DLL1      AGCTCCGGGGTGTTCGAGCTGAAGCTGCAGGAGTTCGTCAACAAGAAGGGGCTGCTGGGG 120 
Pig_DLL1         AGCTCCGGGGTGTTCGAGCTGAAGCTGCAGGAGTTCGTCAACAAGAAGGGGCTGCTGGGA 120 
Human_DLL1       AGCTCTGGGGTGTTCGAACTGAAGCTGCAGGAGTTCGTCAACAAGAAGGGGCTGCTGGGG 120 
Mouse_DLL1       AGCTCCGGCGTATTTGAGCTGAAGCTGCAGGAGTTCGTCAACAAGAAGGGGCTGCTGGGG 120 
                 ***** ** **.** **.*****************************************. 
 
Cattle_DLL1      AACCGCAACTGCTGCCGCGGGGGCGCGGGGCCGCCGCCGTGCGCCTGCAGGACCTTCTTC 180 
Pig_DLL1         AACCGCAACTGCTGCCGCGGAGGCGCGGGGCCGCCGCCGTGCGCCTGCAGGACCTTCTTC 180 
Human_DLL1       AACCGCAACTGCTGCCGCGGGGGCGCGGGGCCACCGCCGTGCGCCTGCCGGACCTTCTTC 180 
Mouse_DLL1       AACCGCAACTGCTGCCGCGGGGGCTCTGG---CCCGCCTTGCGCCTGCAGGACCTTCTTT 177 
                 ********************.*** * **    ***** *********.**********  
 
Cattle_DLL1      CGCGTGTGCCTCAAGCACTACCAGGCCAGCGTGTCCCCCGAGCCGCCCTGCACCTACGGC 240 
Pig_DLL1         CGCGTGTGCCTCAAGCACTACCAGGCCAGCGTGTCTCCCGAGCCGCCCTGCACCTACGGC 240 
Human_DLL1       CGCGTGTGCCTCAAGCACTACCAGGCCAGCGTGTCCCCCGAGCCGCCCTGCACCTACGGC 240 
Mouse_DLL1       CGCGTATGCCTCAAGCACTACCAGGCCAGCGTGTCACCGGAGCCACCCTGCACCTACGGC 237 
                 *****.***************************** ** *****.*************** 
 
Cattle_DLL1      AGCGCCGTCACCCCGGTGCTGGGCACCGACTCCTTCAGCCTCCCGGACGGCGCGGGCGCG 300 
Pig_DLL1         AGCGCTGTCACGCCGGTGCTGGGCGTCGACTCCTTCAGCCTCCCTGACGGCGCGGGCGCC 300 
Human_DLL1       AGCGCCGTCACCCCCGTGCTGGGCGTCGACTCCTTCAGTCTGCCCGACGGCGGGGGCGCC 300 
Mouse_DLL1       AGTGCTGTCACGCCAGTGCTGGGTGTCGACTCCTTCAGCCTGCCTGATGGCGCAGGCATC 297 
                 ** ** ***** ** ******** . ************ ** ** ** **** .***.   
 
Cattle_DLL1      GACCCCGCCTTCAGCAACCCCATCCGCTTCCCCTTTGGCTTCACCTGGCCGGGAACCTTC 360 
Pig_DLL1         GACCCCGCCTTCAGCAACCCCATCCGCTTCCCCTTTGGCTTCACCTGGCCGGGAACTTTC 360 
Human_DLL1       GACTCCGCGTTCAGCAACCCCATCCGCTTCCCCTTCGGCTTCACCTGGCCGGGCACCTTC 360 
Mouse_DLL1       GACCCCGCCTTCAGCAACCCCATCCGATTCCCCTTCGGCTTCACCTGGCCAGGTACCTTC 357 
                 *** **** *****************.******** **************.** ** *** 
 
Cattle_DLL1      TCTCTGATCATTGAAGCTCTCCACACAGATTCTCCTGATGACCTTGCAACAGAGAACCCA 420 
Pig_DLL1         TCTCTGATCATTGAAGCTCTGCACACGGATTCTCCCGATGACCTCGCAACAGAAAACCCA 420 
Human_DLL1       TCTCTGATTATTGAAGCTCTCCACACAGATTCTCCTGATGACCTCGCAACAGAAAACCCA 420 
Mouse_DLL1       TCTCTGATCATTGAAGCCCTCCATACAGACTCTCCCGATGACCTCGCAACAGAAAACCCA 417 
                 ******** ******** ** ** **.** ***** ******** ********.****** 
 
Cattle_DLL1      GAAAGACTTATCAGCCGCCTGGCCACACAGAGGCACCTGGCGGTTGGGGAGGAGTGGTCC 480 
Pig_DLL1         GAGAGACTCATCAGCCGCCTGGCCACACAGAGGCACCTCACCGTGGGCGAGGAGTGGTCC 480 
Human_DLL1       GAAAGACTCATCAGCCGCCTGGCCACCCAGAGGCACCTGACGGTGGGCGAGGAGTGGTCC 480 
Mouse_DLL1       GAAAGACTCATCAGCCGCCTGACCACACAGAGGCACCTCACTGTGGGAGAAGAATGGTCT 477 
                 **.***** ************.****.*********** .* ** ** **.**.*****  
 
Cattle_DLL1      CAGGACCTGCACAGCAGCGGCCGCACAGACCTCAAGTACTCCTACCGCTTTGTGTGTGAT 540 
Pig_DLL1         CAGGACCTGCACAGCAGTGGCCGCACGGACCTCAAGTATTCCTACCGCTTCGTGTGTGAC 540 
Human_DLL1       CAGGACCTGCACAGCAGCGGCCGCACGGACCTCAAGTACTCCTACCGCTTCGTGTGTGAC 540 
Mouse_DLL1       CAGGACCTTCACAGTAGCGGCCGCACAGACCTCCGGTACTCTTACCGGTTTGTGTGTGAC 537 
                 ******** ***** ** ********.******..*** ** ***** ** ********  
 
Cattle_DLL1      GAGCACTACTTCGGGGAAGGCTGCTCCGTCTTCTGCCGCCCCCGAGATGACGCCTTTGGA 600 
Pig_DLL1         GAGCACTACTATGGGGAGGGCTGCTCTGTCTTCTGCCGCCCCCGAGACGACGCCTTTGGC 600 
Human_DLL1       GAACACTACTACGGAGAGGGCTGCTCCGTTTTCTGCCGTCCCCGGGACGATGCCTTCGGC 600 
Mouse_DLL1       GAGCACTACTACGGAGAAGGTTGCTCTGTGTTCTGCCGACCTCGGGATGACGCCTTTGGC 597 
                 **.*******: **.**.** ***** ** ******** ** **.** ** ***** **. 
 
Cattle_DLL1      CACTTCACCTGCGGGGAGAGAGGGGAGAAAGTCTGCAACCCCGGCTGGAAGGGCCAGTAC 660 
Pig_DLL1         CACTTCACCTGCGGGGAGAGAGGCGAGAAAGTCTGCAACCCTGGCTGGAAAGGCCAGTAC 660 
Human_DLL1       CACTTCACCTGTGGGGAGCGTGGGGAGAAAGTGTGCAACCCTGGCTGGAAAGGGCCCTAC 660 
Mouse_DLL1       CACTTCACCTGCGGGGACAGAGGGGAGAAGATGTGCGACCCTGGCTGGAAAGGCCAGTAC 657 
                 *********** ***** .*:** *****..* ***.**** ********.** *. *** 
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Cattle_DLL1      TGCACAGAACCCATCTGTTTGCCAGGGTGCGATGAGCAGCACGGATTTTGTGACAAGCCA 720 
Pig_DLL1         TGCACTGAGCCCATCTGTTTGCCGGGGTGCGACGAGCAGCATGGGTTTTGTGACAAGCCA 720 
Human_DLL1       TGCACAGAGCCGATCTGCCTGCCTGGATGTGATGAGCAGCATGGATTTTGTGACAAACCA 720 
Mouse_DLL1       TGCACTGACCCAATCTGTCTGCCAGGGTGTGATGACCAACATGGATACTGTGACAAACCA 717 
                 *****:** ** *****  **** **.** ** ** **.** **.*: ********.*** 
 
Cattle_DLL1      GGGGAATGCAAGTGCAGAGTGGGCTGGCAGGGCCGGTACTGTGACCAGTGCATTCGGTAC 780 
Pig_DLL1         GGGGAATGCAAGTGCAGAGTGGGCTGGCAGGGCCGGTACTGTGACCAGTGCATTCGGTAC 780 
Human_DLL1       GGGGAATGCAAGTGCAGAGTGGGCTGGCAGGGCCGGTACTGTGACGAGTGTATCCGCTAT 780 
Mouse_DLL1       GGGGAGTGCAAGTGCAGAGTTGGCTGGCAGGGCCGCTACTGCGATGAGTGCATCCGATAC 777 
                 *****.************** ************** ***** **  **** ** ** **  
 
Cattle_DLL1      CCAGGCTGTCTCCACGGCACCTGCCGGCAGCCCTGGCAATGCAACTGCCAGGAGGGCTGG 840 
Pig_DLL1         CCAGGCTGTCTCCACGGCACCTGCCAGCAGCCCTGGCAATGCAACTGCCAGGAAGGCTGG 840 
Human_DLL1       CCAGGCTGTCTCCATGGCACCTGCCAGCAGCCCTGGCAGTGCAACTGCCAGGAAGGCTGG 840 
Mouse_DLL1       CCAGGTTGTCTCCATGGCACCTGCCAGCAACCCTGGCAGTGTAACTGCCAGGAAGGCTGG 837 
                 ***** ******** **********.***.********.** ***********.****** 
 
Cattle_DLL1      GGGGGCCTTTTCTGCAACCAGGACCTCAACTACTGCACGCACCATAAGCCCTGCAGGAAC 900 
Pig_DLL1         GGGGGCCTTTTCTGCAACCAGGATCTGAACTACTGCACACACCACAAGCCCTGCAAGAAC 900 
Human_DLL1       GGGGGCCTTTTCTGCAACCAGGACCTGAACTACTGCACACACCATAAGCCCTGCAAGAAT 900 
Mouse_DLL1       GGGGGCCTTTTCTGCAACCAAGACCTGAACTACTGTACTCACCATAAGCCGTGCAGGAAT 897 
                 ********************.** ** ******** ** ***** ***** ****.***  
 
Cattle_DLL1      GGGGCCACCTGCACCAACACGGGCCAAGGGAGCTACACATGCTCGTGCCGGCCTGGGTAC 960 
Pig_DLL1         GGGGCCACCTGCACCAATACGGGCCAGGGTAGCTACACTTGCTCTTGCCGGCCGGGGTAC 960 
Human_DLL1       GGAGCCACCTGCACCAACACGGGCCAGGGGAGCTACACTTGCTCTTGCCGGCCTGGGTAC 960 
Mouse_DLL1       GGAGCCACCTGCACCAACACGGGCCAGGGGAGCTACACATGTTCCTGCCGACCTGGGTAT 957 
                 **.************** ********.** ********:** ** *****.** *****  
 
Cattle_DLL1      ACGGGGGCCAACTGTGAGACGGAGGTGGACGAGTGCAGCGCGGGGCCTTGCAGGAACGGA 1020 
Pig_DLL1         ACGGGGGCCAACTGTGAGACAGAGGTGGACGAGTGCAAGGCCAGCCCCTGCAGGAATGGA 1020 
Human_DLL1       ACAGGTGCCACCTGCGAGCTGGGGATTGACGAGTGTGACCCCAGCCCTTGTAAGAACGGA 1020 
Mouse_DLL1       ACAGGTGCCAACTGTGAGCTGGAAGTAGATGAGTGTGCTCCTAGCCCCTGCAAGAACGGA 1017 
                 **.** ****.*** ***. .*...* ** ***** .   * .* ** ** *.*** *** 
 
Cattle_DLL1      GGGAGCTGCACGGACCTTGAGAACAGCTACTCCTGCACCTGCCCACCCGGCTTCTACGGC 1080 
Pig_DLL1         GGGAGCTGCACGGACCTCGAGAACAGCTTCTCCTGCACCTGCCCACCTGGCTTCTATGGC 1080 
Human_DLL1       GGGAGCTGCACGGATCTCGAGAACAGCTACTCCTGTACCTGCCCACCCGGCTTCTACGGC 1080 
Mouse_DLL1       GCGAGCTGCACGGACCTTGAGGACAGCTTCTCTTGCACCTGCCCTCCCGGCTTCTATGGC 1077 
                 * ************ ** ***.******:*** ** ********:** ******** *** 
 
Cattle_DLL1      AGGATCTGCGAGCTGAGTGCCATGGTGTGTGCCGACGGTCCCTGCTTCAACGGGGGCCGG 1140 
Pig_DLL1         AGGATCTGCGAGCTGAGTGCTATGGCGTGTGCGGACGGCCCTTGCTTCAACGGGGGCCGG 1140 
Human_DLL1       AAAATCTGTGAATTGAGTGCCATGACCTGTGCGGACGGCCCTTGCTTTAACGGGGGTCGG 1140 
Mouse_DLL1       AAGGTCTGTGAGCTGAGCGCCATGACCTGTGCAGATGGCCCTTGCTTCAATGGAGGACGA 1137 
                 *...**** **. **** ** ***.  ***** ** ** ** ***** ** **.** **. 
 
Cattle_DLL1      TGCTCCGACAACCCCGAGGGCGGGTACACCTGCCGCTGCCCTGGGGGCTTCTCCGGCTTT 1200 
Pig_DLL1         TGCTCTGACAACCCCGAGGGAGGGTACACCTGCCGCTGCCCTGGGGGCTTCTCTGGCTTT 1200 
Human_DLL1       TGCTCAGACAGCCCCGATGGAGGGTACAGCTGCCGCTGCCCCGTGGGCTACTCCGGCTTC 1200 
Mouse_DLL1       TGTTCAGATAACCCTGACGGAGGCTACACCTGCCATTGCCCCTTGGGCTTCTCTGGCTTC 1197 
                 ** ** ** *.*** ** **.** **** *****. *****   *****:*** *****  
 
Cattle_DLL1      AACTGTGAGAAGAAGACGGATTCCTGCAGCTCCTCGCCTTGTTCCAATGGTGCTCAATGC 1260 
Pig_DLL1         AACTGTGAGAAGAAGATGGATTCCTGCACTTCCTCACCCTGTTCCAATGGTGCGCAGTGT 1260 
Human_DLL1       AACTGTGAGAAGAAAATTGACTACTGCAGCTCTTCACCCTGTTCTAATGGTGCCAAGTGT 1260 
Mouse_DLL1       AACTGTGAGAAGAAGATGGATCTCTGCGGCTCTTCCCCTTGTTCTAACGGTGCCAAGTGT 1257 
                 **************.*  **   ****.  ** ** ** ***** ** ***** .*.**  
 
Cattle_DLL1      GTGGACCTCGGCGACGCTTACGCCTGCCGCTGCCAGGCCGGCTTCTCTGGGAGGCACTGT 1320 
Pig_DLL1         GTGGACCTCGGCGATGCCTACCTCTGCCGCTGCCGGGCTGGCTTCTCTGGGAGGCACTGC 1320 
Human_DLL1       GTGGACCTCGGTGATGCCTACCTGTGCCGCTGCCAGGCCGGCTTCTCGGGGAGGCACTGT 1320 
Mouse_DLL1       GTGGACCTCGGCAACTCTTACCTGTGCCGGTGCCAGGCTGGCTTCTCCGGGAGGTACTGC 1317 
                 *********** .*  * ***   ***** ****.*** ******** ****** ****  
 
Cattle_DLL1      GACAACAACGTGGACGACTGTGCCTCCTCCCCATGTGCCCACGGGGGCACCTGCCGGGAC 1380 
Pig_DLL1         GAGGACAACGTGGACGACTGTGCCTCCTCCCCGTGTGCCAATGGAGGCGCCTGCAGGGAC 1380 
Human_DLL1       GACGACAACGTGGACGACTGCGCCTCCTCCCCGTGCGCCAACGGGGGCACCTGCCGGGAT 1380 
Mouse_DLL1       GAGGACAATGTGGATGACTGTGCCTCCTCCCCGTGTGCAAATGGGGGCACCTGCCGGGAC 1377 
                 ** .**** ***** ***** ***********.** **..* **.***.*****.****  
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Cattle_DLL1      GGCGTGAACGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGTGCC 1440 
Pig_DLL1         GGTGTGAACGAGTACTCCTGCACCTGCCCCCCCGGGTACACGGGCAGGAACTGCAGCGCC 1440 
Human_DLL1       GGCGTGAACGACTTCTCCTGCACCTGCCCGCCTGGCTACACGGGCAGGAACTGCAGTGCC 1440 
Mouse_DLL1       AGTGTGAACGACTTCTCCTGTACCTGCCCACCTGGCTACACGGGCAAGAACTGCAGCGCC 1437 
                 .* ******** *:****** ******** ** ** **********.********* *** 
 
Cattle_DLL1      CCCGTCAGCAGGTGCGAGCACGCGCCCTGCCACAACGGGGCCACCTGCCATGAGCGGGCC 1500 
Pig_DLL1         CCCGTCAGTAGGTGTGAGCATTCGCCCTGCCACAACGGGGCCACCTGCCACGAGAGGGCC 1500 
Human_DLL1       CCCGTCAGCAGGTGCGAGCACGCACCCTGCCACAATGGGGCCACCTGCCACGAGAGGGGC 1500 
Mouse_DLL1       CCTGTCAGCAGGTGTGAGCATGCACCCTGCCATAATGGGGCCACCTGCCACCAGAGGGGC 1497 
                 ** ***** ***** *****  *.******** ** **************  **.*** * 
 
Cattle_DLL1      TTCCGCTACCTGTGTGAGTGCGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTC 1560 
Pig_DLL1         CTCCGCTACCTGTGTGAGTGTGCCCGGGGCTACGGGGGCCCCAACTGCCAGTTCCTGCTT 1560 
Human_DLL1       CACCGCTATGTGTGCGAGTGTGCCCGAGGCTACGGGGGTCCCAACTGCCAGTTCCTGCTC 1560 
Mouse_DLL1       CAGCGCTACATGTGTGAGTGCGCCCAGGGCTATGGCGGCCCCAACTGCCAGTTTCTGCTC 1557 
                  : *****  **** ***** ****..***** ** ** ************** *****  
 
Cattle_DLL1      CCCGAGCCGCCCCCGGGCCCCGTGGTGGTGGACCTCACAGAGAAGTACGTGGAGGGCCAG 1620 
Pig_DLL1         CCTGCACCACCCCCGGGCCCCGTGGTGGTGGACCTCACCGAGAAGTACGTGGAGGGCCAG 1620 
Human_DLL1       CCCGAGCTGCCCCCGGGCCCAGCGGTGGTGGACCTCACTGAGAAG---CTAGAGGGCCAG 1617 
Mouse_DLL1       CCTGAGCCACCACCAGGGCCCATGGTGGTGGACCTCAGTGAGAGGCATATGGAGAGCCAG 1617 
                 ** *..* .**.**.** **.. **************  ****.*    *.***.***** 
 
Cattle_DLL1      GCCGGCCCGTTCCCCTGGGTGGCCGTCGGGGCGGGCGTGCTGCTGGTCCTCACGCTGCTG 1680 
Pig_DLL1         ACTGGGCCGTTCCCCTGGGTGGCCGTCTGTGCGGGCGTGGTTCTCGTCCTCATGCTGCTG 1680 
Human_DLL1       GGCGGGCCATTCCCCTGGGTGGCCGTGTGCGCCGGGGTCATCCTTGTCCTCATGCTGCTG 1677 
Mouse_DLL1       GGCGGGCCCTTCCCCTGGGTGGCCGTGTGTGCCGGGGTGGTGCTTGTCCTCCTGCTGCTG 1677 
                 .  ** ** *****************  * ** ** **  * ** ******. ******* 
 
Cattle_DLL1      CTGGGCTGCGCCGCCACGGTGGTCTGCGTGCGGCTGAGGCTGCAGAAGCGCCGGCCCCCT 1740 
Pig_DLL1         CTCGGCTGTGCCGCTGTGGTGGTCTGCACGCGGCTAAGGCTGCAGAAGCGCCGGCCTCCC 1740 
Human_DLL1       CTGGGCTGTGCCGCTGTGGTGGTCTGCGTCCGGCTGAGGCTGCAGAAGCACCGGCCCCCA 1737 
Mouse_DLL1       CTGGGCTGTGCTGCTGTGGTGGTCTGCGTCCGGCTGAAGCTACAGAAACACCAGCCTCCA 1737 
                 ** ***** ** ** . **********.  *****.*.***.*****.*.**.*** **  
 
Cattle_DLL1      GCAGACCCCTGCCGGGGAGAGACAGAGACCATGAACAACCTGGCCAACCGCCAGCGGGAG 1800 
Pig_DLL1         GCCGACCCCTGCCGGGGGGAGACTGAGACCATGAACAACCTGGCCAACTGTCAGCGGGAG 1800 
Human_DLL1       GCCGACCCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGCCAACTGCCAGCGTGAG 1797 
Mouse_DLL1       CCTGAACCCTGTGGGGGAGAGACAGAAACCATGAACAACCTAGCCAATTGCCAGCGCGAG 1797 
                  * **.*****  ****.***** **.**************.*****  * ***** *** 
 
Cattle_DLL1      AAGGACATCTCTGTCAGCGTCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCA 1860 
Pig_DLL1         AAGGACATCTCTGTCAGCGTCATTGGGGCCACGCAGATCAAGAACACCAACAAGAAGGTG 1860 
Human_DLL1       AAGGACATCTCAGTCAGCATCATCGGGGCCACGCAGATCAAGAACACCAACAAGAAGGCG 1857 
Mouse_DLL1       AAGGACGTTTCTGTTAGCATCATTGGGGCTACCCAGATCAAGAACACCAACAAGAAGGCG 1857 
                 ******.* **:** ***.**** ***** ** ************************* . 
 
Cattle_DLL1      GACTTCCACGTGGAGCCCGGCGCGGAGAAAAACGGCCTCACGGCCCGAGACTCTGCCGTG 1920 
Pig_DLL1         GACCTCCAGGCAGAGCCCGGCTCGGAGAAGAATGGCCTCAAGGCTCGAGATCCCGCCGTG 1920 
Human_DLL1       GACTTCCACGGGGACCACAGCGCCGACAAGAATGGCTTCAAGGCCCGCTACCCAGCGGTG 1917 
Mouse_DLL1       GACTTTCACGGGGACCATGGAGCCGAGAAGAGCAGCTTTAAGGTCCGATACCCCACTGTG 1917 
                 *** * ** * .** *. .*. * ** **.*. .** * *.**  **. *  * .* *** 
 
Cattle_DLL1      GGCTGCAACCTGCTGCAGGGCCTTAAGGGCGCCG---CAGCCACGGCGGGGCCCCACAGC 1977 
Pig_DLL1         GGCTATAACCTGCTGCAGGACCTCAAGGGTGCTG---CTGCCACCAGGGACCCACACAGC 1977 
Human_DLL1       GACTATAACCTCGTGCAGGACCTCAAGGGTGACGACACCGCCGTCAGGGACGCGCACAGC 1977 
Mouse_DLL1       GACTATAACCTCGTTCGAGACCTCAAGGGAGATGAAGCCACGGTCAGGGATACACACAGC 1977 
                 *.**. *****  * *..*.*** ***** *. *   * .* .  . **.  * ****** 
 
Cattle_DLL1      GTGCGCGATGCCAAGGGCCAGCCCCAAGGCTCTGCAGGGGAGGAGAAGGGCACCCCG--- 2034 
Pig_DLL1         AAGCCCGATGCCAAGTGCCAGCCCCACGGCTCTGCGGGGGAGGAGAAGGGCACCCTG--- 2034 
Human_DLL1       AAGCGTGACACCAAGTGCCAGCCCCAGGGCTCCTCAGGGGAGGAGAAGGGGACCCCGACC 2037 
Mouse_DLL1       AAACGTGACACCAAGTGCCAGTCACAGAGCTCTGCAGGAGAAGAGAAGATCGCCCCA--- 2034 
                 .:.*  ** .***** ***** *.** .****  *.**.**.******.  .*** .    
 
Cattle_DLL1      ACACTCAGAGGTGGAGAAGCGTCTGAAAGAAAAAGGCCAGACTCTGTGTACTCTGCTTCA 2094 
Pig_DLL1         ACACTCAGGGGTGGAGAAGCACCTGAAAGAAAGAGGCCGGACTCTGTGTACGCCGCTTCA 2094 
Human_DLL1       ACACTCAGGGGTGGAGAAGCATCTGAAAGAAAAAGGCCGGACTCGGGCTGTTCAACTTCA 2097 
Mouse_DLL1       ACACTTAGGGGTGGGGAGATTCCTGACAGAAAAAGGCCAGAGTCTGTCTACTCTACTTCA 2094 
                 ***** **.*****.**..   ****.*****.*****.** ** *  *.  * .***** 
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Cattle_DLL1      AAAGACACAAAGTACCAGTCTGTGTACGTCATATCCGAGGAGCAGGACGAGTGTGTCATC 2154 
Pig_DLL1         AAGGACACCAAGTACCAGTCGGTGTACGTCATATCCGAGGAGAAGGACGAGTGCGTCATC 2154 
Human_DLL1       AAAGACACCAAGTACCAGTCGGTGTACGTCATATCCGAGGAGAAGGATGAGTGCGTCATA 2157 
Mouse_DLL1       AAGGACACCAAGTACCAGTCGGTGTATGTTCTGTCTGCAGAAAAGGATGAGTGTGTTATA 2154 
                 **.*****.*********** ***** ** .*.** *..**..**** ***** ** **. 
 
Cattle_DLL1      GCCACTGAGGTGTGA--------------------- 2169 
Pig_DLL1         GCCACCGAGGGGAGACGTTGGCTCTTGTCCCAGTGA 2190 
Human_DLL1       GCAACTGAGGTGTAA--------------------- 2172 
Mouse_DLL1       GCGACTGAGGTGTAA--------------------- 2169 
                 ** ** **** *:.*                      
 
Accession numbers for cattle, pig, human and mouse sequences are as follows: 
XM_010808803.1, XM_003353151.2, NM_005618.3, NM_007865.3
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Appendix 4: RNAHybrid analysis of sheep and cattle MHC class II genes 
 
RNAHybrid analysis of sheep MHC class II DQA and DRA genes used for flow 
cytometry 
 
TARGET : Sheep_MHCII_DQA1 
length: 1148 
MIRNA  : 17-28 
length: 22 
 
mfe: -22.6 kcal/mol 
p-value: undefined 
 
position  872 
target 5'  A    ACU     UAGAU        G 3' 
            ACAG     UGC     GACCUAGA     
            UGUC     ACG     UUGGAUCU     
miRNA  3' GA    GUUUU                  5' 
 
TARGET : Sheep_MHCII_DQA2.1 
length: 1129  
MIRNA  : 17-28 
length: 22 
 
mfe: -21.4 kcal/mol 
p-value: undefined 
 
position  844 
target 5' U          GAGGACGUUCUAGA         A 3' 
           UGCAG AAGA              CGACCUAGA     
           AUGUC UUUU              GUUGGAUCU     
miRNA  3' G     G    AC                       5' 
 
TARGET : Sheep_MHCII_DQA2.2 
length: 1117 
MIRNA  : 17-28 
length: 22 
 
mfe: -24.5 kcal/mol 
p-value: undefined 
 
position  848 
target 5'  A    A      GACGCACUAGA         A 3' 
            GCAG AGAGUG           CGACCUAGA     
            UGUC UUUUAC           GUUGGAUCU     
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TARGET : Sheep_MHCII_DQA1 
length: 1148 
MIRNA  : 17-17 
length: 22 
 
mfe: -22.7 kcal/mol 
p-value: undefined 
 
position  1043 
target 5'   A       C  UUAU       C  3' 
             UUGUUAC UA    GGGAUCC      
             AGCAGUG AU    UCCUAGG      
miRNA  3' GCA       A             AA 5' 
 
TARGET : Sheep_MHCII_DQA1 
length: 1148 
MIRNA  : 17-17 
length: 22 
 
mfe: -19.8 kcal/mol 
p-value: undefined 
 
position  997 
target 5'       A     U        C 3' 
                 UACUU GGGAUUCU     
                 GUGAA UCCUAGGA     
miRNA  3' GCAAGCA     U        A 5' 
 
TARGET : Sheep_MHCII_DRA 
length: 1205 
MIRNA  : 17-17 
length: 22 
 
mfe: -19.4 kcal/mol 
p-value: undefined 
 
position  1070 
target 5'       C               U 3' 
                 CAU   AGGAUCCUU     
                 GUG   UCCUAGGAA     
miRNA  3' GCAAGCA   AAU           5' 
 
TARGET : Sheep_MHCII_DRA 
length: 1205 
MIRNA  : 17-6 
length: 23 
 
mfe: -23.3 kcal/mol 
p-value: undefined 
 
position  791 
target 5' A    C    AACGGA  UU        G  3' 
           CCUG AGGU      CU  GUUAGAGA      
           GGAU UCCA      GA  CGAUUUUU      
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TARGET : Sheep_MHCII_DQA2.2 
length: 1117 
MIRNA  : 17-6 
length: 23 
 
mfe: -23.6 kcal/mol 
p-value: undefined 
 
position  814 
target 5' C      AGGGAA   G      CCAUCUA      C  3' 
           CCUAGA      GGU CUCUGC       UGAGAG      
           GGAUCU      CCA GAGGCG       AUUUUU      
miRNA  3'                                     AU 5' 
 
TARGET : Sheep_MHCII_DQA1 
length: 1148 
MIRNA  : 17-2 
length: 22 
 
mfe: -24.7 kcal/mol 
p-value: undefined 
 
position  941 
target 5' C    C U     UUCUU       A  3' 
           UCCU C CAUAC     CUCUGGG      
           AGGA G GUAUG     GGGGCCC      
miRNA  3' C    C U                 CA 5' 
 
TARGET : Sheep_MHCII_DQA2.1 
length: 1129 
MIRNA  : 17-2 
length: 22 
 
mfe: -28.1 kcal/mol 
p-value: undefined 
 
position  1020 
target 5' U     CA   GU     ACCAUGAGAUCA       A 3' 
           GUUCU  GUA  UGCCU            CUGGGGU     
           CAGGA  CGU  AUGGG            GGCCCCA     
miRNA  3'            GU                          5' 
 
TARGET : Sheep_MHCII_DQA2.2 
length: 1117 
MIRNA  : 17-2 
length: 22 
 
mfe: -28.1 kcal/mol 
p-value: undefined 
 
position  1022 
target 5' U     CA   GU     ACCAUGAUAUCA       A 3' 
           GUUCU  GUA  UGCCU            CUGGGGU     
           CAGGA  CGU  AUGGG            GGCCCCA     
miRNA  3'            GU                          5' 
 
Appendix 4                                      RNAHybrid analysis of sheep and cattle MHC class II genes 
         
199 
 





MIRNA  : 17-21 
length: 25 
 
mfe: -24.0 kcal/mol 
p-value: undefined 
 
position  962 
target 5'    U                    G 3' 
              GGGAC     UUAAGGUGCU     
              CUCUG     GGUUCCACGA     
miRNA  3' UUGU     UAGUG          A 5' 
 
MIRNA  : 17-14 
length: 25 
 
mfe: -20.3 kcal/mol 
p-value: undefined 
 
position  1109 
target 5'   C     UA    A   AAGAAAU       U 3' 
             UAAUA   UCC UGG       AAAUGCC     
             GUUGU   AGG ACC       UUUACGG     
miRNA  3' CUU     CCG                     U 5' 
 
Cattle DQA1: 
MIRNA  : 17-30 
length: 21 
 
mfe: -18.9 kcal/mol 
p-value: undefined 
 
position  1072 
target 5' U   AU  CU    UAUUC       U 3' 
           GGA  UG  ACGG     CACCCAA     
           UCU  AC  UGUC     GUGGGUU     
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MIRNA  : 17-20 
length: 23 
 
mfe: -19.8 kcal/mol 
p-value: undefined 
 
position  921 
target 5' A       A     UAGUGACUC        U 3' 
           GAU CAG UCCUA         UGAUACAG     
           UUG GUU GGGAU         ACUAUGUC     
miRNA  3' G   U   G                      U 5' 
 
MIRNA  : 17-9 
length: 25 
 
mfe: -25.6 kcal/mol 
p-value: undefined 
 
position  1102 
target 5' G     A UCU       AU        A 3' 
           AUCAG G   UUCUUAG  UAACUCUG     
           UGGUC C   AGGAAUC  AUUGAGAU     
miRNA  3' A     C UU                    5' 
Sheep DRA1: 
MIRNA  : 17-25 
length: 21 
 
mfe: -19.5 kcal/mol 
p-value: undefined 
 
position  888 
target 5' C   A ACA    UGCUU       U 3' 
           UGA G   ACCA     CAGCAUU     
           ACU C   UGGU     GUCGUAA     
miRNA  3'     C G      UUC         C 5' 
 
MIRNA  : 17-17 
length: 22 
 
mfe: -19.4 kcal/mol 
p-value: undefined 
 
position  1070 
target 5'       C               U 3' 
                 CAU   AGGAUCCUU     
                 GUG   UCCUAGGAA     







Appendix 4                                      RNAHybrid analysis of sheep and cattle MHC class II genes 
         
201 
 
MIRNA  : 24-1 
length: 26 
 
mfe: -27.6 kcal/mol 
p-value: undefined 
 
position  962 
target 5'  G       AA       UUAUUCCCUGUC        C 3' 
            GU  UCU  UGUGUAG            UACUGCUC     
            CA  AGA  ACACAUC            AUGACGAG     
miRNA  3' UA  AC   CG                             5' 
 
Cattle DRA1: 
MIRNA  : 17-17 
length: 22 
 
mfe: -19.4 kcal/mol 
p-value: undefined 
 
position  1128 
target 5'       C               U 3' 
                 CAU   AGGAUCCUU     
                 GUG   UCCUAGGAA     
miRNA  3' GCAAGCA   AAU           5' 
 
MIRNA  : 24-1 
length: 26 
 
mfe: -20.9 kcal/mol 
p-value: undefined 
 
position  1033 
target 5'  A   A  CC    C           C 3' 
            GUU UU  CUGU    UACUGCUC     
            CAA AG  GACA    AUGACGAG     
miRNA  3' UA   C  AC    CAUC          5' 
 
Cattle DRB: 
MIRNA  : 17-9 
length: 25 
 
mfe: -21.8 kcal/mol 
p-value: undefined 
 
position  889 
target 5'  C    CUUCUUCACAGCAU    AGGUU    GCU   UGC       U 3' 
            CCAG              GGAA     UCCU   UAG   UAACUCU     
            GGUC              CCUU     AGGA   AUC   AUUGAGA     
miRNA  3' AU                                               U 5' 
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RNAHybrids of ovhv2-miR-17-30 and ovhv2-miR-17-14 predicted to target firefly and 
renilla luciferase  
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -22.5 kcal/mol 
p-value: 1.000000e+00 
 
position  4070 
target 5' C  CG  GU  UGUUCGUGGACG           G 3' 
           GG  GA  GG            AGGUGCCCAAG     
           UC  CU  CC            UCUGUGGGUUU     
miRNA  3'    UA  GU                           5' 
 
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -20.4 kcal/mol 
p-value: 1.000000e+00 
 
position  3932 
target 5' C   G    C  CC        C 3' 
           GGA UGGC GG   UGCCCGA     
           UCU ACUG CC   GUGGGUU     
miRNA  3'          U  UCU       U 5' 
 
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -19.3 kcal/mol 
p-value: 1.000000e+00 
 
position  2945 
target 5'  C       A   AGCUGCCUAU        A 3' 
            GUG CAG AGA          CAUCCAGA     
            UAC GUC UCU          GUGGGUUU     
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target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -18.4 kcal/mol 
p-value: 1.000000e+00 
 
position  2703 
target 5' G     U U U          C 3' 
           AGAUG C G   GCGCCUGG     
           UCUAC G C   UGUGGGUU     
miRNA  3'       U U CUC        U 5' 
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -17.3 kcal/mol 
p-value: 1.000000e+00 
 
position  3812 
target 5' C  G    A CACUUCUUCAUCGU   C        G 3' 
           GA GACG G              GGA CGCCUGAA     
           CU CUGU C              UCU GUGGGUUU     
miRNA  3' U  A    C                             5' 
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -15.0 kcal/mol 
p-value: 1.000000e+00 
 
position  3272 
target 5'    C    UGUUCACCACCCU    C       U 3' 
              GGCA             GG G UACCUGA     
              CUGU             CC C GUGGGUU     
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target: psiCHECK-2- Renilla 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -18.9 kcal/mol 
p-value: 1.000000e+00 
 
position  1299 
target 5'      C U    C        G 3' 
                C GGAG CAUUCAAG     
                G CCUC GUGGGUUU     
miRNA  3' UCUACU U    U          5' 
 
target: psiCHECK-2- Renilla 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -16.9 kcal/mol 
p-value: 1.000000e+00 
 
position  1197 
target 5' C  A  G  C    AAAUGG        A 3' 
           GA GA GG GAGA      UGCUUGAG     
           CU CU UC CUCU      GUGGGUUU     
miRNA  3' U  A  G                       5' 
 
target: psiCHECK-2- Renilla 
length: 6273 
miRNA : ovhv2-miR-17-30 
length: 21 
 
mfe: -16.8 kcal/mol 
p-value: 1.000000e+00 
 
position  1427 
target 5'    G   C  C  C  UC        A 3' 
              GGC AG GA GA  UGCCUAAG     
              CUG UC CU CU  GUGGGUUU     
miRNA  3' UCUA                        5' 
 
target: psiCHECK-2- Renilla 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -16.8 kcal/mol 
p-value: 1.000000e+00 
 
position  1373 
target 5'       A      CAAGCCCGACGU        U 3' 
                 GGGAGG            CGUCCAGA     
                 UCCUCU            GUGGGUUU     
miRNA  3' UCUACUG                            5' 
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target: psiCHECK-2 - Renilla 
length: 6273 
miRNA : ovhv2-miR-17-30  
length: 21 
 
mfe: -15.0 kcal/mol 
p-value: 1.000000e+00 
 
position  1050 
target 5'    C   U     GCU       C 3' 
              GAC GGGGG   UGUCUGG     
              CUG CCUCU   GUGGGUU     
miRNA  3' UCUA   U               U 5' 
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-14  
length: 25 
 
mfe: -27.2 kcal/mol 
p-value: 1.000000e+00 
 
position  4068 
target 5'  C       AGUGGU    G   ACG       C 3' 
            GCGGCGG      GUUC UGG   AGGUGCC     
            UGUUGUC      CGAG ACC   UUUACGG     
miRNA  3' CU                 G             U 5' 
 
 
target: psiCHECK-2 - firefly 
length: 6273 
miRNA : ovhv2-miR-17-14  
length: 25 
 
mfe: -19.6 kcal/mol 
p-value: 1.000000e+00 
 
position  2677 
target 5' U     UCACCUAU  C A  A   C        U 3' 
           GGACA        GC G GU CUU GAGAUGUC     
           CUUGU        UG C CG GGA CUUUACGG     
miRNA  3'                 U    A   C        U 5' 
 
 
target: psiCHECK-2 - Renilla 
length: 6273 
miRNA : ovhv2-miR-17-14  
length: 25 
 
mfe: -22.9 kcal/mol 
p-value: 1.000000e+00 
 
position  1095 
target 5' A     GAUCA    CAUCGUCCA G   A        U 3' 
           GACAA     AGGC         U CUG GAGUGUCG     
           UUGUU     UCCG         A GAC UUUACGGU     
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miRNA  3' C     G                  G   C          5' 
 
target: psiCHECK-2 - Renilla 
length: 6273 
miRNA : ovhv2-miR-17-14  
length: 25 
 
mfe: -19.2 kcal/mol 
p-value: 1.000000e+00 
 
position  1431 
target 5' C       AU  G   A        C 3' 
           AGCGACG  CU CCU  AGAUGUU     
           UUGUUGU  GA GGA  UUUACGG     
miRNA  3' C       CC      CC       U 5' 
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Appendix 6: Immunofluorescence of pcDNA3.1+, Ov2HA-pcDNA3.1+ and Ov2-
pcDNA3.1+ stained with an anti-Ov2 antibody and DAPI 
 
  
Appendix 6                      Immunofluorescence of pcDNA3.1+, Ov2HA- and Ov2-pcDNA3.1+ 
         
209 
 





























Appendix 6                      Immunofluorescence of pcDNA3.1+, Ov2HA- and Ov2-pcDNA3.1+ 
         
210 
 





























Appendix 6                      Immunofluorescence of pcDNA3.1+, Ov2HA- and Ov2-pcDNA3.1+ 
         
211 
 





























Appendix 6                      Immunofluorescence of pcDNA3.1+, Ov2HA- and Ov2-pcDNA3.1+ 
         
212 
 









Appendix 7                                                       Proteins identified by Mass Spectrometry analysis  















Appendix 7: Proteins identified by Mass Spectrometry in pcDNA3.1+ and 
Ov2HA-pcDNA3.1+ immunoprecipitated samples 
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M0R0F0 40S ribosomal protein S5 (Fragment)  (RPS5) 934 11 
P62829 60S ribosomal protein L23  (RPL23) 826 9 
P0CW22 40S ribosomal protein S17-like  (RPS17L) 652 9 
P62269 40S ribosomal protein S18  (RPS18) 623 12 
P62280 40S ribosomal protein S11  (RPS11) 358 7 
P62701 40S ribosomal protein S4, X isoform  (RPS4X) 356 8 
P62081 40S ribosomal protein S7  (RPS7) 341 8 
P10412 Histone H1.4  (HIST1H1E) 323 5 
P62249 40S ribosomal protein S16  (RPS16) 317 8 
P07437 Tubulin beta chain  (TUBB) 231 8 
P68363 Tubulin alpha-1B chain  (TUBA1B) 230 5 
Q9Y383 Putative RNA-binding protein Luc7-like 2  (LUC7L2) 223 4 
P04350 Tubulin beta-4A chain  (TUBB4A) 213 7 
P62851 40S ribosomal protein S25  (RPS25) 209 7 
P23396 40S ribosomal protein S3  (RPS3) 200 6 
Q5VTE0 Putative elongation factor 1-alpha-like 3  (EEF1A1P5) 180 5 
P62266 40S ribosomal protein S23  (RPS23) 179 6 
P62273 40S ribosomal protein S29  (RPS29) 172 5 
E1P5S2 RNA-binding protein 39  (RBM39) 164 6 
P08107 Heat shock 70 kDa protein 1A/1B  (HSPA1A) 162 4 
P39019 40S ribosomal protein S19  (RPS19) 157 5 
P10809 60 kDa heat shock protein, mitochondrial  (HSPD1) 139 4 
P06733 Alpha-enolase  (ENO1) 134 6 
E7ETK0 40S ribosomal protein S24  (RPS24) 124 6 
P62913 60S ribosomal protein L11  (RPL11) 118 4 
P62263 40S ribosomal protein S14  (RPS14) 108 3 
H7BY10 60S ribosomal protein L23a (Fragment)  (RPL23A) 106 3 
E9PR30 40S ribosomal protein S30  (FAU) 104 3 
P60709 Actin, cytoplasmic 1  (ACTB) 100 6 
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Q15365 Poly(rC)-binding protein 1  (PCBP1) 100 4 
P14618 Pyruvate kinase PKM  (PKM) 93 3 
S4R435 Protein RPS10-NUDT3 (Fragment)  (RPS10-NUDT3) 86 4 
P58876 Histone H2B type 1-D  (HIST1H2BD) 80 3 
P60866 40S ribosomal protein S20  (RPS20) 78 3 
P62854 40S ribosomal protein S26  (RPS26) 74 2 
P62753 40S ribosomal protein S6  (RPS6) 69 2 
E7EUT5 
Glyceraldehyde-3-phosphate dehydrogenase  
(GAPDH) 56 3 
H0YMV8 40S ribosomal protein S27  (RPS27L) 52 2 
P62937 Peptidyl-prolyl cis-trans isomerase A  (PPIA) 52 2 
Q06830 Peroxiredoxin-1  (PRDX1) 47 3 
K7EMH1 60S ribosomal protein L22 (Fragment)  (RPL22) 46 2 
B7Z4C8 60S ribosomal protein L31  (RPL31) 43 2 
X1WI28 60S ribosomal protein L10 (Fragment)  (RPL10) 41 2 
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M0R0F0 40S ribosomal protein S5 (Fragment) (RPS5)  1227 10 
P62829 60S ribosomal protein L23 (RPL23) 1043 8 
P0CW22 40S ribosomal protein S17-like (RPS17L) 958 9 
P62269 40S ribosomal protein S18 (RPS18) 925 13 
P62701 40S ribosomal protein S4, X isoform (RPS4X) 757 8 
P62280 40S ribosomal protein S11 (RPS11) 599 7 
Q9Y383 Putative RNA-binding protein Luc7-like 2 (LUC7L2) 593 7 
Q9NQ29 Putative RNA-binding protein Luc7-like 1 (LUC7L) 254 4 
P10412 Histone H1.4 (HIST1H1E) 429 4 
P68363 Tubulin alpha-1B chain (TUBA1B) 405 7 
P62851 40S ribosomal protein S25 (RPS25) 373 7 
P62081 40S ribosomal protein S7 (RPS7) 372 8 
P39019 40S ribosomal protein S19 (RPS19) 371 5 
P07437 Tubulin beta chain (TUBB) 358 10 
P62249 40S ribosomal protein S16 (RPS16) 339 6 
P10809 60 kDa heat shock protein, mitochondrial (HSPD1) 316 3 
P06733 Alpha-enolase (ENO1) 315 6 
P08107 Heat shock 70 kDa protein 1A/1B (HSPA1A) 296 10 
E9PI65 
Heat shock cognate 71 kDa protein (Fragment) 
(HSPA8) 106 3 
P62266 40S ribosomal protein S23 (RPS23) 294 5 
P62273 40S ribosomal protein S29 (RPS29) 292 4 
P62854 40S ribosomal protein S26 (RPS26) 287 3 
H7BY10 60S ribosomal protein L23a (Fragment) (RPL23A) 253 3 
E9PR30 40S ribosomal protein S30 (FAU) 234 3 
P23396 40S ribosomal protein S3 (RPS3) 233 7 
P14618 Pyruvate kinase PKM (PKM) 206 3 
P46776 60S ribosomal protein L27a (RPL27A) 199 5 
P42766 60S ribosomal protein L35 (RPL35) 199 2 
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E7ETK0 40S ribosomal protein S24 (RPS24) 198 5 
Q06830 Peroxiredoxin-1 (PRDX1) 185 3 
P62937 Peptidyl-prolyl cis-trans isomerase A (PPIA) 181 5 
P08238 Heat shock protein HSP 90-beta (HSP90AB1) 142 4 
P07900 Heat shock protein HSP 90-alpha (HSP90AA1) 57 2 
P62263 40S ribosomal protein S14 (RPS14) 136 4 
Q14498 RNA-binding protein 39 (RBM39) 130 5 
C9J4Z3 60S ribosomal protein L37a (RPL37A) 123 2 
P07195 L-lactate dehydrogenase B chain (LDHB) 121 2 
S4R435 Protein RPS10-NUDT3 (Fragment) (RPS10-NUDT3) 120 5 
H0Y5B4 60S ribosomal protein L36a (Fragment) (RPL36A) 115 2 
A2A3R5 40S ribosomal protein S6 (RPS6) 105 2 
Q15365 Poly(rC)-binding protein 1 (PCBP1) 100 4 
F5H4F9 40S ribosomal protein S3a (RPS3A) 99 3 
P60866 40S ribosomal protein S20 (RPS20) 86 3 
P62913 60S ribosomal protein L11 (RPL11) 82 3 
P60709 Actin, cytoplasmic 1 (ACTB) 75 5 
J3KPD9 Nucleoside diphosphate kinase B (NME2) 74 2 
B7Z4C8 60S ribosomal protein L31 (RPL31) 73 2 
E7EUT5 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 71 3 
P50990 T-complex protein 1 subunit theta (CCT8) 62 2 
P62241 40S ribosomal protein S8 (RPS8) 60 2 
C9J9K3 40S ribosomal protein SA (Fragment) (RPSA) 57 2 
Q2VSN7 Ov2 protein  55 2 
X1WI28 60S ribosomal protein L10 (Fragment) (RPL10) 48 3 
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P42766 60S ribosomal protein L35 (RPL35) 142 
C9J4Z3 60S ribosomal protein L37a (RPL37A) 106 
P62857 40S ribosomal protein S28 (RPS28) 97 
H0Y8L7 40S ribosomal protein S3a (Fragment) (RPS3A) 96 
H0YH80 
Heterogeneous nuclear ribonucleoprotein A1 (Fragment) 
(HNRNPA1) 70 
J3KNN5 
Probable ATP-dependent RNA helicase DDX41 (Fragment) 
(DDX41) 68 
G3V461 Creatine kinase B-type (Fragment) (CKB) 64 
C9JNW5 60S ribosomal protein L24 (RPL24) 62 
P07195 L-lactate dehydrogenase B chain (LDHB) 55 
A6NE09 40S ribosomal protein SA (RPSAP58) 54 
P37108 Signal recognition particle 14 kDa protein (SRP14) 54 
P62979 Ubiquitin-40S ribosomal protein S27a (RPS27A) 53 
E9PN89 Heat shock cognate 71 kDa protein (Fragment) (HSPA8) 50 
D3YTB1 60S ribosomal protein L32 (Fragment) (RPL32) 49 
F5GZK5 T-complex protein 1 subunit eta (CCT7) 49 
E9PLM6 Midkine (MDK) 44 
 
  
Appendix 8  Proteins identified by Mass Spectrometry analysis with only one unique peptide 









P62857 40S ribosomal protein S28 (RPS28) 140 
H0YLA2 Signal recognition particle 14 kDa protein (SRP14) 108 
C9JNW5 60S ribosomal protein L24 (RPL24) 91 
E9PLD3 Uncharacterized protein OS=Homo sapiens) 91 
P18669 Phosphoglycerate mutase 1 (PGAM1) 84 
B7Z2F4 T-complex protein 1 subunit delta (CCT4) 80 
P22626 
Heterogeneous nuclear ribonucleoproteins A2/B1 
(HNRNPA2B1) 79 
M0R1M6 Ubiquitin-60S ribosomal protein L40 (Fragment) (UBA52) 76 
U3KQK0 Histone H2B (HIST1H2BN) 72 
G3V461 Creatine kinase B-type (Fragment) (CKB) 67 
K7EJ44 Profilin 1, isoform CRA_b (PFN1) 62 
P62979 Ubiquitin-40S ribosomal protein S27a (RPS27A) 62 
J3KPP4 
Cisplatin resistance-associated overexpressed protein, isoform 
CRA_b (LUC7L3) 57 
H0YH80 
Heterogeneous nuclear ribonucleoprotein A1 (Fragment) 
(HNRNPA1) 51 
H7BY16 Nucleolin (Fragment) (NCL) 51 
K7ELC2 40S ribosomal protein S15 (RPS15) 48 
E7EQG2 Eukaryotic initiation factor 4A-II (EIF4A2) 48 
P62244 40S ribosomal protein S15a (RPS15A) 47 
Q5T6W1 Heterogeneous nuclear ribonucleoprotein K (HNRNPK) 47 
K7EJT5 60S ribosomal protein L22 (Fragment) (RPL22) 41 
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MIRNA  : ovhv2-miR-17-23 
length: 21 
 
mfe: -19.3 kcal/mol 
p-value: undefined 
 
position  820 
target 5'   A  AAAAAGG         C 3' 
             GG       CAGUGUGUA     
             UC       GUCACACAU     
miRNA  3' AGA  GAGAAA          A 5' 
 
MIRNA  : ovhv2-miR-17-17 
length: 22 
 
mfe: -23.7 kcal/mol 
p-value: undefined 
 
position  977 
target 5'     G      ACUUUUUAUCC          A 3' 
               GUUGCU           UGGGGAUCCU     
               CAGUGA           AUUCCUAGGA     
miRNA  3' GCAAG                           A 5' 
 
MIRNA  : ovhv2-miR-17-13 
length: 23 
 
mfe: -24.3 kcal/mol 
p-value: undefined 
 
position  1072 
target 5' A   U  GAGGGGA     GAUAG        A 3' 
           ACC CG       UC CA     GGACCCAA     
           UGG GC       AG GU     CCUGGGUU     
miRNA  3'     C           A  ACAA           5' 
 
MIRNA  : ovhv2-miR-17-13 
length: 23 
 
mfe: -21.3 kcal/mol 
p-value: undefined 
 
position  1104 
target 5'              C         G 3' 
                        UGGACCCAA     
                        ACCUGGGUU     
miRNA  3' UGGCGCAGAGUACA           5' 
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RNAHybrid analysis against the mutated Ov2 sequence 
 
MIRNA : ovhv2-miR-17-10 
length: 23 
 
mfe: -14.9 kcal/mol 
p-value: undefined 
 
position  93 
target 5'    A       UCAC            A 3' 
              AGG GCA    GC   AAUUUUA     
              UCC CGU    CG   UUGAAGU     
miRNA  3' UAGG   A         ACA         5' 
 
RNAHybrid analysis against the Ov2 sequence allowing for G:U pairing and perfect 
complementarity between nucleotides 1 and 7 or nucleotides 2 and 8 
MIRNA : ovhv2-miR-17-10 
length: 23 
 
mfe: -15.0 kcal/mol 
p-value: undefined 
 
position  285 
target 5' U     UAGUG     CAUG GGGAGAAGUUACAAA       U 3' 
           UCUAG     GCGGU    G               UGAUUUU     
           AGGUC     CGUCG    C               AUUGAAG     
miRNA  3' U     CA        A                          U 5' 
 
MIRNA : ovhv2-miR-17-10 
length: 23 
 
mfe: -17.5 kcal/mol 
p-value: undefined 
 
position  454 
target 5' U  A    AGAAG     GAACA       G 3' 
           UC CAGG     GCAGU     GGUUUUG     
           AG GUCC     CGUCG     UUGAAGU     
miRNA  3' U       A         ACA           5' 
 
MIRNA : ovhv2-miR-61-1 
length: 25 
 
mfe: -19.7 kcal/mol 
p-value: undefined 
 
position  477 
target 5'  G        AAG   UA        A 3' 
            GUU UUGG   AGC   UUCCCAG     
            CAG AGUC   UCG   AGGGGUU     
miRNA  3' UG   C    GG    UGC         5'
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